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Ovarian cancer causes over 4,200 deaths in the U.K. per annum. This is
because it presents late, resulting in an extremely poor prognosis.
Tumour-suppressor genes(TSGs) are intimately involved in
carcinogenesis. In sporadic ovarian cancer, few important genes of this
type have been described.
To investigate new TSG regions, I used PCR based polymorphic
microsatellites to define regions of frequent loss of heterozygosity
(LOH) throughout chromosome 11 especially at llpl5.5-15.1 and llq23-
qter in DNA blood/tumour pairs from 60 patients with ovarian
neoplasms. LOH at llq23-qter was significantly associated with
advanced stage and adverse actuarial survival. Integration of this LOH
data with chromosome 17 LOH data allowed construction of a
multistep model for ovarian cancer. Refinement of the llq23-qter
region revealed an 8.5Mb LOH region between D11S934 and D11S1320
(Ilq23.3-q24.3) retaining the above survival association.
To test the causality of the LOH observations, I introduced
normal chr 11 by microcell mediated chromosome transfer (MMCT)
into an ovarian cancer cell line. I used 556.1.5, a human
monochromosome somatic cell hybrid to transfer neor-tagged chr 11
into a Hygr subline of OVCAR3 (OH3), an ovarian cancer line with a
chr 11 rearrangement. I have analysed 14 microcell hybrid clones
(MHCs) from 5 experiments. Chr 11 transfer was confirmed by PCR, in-
situ hybridisation and microsatellite analysis.
Interestingly, chr 12 MMCT, originally intended as a negative control
was shown to inhibit the growth of OH3 in-vitro and in-vivo
suggesting the presence of a TSG on this chromosome also.
Appropriate controls were generated by transfer of a "neutral"
chromosome from neo-transfected OVCAR3 by MMCT to OH3.
Chrll MHCs remained immortalised, and demonstrated
significant in-vitro growth inhibition. This inhibition was not due to
cell cycle block (DNA FACS analysis) or apoptosis (FITC labelled
v
Annexin-V and fluoro-TUNEL FACS analysis). MHCs were
significantly reduced in their ability to invade matrigel in the transwell
invasion assay. MHCs retaining whole chr 11 showed significant
reduction in invasiveness compared with MHCs taking up all chr 11 as
far as llq22. Soft agar clonogenicity was unaltered. Xenografts of chr 11
MHCs showed reduced growth rather than suppression of
tumorigenicity.
Further analysis of the inhibition of invasiveness associated with the
introduction of llq revealed that components of this include specific
inhibition of attachment and spreading to laminin coated plastic, and
abrogation of the stimulation of tumour cell migration in response to
a collagen IV or fibronectin mediated haptotactic signal.
These studies suggest that the gene within a 4.5 Mb interval on distal
chromosome llq24 functions as an ovarian cancer progression-
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1.1 Epithelial ovarian cancer: causation and disease distribution
1.1.1 Epidemiology
Ovarian cancer is the most common cause of death from
gynaecological malignancy, and the fifth commonest cause of cancer
death in women after breast, lung, colon and (in the UK) stomach
cancer. About 5,000 cases occur annually in the UK, with
approximately 4,200 deaths in the same period (Chang et al, 1994). This
high mortality rate is due to presentation at an advanced stage of the
disease as symptoms of the disease are insidious in onset and non¬
specific in nature. Approximately 1 woman in 70 will develop ovarian
cancer, and 1 woman in 100 will die from it. Incidence is age-related,
peaking at 55 per 100,000 per year in the 7th and 8th decades, with the
disease being uncommon in those under 45 (less than 15 cases per
100,000 per year). The overall five-year survival rate is poor; about
30%, primarily due to the late presenting nature of the disease. There is
a particularly high incidence in Scandinavia, followed by Northern
Europe and North America. Despite being industrialised, Japan has a
particularly low incidence of the disease; however, the incidence
increases sharply in Japanese migrants to the USA and their daughters
(a phenomenon seen in common with other cancers), suggesting
profound environmental components to aetiology (Herrinton et al,
1994).
Demographically, there are wide mortality rate differences; Denmark
having a mortality rate six times that of Japan. These may be due to
genetic differences between populations (Parazzini et al, 1991)
There has been a slight improvement in ovarian cancer survival over
the last two decades, almost certainly due to improved multimodality
therapies. This improvement has been more pronounced in younger
patients (less than 50 years old). The age-specific mortality rate curve in
those with ovarian cancer becomes parallel to that of the general age-
specific mortality rate at 15-20 years post diagnosis, indicating those
who may be "cured" of their disease by that time.
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1.1.2 Aetiology
Ninety-five percent of all patients with ovarian cancer have no family
history, suggesting that almost all cases can be attributed to
spontaneous or environmentally induced carcinogenesis. Many
individual environmental factors have been examined. The
epidemiological studies that are published for these potential factors
are diverse in their methodologies and power. What is clear is that for
many factors, the epidemiological data is (a) conflicting from study to
study and (b) small in magnitude of effect, often at the limits of what is
legitimately detectable by the study designs. Putting these points
together with that of publication bias gives an idea of how opaque this
area continues to be. Potential candidate carcinogens such as tobacco
(Whittemore et al, 1988 ), ascending (talc) (Cramer et al, 1982a; Harlow
et al, 1992; Wehner et al, 1994) asbestos, alcohol (Gwinn et al, 1986; Kato
et al, 1989) have been examined and do not seem to confer excess risk.
The low incidence of the disease in Japan does suggest that the causes
are not simply due to environmental carcinogens as a result of
industrialisation; however, the rising incidence in Japanese migrants
to the USA suggests environmentally related carcinogenesis. Whether
this is due to carcinogenesis from, say, dietary or other sources in the
USA, or whether there are dietary or other protectants that prevent
environmentally associated carcinogenesis in Japan is unknown.
Coffee drinking has been variously ascribed with slightly increased risk
or no risk depending on the epidemiological overview or opinion, and
there may be some consensus that a slightly increased risk of ovarian
cancer is associated with coffee ingestion (Byers et al, 1983; Cramer et al,
1984; Whittemore et al, 1988).
Initial evidence that consumption of animal fat is associated with an
increased risk of ovarian cancer (Cramer et al, 1984), was followed with
a large case/control study into diet and ovarian cancer risk. This study
suggested that every lOg of ingested saturated fat per day increased
ovarian cancer risk by 20%, whereas the same ingested weight of
vegetable fibre reduced ovarian cancer risk by 37% (Risch et al, 1994).
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The extent of independence of these factors is unclear. However, this
seemingly unambiguous study is unique, there are very few other
confirmatory studies, and meta-analytically its findings should be
treated cautiously.
Although no relationship has been shown between the exogenous
ingestion of oestrogen and the incidence of ovarian cancer (Kaufman
et al, 1989), re-examination of this area may be warranted with these
new observations because of the role of oestrogens and other steroid
hormones often present in saturated animal fat (Risch et al, 1994), the
role of phytoestrogens acting to inhibit endogenous oestrogen
production, (Adlercreutz et al, 1992; Adlercreutz et al, 1993; Mousavi et
al, 1993) and the role of vegetable fibre in binding oestrogen in the gut
(Rose et al, 1991; Goldin et al, 1994).
During the late 1980's, a case/control study was performed which
showed an association between higher consumption of
Lactose/Galactose (in the form of yoghurt and cottage cheese) and
lower levels of the enzyme galactose-l-phosphate uridyl transferase in
erythrocytes in ovarian cancer cases compared with controls (Cramer
et al, 1989). Deficiency of this enzyme may be a genetic risk factor for
early menopause. Early menopause may be associated with
hypergonadotrophic hypogonadism, and such hormonal perturbation
may be involved in the patho-aetiology of ovarian cancer (Cramer et
al, 1990). This work awaits confirmation by follow-up studies.
1.1.3 Hormonal factors and incessant ovulation
Although no formal evidence exists to suggest that exogenous
oestrogens or other steroid hormones have a role to play in the
initiation of ovarian cancer in humans, there is quite a body of
literature that would suggest that ovarian cancer is hormone sensitive.
The ovary is the main site of synthesis of oestrogen and progesterone
and is also a target organ for these hormones. The actions of these
hormones are mediated by specific intracellular receptors which
function as hormone-inducible nuclear transcription factors with
8
context-specific, often conflicting effects on proliferation and
differentiation of target tissues (O'Malley et al, 1990).
Progesterone receptor (PR), whose gene is located on chromosome
Ilq22-q23 (Rousseau-Merck et al, 1987), is regulated by oestradiol via
the oestrogen receptor (ER) (Horwitz et al, 1978). Oestradiol induced PR
expression has been demonstrated in ovarian cancer cell lines which
express ER (Langdon et al, 1994).
Ovarian cancer has been reported to respond to antioestrogens in about
10-20% of cases, and to progestins with an average of 36%, within a
range between 0% and 60% (Slotman et al, 1988; Bonte et al, 1979).
That histopathological subtypes of epithelial ovarian cancer (EOC)
differ in their tumoural PR expression is suggested by at least 6 reports
that endometrioid ovarian carcinomas contain relatively more PR
than other histological types, (Slotman et al, 1988) and that PR
positivity is associated with well differentiated ovarian tumours in
premenopausal women (Friedman et al, 1979). Tumoural PR content
has prognostic significance in several studies, (Sevelda et al, 1990;
Slotman et al, 1988) but the associations are not unequivocal (Rose et
al, 1990; Masood et al, 1989).
Oestrogen receptors have been measured in ovarian cancer in many
studies; the evidence for an association of tumoral ER content with
prognosis is conflicting (Kieback et al, 1993a; Kieback et al, 1993b;
Masood et al, 1989; Sevelda et al, 1990 ).
Although exogenous oestrogens do not appear to be associated with
the development of human ovarian carcinoma (despite evidence that
chronic oestrogen and progestin administration in animal studies
results in ovarian cancer (Gardner et al, 1958; Jabara et al, 1962),
hormonal perturbations with consequent effects on ovulation appear
to profoundly affect the development of ovarian cancer, as predicted by
the hypothesis of "Incessant ovulation". To this extent, the aetiology of
ovarian cancer may furthermore be considered to be endocrine related.
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In 1971, Fathalla proposed that "Incessant ovulation" results in
repeated proliferative repair cycles of damaged ovarian surface
epithelium (Fathalla, 1971). These epithelial cells can acquire genetic
damage during proliferative repair, and this cumulative genetic
damage due to repeated ovulatory cycles predisposes to the
development of ovarian cancer. This hypothesis is perfectly
understandable if one considers that in a panmyctic natural state a
female might only ovulate 20-40 times in her life due to recurrent
childbearing, whereas in late twentieth-century economically-
developed societies, this figure may be an order of magnitude higher.
Thus any factor which reduces the number of times a woman ovulates
(late menarche, oral contraceptive use, multigravidity, prolonged
lactation, early menopause) can be predicted to reduce ovarian cancer
risk.
Nulliparity and a low mean number of pregnancies have been
associated with increased risk (Cramer et al, 1983). Conversely,
childbirth confers a protective effect, and the magnitude of this
protective effect relates to parity with an estimated 30-60% reduction in
risk for those women with 2 or more pregnancies.
Increased total pregnancy and lactation time also confer a protective
effect (Weiss et al, 1981).
Ovarian cancer risk is decreased 30-60% by the use of oral
contraceptives; in one study, ingestion of oral contraceptive over a 5
year period was associated with 37% reduction in ovarian cancer risk;
this effect was observed to persist for several years after cessation of the
oral contraceptive (Cramer et al, 1982b). Therefore the hypothesis is
consistent with the idea that by reducing the number of ovulations
and their associated damage-repair cycles the risk of ovarian cancer is
lowered.
The high gonadotrophic milieu of the post-menopausal state may
confer additional risk (Cramer et al, 1983)
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Fertility drugs (exogenous gonadotrophins and stimulants of pituitary
gonadotrophins which act by ovarian hyperstimulation) have been
suggested to confer increased risk (as might be expected from the
Fathalla hypothesis); however the evidence is not unequivocal. A
small cohort study showed no apparent increase in risk of ovarian
cancer, although there was an increase in endometrial cancer (Ron et
al, 1987). A subsequent review of 12 American case/control studies
suggested a threefold increase risk of ovarian cancer in women who
had used fertility drugs (Whittemore et al, 1992; Whittemore et al,
1993). However, it has been pointed out that this was a small study
with wide confidence intervals; in addition, controls lacked a history of
infertility, and this presents a problem as nulliparous women are
intrinsically at increased ovarian cancer risk (Spirtas et al, 1993).
Recently, another case/control study in nearly 4000 women reported
that women treated with infertility drugs had a 2.5 times increased risk
of ovarian cancer compared to the general population (Rossing et al,
1994). Women undergoing fertility treatment therefore need to know
that they may be at increased risk of ovarian cancer, although this
information requires careful presentation management given its
equivocacy.
1.2 Epithelial ovarian cancer: biology and pathophysiology
1.2.1 Developmental histogenesis
The bewildering array of different neoplasms arising from the ovary
can be understood if one considers the embryological development of
the female reproductive system, the range of epithelial tissue types that
it generates, and the physiology of the ovary (Langman, 1975).
As early as the fourth week after fertilisation, the developing gonads
commence as the genital ridge in the embryo by a proliferation of
coelomic epithelium (a cell layer of mesodermal origin which goes on
to form the peritoneal epithelial lining). Primordial germ cells appear
at week six and migrate from the wall of the yolk sac to the genital
ridge.
11
As the germ cells invade the genital ridge, the overlying coelomic
epithelium proliferates and invades the underlying mesenchyme
where it forms intimate relationships, surrounding the germ cells in
structures called sex-cords. As the ovary develops the sex-cords form
irregular clusters and the central part of the ovary loses the cords.
These are replaced by vascular stroma and become the ovarian
medulla. The cords proliferate in the cortical region and form oogonia
while the surrounding epithelial cells form the enveloping follicular
cells.
The mesonephric (Wolffian) duct that goes on to connect the gonads to
the urethra in the adult male has no way of connecting with the
developing ovarian cortex, and so germ cells in the adult female must
be shed from the ovarian epithelium rather than transported in the
same way as spermatozoa. At week six, a second duct forms from the
coelomic epithelium dorsal to the Wolffian(mesonephric) duct. This is
the Miillerian (paramesonephric) duct which at the cranial end opens
into the coelomic cavity (forming the future fallopian tubes), and at
the caudal end fuses with the contralateral Miillerian duct to form the
uterine canal. In the female, the Miillerian duct continues to develop
into the main genital duct while the Wolffian duct atrophies almost
completely. As the ovary develops and migrates caudally, so the
Mullerian duct goes on to form the fallopian tubes, the uterine body
and the uterine cervix, each with distinctive lining epithelia.
Although in continuity with these structures, the vagina develops
separately, arising from the urogenital sinus located caudally.
Common epithelial tumours of the ovary (including epithelial
ovarian cancer) therefore arise from the ovarian surface epithelium
(derived from the primitive coelomic mesothelium), and exhibit a
range of histological structures which have appearances similar to
other Mullerian derived structures; i.e. serous differentiation (similar
to fallopian tube epithelium), endometrioid differentiation (uterine
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body endometrium) and mucinous differentiation (endocervical
epithelium).
Structures within the ovary not derived from this epithelium produce
much rarer tumour types. The mesoderm underlying the primitive
coelomic mesothelium generates theca, granulosa, Leydig and Sertoli
cells, and all these cell types can give rise to tumours. The primordial
germ cells go on to form oocytes and from these can arise a range of
germ cells tumours. Dysgerminoma, teratoma (often mature, benign
and of parthenogenetic origin in females) and embryonal carcinoma
may occur. They will not be discussed further here (see figure 1.1).




























1.2.2 Pathology Of The Common Epithelial Tumours
Epithelial ovarian carcinomas represent over 90% of all ovarian
malignant neoplasms. Epithelial neoplasms of the ovary comprise
benign tumours, borderline tumours (tumours with low malignant
potential), and frank epithelial carcinoma. These three categories of
neoplasm usually exhibit Miillerian histogenic differentiation as
described above.
1.2.2.1 Benign tumours
These tumours have an excellent prognosis. The essential cytological
features of benign tumours are a single layer of columnar cells, lack of
cellular atypia, a normal nucleocytoplasmic ratio, few mitoses, and no
evidence of either microinvasion or frank invasion into the
underlying stroma. Benign tumours usually exhibit either serous or
mucinous differentiation. These tumours are usually cystic and can
grow to enormous size.
Half of all serous tumours are benign serous cystadenomas. They are
sometimes bilateral, and generally unilocular with a few intracystic
papillae which may be either pedunculated with fronds or sessile. The
fluid within the cyst is watery (serous). The serous epithelium is well
differentiated, and forms a regular single layer of cuboidal cells with
centrally placed nuclei lying on loose stroma.
Mucinous cystadenomas constitute 80% of all mucinous tumours.
These benign tumours are almost always unilateral. The cysts are
multilocular containing a gelatinous mucinous secretion. The
epithelium consists of tall columnar epithelial cells with basal nuclei.
Sometimes this epithelium is similar to endocervical epithelium
consistent with a Miillerian origin, however, more commonly the
epithelium is reminiscent of colonic mucinous glandular epithelium
with the presence of goblet or Paneth cells, suggesting a tumour of
non-Miillerian origin.
Occasionally spillage of mucin-secreting epithelial cell clusters into the
peritoneal cavity can result in pseudomyxoma peritonei, a chronic and
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often ultimately fatal condition with mucinous secretion filling the
peritoneum and causing bowel obstruction without destructive
invasion.
Brenner tumours are usually benign ovarian tumours in which there
are cords of urothelium embedded in a dense stroma. This tumour is
thought to arise from remnants of Wolffian origin (see above), part of
the primitive urothelial system.
Endometrioid and clear cell tumours are rarely benign.
1.2.2.2 Borderline tumours (tumours of low malignant potential,
IMP)
These tumours have a good prognosis generally. Borderline tumours
are characterised histologically by the presence of pseudostratification
of the cells forming the tumour's epithelial lining on a fibrovascular
underlying stroma. Nuclear and cellular atypia, increased mitotic
activity and detachment and reimplantation of neoplastic cell clusters
are all features. However, the pathological diagnosis also requires the
absence of neoplastic cell invasion of the underlying stroma. This last
feature differentiates borderline tumours from malignant invasive
tumours.
Serous LMP tumours, the commonest histological type of borderline
tumour, in addition to the above, may also contain psammoma bodies
(histological structures which confer a favourable prognosis on serous
tumours), and may be multicentric (the clonality of which is currently
unclear).
Mucinous LMP tumours are less common than serous LMPs and may
be difficult to distinguish from malignant tumours. Again, the
majority show intestinal rather than Miillerian differentiation, and
pseudomyxoma peritonei may be a complication.
Endometrioid LMPs constitute a fifth of all endometrioid tumours and
may be associated with endometriosis (as can clear cell LMPs).
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1.2.2.3 Malignant tumours (epithelial ovarian cancer)
Frank ovarian adenocarcinomas carry an extremely poor prognosis if
disseminated from the primary site (which they do in the majority of
cases). The primary tumours often contain solid regions of malignant
tissue which can grow rapidly and often exhibit haemorrhagic and
necrotic regions. The tumour tends to invade destructively and may
breach the ovarian capsule, inducing adhesions locally and spreading
into the peritoneal cavity.
The histological hallmarks of malignant tissue are the same as for
borderline tumours, with cellular atypia, a high nucleocytoplasmic
ratio, and frequent mitoses. There is, however, destructive invasion of
the underlying stroma by the malignant adenocarcinoma cells. As part
of histopathological diagnosis, an attempt at estimating the degree of
differentiation of ovarian adenocarcinomas should be made (Baak et
al, 1987). Well differentiated carcinomas demonstrate little cellular
atypia and relatively few mitoses ( grade 1). Moderately differentiated
carcinomas exhibit retention of the histological differentiation but
there is increasing cellular atypia and more frequent mitoses (grade 2).
Poorly differentiated carcinomas are more aggressive still, with
abundant mitoses and sheets of poorly or undifferentiated cells with
often very few features providing clues to the histological category
(grade 3). Tumours can entirely lose their histogenic features leaving
an undifferentiated adenocarcinoma, which is rapidly growing and
behaves aggressively.
One third of all serous tumours are malignant, and serous
adenocarcinomas account for just under half of all epithelial ovarian
cancers (EOCs). They are frequently bilateral and are often cystic with
solid regions within.
Endometrioid tumours are usually malignant, they account for about
15% of all EOCs. They are usually less cystic than serous and mucinous
adenocarcinomas. In a quarter of cases endometrioid adenocarcinomas
may co-exist with endometrial carcinoma, and have identical
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histology. They can also co-exist with, or arise on, a previous site of
endometriosis (Heaps et al, 1990)
Mucinous adenocarcinomas account for only one fifth of all mucinous
tumours, and represent only about 12% of EOCs. They are frequently
cystic and multilocular, may be bilateral, and are often well
differentiated when recognised.
Clear cell carcinomas are uncommon (6% of EOCs) and so-called
because of the appearance of the cytoplasm after removal of the
abundant cytoplasmic glycogen during the specimen preparation
process. Like endometrioid carcinoma, they may co-exist with
endometriosis.
Undifferentiated EOCs account for about 17% of the total, and tend to
behave in an aggressive fashion.
1.2.3 The early histological lesion and relationships between benign,
borderline and malignant disease.
The FIGO staging system (FIGO Cancer Committee, 1986) (Table 1.1)
and the anatomical view of epithelial tumour spread suggests an
orderly progression from normal cell through benign tumour to early
malignant tumour followed by the breaching of an underlying serosal
layer with vascular and lymphatic tumour dissemination, and finally,
metastases. However, although such a pathological multistep model
may be valid for colorectal cancer (Vogelstein and Kinzler, 1993), the
evidence does not favour this for ovarian cancer.
Relatively little work has been done on the features and the nature of
the earliest histological lesion in ovarian cancer. In patients who had
oophorectomy where ovarian carcinoma was not recognised
preoperatively, and who were found to have de novo ovarian
carcinoma (i.e. without atypical lesions) on review, tumours were
small, ranging from microscopic foci to 7 mm diameter. The tumours
were all unilateral, and some were multifocal. They arose from the
surface epithelium or from the crypts/inclusion bodies associated. The
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non-carcinomatous surface epithelium and inclusion bodies exhibited
"severe atypia" in a fifth of cases, suggesting a preneoplastic lesion.
Several women went on to develop peritoneal carcinomatosis,
suggesting stage III disease essentially from the outset, with fatal
outcome. A significant proportion had normal serum CA125 levels
(see below) and their tumours would not have been detected
radiologically. It is therefore clear that some ovarian cancer are capable
of progressing from microscopic ovarian malignant disease straight to
potentially fatal stage III disease with no prospect of screening related
intervention (Bell et al, 1994).
The presence of multifocality, atypia and inclusion cysts in these very
early malignant lesions suggests the possibility of field changes
affecting the ovarian epithelium. A case/control study examining in
detail the contralateral ovaries from patients with unilateral ovarian
carcinoma compared to age-matched controls showed a significantly
higher number of inclusion cysts in the unaffected ovaries of ovarian
cancer patients with frequent evidence of serous metaplasia within
these inclusion cysts. In the ovarian cancer patient group, an age
related increase in the number of inclusion cysts was seen, which was
not observed in the control group (Mittal et al, 1993). These features
suggest an histologically abbreviated route to malignant ovarian
cancer.
Over 90% of specimens of mucinous epithelial ovarian cancer contain
surrounding benign neoplastic epithelium. In a quarter of cases one
can observe a region of transition from benign to malignant tissue
(Puis et al, 1992). Such benign epithelia are seen frequently in
mucinous carcinomas but relatively infrequently in serous
carcinomas, with a suggestion therefore that serous carcinomas may
arise de novo more frequently than mucinous carcinomas. A recent
analysis (Zheng et al, 1995) demonstrated that approximately 50% of
ovarian cystadenocarcinomas contained p53 mutations, whereas there
was no evidence of p53 mutation in 37 benign and borderline
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epithelial tumours. They next identified malignant tumours with
contiguous regions of apparently benign neoplasia and demonstrated
that benign looking regions contained the same mutations in p53 as
were present in the adjacent malignant regions. These findings suggest
that benign neoplasia in the context of cystadenocarcinoma represents
a genetically and biologically distinct entity from the solitary benign
cystadenoma, and that at a molecular level it is clonally contiguous
with the adjacent malignant tumour. Whether these benign regions
represent precursors that progress to frank adenocarcinoma or are
products of a differentiating effect such as that seen in teratoma is
unclear and hinges on further analysis of these regions to demonstrate
whether or not they share the full complement of genetic
abnormalities found in the adjacent adenocarcinoma. It is of interest
that first and second degree relatives of ovarian cancer patients have
five times the incidence of benign tumours compared to those without
a family history (Bourne et al, 1991).
Endometriosis may well be a premalignant condition. It co-exists with
endometrioid cancer in nearly a third of cases; and with clear cell
carcinoma in a half of cases, and there are documented cases of
endometriosis progressing to epithelial ovarian cancer in some
patients taking exogenous oestrogens (Heaps et al, 1990).
In contrast, true serous borderline tumours ( i.e. without evidence of
invasion) undergo malignant transformation in only 0.7% of cases
(Kurman et al, 1993), suggesting that the pathways to LMP tumours do
not form part of the multistep pathway from normal surface
epithelium to epithelial ovarian cancer.
These phenotypic lesions do not preclude molecular lesions in
phenotypically normal ovarian surface epithelium, and there is
evidence that mutant or over-expressed normal p53 is detectable in
apparently normal epithelia adjacent to ovarian neoplastic tissue
suggesting the possibility of phenotypically normal precursor lesions.
To what extent this represents a molecular field change is unknown.
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1.3 Epithelial Ovarian Cancer: Clinical Management and Prevention
1.3.1 Prognostic Factors
Many features of ovarian cancer; surgical, pathological and biological
may be associated with survival. It is of importance whether these so-
called prognostic factors are truly independent in themselves or simply
reflect associations with other prognostic factors. Multivariate
statistical methods have been used to answer this question. Such
analyses suggest that there are general independent prognostic factors
such as younger patient age and good performance status.
Lower FIGO stages (see below), well differentiated tumours (lower
tumour grade), low residual tumour volume, and low pre-operative
tumour volume are also favourable independent prognostic factors
(de-Souza et al, 1992). Serum CA125 (see below) measured three
months after the start of chemotherapy correlated well with survival
of patients (Sevelda et al, 1989).
Patients with clear cell histology have worse prognosis, specifically in
early stage disease (Guthrie et al, 1984; O'Brien et al, 1993).
Flow cytometric analysis of tumoral DNA content can indicate the
presence of aneuploid tumour populations and is a significant adverse
independent prognostic factor (Friedlander et al, 1984; Friedlander et al,
1988).
However, it is not enough to simply derive prognostic indices from
multivariate analysis, these factors must then be applied in prospective
studies to test their usefulness in practice.
The use of molecular biological analysis will hopefully yield tumoral
markers which have prognostic utility. Tumoural oestrogen and
progesterone receptor content, erb-b2 (HER2/neu) and epidermal
growth factor receptor levels are promising candidates. The data
examining the role and independence of p53 abnormality as a
prognostic factor in ovarian cancer is conflicting, with some
investigations showing no association with p53 abnormalities (Kohler
et al, 1993; Niwa et al, 1994; Sheridan et al, 1994; Frank et al, 1994); and
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others showing that p53 status functions as an independent prognostic
factor (Henriksen et al, 1994; Klemi et al, 1994; Levesque et al, 1995;
Vanderzee et al, 1995). P53 mutation is reported to be significantly
associated with serous histology (Eccles et al, 1992; Niwa et al, 1994).
Recent data suggests that those ovarian cancers which have a normal
p53 gene by sequence analysis are more likely to respond to
chemotherapy than those with p53 mutation (Al-Azraqi et al, 1995).
The use of some of these markers in combination (PR, DNA ploidy, S-
phase fraction and Ki67, a marker of cell cycling) has been shown to
have similar (though prognostically independent) power to FIGO stage
in correlation with progression free interval and overall survival of
ovarian cancer patients (Kaufmann et al, 1995).
1.3.2 Staging And Primary Surgical Treatment
The most powerful determinant of prognosis for epithelial ovarian
cancer is the extent to which the malignant tumour has disseminated
from its primary site at the time of diagnosis. In order to stage the
patient adequately, thorough surgical evaluation by exploratory
laparotomy needs to be undertaken. Removal of all tumour within the
pelvis and peritoneal cavity offers the patient the best chance of
ultimate control of their disease. Thus definitive surgery is employed
with abdominal exploration in a procedure that constitutes primary
treatment as well as indicating the patient's prognosis.
This rigorous approach to surgical evaluation has resulted in the
widespread adoption of the FIGO staging system (FIGO Cancer
Committee, 1986) for ovarian cancer, where ascending stage correlates
with worsening prognosis (Table 1.1). Accurate staging of the patient is
crucial as it determines subsequent therapy, which will contribute to
outcome.
If there is obvious evidence of tumour spread, debulking of residual
tumour masses (up to a maximum diameter of 10 cm) to under 2 cm
maximum diameter should be undertaken as there is evidence that
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this results in better response and survival with subsequent chemo- or
radio- therapy.
Table 1.1 The FIGO staging classification
Stage Description
Stage I Growth limited to ovary
la One ovary involved, no ascites, capsule intact, no tumour
on the external surface
lb Both ovaries involved, no ascites, capsule intact, no
tumour on the external surface
Ic tumour on ovarian surface, rupture of capsule, malignant
ascites present/positive peritoneal washings
Stage II Growth limited to the pelvis
Ha Extension to gynaecological adnexae; uterus/fallopian
tubes
nb Extension to other pelvic tissues
He Stage Ha or lib with tumour on the surface of both ovaries,
rupture of the capsule, malignant ascites, or positive
peritoneal washings
Stage III Growth extending to peritoneal cavity- including
peritoneal surface seedlings, omentum, or serosal surfaces
of viscerae
Ula Grossly limited to the true pelviswith negative lymph
nodes, but microscopic seedling of the abdominal
peritoneal surface
fflb Tumour involves one or both ovaries with histologically
proven implants of the abdominal peritoneal surfaces,
none > 2cm
nic Abdominal implants >2cm diameter and/or positive
retroperitoneal lymph nodes
Stage IV Metastases to distant sites; pleural effusions must be
cytologically positive
1.3.3 Chemotherapy
Patients who do not have early-stage ovarian cancer with good
prognostic features (Stage Ic, Stage I with moderately/ poorly
differentiated carcinoma, Stage II-IV disease, and clear cell carcinoma
irrespective of stage) should receive chemotherapy as first-line
adjuvant therapy. "Advanced disease" can be considered according to
the consequences of laparotomy: whether or not debulking was
optimal. "Optimal" or "small volume disease" in a European context
is defined as maximum residual diameter 2 cm after surgery. Above
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these diameters patients are regarded as having "sub-optimally
debulked" or "large volume" disease.
1.3.3.1 Platinum analogues
Standard chemotherapy generally consists of platinum containing
regimens, usually with an alkylating agent.
The best results suggest that using multimodality therapy, the five year
survival of advanced (stage III-IV) epithelial ovarian cancer can be
improved from approximately 12% to approximately 30%.
Platinum analogues (e.g., cis-diamino-dichloro-platinum, CDDP)
function as cytotoxic drugs by binding to amino or hydroxyl groups of
nucleoside bases and forming DNA intra-strand and inter-strand
crosslinks. This DNA crosslinking results in interference with
replication/repair mechanisms.
In those with small volume disease, a significant survival advantage
was seen for the use of platinum (Neijt et al, 1994).
Abrogation of platinum drug resistance in vitro has been observed
when tamoxifen is added concurrently. The mechanism underlying
this observation is obscure, and is under intensive investigation
(McClay et al, 1992; Nakata et al, 1995). However, clinical studies do not
support the use of a platinum/tamoxifen at the moment (Schwartz et
al, 1989).
The combination of platinum with interferon based on in-vitro
evidence for synergy between platinum and interferon in ovarian
cancer (Nehme et al, 1994) to improve response rates has produced
only modest clinical benefit (Markman et al, 1992; Ferrari et al, 1994).
Results from a randomised study attempting to reduce the toxicity of
cis-platinum using glutathione (an intracellular free radical scavenger)
suggest that more full dose cycles can be given on time with significant
reduction in nephrotoxicity. The incidence of nausea, vomiting and
neuropathy were significantly reduced in the glutathione group. The
response rate was not reduced, suggesting that glutathione improved
the therapeutic index of cis-platinum (Smyth et al, 1995).
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1.3.3.2 Taxanes
Taxanes are natural (taxol) and semi-synthetic (taxotere) diterpenoids.
Taxol (Paclitaxel) was discovered in 1971 when it was isolated from the
bark of the western yew tree (Taxus brevifolia). Taxoids induce tubulin
polymerisation, and also prevent the depolymerisation of
microtubules resulting in stable, non-functional microtubules
disrupting cellular organisation and producing effective mitotic arrest.
The American gynecologic oncology group (GOG protocol 111) have
recently reported mature data from a randomised study of sub-
optimally debulked ovarian cancer patients, comparing standard first
line chemotherapy (cyclophosphamide/cis-platinum, CP) with taxol
/cis-platinum (TP). Both the complete and partial response rates were
significantly increased in the taxol/platinum arm. Median survival
was increased from 2 years (cyclophosphamide/cis-platinum) to 3 years
for the taxol/platinum arm (McGuire et al, 1995). The impact of this
study has been to impose platinum/taxol as the gold standard in
adjuvant chemotherapeutic treatment of ovarian cancer.
1.3.3.3 Drug resistance
It is generally accepted that chemotherapy fails to eradicate cancer due
to a combination of intrinsic and acquired drug resistance.
Physiological host factors may alter drug disposition within the body
resulting in a reduction of the amount of active drug getting to the
tumour (reduced activation, enhanced excretion and breakdown), but
resistance is determined more by tumour cellular factors. In terms of
ontogeny, tumour cells represent extremely old human cells (having
ceaselessly divided over a long period of time), and have acquired
many genetic lesions that allow them to escape normal growth
regulation. They can evoke mechanisms to circumvent attempts to
control their growth. One manifestation of this survival pathway
redundancy is drug resistance.
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Tumour cells may limit drug accumulation by influx pump inhibition
or by efflux pump augmentation(multi-drug resistance, p-
glycoprotein).
Intracellular inactivators of drugs may be upregulated by tumour cells.
Such inactivators include scavenger antioxidants such as glutathione
for example, which binds intracellular platinum among other drugs
and may prevent DNA adduct formation.
Damage to genes which maintain the stability and integrity of the
genome allow the cells to deregulate their tight control over the
genome with rapid and often bizarre changes mediated by selective
pressure from a hostile environment. p53 abnormality and mutation
of mismatch repair genes resulting in the 'promutator phenotype'
may contribute to a phenotype tolerant to the adverse environment
created by the cytotoxic milieu. This may manifest in the ability to
circumvent apoptosis (programmed cell death) by mutations acquired
in proteins involved in the pro-apoptotic pathway.
Additionally, tumour cells may be able to develop DNA repair
mechanisms that are more efficient than normal, counteracting the
genotoxic effects of cytotoxic chemotherapy, and hence contributing to
resistance to DNA damaging drugs. An overview of DNA repair
mechanisms is beyond the scope of this thesis: many enzymes are
involved in the process of damage recognition, nucleotide excision, re-
synthesis of the damaged region with fidelity, and ligation to re¬
establish the continuity of chromatin.
Drug resistance may also be associated with alteration of the
topoisomerase pathway (either by mutation or altered expression).
This enzyme is involved in cleavage of DNA, passage of a DNA strand
through the cleaved segment and resealing of the DNA. Type I
topoisomerases cleave only one strand; type II cleave both strands.
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1.4 Molecular Genetics of Epithelial Ovarian Cancer
1.4.1 Molecular epidemiology and genetic linkage
1.4.1.1 Molecular epidemiology
The molecular study of genes involved in carcinogenesis has opened
new avenues into epidemiology. It is possible by analysis of genes
thought to be important in the aetiology of a particular tumour type to
make inferences about causation, the relative balance of inherited to
somatic events and whether the somatic events are due to
environmental or spontaneous processes. For instance, p53 is one of
the genes most commonly mutated in cancer. Molecular epidemiology
of the p53 gene in hepatocellular carcinoma where aflatoxin has been
the underlying carcinogen reveals a high frequency of transversions
(mutation where purines are replaced by pyrimidines or vice versa) of
the guanine to thymine (G to T) type at a specific site of the gene's
sequence (codon 249) (Bressac et al, 1991). The presence of
transversions at such sites represent events related to exogenous
carcinogens, whereas transitions (conversion of pyrimidine to
pyrimidine, or purine to purine) are more likely to be due to errors of
fidelity during DNA replication, which may be a spontaneous process.
p53 is frequently mutated in epithelial ovarian cancer; however
similar analysis of the p53 gene in ovarian cancer revealed no such
transversion "hot-spots"; mutation of transition type were
predominant (72% of all mutation events detected) and dispersed
throughout the gene(predominantly exons 5 to 8) (Kohler et al, 1993).
This predominance of transition mutations suggests that the impact of
environmental carcinogens to the development of ovarian cancer may
be minimal. Although this data is generally supported by the
epidemiological evidence available, it is important to remember that
environmental carcinogens may mediate their action on other genes
involved at other stages of ovarian cancer development.
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1.4.1.2 Inherited predisposition: overview
Clearly defined predisposing /hereditary factors account for only about
5% of patients with ovarian cancer, as judged by familial clustering. In
most of these familial cases, the aetiology is probably multifactorial,
consisting of both environmental and genetic elements. Women with
one first degree relative affected run a 5% lifetime ovarian cancer risk
(1 in 20). The risk associated with having 2 or more affected first degree
relatives is 7% (1 in 15).
Those with definable autosomal dominant syndromes run a much
higher risk (40-50%) of developing ovarian cancer, but these
individuals constitute only about 3% of women with two affected first
degree relatives (Narod, 1994).
Three such hereditary syndromes have been defined, and patients with
these tend to be younger(usually 10 or more years less than the
median) and have bilateral and multifocal tumours more commonly.
Major international efforts have been and are in progress to identify
the spectrum of genes involved in these syndromes.
Hereditary site-specific ovarian cancer is rare and in the majority
linked to BRCA1 (Steichen-Gersdorf et al, 1994, a putative tumour
suppressor gene located on chromosome 17q (see "BRCA1" below).
Hereditary breast/ovarian cancer is diagnosed in the presence of
familial clustering of breast and ovarian cancer. Hereditary ovarian
cancer is most likely to occur as part of this syndrome. Again, most of
these are BRCA1 linked (Easton et al, 1993a).
The type II Lynch syndrome incorporates hereditary non-polyposis
colorectal cancer (Lynch syndrome I) with gastrointestinal (gastric,
small intestinal, pancreatic), gynaecological (endometrial and ovarian),
urological or breast cancer (Lynch et al, 1985a; Lynch et al, 1985b; Lynch
and Lynch, 1993). This syndrome is linked to a family of DNA
mismatch repair genes, disruption of which result in "pro-mutator"
effects on the genome, often observed as a high incidence of
microsatellite instability. These genes have been designated hMSH2
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(Fishel et al, 1993), hMLHl (Kolodner et al, 1995), hPMSl and hPMS2
(Nicolaides et al, 1994).
1.4.1.3 BRCA1 and ovarian cancer
The BRCA1 gene is large, extending over 100 Kb of genomic DNA,
with 24 exons. It encodes a protein of 1863 amino acids that is expressed
in many tissues during development, including thymus, breast and
testis (Miki et al, 1994). It has a ring finger domain consistent with
DNA binding and can localise to the nucleus but there is, as yet, no
proof that it acts as a transcription factor. It is strongly expressed in the
epithelial cell layer of the adult ovary but expression appears to be
reduced in malignant cells (Thompson et al, 1995). BRCA1 is expressed
in rapidly proliferating cell types undergoing differentiation, and its
expression is induced in oophorectomised animals after treatment
with 17 beta-oestradiol and progesterone (Marquis et al, 1995). An
inhibitory role for BRCA1 has now been determined in breast and
ovarian cancer cell lines. Transfection of these cell lines with plasmid
expressing wild-type BRCA1 inhibits growth, although this is not the
case for colon or lung cancer cell lines, demonstrating a tissue specific
effect. Though somatic mutation of BRCA1 is evidently rare, loss of
the wild type allele has been found in many studies of ovarian and
other tumours occurring in carriers of a germ-line mutation and, as
noted above, LOH on 17q, including the BRCA 1 locus, is a common
event in ovarian cancer (Takahashi et al, 1995; Cornelis et al, 1995).
BRCA1 therefore has most of the characteristics of a tumour
suppressor gene.
The aggregate mutation frequency of BRCA1 in Western populations
is between 0.03% and 0.1% (Easton et al, 1993). Ashkenazy Jews have a
particular mutation (185 del AG) at a frequency approaching 1%
(Struewing et al, 1995).
Germ line mutations are found at many different positions within
BRCA1. The majority of described mutations are nonsense or frame-
shift, generating a truncated protein. About 25% appear to be
28
regulatory changes, inhibiting transcription of one allele. Overall,
there is about a three-fold greater risk of breast than ovarian cancer
among carriers of BRCA1 mutations but the data suggest that these
relative risks are not uniform in different families (Easton et al, 1993b).
Findings from a British study (Gayther et al, 1995) indicate that
mutations closer to the 5' end of the gene carry a higher risk of ovarian
cancer. Interestingly, although transfection of a 3'BRCAl mutant
(1835stop) does not inhibit the growth of breast cancer, it still does
inhibit the growth of ovarian cancer cells (Holt et al, 1996).
Furthermore, this 3' mutation appears to to map to BRCAl's putative
granin consensus sequence (Jensen et al, 1996), and this suggests a
mechanism for mutational differences involved in tumours of
different tissue origins.
Other explanations for non-uniform distribution of breast and ovarian
cancer risks in BRCA1 families include the use of exogenous
hormones. Prolonged use of the combined oral contraceptive "pill"
has been shown to reduce the risk of ovarian cancer (Parazzini et al,
1991) (see above). Co-inheritance of modifying genes may influence the
"BRCA1 phenotype". The presence of rare alleles at the HRAS1 VNTR
locus (1 Kb downstream of the HRAS1 proto-oncogene) conferred a 2.1
fold increased risk for ovarian cancer in BRCA-1 carriers compared
with BRCA1 carriers harbouring common alleles only. Susceptibility to
breast cancer was not altered by the presence of the rare alleles in
BRCA1 carriers and so the allele appears to specifically modify the
ovarian cancer risk in this inherited syndrome (Phelan et al, 1996).
The lifetime risk of ovarian cancer in a carrier of a BRCA1 mutation is
estimated at between 20 and 80% (Easton et al, 1993). The tumours
rarely present under age 35 and though, in most studies, the age of
onset of the disease has tended to be younger than for sporadic cases,
there is some disagreement as to the value of age of onset as a marker
for genetic predisposition; Screening is available for high risk
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individuals but its value is unproven. (see "prospects for prevention"
above)
1.4.1.4 BRCA2 and ovarian cancer
It appears that a significant proportion of inherited breast cancer may
be attributable to a susceptibility gene located on chromosome 13ql2-
ql3 which has been called BRCA2 (Wooster et al, 1994). The initial
impression is that it does not confer substantial increase in the risk of
ovarian cancer, however, 13q LOH in the presence of normally
expressed Rb-1 product suggests that it may have some role in ovarian
cancer. The gene was cloned late in 1995 (Wooster et al, 1995) and
consists of an 11-12 kb messenger RNA encoded by a 27 - exon gene
spanning 70 kB of DNA. It encodes a 3418 aa protein of about 350 kd.
The gene has no obvious strong homologies; the mouse and human
genes share only about 55-60% homology. However, it contains 8
copies of a highly conserved repeat element dispersed throughout the
gene, whose function is as yet unclear. Over 50 mutations have been
described in BRCA2, nearly all of which are frame-shift or nonsense,
and no mutational hotspots have been identified (Couch et al, 1996;
Neuhausen et al, 1996; Phelan et al, 1996; Wooster et al, 1995). In one of
these reports, only 2 of 17 non-BRCAl-linked breast/ovarian cancer
families contained a BRCA2 mutation (Couch et al, 1996). These
findings suggest that perhaps a greater than previously accounted for
proportion of inherited ovarian cancer may be linked to a third
susceptibility locus.
It seems likely that the absolute lifetime risk of ovarian (as distinct
from breast) cancer will be considerably lower than for BRCA1
mutation carriers but it may well be high enough to raise questions of
screening and/or preventive surgery (Ford and Easton, 1995).
1.4.1.5 Other recessive genes in ovarian cancer
Similarly, over the next few years our understanding of the clinical
consequences of RER gene mutations is bound to grow and it may
emerge that for some individuals, perhaps depending on the precise
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mutation present or the details of the family history - or both - specific
action will be appropriate in relation to the ovarian cancer risk.
The possibility of a separate ovarian cancer gene, distinct from those
mentioned above, responsible for some familial cases has not been
formally ruled out but epidemiological studies indicate that if it exists
at all, it cannot account for more than a small proportion of cases.
Relatively common lower penetrance gene aberrations (notably of
ATM, mutations in which cause Ataxia Telangiectasia in the
homozygous state) (Savitsky et al, 1995) have been invoked to explain
a significant proportion of breast and some other cancers. However,
there is no evidence at present to suggest that they are important in
ovarian cancer.
1.4.2 Structural Genetic Alterations in Ovarian Cancer
1.4.2.1 Cytogenetics
As would be expected from a disorder caused by lesions to the somatic
genome, gross chromosomal abnormalities are evident in ovarian
cancer. The methodological simplification associated with using
malignant cells from ascites specimens for cytogenetic analysis have
generally skewed the data towards more advanced ovarian
malignancies, with evidence of the bizarre end-products of extreme
genomic instability. A problem associated with this approach is how to
ascribe causality (via genetic lesions underlying the chromosomal
aberrations) to the observed cytogenetic lesion, and one can try to
describe frequent non-random rearrangements such as those described
for haematological tumours. Often, however, the complexity of the
rearrangements precludes such definitive comment and therefore one
has to use molecular genetics, using both structural and functional
studies to attempt to answer this question.
Among those cytogenetic lesions that are frequently reported are those
involving chromosomes 1,3,6,9,11,12,17,19 and X (Jenkins et al, 1993;
Bello et al, 1990; Pejovic et al, 1992).
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In ovarian cancer, cytogenetic analysis has demonstrated partial
deletions of chromosome 11 affecting both long and short arms
(Jenkins et al, 1993; Bello et al, 1990; Pejovic et al, 1992).
In-situ hybridisation methods provide refinement to the cytogenetic
data. Iwabuchi and colleagues (Iwabuchi et al, 1995) utilised
comparative genomic hybridisation (CGH) in a series of 56 ovarian
tumours including 44 ovarian cancers. Copy number abnormalities
were more frequent in high grade cancers and not present in any of the
benign tumours. In only 31% of cases overall was there concordance
between LOH for a chromosome arm and physical deletion as judged
by CGH. This finding is highly instructive in demonstrating that
flanking regions which do not show LOH must contribute to the
discrepancy between published LOH and CGH analyses of the same
regions and demonstrates that concordance occurs mainly where
contiguous LOH is long enough to approach the limits of resolution
defined by CGH. Of the most frequent 18 copy number abnormalities
detected, 13 were instances of increased copy number. The 6 most
frequent observable CGH reductions of copy number were 17 pter-q21 (
46%; containing p53), 16q (38%), 8p21-p23 (27%), Xp (27%) and whole 19
(27%).
1.4.2.2 Loss ofHeterozygosity
Molecular analysis of sporadic ovarian cancer has absorbed a large
research effort over the last 10 years. A genome mapping approach
using polymorphic DNA probes has been used to identify regions of
possible deletion (often based on prior cytogenetic evidence of specific
frequent chromosomal disruption). This approach is based on the
hypothesis proposed by Knudson (Knudson, 1971) extrapolated from
classical genetics observations in hereditary retinoblastoma. Knudson
studied 48 cases of retinoblastoma and observed 3 familial cases with
multifocal disease and earlier ages of onset. This data when analysed
produced empirical data which were consistent with the hypothesis
that two mutational events were required for either familial or
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sporadic retinoblastoma. Later, these hits were postulated to be
associated with loss of function which in turn uncovered the
neoplastic state. This "two-hit" hypothesis has become a paradigm for
the characterisation of tumour suppressor genes, and such "allele loss"
studies presume that one "hit" is due to a deletion involving one
allele, the other hit being a more subtle event such as a point
mutation. As mentioned, this concept can be extended to anonymous
polymorphic loci in the vicinity of observed frequent non-random
sites of cytogenetic disruption as a way of identifying potential sites of
tumour-suppressor genes by loss of heterozygosity (LOH) in tumour
DNA as compared with constitutive genetic material.
LOH does not provide direct proof of a tumour suppressor gene.
However, specific chromosomal regions demonstrating very high
levels of LOH flanked by regions of much lower loss provide attractive
candidate regions for a positional cloning approach.
Many ambiguities and difficulties exist in the interpretation of LOH
data. This is reflected in the sometimes strikingly discordant results
published by different groups examining the same chromosomal
regions. Firstly, published studies often contain small numbers of
tumours. Even in larger studies bias may still be introduced by
unrepresentative populations of early or advanced stage, low or high
grade, and altered proportions of histological type tumours.
Furthermore, surgical procedures may not be standardised from centre
to centre e.g., a tumour labelled as 'early' may in fact be advanced due
to inadequate surgical sampling.
Secondly, technical considerations may create problems. The extent to
which tumour is dissected free of contaminating normal tissue is
important since increasing amounts of normal contamination will
reduce the observed allele imbalance and thus reduce the final LOH
rate at a particular locus. The cut-off value for meaningful allele
imbalance varies between studies from 30% to 50% reduction in
intensity comparing the ratio in normal tissue with the ratio of alleles
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in tumour tissue. Clearly this will have an impact on the reported
LOH rate. Furthermore, the frequency of LOH required at any locus in
order to ascribe significance to the locus is not defined. Some workers
have suggested that LOFf occurring above a baseline level of 35%
represents potentially causative alterations, and frequencies below this
represent secondary phenomena (background noise) associated with
generalised genomic instability (Cliby et al, 1993), but these cut-offs are
arbitrary and vary widely.
Thirdly, variation in reported LOFI rates on chromosome arms may be
due to the informativeness and density of the polymorphic markers
used. There is increasing evidence that LOFI may be restricted to
narrow sub-chromosomal regions, and thus a single polymorphic
marker per chromosome arm such as employed in many allelotype
studies may yield unrepresentative information.
The finding of statistical associations with clinicopathological features
may suggest possible functions of such regions (Eccles et al, 1992). One
major drawback of this type of analysis is that many random allele
losses may occur in advanced sporadic tumours which may have no
causal relationship with the neoplastic process, but merely represent
consequences of primary genome instability associated with cancer.
1.4.2.3 Loss of heterozygosity in ovarian cancer
To date, there have been over 53 LOH studies looking at epithelial
ovarian cancer and assessing allele loss at loci of every chromosome
arm. These studies are summarised as a table of chromosomal arms
exhibiting significant LOH (>35%) in ovarian cancer (Table 1.2),
representing 1996 updates of a review written in early 1994 (Shelling et
al, 1995). This table does not take into account the data generated in
this thesis.
Although the term LOH is used interchangeably with allele imbalance
in this work, it must be borne in mind that imbalance can also be a
consequence of allele specific amplification and need not necessarily
imply deletion of a region of DNA. Furthermore, amplification of a
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region of DNA is not mutually exclusive with loss of function at a
tumour suppressor locus; loss of a chromosome or subchromosomal
region may occur with reduplication of the other allele/chromosome,
and amplification of a region of DNA is not necessarily associated with
gain of function if accompanying inactivating mutations are involved.
Table 1.2 LOH rates of chromosome arms in epithelial ovarian cancer















An example of the curious relationships between LOH and gene
mutation is found for BRCA 1, the recently cloned familial
ovarian/breast cancer gene. This was initially expected to exhibit
profound effects in the sporadic counterparts of the disease. It came as
some surprise therefore when it was reported that in an apparently
sporadic series of 12 ovarian and 32 breast cancers with LOH found
using tightly linked and intra-genic microsatellites, only four had
mutations of the gene, and in these four, the mutations were found in
the germline - suggesting previously undetected familial cases (Futreal
et al, 1994). Subsequently a further report (Merajver et al, 1995)
demonstrated that of 47 ovarian cancers with LOH at one or both of
two polymorphic CA repeat microsatellites intra-genic to the BRCA 1
gene, 4 exhibited evidence of somatic mutation by single strand
conformational polymorphism analysis (SSCP). However, this still
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leaves 90% of the tumours with LOH with no obvious BRCA 1
mutation. It may be that all these LOH examples will ultimately be
accounted for by more thorough analysis of the BRCA 1 region
including flanking regulatory regions. Alternatively this discrepancy
points to a second gene involved in sporadic cancers of ovary and
breast in this region.
Since only a few loci have been studied on each chromosomal arm,
further analysis is bound to yield more regions of LOH which have not
been delineated thus far, and many chromosomal arms will be subject
to interstitial loss rather than whole arm or whole chromosome loss
which are particularly common for chromosome 17 in ovarian cancer
(Foulkes et al, 1993; Tavassoli et al, 1993), and likely to be related to the
presence of the p53 gene on this chromosome.
1.4.3 Molecular pathology of ovarian cancer
Ovarian cancer LOH studies have identified frequent losses on
chromosomes containing identified tumour suppressor genes such as
p53 on chromosome 17p, RBI and BRCA2 on chromosome 13q,
BRCA1 on 17 q21 and DCC on chromosome 18q. Only p53 has
demonstrated frequent somatic mutation consistent with the LOH
findings. For other chromosomes, the rate of detectable somatic
mutation is discordantly low compared with the observed high rate of
LOH. This suggests either that these are not the involved suppressor
genes, or that there is a preferentially high rate of functional mutation
which involves non-coding (e.g. regulatory regions), or that LOH
analysis reflects non-significant random "downstream ripples"
associated with generalised genomic instability rather than reflecting
dysfunction of a "prime-mover" (a TSG). This underpins the need for
LOH studies to be supported by functional studies to confirm the
relevance of these changes.
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1.4.3.1 p53 in ovarian cancer
p53, a multifunctional protein involved in cell-cycle control and
genome stability is one of the most commonly altered proteins in
cancer(Reviewed in Carson and Lois, 1995; Elledge and Lee, 1995;
Haffner and Oren, 1995).
The p53 gene is composed of 11 exons, the first of which is non-coding
and localised 8 to 10 Kb upstream of exons 2 through 11 on the short
arm of human chromosome 17 . There are five conserved domains
within the the coding regions of the gene which contain 80% - 90% of
described functional p53 mutations. p53 structure is not similar to any
other known DNA binding proteins. Two antiparallel beta sheets
anchor peptide loops which directly contact DNA and also stabilise the
shape of the molecule. p53 monomers assemble into tight dimer pairs,
then symmetrical tetramers held together through multiple molecular
interactions. The carboxyl end of the p53 protein can also bind to
broken DNA ends. p53 has a sequence-specific transactivator domain
located in the central 'core' of the protein, comprising residues 90-290.
Normal or wild type P53 is involved in several downstream functions:
DNA damage detection, apoptosis and growth arrest. p53 protein has
the capacity to detect and bind sites of primary DNA damage (in the
form of insertion/deletion mismatches or broken DNA ends). This
functional ability to detect DNA damage maps to the carboxyl terminus
of the protein forming high affinity complexes with the damaged DNA
site, and providing a focus for the subsequent assembly of proteins
involved in DNA repair. One of these potential partners is a factor
implicated in DNA excision repair known as ERCC3. Binding to DNA
has also been shown to protect p53 from rapid proteolysis, which is
consistent with the observed stabilisation and accumulation of p53
protein in DNA-damaged cells.
p53 protein can also mediate cell death by apoptosis. This
morphologically distinct form of cell death is an active response to cell
stimuli. Cell volume shrinks, chromatin condenses, and the nucleus
fragments. Phagocytes ingest and destroy apoptotic cells without
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provoking inflammation. p53 mediated growth arrest or apoptosis
depends partly of the state of cellular activation. Conflicting growth
regulatory signals, sustained p53 synthesis due to extensive un¬
repaired DNA damage, or p53 activation after irreversible
commitment to replication can drive a cell to apoptosis. Apoptosis can
also occur without the presence of p53 via a steroid mediated pathway.
The retinoblastoma protein (pRb) family are implicated in the
relationship between p53 mediated growth arrest and apoptosis. pRb is
normally required for imposing a p53 mediated G1 arrest. If pRb is
functionally inactive, either physiologically or pathologically, the
growth-inhibitory activity of wild-type p53 is converted into an
apoptotic fate.
As mentioned above, DNA damage stimulates the production of the
p53 protein, in turn transactivating genes such as p21 and GADD45 via
p53's central core domain. Transcriptional activity is mediated by a
domain located at the amino end of the p53 protein. GADD45 is
involved with growth arrest in the presence of DNA damage. p21,
however, inhibits the activities of cyclin-dependent kinase enzymes
which are responsible for pushing the cell through its cycle for
division. This allows for cell arrest at the Gl/S phase junction and
time for DNA repair. On restoration of DNA integrity, proliferation
resumes. Both GADD45 and p21 interact with and inhibit PCNA
(proliferating cell nuclear antigen), the function of which is to
stimulate DNA synthesis allowing co-ordination of two separate
processes; cell cycling/division and DNA synthesis.
Functional p53 mutations usually affect trans-activation domains.
More that 90% of the substitution mutations reported so far in
malignant tumours are clustered between exons 5 and 8 and most are
localised in the evolutionarily conserved regions.
Most p53 mutants fall into one of two classes: DNA contact mutants or
structural mutants. DNA contact mutants of p53 are unable to bind
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specific DNA target sequences because of substitution of crucial DNA
contact residues, including mutational hot spots, such as arginine-248
and arginine-273. Structural mutants, on the other hand, lose specific
DNA binding capacity because of abnormal conformation of the
protein. Central core mutations are the main mutations affecting
trans-activation.
It has been suggested that greater than 60% loss of p53 function is
needed to result in a tendency towards neoplastic transformation or
growth.
The presence of transversions (mutation where purines are replaced by
pyrimidines or vice versa) represent events related to exogenous
carcinogens, whereas transitions (conversion of pyrimidine to
pyrimidine, or purine to purine) are more likely to be due to errors of
fidelity during DNA replication, which may be a spontaneous process.
p53 is frequently mutated in epithelial ovarian cancer and its sequence
analysis reveals no transversion "hot-spots"; mutation of transition
type were predominant (72% of all mutation events detected) and
dispersed throughout the gene(predominantly exons 5 to 8 (Kohler et
al, 1993). This predominance of transition mutations suggests that the
impact of environmental carcinogens to the development of ovarian
cancer may be minimal.
The role and independence of p53 abnormality as a prognostic factor in
ovarian cancer is conflicting, with some investigations showing no
association with p53 abnormalities (Frank et al, 1994; Kohler et al, 1993;
Niwa et al, 1994; Sheridan et al, 1994) and others showing that p53
status functions as an independent prognostic factor (Henriksen et al,
1994; Klemi et al, 1994; Levesque et al, 1995; Vanderzee et al, 1995). p53
mutation is reported to be significantly associated with serous
histology (Eccles et al, 1992; Niwa et al, 1994). Recent data suggests that
those ovarian cancers which have a normal p53 gene by sequence
analysis are more likely to respond to chemotherapy than those with
p53 mutation (Al-Azraqi et al, 1995). Recently, a p53 polymorphism
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designated p53PIN3 has been identified; homozygotes were 9 times
more frequent in a cohort of ovarian cancer patients than in a control
group. The polymorphism is due to a 16bp insertional tandem repeat
in intron 3 of p53 (Wang et al, 1996). The underlying basis of this
association is not yet understood.
1.4.3.2 Ovarian cancer and the cell cycle
Unregulated growth as a result of unchecked progression through the
cell cycle is one of the defining features of malignancy. In recent years
there have been great advances in our understanding of the
subcellular machinery responsible for controlling the cell cycle and its
relevance to cancer (Clurman et al, 1995; Kamb et al, 1995; Marx et al,
1994).
At the heart of the cell cycle "engine" are phosphorylating enzymes,
cyclin-dependent kinases (CDKs) which associate as complexes with
activating holoenzymes (cyclins) and are responsible for driving the
cell through each of the checkpoints Gl/S, S/G2 and G2/M (Nigg et al,
1995; Morgan et al, 1995). One of the major substrates through which
CDKs mediate their effects at the major Gl/S checkpoint is the
retinoblastoma protein Rb. Rb forms a complex with E2F, a
promiscuous transcription factor. When Rb is phosphorylated by
CDKs, E2F is released to mediate co-ordinated transcription of genes
required for entry into S phase (Weinberg et al, 1995; Cobrinik et al,
1992).
The CDKs are regulated by specific inhibitors (CDKIs) which suppress
cycling by binding either to cyclin/CDK complexes (an activity
exemplified by the Cip/Kip group of proteins; p21, p27, p57) or to
monomeric CDKs (e.g. the INK4 group of CDKs pl5, pl6, pl8, pl9).
The latter are more specific since they block the actions of the D-cyclins
only. Upstream regulation of the CDKIs is important in signal-
mediated control of the cell cycle. For example, p21 is activated by p53
in response to DNA damage while p27 and pl5 are induced by
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TGF-beta (Toyoshima et al, 1994). Recently, some evidence has been
presented that oestradiol can stimulate cyclin/Cdks in ovarian cancer
cell lines (Ahamed et al, 1996). Oestradiol has also been shown to
stimulate BRCA1 expression in an ovarian cancer cell line
(Romagnolo et al, 1996).
The role of these genes in ovarian cancer is starting to become
apparent. Deletion (even homozygous deletion) of pl6 is found rather
frequently in several types of cancer including ovarian cancer - both
primary tumours and cell lines. LOH studies show frequent disruption
of the pl6 region on chromosome 9p but this is rarely accompanied by
mutation of the retained pl6. It has been postulated that deletion
events at this locus are more powerfully tumorigenic (and therefore
selected for) because they also involve the adjacent pl5 gene (Schultz et
al, 1995; Nobori et al, 1994).
As discussed earlier, amplification at llql3, though less common than
in breast cancer, does occur in ovarian tumours and is usually
associated with over-expression of cyclin D1 (Alama et al, 1996;
Zuckerberg et al, 1995).
Over-expression of MDM2, which has been described as a mechanism
for inactivation of p53, for example in sarcomas (Leach et al, 1993)
occurs rarely in ovarian cancer (Foulkes et al, 1995). Mutations of p21
are infrequent in ovarian tumours, but varying levels of p21
expression were observed which did not correlate with p53 expression
(Milner et al, 1996). However, there is evidence that p21 is associated
with better differentiation status and tumour grade, and in this series,
p21 positive staining was associated strongly with good survival of
patients with ovarian cancer when tumours with mutant p53 were
excluded (Al-Azraqi et al, 1996).
1.4.3.3 Mutation of Oncogenes and Signal Transduction Pathivays in
Ovarian Cancer
Much of the interest in dominantly acting genes in ovarian tumours
has centred on the role of growth factors and their receptors. Epidermal
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growth factor receptor (EGFR, pl70), erbB-2 (HER-2 / neu, pl85) and
macrophage colony stimulating factor receptor (FMS, pl65) are all
trans-membrane proteins with tyrosine kinase activity in their
cytoplasmic domains and over-expression of each has been shown to
correlate with poor prognosis in epithelial ovarian cancer. The effect of
ligand binding is to activate the tyrosine kinase domain, which in turn
phosphorylates tyrosine residues on other cytoplasmic enzymes such
as phospholipase C-gamma which cleaves diacylglycerol from
membrane phospholipids, generating a second messenger with
powerful mitogenic activity (Bast et al, 1993; Berchuck et al, 1994).
Twenty percent of ovarian cancers exhibit HER-2 / neu gene
amplification, though over-expression at the protein level is
demonstrable by immunohistochemistry in a somewhat higher
proportion (around 30%) (Berchuck et al, 1990; Slamon et al, 1989).
Immunohistochemistry is only a semi-quantitative technique and its
interpretation can be subjective. Nevertheless it carries the advantage
that tumour cells can be assessed on an individual basis without the
problems associated with stromal and / or admixed normal epithelial
cells encountered in tissue extracts.
Production of anti-pl85 (HER-2 / neu) antibody has potentially
profound therapeutic implications since it inhibits the growth of erbB-
2 expressing tumours. This effect has been shown to involve down-
regulation of intracellular diacylglycerol production (Deshane et al,
1994).
In over 80% of epithelial ovarian cancers, cultures established directly
from fresh biopsies and examined within 24 hours revealed double
minute chromsomes in at least a proportion of the cells (McGill et al,
1993). Double minutes are unstable genetic elements carrying
amplified portions of the genome that commonly include dominantly
activating oncogenes. Their presence at such high frequency in ovarian
cancer highlights the importance of oncogenes in this disease. In some
instances, the growth factor receptor genes mentioned above are likely
42
to be incorporated in the double minutes but other oncogenes are also
implicated in ovarian cancer. This double minute DNA has been
microdissected, PCR amplified and fluorescently labelled as a FISH
probe. The unique amplified sequence hybridised with 8q24, the site of
c-myc (McGill et al, 1996).
c-myc amplification and / or over-expression has been detected in over
20% of ovarian cancers, particularly of serous histology (Yokota et al,
1986). Where it is amplified or over-expressed, it may present a
therapeutic target since, for example, cyclopentone antitumour
prostaglandins inhibit c-myc expression, causing a G1 block and
leading to apoptosis of tumour cells (Kikuchi et al, 1994)
Amplification of the ras gene family does occur (Filmus et al, 1985) but
more commonly they appear to be activated by point mutations. In
some studies, mutation of K-ras was noted, more often in borderline
than in malignant ovarian tumours activity (Bast et al, 1993; Berchuck
et al, 1994); but other reports suggest that K-ras mutations are usually
associated with advanced stage cancers (Chien et al, 1993; Park et al,
1995)
A number of growth factors with possible autocrine functions have
been investigated in ovarian cancer. The fibroblast growth factor genes
fgf3 and fgf4 are among these and amplification of fgf4 in particular
appears to correlate with advanced FIGO stage (Jaakkola et al, 1993;
Rosen et al, 1993).
The macrophage colony stimulating factor (CSF-1) is the natural ligand
for pl65 c-fms and over-expression of either is associated with poor
prognosis (Baiocchi et al, 1991). CSF-1 not only stimulates proliferation
of ovarian cancer cell lines but also stimulates invasive behaviour in
vitro, an effect which is probably mediated through urokinase
(Chambers et al, 1995). It is known that the expression of urokinase
plasminogen activator correlates strongly with tumour invasiveness
in vivo.
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1.4.4 Ovarian Cancer Progression: Attachment, Invasion,
Angiogenesis and Metastasis.
1.4.4.1 Tumour cell attachment, migration and invasion
The capacity of neoplastic cells to invade and metastasize are
fundamental distinguishing features of benign from malignant
tumours.
The basement membrane, a thin continuous sheet which separates
epithelial cells from adjacent stroma, plays a critical role as a barrier
against invasion. The predominant components of the basement
membrane are laminin, a large multifunctional glycoprotein, collagen
IV and heparan sulphate proteoglycan. Basement membranes form
barriers that block the passage of cells and macromolecules but become
permeable at sites of tissue development, repair, inflammation and
where the membrane contacts invasive malignant neoplasms.
The complex process of invasion consists of three principal steps
whereby an invasive malignant neoplasm crosses its tissue
compartment boundary to access and grow within an inappropriate
tissue site, initially in adjacent stroma, and later, as a metastasis at a
distant site. Tumour invasion is a process that consists of three major
steps: a) tumour cell detachment/attachment; b) enzymatic
degradation of the basement membrane; and c) migration of tumour
cells to the adjacent tissue compartment,
a) Tumour cell detachment and adhesion
In order to invade, a tumour cell must firstly detach from its
neighbour and then attach to the underlying basement membrane.
Cadherins, cell adhesion molecules that mediate intercellular
attachment, maintain attachment between epithelial cells. Down
regulation or loss of cadherin expression is associated with
invasiveness in carcinomas.
An optimal level of adhesion (attachment to the basement membrane)
is required for cancer cells to successfully invade. Adhesion of cells to
the basement membrane is mediated by a family of cell surface
receptors called integrins. Integrins are heterodimeric protein
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complexes which link cytoskeletal microfilaments (e.g. Actin, vinculin
and talin) to extracellular matrix (ECM) proteins such as laminin,
fibronectin, collagen and vitronetin. Integrins mediate their binding
through a specific tripeptide motif, and this tripeptide has been shown
to inhibit tumour cell invasion in-vitro and in-vivo. A balance of
integrin expression is thought to be required for optimal invasiveness
of tumour cells. Integrin under-expression does not allow tumour cells
to adequately attach to the basement membrane (reviewed in
Aznavoorian et al, 1993) Similarly, integrin over-expression may
inhibit the capacity of tumour-cells to dis-attach from the basement
membrane and therefore render those cells less invasive (Giancotti
and Ruoslahti, 1990). Over-expression of a specific 67 kD laminin
receptor (67LR) was first described by Lance Liotta and shown to be
important for cancer cell adhesion to and invasion into the extra¬
cellular matrix (Liotta et al, 1984) and over-expression of 67LR has been
associated with progression of various cancers (Pellegrini et al, 1995).
Expression of 67LR has been shown to be increased in patients with
progressive ovarian cancer (van den Brule et al, 1996). OVCAR3 cells
incubated with laminin peptide fragments prior to intra-peritoneal
injection failed to induce tumours in nude mice (Olt et al, 1996).
b) Basement Membrane degradation by tumour cells
Tumour cells generate a zone of lysis at the site of their attachment of
the basement membrane. This is achieved by production of proteolytic
enzymes which are secreted as pro-enzymes and have both activators
and inhibitors to regulate their activity.
Several families of proteases are produced, the most important of
which are the matrix metalloproteinases (MMPs). This family can be
grouped into 3 types according to their substrate specificity: MMP-1 or
interstitial collagenase (Templeton et al, 1990) degrades fibrillar
collagens (types I, II and III). MMP-2 and MMP-9 are the type IV
collagenases (Collier et al, 1988). MMP-3 or stromelysin consists of 3
types (Wilhelm et al, 1987). Stromelysin-1 (which degrades laminin)
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stromelysin-2 (degrades fibronectin) and matrilysin (degrades
proteoglycan core proteins). A cluster of such matrix
metalloproteinases resides on chromosome llq. The transcriptional
regulatory regions of MMP genes contain binding sites for the
transcription factors Ets and AP-1. In transfection assays, these
transcription factors induce the expression of matrix metalloproteinase
RNAs and thereby confer the invasive phenotype of MCF-7 breast
cancer cells (Kaya et al, 1996).
Three other classes of protease are involved in this proteolytic activity,
the most important of which is the serine protease uPA (urokinase-
type plasminogen activator) whose expression appears to be closely
related to enhanced invasion and metastasis. It converts inactive
plasminogen to the active enzyme plasmin which can degrade
collagen, fibronectin, fibrin and laminin (Liotta et al, 1981)
The expression of these proteolytic activities is tightly regulated.
Natural Tissue inhibitors of metalloproteinases (TIMPs) are present to
regulate the activity of MMPs, and localised secretion of MMPs until
the effect of ubiquitously located TIMPs is locally overcome provides a
highly focal degradative process which has a normal role in repair,
tissue remodelling and the response to infection (Khokha et al, 1989).
c) Tumour cell migration
Having degraded the basement membrane the tumour cell must
actively migrate to the adjacent tissue compartment that it will occupy.
Cell motility, a normal cellular function, begins with polarisation and
orientation of the cell followed by formation of pseudopodia (by
membrane extension) at the cell's leading edge. The pseudopodium
then forms attachments with the ECM and produces a contractile force
to move the cell forward by a series of attachment and dis-attachment
steps involving the cellular receptors that bind the matrix. Specific
signals give direction and urgency to migration, including matrix
components, growth factors, and scatter factors. Tumour cells
additionally produce autocrine chemotactic factors.
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The biology of ovarian cancer and the function of genes in other
tumours suggests many possible candidates of which the above are
examples but by no means an exhaustive list. Few of these genes have
been shown to have an important role in ovarian cancer as yet. The
human genome mapping project will undoubtedly produce many
more candidates worthy of study, some as part of the project, but others
by positional cloning of ovarian cancer associated genomic regions.
The aim of this thesis was to take this approach in the light of genetic
studies of loss of heterozygosity taking into consideration the
clinicopathological features which distinguish ovarian cancer
1.5 The Role of Chromosome 11 in Ovarian and Other Neoplasms
1.5.1 Loss of heterozygosity of Chromosome lip
LOH studies in many tumour types have provided evidence for
putative tumour suppressor genes located on chromosome 11.
Table 1.3 outlines the major studies that have defined regions of LOH
on the short arm of solid tumours other than ovarian cancer.
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Table 1.3 Studies demonstrating chromosome lip LOH in
cancers other than ovarian
Tumour Region of LOH Reference
Wilms' tumour llpl3 Fearon et al 1984,
Orkin et al 1984,
Reeve et al 1984
Hepatoblastoma lip Koufos et al 1985
Sporadic Wilms' llpl5.5 Reeve et al 1989
tumour
Bladder cancer llpl5.5 Fearon et al 1985
Rhabdomyosarcoma llpl5.5 Scrable et al 1987
Lung carcinoma llpl5.5 and
Ilpl3-ql3
Weston et al 1989
Breast carcinoma llpl5.5 Ali et al 1987
Testicular teratoma llpl5.5 Lothe et al 1989
Two regions, llpl5.5 and llpl3 (site of the Wilms' and WAGR loci)
repeatedly appear as important loci in these tumour series. It is
important to note that most of these studies were performed in the
1980's, prior to PCR and access to abundant, highly polymorphic, well
localised markers.
In ovarian cancer, frequent LOH has been demonstrated at llpl5 (Lee
et al, 1989; Lee et al, 1990; Kiechle-Schwarz et al, 1993; Gallion et al,
1992; Vandamme et al, 1992; Viel et al, 1992; Eccles et al, 1992) although
not all studies have confirmed this high level of loss (Zheng et al, 1991;
Sato et al, 1991; Yang-Feng et al, 1992). A proximal locus at llpl3 (site of
WT1) exhibits lower levels of LOH in ovarian cancer (Vandamme et
al, 1992; Viel et al, 1992; Bruening et al, 1993). A minority of these
studies have proposed a correlation of lip LOH with poorly
differentiated (Zheng et al, 1991; Kiechle-Schwarz et al, 1993) and more
advanced (Viel et al, 1992) tumours, but in general patient numbers
have been small and follow-up times short. Table 1.4 summarises the
literature for chromosome lip LOH in ovarian cancer (12 publications)
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Table 1.4 Ovarian cancer LOH rates on chromosome lip
Loci Position LOH/HET % LOH
Ha-ras llpl5.5 (dist.) 66/175 38%
INS/HB Ilpl5.5 (prox.) 51/169 30%
CALC Ilpl5.4 17/46 37%




Three candidate tumour-suppressor genes are found on chromosome
lip. p57 is a cell cycle gene located at llpl5.5. This has been excluded as
the gene responsible for tumour suppression in Wilms' tumour cell
line suppressed hybrids (see below) and appears not to be involved in
sarcomas which commonly have disruption at llpl5.5. WT1 has been
investigated in ovarian cancer. Despite 39% LOH in this region,
Bruening and colleagues showed that WT1 was not mutated in
ovarian cancer (Bruening et al, 1993).
The third tumour suppressor, KAI-1 (Dong et al, 1995, see below), a
prostate cancer metastasis suppressor, has not been investigated in
ovarian cancer.
1.5.2 Loss of heterozygosity of Chromosome llq
Proximal chromosome llq LOH
Analysis of chromosome llq has highlighted a different pattern of
solid tumour involvement.
Proximally, allele imbalance at llql3 has been reported for cervical
cancer (Srivatsan et al, 1991a), neuroblastoma (Srivatsan et al, 1991b)
multiple endocrine neoplasia typel (Fujimori et al, 1992; Larsson et al,
1988), melanoma (Tomlinson et al, 1993), and B cell tumours
(Williams et al, 1993)
Molecular studies of the proximal llq region have shown low levels of
allele imbalance in ovarian cancer (Foulkes et al, 1993; Li et al, 1991;
Lee et al, 1989; Sato et al, 1991; Viel et al, 1992).
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Distal chromosome llq LOH
Early molecular studies showed abnormalities in human leukaemias
at llq23 (Zieman-van der Poel et al, 1991), RCK(lymphoma) cell line at
llq23 (Akao et al, 1992), hereditary paragangliomas at llq23-qter
(Heutnik et al, 1992) and Ewing's sarcoma at llq24.
Until 1994, the only study that looked specifically at distal llq in
common solid tumours was in fact performed by Foulkes and
colleagues studying ovarian cancer (Foulkes et al, 1993). They recorded
a high level of LOH at llq23.3-qter in a small sample of tumours.
Following this report the telomeric half of llq has been the subject of
extensive investigation in many studies of solid tumours (see Table
1.5).





























llq23 67% Tomlinson et al
1993
The salient features of these investigations are the definition of several
regions of LOH within the interval Ilq22-q25 in several solid tumour
types. Many of these regions were defined concurrent with or post¬
dating my studies, I will present and discuss these later.
Foulkes and others did demonstrate that llq LOH was infrequent
centromerically but much higher telomerically, and this is outlined in
Table 1.6.
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Table 1.6 Ovarian cancer LOH rates on chromosome llq










S147 llq24.1 8/12 67%
The gene for Ataxia-Telangiectasia (ATM) was recently identified and
is located at Ilq22-q23 (Savitsky et al, 1995) It is postulated that ATM
heterozygotes may be at increased risk of breast cancer but recent
mutation analysis revealed that there were no significant ATM
mutations in a cohort of patients with breast cancer (Vorechovsky et al,
1996). Analysis has not yet been performed in ovarian cancer. The
progesterone receptor is also a candidate tumour-suppressor gene. The
preceding discussion on hormonal factors (see above) has outlined the
inhibitory role of PGR on breast and ovarian cancer growth. A
constitutional polymorphism in intron G of the PGR gene has been
shown to be associated with an increased incidence of sporadic ovarian
cancer, suggesting a potential role for PGR as a tumour suppressor
(Rowe et al, 1995).
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1.6 Somatic cell genetics and the functional identification of tumour-
suppressor gene regions
1.6 Somatic Cell Hybrids
1.6.1 Historical introduction
The development of somatic cell hybrids in 1960 (Barski et al, 1961),
which are cells containing all or a part of the genetic complement of
two distinct somatic cell lines, has proven to be of immense
importance in the study of mammalian genes. Although it was clear
from the outset that these resources would be useful, it was not until
methods became available for enriching for the hybrids above
background non-hybrid cells that their potential was unleashed for
gene mapping and complementation.
Selectable systems
In 1964, Littlefield fused together two mouse cell lines each containing
different negative selectable markers. One cell line was deficient in
hypoxanthine-guanidine phosphoribosyl transferase (HGPRT), the
other was deficient in thymidine kinase (TK). Each of these enzymes
are required to synthesise the appropriate nucleotides from the
nucleosides hypoxanthine and thymidine respectively when the de-
novo nucleotide synthetic pathway is blocked by aminopterin (an
inhibitor of dihydrofolate reductase, DHFR). Therefore, in the absence
of HGPRT or TK the cell will not grow on a medium containing
hypoxanthine, aminopterin and thymidine (HAT). Littlefield's cell
fusion experiment allowed the HGPRT and TK from each cell
containing that enzyme to cross-complement the HGPRT" and TK"
phenoypes thereby allowing only the somatic cell hybrid to grow in
HAT medium (Littlefield, 1964). This enrichment or selectable system,
which remains an important tool today, provided the impetus to
devise other selectable systems for use in somatic cell genetics
culminating in the development of a series of bacterial dominant
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selectable markers utilised for selection of tagged eukaryotic
chromosomes and cells (see below).
1.6.2 Inter-specific somatic cell hybrids
The first inter-specific somatic cell hybrids (produced by fusion of cells
from different species) were produced between mouse and human
cells by Harris and Watkins in 1965 (Harris and Watkins, 1965). The
creation of inter-specific hybrids allowed the human chromosomal
complement to be segregated into one or a few chromosomes in a
rodent chromosomal background, and this allowed the
characterisation of one or a few chromosomes at a time. The result was
an explosion in the number of cloned genes and markers mapped
cytogenetically.
Reduced inter-specific hybrids which complemented the recessive
genetic defect of a TK~ mutant rodent line demonstrated the second
great opportunity of somatic cell hybridisation: the localisation of the
gene complementing the mutant phenotype to a chromosome, thereby
allowing workers a glimpse of our ability in the future to clone
eukaryotic genes by their function (Migeon and Miller, 1968). The
development of Giemsa banding (Sumner et al 1971), immuno¬
chemical identification of cell surface antigens (reviewed by
Tunnacliffe et al 1983), and the advent of nucleic acid hybridisation
technology (Southern, 1975) allowed strategies for rapid
characterisation of somatic cell hybrids, establishing them as powerful
tools for biology.
1.6.3 Somatic cell hybrids, gene mapping and positional cloning
As indicated above, the ability to unambiguously demonstrate physical
linkage of a gene to a particular chromosome became a reality with the
development of monochromosome inter-speciic hybrid panels. These
panels have been produced from disparate sources. Some were
produced by fortuitous reduction segregation events that remained
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stable despite lack of a selectable marker, such as chromosome 11 in
CHO cells (Kao et al 1976). Other hybrids were generated using natural
cross complementation of an interspecific mutation such as TK"
mouse lines and human chromosome 17 (Migeon and Miller 1968).
However, the most robust method has proven to be the introduction
of dominant bacterial selectable markers into human chromsome
prior to the creation of the hybrids (Koi et al, 1989a).
Having assigned a cloned gene or sequence to a chromosome, the next
step is to localise it precisely either for mapping purposes (in the case of
a cloned gene) or for positional cloning (in the case of a sequence
physically closely linked to an un-cloned gene). Fragmentation of
chromosomes in hybrids allows panels to be generated containing
stable sub-chromosomal segments providing a useful way of assigning
a locus to a particular region of chromosome. Chromosomal
rearrangements such as translocations or deletions may either occur
spontaneously or be induced in culture and mapping loci with respect
to the rearrangement helps in regional assignment. The ability of
gamma irradiation to cause gross chromosomal damage has been used
to generate fragmented and rearranged chromosomes for mapping.
Important experiments by Goss and Harris showed that irradiating
human lymphocytes before fusing them with HPRT" rodent cells
generated somatic cell hybrids with fragmented chromosomes. Growth
on HAT medium identified rearranged fragments of the X
chromosome clustered around the human HPRT locus. Furthermore
they were able to establish an ordered set of physically linked genes in
the vicinity of this locus (Goss and Harris, 1975). The irradiation fusion
gene transfer (IFGT) strategy has been scaled up and combined with
two powerful techniques; the polymerase chain reaction (PCR) and
fluorescence in-situ hybridisation (FISH) to provide detailed physical
maps of whole chromosomes. A particularly good example has been
the construction of a detailed sequence tagged site (STS) map
incorporating integrated information from microsatellites, cloned
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genes, and expressed sequence tags (ESTs) spanning the whole of
human chromosome 11 (James et al, 1994). Using the J1 CHO somatic
cell hybrid which contains human chromosome 11 in a Chinese
hamster ovary background (Kao et al 1976), Richard III and colleagues
generated a panel of 102 human-hamster radiation hybrid (RH) cell
lines by X-irradiation of the J1 cells (Richard III et al, 1991; Richard III et
al, 1993). From these cell lines, James and colleagues selected 86 RH cell
lines which formed overlapping fragments spanning the whole of
human chromosome 11. The analysis of sufficient numbers of hybrids
ensured that any conflicting data produced by intra-chromosomal
rearrangement due to radiation fragmentation is statistically
neutralised. Distances between adjacent markers were estimated in
cR90oo (cR)- A distance of 1 cR (centi ray) between two markers
corresponds to a 1% frequency of breakage between the markers after
exposure to a 9000 rad dose of X-rays. The total length of the
chromosome 11 RH map was found to be 2867 cR. Based on an
estimated size of 144 Mb for the chromosome (Morton 1991 [PNAS]),
James et al suggested that 1 cRqqqq was equivalent to 50.2 Kb (James et
al, 1994). This figure is consistent with estimates from other
chromosomes (Cox et al, 1990; Abel et al, 1993). By analysing the
patterns of co-segregation of markers by PCR (whether each STS is
present or absent in each hybrid), 506 STSs were mapped into 299
unique positions on the chromosome with odds of >10:1. The average
resolution between markers was high at 480 Kb. A more robust subset
of markers ordered with odds of at least 1000:1 formed an underlying
framework of this map consisting of 260 STSs at 143 unique positions
giving an average resolution of the map at 1 Mb. This integrated,
highly ordered physical map is clearly the way forward towards
construction of robust STS based physical maps using YAC contigs. The
provision of a physical RH STS map provides an attractive reference
for building and cross-screening of YAC contigs in order to avoid the
problems caused by chimaerism. As a starting point for the mapping
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component in this thesis, I used this radiation hybrid map as a way of
ordering LOH data from patient specimens and relating it to physical
mapping data from microcell fusion experiments.
1.6.4 Somatic cell hybrids and functional gene cloning
Somatic cell genetics from the outset held an alluring promise of
cloning genes by function. Complementation of a readily isolated
phenotype, e.g. a cell surface marker, allows a rational approach to
heirarchical strategies whereby whole cell fusion, then microcell
mediated chromosome transfer can delineate the chromosome and
perhaps the chromosomal segment on which the gene resides.
Unfortunately, there is no direct route to the gene beyond this,
although complementary strategies can be brought to bear on the
problem. One can a) transfer stable subchromosomal fragments, b)
prepare DNA for transfection either from mitotic plate preparations or
by standard preparation of naked DNA, c) adopt a difference cloning
approach to clone cDNAs, or d) take a laborious positional cloning
approach (as outlined above).
Cell lines with stable subchromosomal fragments generated by X-
irradiation of packaged chromosomes prior to their transfer to other
cell lines (XMMCT, see microcell mediated chromosome transfer
below) can be used for complementation to refine the position of a
gene of interest (Dowdy et al, 1990; see below). Microcells prepared
from the somatic cell hybrid can be irradiated prior to microcell fusion
and transferred back to the rodent cell line to create somatic cell
hybrids with fragmented human chromosomes that have not re¬
arranged with rodent chromosomes. The use of homologous
recombination to multiply target the human repetitive component of
monochromosome somatic cell hybrids with a dominant selectable
marker has been successfully achieved (Watson et al, 1995). Introduced
with the dominant selectable marker are a variety of useful features,
including unique restriction sites and markers to allow rescue of the
human DNA fragments into yeast and bacterial vectors. X-MMCT
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using these hybrids can generate a variety of non-rearranged stable
subchromosomal somatic cell hybrids carrying a dominant selectable
marker. The use of these fragmented donor cell lines to complement
the desired phenotype by MMCT in a biologically appropriate cell line
and assay creates the next resource for the heirarchical approach to
functional cloning: a cell line which is functionally complemented
bearing a targeted cloning vector nearby. If the assay can be repeated in
cell lines from a different species, cloning of regions of the
transgenome is more readily achievable. However, many clinically
relevant phenotypes are human and tissue specific (e.g., tissue
restrictions of tumour suppressor gene effects in specific tumour types)
and therefore intra-specific functional assays may be more relevant.
Increasingly, transgenic workers have been able to perform stable YAC
transfer into ES cells to study the expression of stretches of chromatin
containing genes of interest which have been manipulated (Van
Heyningen et al, 1995b; Schedl et al, 1996). These approaches have not
however met with success in somatic cells, although as a technical
excercise, they should ultimately yield to refinement of the technique.
The next step Heirarchical step down in practice currently is to perform
chromosome mediated gene transfer (McBride and Ozer 1970,
Klobutcher and Ruddle 1979), whereby calcium phosphate transfection
of isolated mitotic chromosomes is performed on the same recipient
cells used for MMCT, and the same assay is again selected for along
with the dominant selectable marker. This time the selectable marker
with cloning vector and 1-50 Mbp of flanking DNA are transferred
with the gene responsible for the observed functional
complementation. Analysis of this transgenome and its subsequent
direct cloning by preparative pulse field gel electrophoresis (PFGE) into
yeast or bacterial chromosome vectors allows further characterisation
of the functional region in order to clone the gene of interest.
The main drawbacks of CMGT are firstly, co-transfer of discontinuous
non-selected DNA since unlike MMCT there is little regulation over
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the amount of chromatin transferred and its rearrangement. Secondly,
re-arrangements sustained by transferred chromatin between the
selectable marker and the functional region may be misleading.
Thirdly it is preferable to use a complemented cell line as a source for
CMGT since performing CMGT directly from the inter-specific donor
somatic cell hybrid runs the risk of complementing the defect with
discontinuous co-transferred conserved murine genes of similar
function.
Two interesting PCR based techniques have been developed to clone
expressed sequence differences between functionally complemented
hybrids. The first technique, differential display, uses random PCR
primers to identify expression differences by RT-PCR which can then
be cloned and lead to identification of transferred or differentially
regulated expressed sequences. The second (and much more powerful)
method is an adaptation to study cDNA populations of
representational difference analysis (RDA, Lisitsyn et al, 1993). cDNA-
RDA consists of subtraction hybridisation between restricted cDNA
populations from the non-complemented and complemented cell
lines. The population of cDNAs expressed by the complemented
phenotypes are then amplified, and the process is repeated twice more
until all co-expressed sequences are eliminated leaving only sequences
specifically expressed by the complemented phenotype (Hubank and
Schatz, 1994). A potential problem is the expression of a point mutated
transcript in the non-complemented cell line, however, this is clearly a
powerful complementary approach to the strategies discussed above.
1.6.5 Suppression of the cancer phenotype by somatic cell
hybridisation
Barski (Barski et al, 1961) had shown that when highly
malignant mouse cells were grown in a mixed culture with mouse
cells of low malignancy, spontaneous hybrids arose one of which
remained highly malignant. Fusion of this highly malignant line with
mouse fibroblasts also produced a hybrid line which was highly
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malignant. These studies suggested that malignancy behaved as a
dominant phenotype. However, these hybrids had not been
sufficiently analysed karyotypically; chromosome losses could have
occurred in the hybrids and have been selected for by increased growth
rate. Harris and co-workers re-investigated the phenotype of
hybridisation of malignant with non-malignant cells and published
their results in 1969 (Harris et al 1969). They used three murine
malignant cell lines, one a murine mammary carcinoma (Ehrlich
tumour) and two murine sarcomas (SEWA, an osteogenic sarcoma,
and MSWBS, a myosarcoma) all of which had been converted to a
lethal ascites model. These malignant cells were fused using sendai
virus with mouse A9 fibroblast cell line, a non-malignant cell line.
Harris demonstrated that all three malignant cell lines were
suppressed for malignancy when fused with A9 cells. They also
showed that these hybrids produced revertants back to the malignant
state in association with loss of chromosomes. This study suggested
that the neoplastic phenotype, far from being a dominant trait was in
fact a recessive phenotype, complemented by restoration of 'normal'
genetic material.
Despite these elegant findings, many other workers found these results
difficult to repeat. It became obvious that loss of chromosomes from
the cell hybrids due to karyotypic instability was responsible of re-
expression of tumorigenicity. These revertants were particularly
obvious in rodent intraspecific hybrids (formed by fusion of rodent
tumour cell lines with rodent "normal" cell lines) and human/rodent
interspecific hybrids. Stable tumour-suppressed hybrids were finally
generated utilising human intraspecific fusion (Stanbridge, 1976).
Revertants to tumorigenicity occurred fairly infrequently in these
hybrids. Careful karyotypic analysis of these tumorigenic revertants did
in some cases allow workers to make the association of tumorigenic
reversion with the loss of a chromosome. Although this does not
constitute proof, it is a powerful piece of circumstantial evidence. The
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most persuasive such piece of evidence came from studies utilising
intraspecific HeLa X human fibroblast cell hybrids. Hybrids retaining
both normal fibroblast chromosome 11 copies were completely
suppressed for tumorigenicity. However, loss of one of the normal
copies of chromosome 11 was associated with reversion to
tumorigenicity (Stanbridge and Ceredig, 1981; Srivatsan et al,
1986).This suggested not only a specific tumour-suppressor element on
chromosome 11 but a dosage effect whereby two genomic elements
acting in a dose dependent manner were required to suppress
tumorigenicity. It would have been extremely interesting to observe
the effect on a tumorigenic revertant cell hybrid containing one copy of
normal chromosome 11 of returning specifically a second normal copy
of chromosome 11. However, at this time there was no specific method
of returning a specific chromosome to a cell line and it required a
technically difficult and prolonged period of method development
before such an experiment became possible.
1.6.6 Microcell Mediated Chromosome Transfer
The observation of reversion to tumorigenicity of cell hybrids in
association with specific chromosomal loss suggested an obvious and
attractive experiment: to observe the functional effects of returning
that chromosome to the hybrid. However, a convergence of cell
biological technologies was required before such an experiment became
a feasible, and the development of microcell mediated chromosome
transfer (MMCT) allowed a chromosome to be transferred and stably
retained as a discrete structural unit in succeeding generations of
hybrid cells (unlike other methods of DNA transfer which result in
rapid degradation of non-selected DNA). The retention of specific
chromosomes would require their tagging with endogenous or
exogenously introduced dominant selectable markers which could be
used as a selectable system in the recipient cells.
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In 1974, Ege and Ringertz were able to generate microcells; subnuclear
particles containing a restricted subset of murine genetic material
surrounded by a rim of cytoplasm and an intact plasma membrane.
The incubation of murine cells with the mitotic inhibitor colcemid
resulted in metaphase block, and continued exposure to colcemid
resulted in a reformation of the nuclear membrane around the mitotic
chromosomes scattered around the cell in the absence of a mitotic
spindle producing the appearance of micronuclei. The cells were
grown on plastic discs, which were placed in media filled centrifuge
tubes and centrifuged at 12,000 x g for 20 minutes at 34^C in the
presence of cytochalasin-B, an inhibitor of actin filament formation.
This resulted in enucleation of >95% of the cells on the discs, and the
resultant suspension contained the free microcells (Ege and Ringertz,
1974).
In 1977, Fournier and Ruddle were able to transfer murine
chromosomes contained within microcells into mouse, human and
Chinese hamster cell lines (Fournier and Ruddle, 1977). For the first
time they were able to create viable somatic cell hybrids containing
one, or a few transferred chromosomes. They used three mouse
fibroblast cell lines: A9 which lacks both hypoxanthine
phosphoribosyltransferase (HPRT") and adenine phosphoribosyl-
transferase (APRT~); B82, deficient in thymidine kinase (TK~); and
CT11C|, an APRT", HPRT+ line. Microcells were produced using the
Ege and Ringertz method. The crude microcell preparation was
purified by sedimentation on a bovine serum albumin gradient. The
upper fractions were pooled, containing the smallest structures which
included the purified microcells. Inactivated Sendai virus was used to
attach and fuse the microcells to a monolayer of recipient cells. The
cells were allowed to recover for 24 hours, split into a number of small
flasks and selected on HAT medium (see above). Hybrid clones
appeared after 2-4 weeks. Microcells from A9 cells were used to
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complement the TK" phenotype of B82. The modal chromosome
number of the intraspecific hybrids were consistent with transfer of
one or a few chromosomes only. Interspecific hybrid were generated by
transferring murine microcells into Chinese hamster and human
(HeLa) cell lines.
The development of the technique of microcell mediated chromosome
transfer (MMCT) was clearly a powerful development in somatic cell
genetics, however micronucleation of normal diploid human cells
proved to be extremely difficult (Tourian et al, 1978). Human cells
typically produced micronuclei with only low efficiency, or the
produced microcells were not viable.
In 1980, McNeill and Brown defined the conditions for
micronucleation of human foreskin diploid fibroblasts; using high
concentrations of colcemid they were able to micronucleate 40-60% of
the cells (McNeill and Brown, 1980). Rather than BSA gradient
purification, they filtered the crude microcell preparation through a 3
um Nucleopore polycarbonate membrane. The resultant preparation
contained microcells, was free of whole cells and contained less than
1% contaminating karyoplasts. In contrast to the Sendai virus fusion
protocol used by Fournier and Ruddle, McNeill and Brown used
Phytohaemagglutinin-P (PHAP), a lectin, to attach the human
microcells to the recipient mouse TK" cells and then used polyethylene
glycol (PEG) to fuse the attached microcells with the recipient cells. The
cells were selected on HAT medium and clones emerged at 2-3 weeks.
Karyotypic analysis revealed that this technique reliably transferred a
single human chromosome 17 into the murine recipient.
The ability to transfer a single human chromosome into a mouse cell
line allowed the generation of interspecific human monochromosome
somatic cell hybrids. These would have a central role in gene mapping
and the elucidation of gene expression and regulation. McNeill and
Brown's experiment had utilised a naturally sited selectable marker
that could be utilised in their assay system. However, other
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chromosomes did not have other such markers, and the next step in
the creation of monochromosome somatic cell hybrids was the
development of exogenously introduced selectable markers into
human chromosomes prior to their transfer into mouse fibroblast
cells.
More recently, a protocol has been developed that allows microcells to
be generated directly from mitotic cells for MMCT (Stubblefield and
Pershouse, 1992). This method used a short treatment of colcemid (2-5
hours) of proliferating donor cells to generate cells blocked in mitosis.
The mitotic cells were shaken off the flasks and transferred to an
isotonic percoll gradient buffered with HEPES and containing
cytochalasin-B. After centrifugation at 37^C the microcell preparation
was filtered, attached and fused in the usual way. The major
advantages of this protocol were firstly speed and secondly that the
majority of microcells contained only one chromosome since
micronucleation of several chromosomes at once did not occur.
1.6.7 Introduction of dominant selectable markers into normal
human chromosomes for MMCT.
The exogenous introduction of the XGPRT marker by transfection of
the plasmid pSV2gpt into HPRT" HeLa cells, rendered them viable in
E1AT medium (Saxon et al, 1985). The randomly integrated plasmid
allowed several chromosomes to be selected for after microcell fusion
into an HPRT" mouse fibroblast cell line. Although these resources of
human chromosome somatic cell hybrids were excellent for gene
mapping, they could not be used widely for tumour-suppression
studies, as the XGPRT marker was not dominant with respect to
HPRT+ human cells. However, the first examples of MMCT of human
chromosomes from monochromosome somatic cell hybrids into
human tumour cell lines were achieved using a t(X;ll) carrying HPRT
into HPRT deficient tumour cell lines (see below).
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Generation of human chromosome somatic cell hybrids tagged with
the truly dominant selectable marker neo, the E. coli neomycin
resistance gene (which confers resistance to the antibiotic G418) was
achieved in 1987 (Lugo et al, 1987). Human diploid fibroblasts were
infected with a defective retrovirus derived from Moloney leukaemia
virus and carrying the neo gene driven from its long terminal repeat
promoter. The infected fibroblasts were grown in G418 and microcells
were produced from them and transferred into the mouse fibroblast
cell line 3T6 by MMCT. Somatic cell hybrids carrying dominantly
tagged chromosomes 11, 14, 20 and 21, were generated which could be
used for MMCT into any human cell line and selected for.
A larger series of neo-tagged human monochromosome somatic cell
hybrids were subsequently generated by Koi and co-workers (Koi et al,
1989a, see above). They transfected normal human fibroblasts (MRC-5
and NT1-4) with pSV2-neo plasmid DNA and isolated G418 resistant
clones. From these they performed MMCT into mouse A9 cells, and
isolated 13 stable microcell hybrid clones containing a dominantly
tagged human monochromosome 1, 2, 5, 6, 7, 8, 10, 11, 12, 15, 18, 19 and
20. They confirmed these somatic cell hybrids as useable donors for
MMCT into human recipient cell lines (Koi et al, 1989b).
More recently, a complete panel of 23 stable monochromosome
somatic cell hybrids has been generated (Cuthbert et al, 1995). The
human chromosomes were tagged with a selectable fusion gene Hytk
and introduced in a retroviral vector into normal human fibroblasts,
and then transferred into mouse A9 cells. Hytk allows both positive
(Hygromycin) and negative (Ganciclovir) selection. The latter marker
allows for "flip-flop" demonstration of phenotype reversion, useful in
confirmation of chromosome associated functions.
A more sophisticated approach to tagging has been adopted by Watson
and co-workers (Watson et al, 1995). This involved the introduction of
a dominantly selectable marker specifically into the human
component of the somatic cell hybrid. Watson constructed vectors
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containing the neo-marker and human-specific repeat sequences.
Vectors containing the Long interspersed nuclear element (LINE) LI
repeats did specifically mediate insertion into the human chromosome
by homologous recombination in J1-C4, a human monochromosome
11 somatic cell hybrid in Chinese hamster ovary background. Other
unique features of the vector were the presence of the yeast selectable
marker Leu2 for cloning the fragments of chromosome DNA in yeast,
and the bacterial selectable marker Amp for cloning in cosmids.
Additionally, the unique restriction sites I-Scel and LacO provided
unique cutting sites for the integrated vector. This resource provides a
direct route from functional effect by whole chromosome introduction
to cloned fragments in yeast or bacterial vectors. Repeat mediated
targeting can generate human chromosomes tagged at many sites,
providing an obvious route to reduced or fragmented hybrids.
1.6.8 Cell Biological assays for the cancer phenotype
1.6.8.1 In-vivo studies of the cancer phenotype
Conventional, but simplistic, definitions of the function of tumour
suppressor genes have led to arbitrary implementation of a gold
standard. In his influential review, Stanbridge states that "there is no
facile method for assaying tumour suppressor function other than the
in-vivo tumorigenicity testing in immune deficient mice". Using the
narrow definition that a tumour suppressor gene is a gene that
completely stops the development of a tumour, then Stanbridge is
correct, since no assay provides an assessment of in-vivo
tumorigenicity as satisfactorily as an assay of in-vivo tumorigenicity!
However, if one examines Stanbridge's own definition of a tumour
suppressor gene, he states "[the phenomenon of] tumour suppression
indicated that a gene (or genes) from a normal cell might replace a
defective function in the cancer cell and render it responsive to
normal regulators of cell growth". This is, of course, intuitively much
more satisfactory as a definition, and immediately suggests that the
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above gold standard is not a gold standard at all: suppression of
tumorigenicity is clearly a highly specific assay: when suppression
occurs one has clearly introduced a tumour suppressor gene. However,
this assay is not very sensitive, and failure to suppress tumorigenicity
in nude mice cannot be taken to mean that the gene of interest is not a
tumour suppressor gene (by Stanbridge's own definition above).
The ability of malignant tumours to spread from their original site to
form metastases is the main obstacle to successful cancer treatment.
The complexities of the metastatic process involve not just tumour
cells, but also host cells and the extracellular matrix. The process begins
with tumour cells disattaching from their normal site, attaching to the
basement membrane, penetrating the basement membrane, invading
the underlying stroma by migration, local destruction and
proliferation. Accessing blood vessels by an active angiogenic or
invasive process, or accessing lymphatics allows tumour cells to
disseminate to distant sites. At those sites, specific processes of
attachment, local destruction and proliferation occur, followed by
further spread.
Given its complexities, there may be components of the cancer process
that can not be detected using the subcutaneous tumorigenicity assay.
Other in-vivo assays are increasingly used to assay for tumour
suppressor genes.
One type of assay begins with the premise that solid tumours rarely
metastasise under the skin. Attempts have therefore been made to
implant cancer cells orthotopically to the site of origin of the tumour
and observe its behaviour from the primary site, e.g. inoculation of
ovarian cancer cells under the ovarian surface epithelium of nude or
SCID mice. This is a demanding technique and although it may have
the shortcoming that the cancer cell lines may have been developed
from metastases in the first place, it is a more rational approach to
assessing contextual behaviour of cancer cells hopefully in an
appropriate autocrine and paracrine milieu, and one can observe the
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entire cancer process as it might happen naturally after establishment
of a primary tumour (Fu et al, 1993).
Another type of assay addresses the possibility that although a
suppressor gene may not inhibit primary tumour formation, its
inactivation is an essential step for cancer cells to metastasise from
their primary site. Injection of cells into the bloodstream followed by
counting either pulmonary or splenic metastases after a suitable time
interval have been developed successfully and several chromosomes
introduced into particularly melanoma, prostate and breast cancer
lines have demonstrated suppression of metastasis forming ability
with no perceptible influence on subcutaneous tumorigenicity (Dong
et al, 1995; Miele et al, 1996; Phillips et al, 1996). More recently an assay
for formation of intra-peritoneal metastases from ovarian cancer cells
has been developed (Fu et al, 1993).
1.6.8.2 In-vitro assays of the cancer phenotype
With increased understanding of the multiple components of the
neoplastic process, somatic cell geneticists should turn their attention
to more sophisticated in-vitro cell biological techniques that can assay
specific components of this process.
Following initiation and promotion steps which alter the balance
between cell proliferation and death, resulting in an immortal clonal
tumour at a primary site, the first stage of the metastatic process
involves interactions with the extra-cellular matrix, and can be
separated into 3 defined sequential steps: attachment, proteolysis and
migration. Thereafter angiogenesis not only ensures that the metabolic
needs of the growing tumour are met, but also provides an obvious
route for dissemination of tumour cells to other sites in the organism
allowing establishment of metastatic deposits.
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1.6.8.3 Tumour cell proliferation, death and the cell cycle
Direct quantitation of cell growth on tissue culture plates allows basic
functional effects on growth to be assessed. A property of cancer cell
growth is that of serum independence. Thus progressive reduction in
serum added to the culture media may accentuate the effect associated
with introduction of a TSG. Effects on contact inhibition may be
assessed by estimation of saturation density of the cells after prolonged
continuous growth in-vitro. Surrogate endpoints such as cell doubling
time may be estimated using these techniques.
DNA fluorescence activated cell sorting (DNA-FACS) analysis of
propidium iodide stained cells allows comparison of the cell cycle
distribution of the cells before and after introduction of a TSG to assess
its involvement in cell cycle regulation (see cell cycle, above).
Several methods can be used to assess if perceived growth inhibition
may be due to the introduction of senescence or pro-apoptotic
functions. Direct observation of growing cells and of material shed into
tissue culture media is a simple but valuable methods of assessing
growth arrest and cell death. FACS analysis can indicate early changes
in apoptosis (Annexin V assay) and combined early and late markers of
cell death (Fluoro-TUNEL test).
The clonogenic soft agar assay
The capacity of tumour cells to grow on a non-solid surface is a
defining characteristic. Several assays have been developed based
around the ability of tumour cells to grow in soft (0.3%) agar. The
clonogenic soft agar assay correlates most closely as an in-vitro test
with in-vivo tumorigenicity.
1.6.8.4 Invasion assays
Connective tissues have been used to assess tumour cell invasion in-
vitro. However, tissue systems such as bladder wall (Hart and Fidler,
1978), amnion (Fiotta et al, 1980), chicken chorioallantoic membrane
(Marcel et al, 1981), and lens capsule (Starkey, 1984) have proved
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difficult to standardise. In order to improve reproducibility and
introduce quantitation to the tumour cell invasion assay, reconstituted
basement membrane has been used as the basis of several such assays.
In 1986, Terranova and colleagues (Terranova et al, 1986) constructed a
compressed disc composed of laminin and collagens type I and IV.
They used this disc as a barrier to assess tumour cell invasion in a
Boyden chamber (a modified tissue culture chamber composed of a
fenestrated filter that allows the passage of cells upon which the disc is
placed).
In 1982, Kleinman and colleagues had developed a method for
extracting a multicomponent preparation of natural solubilised tissue
basement membrane from the Engelbreth-Holm-Swarm (EHS) mouse
sarcoma, a tumour rich in extracellular matrix proteins (Kleinman et
al, 1982). This preparation was commercially produced as a
standardised preparation called Matrigel. Matrigel is composed
principally of laminin and collagen type-IV. It also contains heparan
sulphate proteoglycans, entactin and nidogen. It also contains TGF-B,
FGF, tPA and other growth factors.
In 1987, Albini and co-workers used Matrigel to coat the porous filters
of a Boyden chamber and thereby developed the first reproducible
quantitative tumour cell invasion assay (Albini et al, 1987). Further
refinements followed with the adaptation of the quantitative
colorimetric MTT assay to the method in 1990 (Schlechte et al, 1990)
and improvements in the uniformity of matrigel coating by water-
repellent treatment of the Boyden chamber (Imamura et al, 11994).
1.6.8.5 Tumour cell attachment assay
Attachment of cells to tissue culture plastic can be assessed
quantitatively. Alterations in tumour cell attachment as a result of
introduction of a TSG may be specific for receptors binding individual
components of the ECM. The attachment assay therefore involves
coating the tissue culture plastic with purified components of the ECM
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such as collagen IV, fibronectin or laminin. The cells can then be
assayed for their specific ability to attach to particular components of
the ECM before and after introduction of a TSG, and therefore
alterations in integrin pathway regulation as a result of TSG
introduction can be addressed.
1.6.8.6 Tumour cell migration assay
In a similar way, introduction of a TSG may correct signal transduction
pathways that allow the cell once more to respond to specific growth
inhibitory signals, reflecting a reduction in cell migration. These assays
are performed in transwells similar to Boyden chamber used in
invasion assays.
1.6.9 Chromosome 11 tumour suppression studies in human cancer
cell lines
The first demonstration of transfer of a single human chromosome to
a human tumour cell line was reported by Saxon and colleagues in
1986 (Saxon et al 1986). A human fibroblast cell line was identified with
a balanced translocation chromosome , t(X; 11) with llpter-q23
translocated to Xq26-qter, thereby translocating the HPRT marker to
chromosome 11. This cell line was fused to HPRT deficient A9 cells
and a resulting somatic cell hybrid clone was used as a microcell donor
line. A somatic cell hybrid between HeLa and normal human
fibroblasts, originally non-tumorigenic, which had reverted to
tumorigenicity and was also HPRT", was used as recipient.
Transfer of t(X; 11) to the hybrid and also to HeLa cell line suppressed
subcutaneous tumorigenicity in nude mice whereas MMCT of the X
chromosome did not. The HeLa tumour suppressor was localised to
llq by mapping of the microcell hybrids (Misra et al, 1989)
The same translocated chromosome 11 was shown to suppress
tumorigenicity in the HPRT" variant of the Wilms' tumour cell line
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G401. In the same series of experiments the X chromosome and a t(X;
13) did not suppress tumorigenicity of G401 (Weissman et al, 1987).
Using a [der(ll)t(X;llp)(q21;ql3)] Dowdy and colleagues showed that
llpter-ql3 suppressed the tumorigenicity of G401. They then generated
two radiation reduced hybrids, one with a deletion of Ilpl5.5-pl4.1 and
the other with a deletion of Ilpl3-pl2. Only the latter suppressed
tumorigenicity. This excluded the WT1 locus (Call et al, 1990; Gessler et
al, 1990)) as the tumour-suppressor gene in G401 Wilms' tumour cell
line and suggested that the suppressor lay within the interval pl5.5-
pl4.1. A second locus had been mapped in Wilms' tumour by LOH to
llpl5.5 (Reeve et al, 1989), dubbed WT2, and Dowdy and colleagues
therefore suggested that the functional locus mapped to this region
(Dowdy et al, 1991). More recently, the CDK inhibitor p57^P^ was
cloned by homology with p21 and p27 (Lee et al, 1995; Matsuoka et al,
1995) and was localised to llpl5.5, within a 500 kb region that includes
WT2. Northern analysis comparing G401 parent line, G401/chr 11
suppressed microcell hybrids, and G401/chr 11 non-suppressed hybrids
revealed no correlation of expression of the 0.8 Kb p57 transcript with
suppression of tumorigenicity, suggesting that p57 is not WT2 (Reid et
al, 1996).
In 1989, Koi and colleagues transferred a human chromosome 11 into
SiHa, a human cervical carcinoma cell line. In 4 out of five clones,
there was suppression of tumorigenicity, in the final clone there was a
reversion event causing loss of the introduced chromosome and
tumour forming ability in nude mice (Koi et al, 1989). This work was
extended by the same group, demonstrating that chromosome 11 could
suppress tumorigenicity of the human endometrial carcinoma cell line
HHUA and the human rhabdomyosarcoma cell line A204 but that
there was no effect of this chromosome in the human renal carcinoma
cell line YCR-1 (Oshimura et al, 1990). The suppressor region was
localised to llpl5 in rhabdomyosarcoma cells, but a second growth
suppressor was mapped to the long arm in these cells since hybrids
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carrying only the long arm were also inhibited for growth (Loh et al,
1992).
In an attempt to further localise the site of this llpl5 suppressor in
rhabdomyosarcoma cells, Koi and colleagues constructed an elegant
strategy using "subchromosomal transferable fragments" or STFs (Koi
et al, 1993). Until this work, a direct route from functional whole
chromosomes to a positional map of the region containing the
suppressor gene was difficult to achieve. This is because the whole
chromosome is a stable transferable fragment, the selectable marker is
located distantly, and it is therefore too big to localise a gene region by
any means other than a serendipitous rare breakage event located close
to the gene. Although yeast artificial chromosome (YAC) transfer is a
possible approach to localise the region, and has been achieved in
somatic cells, thousands of specific YACs would be required to cover
the chromosome. Furthermore, since the desired phenotype (growth
suppression) is normally selected against, direct expression cloning of
the suppressor gene of interest would be unlikely to be successful using
this method.
Koi's elegant strategy consisted of taking a t(ll;X) A9 somatic cell
hybrid and transfecting it with a neo^ plasmid. 18,000 neo^ clones
were pooled and used for MMCT to A9 cells, double selecting on FIAT
and G418. 90 clones that survived double selection were pooled and
microcells were generated from them and gamma-irradiated prior to
fusion. 85 neo^ A9 clones were isolated and characterised. Nine llpl5
fragments were transferred to Chinese hamster ovary cells as
unchanged fragments and these A9 donors therefore contained stable
subchromosomal transferable fragments (STFs). These STFs were then
transferred to rhabdomyosarcoma cell line RD. The llpl5 STFs
suppressed growth of this line. Using RFLP analysis, the critical region
was mapped to a 6 Mb region on llpl5.5. It is intriguing to note that
the 500 Kb region encompassing the centromeric end of this region is
the same region defined by Weissman's group as containing the WT2
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locus and p57 (Reid et al, 1996). Interestingly, in a series of 75 soft tissue
sarcomas and 51 Wilms' tumours, analysis of the p57^P^ gene by
Southern blot, comparative multiplex PCR, PCR-SSCP, and DNA
sequencing failed to reveal any deletions or point mutations (Orlow et
al, 1996), further suggestive evidence that the WT2 locus may be the
same for Wilms' tumour and rhabdomyosarcoma and is not p57.
Negrini demonstrated that chromosome 11 suppressed tumorigenicity
of MCF-7 breast cancer cell line but had no effect on the tumorigenicity
of the MDA-MB-231 breast cancer line. Additionally, MCF-7 microcell
hybrids that lost the p-arm regained tumorigenicity but remained
significantly growth suppressed, this being the third piece of functional
evidence for an llq suppressor gene (Negrini et al, 1994) after the
observations in HeLa (Misra et al, 1989) and rhabdomyosarcoma (Loh
et al, 1992). Recently, it has been shown that although chromosome 11
does not suppress the tumorigenicity of the MDA-MB-435 cell line, it
does abolish the in-vivo formation of metastases (Phillips et al, 1996).
Chromosome 11 has also been shown to suppress tumorigenicity of
human cell lines derived from cutaneous carcinoma (Conway et al,
1992), lung adenocarcinoma (Satoh et al, 1993), thyroid carcinoma
(Yoshida et al, 1994), neuroepithelioma (Chen et al, 1995).
Chromosome 11 has also been transferred to ovarian cancer cell lines
(see below).
Additionally, chromosome 11 transfer showed no suppression of
tumorigenicity of human cell lines derived from colorectal carcinoma
(Tanaka et al, 1991) and renal carcinoma (Yoshida et al, 1994).
However, inhibition of in-vitro growth rate was observed for the
colorectal carcinoma cell line (Tanaka et al, 1991).
1.6.10 Suppression of the cancer phenotype by transfer of other
chromosomes
There have been over 130 publications utilising microcell transfer
since Saxon's first experiments with MMCT into HeLa. Many of these
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have been performed using normal human chromosomes transferred
into human cancer cell lines. This information is summarised in table
1.7.
In only one case has the functional approach resulted in cloning of a
novel tumour suppressor gene (Ichikawa et al 1992, Dong et al, 1995,
see below).
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Table 1.7a Functional analysis by MMCT in different cancer cell lines
chr 1 chr 2 chr 3 chr 4 chr 5 chr 6 chr 7 chr 8 chr 9 chr 10
Fibrosarcoma Tum.Sup HT1080 No Effect HT1080 No Effect HT1080
(Kugoh el at. 1990) Kugoh el al. 1990) (Kugoh et al. 1990)
Tum.Sup 1q23 HT1080
(Klein el al , 1994)
Rhabdomyosarcoma
Renal Carcinoma Tum.Sup 3p YCR
(Shimizu et al. 1990)
Senesc. 3p14 SN12C
(Sanchez el al, 1994)
Tum.Sup 3p No Effect
(Yoshida et al. 1994) (Yoshida et al, 1994b)
Colon Carcinoma Tum.Sup 1p36 COKFu No Effect HCT 116 Senesc. HCT116 Tum.Sup COKFu Tum.Sup/I.S. 8p12-ter COKFu
(Tanaka el at. 1993) (Koi et al. 1994) (Koi et al. 1994) (Tanaka et al, 1991) (Tanaka et al 1996)
Tum.Sup
(Rodriguez-Alfagemo et al 1992)
Tum.Sup. SW480
(Goyette et al 1992)
Breast Carcinoma Tum.Sup MDA-MB-231 6q2
Senesc. MCF-7 6q2
(Negrini et al 1994)
Ovarian Carcinoma Tum.Sup 3p23-24.2 HEY Senesc. 6q14-21SKOV3
(Rimessi et al, 1994) (Sandhu et al, 1996)
Lung Carcinoma Tum.Sup A549 Tum.Sup A549
(Satoh et al, 1993) (Satoh et al. 1993)
Melanoma Tum.Sup
(Trent et al, 1990)
Met.Sup. C8161
(Welch et al, 1994)
Tum.Sup UACC903 dose effect
Growth Sup. MelJuSo
(Robertson et al. 1996)
Neuroepithelioma
Cervical Carcinoma
Endometrial Carcinoma Tum.Sup. HHUA Tum.Sup HHUA Tum.Sup HHUA
(Yamada el al. 1990) (Yamada et al, 1990) (Yamada et al, 1990)
Wilms' Tumour
Glioblastoma No Effect U251 Tum.Sup U251
(Pershouse el al. 1993) (Pershouse t al, 199:
Prostatic Carcinoma No Effect DU145 Tum.Sup PC3 Met.Sup. Tum.Sup
(Berube el al, 1994) (Ewing al. 1995) (Ichikawa et al, 1994) (Banerjee et al, 1992)
Teratocarcinoma Tum.Sup PA Tum.Sup PA-1
(McGowan-Jordan et al. 1994) (McGowan-Jordan et al, 1994)
Oral Carcinoma Tum.Sup 3p HSC2/3/4 No Effect HSC2/4
(Uzawa et al, 1995) Tum.Sup HSC3
(Uzawa et al, 1995)
Neuroblastoma Senesc. t(X;1p) NGP.1A
No Effect t(X;1q) NGP.1A
(Bader et al. 1991)
Cutaneous Carcinoma
Thyroid Carcinoma No Effect TTA-1
(Yoshida et al, 1994a)
Osteosarcoma
Tum.Sup= tumour suppression. senesc=senescence. Cell line
used is given, as is the chromosome fragment when
determined.
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Table 1.7b Functional analysis by MMCT in different cancer cell lines
(continued)
X-chromosome
Fibrosarcoma Turn. Sup HT1080
(Kugoh et al, 1990)
No Effect HT1080 No Effect HT1080
(Kugoh et al, 1990) Anderson et al, 1994)
Rhabdomyosarcoma Tum.Sup R.D. 11 p15
(Koi et al, 1993)
Growth Sup. A204 11p15, 11q
(Loh et al, 1992)
Renal Carcinoma
No Effect
(Yoshida et al, 1994)
Colon Carcinoma No Effect COKFu
(Tanaka et al, 1991)
Breast Carcinoma um.Sup.11p/G.S. 11q MCF7
No Effect MDA








(Rimessi et al, 1994)
Tum.Sup. A549




(Chen et al, 1995)
Tum.Sup. t(11;X) HeLa
(Saxon et al, 1986)
Tum.Sup. SiHa
(Koi et al, 1989)
Endometrial Carcinoma Tum.Sup. HHUA




(Weissman et al, 1987)
Tum.Sup. 11p15.5-14 G401
(Dowdy et al, 1991)
Turn.Sup. COKFu
(Tanaka et al, 1991)
No Effect SW480 Senesc. SW480
(Goyette et al 199.oyette et al 1992)
Growth Sup. SW480
(Goyette et al 1992)
No Effect MCF-7 Senesc. MCF-7 non p53
(Casey et al, 1993) (Casey et al, 1993)
Senesc. MCF-7/MDA = p53
(Negrini et al 1994)
Tum.Sup.not p53/NM23
(Rinker-Schaeffer et al, 1994)
Tum.Sup. CAL51 not p53/BRCA1
(Theile et al, 1995)
Senesc.








(Chen et al, 1995)
Tum.Sup.. HHUA
(Yamada et al, 1990)
No Effect
(Weissman et al, 1987)
No Effect
(Weissman et al, 191
Prostatic Carcinoma Met. Sup.
(Ichikawa et al, 1992)
Met. Sup.
(Rinker-Schaeffer et al, 1994)
Tum.Sup. 12q13 DU145




(McGowan-Jordan et al, 1994)
Neuroblastoma Differentiate NGP.1A
(Bader et al, 1991)
Met. Sup.
(Rinker-Schaeffer et al, 1994)
Tum.Sup. NGP.1A





(Conway et al, 1992)
Tum.Sup. TTA-1
(Yoshida et al, 1994)
Senesc.
(Banerjee et at, 1992)
Tum.Sup=tumour suppression. senesc=senescence. Cell line used is
given, as is the chromosome fragment when determined.
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1.6.9 Functional cloning of a chromosome 11 metastasis suppressor
gene
The only example to date of functional cloning of any tumour
suppressor gene was the cloning of KAI1 (kang ai, Chinese for
anticancer) by Dong and colleagues (1995). They initially showed that
metastatic ability of rat AT6.1 prostate cancer cells was suppressed by
fusion with non-metastatic cancer cells (Ichikawa et al, 1991). MMCT of
human chromosome 11 suppressed metastatic ability, and the gene
was mapped from these hybrids to llpll.2-13 (Ichikawa et al, 1992).
They isolated human genomic DNA fragments from metastasis
suppressed rat prostate cancer cells bearing only the llcen-pl3
chromosomal region using human-specific Alu-element mediated
PCR (Alu-PCR). The Inter-Alu fragments of unique DNA were then
used to screen a cDNA library derived from the same cell line. Five
cDNAs were obtained which were expressed in suppressed but not in
metastatic hybrids by RT-PCR. One of the sequences designated KAI1
was localised to llpll.2by FISPl. Northern analysis revealed that KAI1
encoded a 2.4 Kb transcript, and was expressed in non-metastatic rat
prostate cancer cells and normal human tissue, but not in the
metastatic line and hybrids. KAI1 encodes a 267 amino acid protein
with transmembrane domains. KAI1 was cloned into an expression
vector and transfected into AT6.1 rat prostate cancer cells, which
resulted in suppression of lung metastases in-vivo, inhibition of
invasive ability but no alteration of growth rate in-vitro.
KAI1 belongs to a family of membrane glycoproteins called the
Leucocyte surface proteins which are thought to function in cell-cell
and cell-ECM interactions. Clearly, a functional assay using rodent cells
greatly facilitated the cloning of this gene, and represents a paradigm in
functional cloning of tumour suppressor genes.
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1.6.11 Ovarian carcinoma tumour suppression by monochromosome
transfer
Ovarian cancer has been the subject of functional analysis using
several monochromosomes. In 1993 Cao and co-workers presented a
poster showing that they had introduced normal chromosomes 11 and
19 into HOC8, a human ovarian cancer cell line. Whilst chromosome
19 had no effect on HOC8, chromosome 11 prolonged the doubling
time of HOC8 and reduced the soft agar colony forming efficiency of
these cells (Cao et al, 1993). In-vivo tumorigenicity was not assessed.
However, this work remains unpublished after 4 years.
In 1995 another poster was presented by the same group (Cao et al,
1995) this time presenting results of transferring chromosomes 11 and
17 to the human ovarian cancer cell line SKOV-3, and demonstrated
that in-vitro doubling time was prolonged for both chromosome 11
and 17 introduction. In-vivo suppression of tumorigenicity in nude
mice was observed in 2 of 4 chromosome 17/SKOV-3 microcell hybrids
and in 3 of 5 chromosome 11 /SKOV-3 microcell hybrids.
Rimessi and colleagues transferred chromosomes 3 and 11 into an
ovarian carcinoma cell line HEY (Rimessi et al, 1995).
Chromosome 3 powerfully suppressed tumorigenicity and altered the
phenotype of HEY cells. By deletion mapping of hybrids that were not
suppressed for tumorigenicity, three regions were found to be
involved, two regions in the interval 3p23-24.2 and one at 3p21.1-21.2.
These regions concur with the LOH analysis in sporadic ovarian
cancers which localised the region to 3p21-p25 (Ehlen and Dubeau,
1990) and do not include the recently cloned FHIT gene (encompassing
the fragile site at 3pl4.2) involved in renal, gastrointestinal and lung
cancer (Ohta et al, 1996; Sozzi et al, 1996). A candidate gene involved in
mismatch repair has been cloned from the 3p21-p23 interval (Bronner
et al, 1994), but its role in ovarian cancer is not yet determined.
The effect of chromosome 11 introduction into HEY cells was
markedly different. Cellular morphology and the immortalised
phenotype were unaltered. However, the in vitro growth rate and
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clonogenicity in soft agar were reduced. Tumorigenicity was not
consistently controlled by chromosome 11 transfer. Although Rimessi
and colleagues downgrade the role of chromosome 11 since it does not
suppress tumorigenicity in the nude mouse assay, the pattern that they
and Cao's group observed might, in fact, be quite consistent with the
action of a late-acting tumour progression suppressor which although
it does not determine fundamental neoplasia, has more subtle effects
not easily detected using the crude assays available, perhaps reflected
here in altered growth rate and cloning efficiency, but nevertheless is a
powerful determinant of tumour progression. The work of Negrini
and colleagues and of Phillips and colleagues (see above) clearly
demonstrate that although chromosome 11 does not suppress
tumorigenicity of the MD-MBA breast carcinoma cell line, it does
suppress the formation of metastases produced by the cell line,
arguably as important a clinical endpoint as subcutaneous
tumorigenicity. This raises interesting questions about the
appropriateness of subcutaneous xenograft tumorigenicity in
immunodepleted rodents as the only - or even the major - end point
of chromosome transfer experiments designed to look for functionally
important tumour suppressor genes, given that the clinical course of
cancers may be strongly influenced by genetic events occurring later in
the evolution of the disease.
Introduction of the X chromosome seems to carry a functional
senescence gene (Horikawa et al, 1996)
Transfer of chromosome 6 also causes senescence of ovarian cancer
lines SKOV3, OVCAR3,, whereas chromosome 10 and 14 do not
(Sandhu et al, 1996). Sandhu and colleagues went on to show that
introduction of the chromosomal fragment 6ql3-q21 restored
senescence to human and rat ovarian cell lines. They designated this
locus SEN6A, distinct from the SEN6 locus located in the interval
6q21-qter which restores senescence to SV40 immortalised human
fibroblasts but not to ovarian tumour cells(Sandhu et al 1994). LOH
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data implicate three distinct regions of chromosome 6q: 6ql4-ql5,
6ql6.3-q21 and 6q21-q23 in the progression of ovarian cancer (Orphanos
et al, 1995).
Another group performing the same experiment transferring
chromosome 6 into SKOV-3 and HEY cells did not induce senescence
but did completely suppress tumorigenicity and anchorage
independence of these cell lines, whereas introduction of chromosome
llq produced no measurable phenotypic change (Wan et al, 1996). It is
therefore clear that under differing laboratory conditions, a senescence
function may be a non-senescent tumour suppressor in the same cell
line, raising the possibility that the earlier definitions of workers may
be to some extent merging.
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Fresh primary ovarian tumour tissue from 60 patients was transferred
directly to dry ice or liquid nitrogen and stored at -70°C until
processing. Heparinised blood was obtained from 39 of these patients
post-operatively. For the remaining 21 patients fragmented
constitutive DNA was extracted from regions of normal tissue from
formalin fixed blocks. FIGO staging, histopathology and differentiation
state were determined and reviewed in a standardised fashion at a
multidisciplinary combined gynaecological oncology clinic. Treatment
was planned and delivered in accordance with standard protocols
implemented by the multidisciplinary clinic at the time, which
consisted of the best possible surgical debulking followed by
adjuvant/palliative chemotherapy. The principal chemotherapeutic
agents used were chlorambucil, cis-platinum and carboplatinum.
Follow-up data on this group are therefore complete and
comprehensive. Minimum follow-up is 24 months, and all deaths that
have occurred have been due to ovarian cancer. Patient characteristics
are outlined in table 3.1(LOH results).
2.1.2 Extraction of High Molecular Weight DNA
Up to 3 X 107 Cells were harvested by centrifuging at 1200 rpm for 5
minutes. The supernatant was removed without disturbing the cell
pellet. 6 ml reagent B was added to the tube and the cells were
resuspended by brief vortexing. The solution was transferred to a 15 ml
polypropylene tube, and 45 pi of 50 pg/ml RNAase A solution was
added and incubated for 30 minutes at 37°C.
Deproteinisation was performed by adding 1.5 ml 5M sodium
perchlorate and shaking the solution on a shaker for 15 minutes at
room temperature. The tube was then incubated at 65°C for 25 minutes
in a shaking water bath.
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DNA extraction was then performed by adding 5.5 ml cold chloroform
(stored at -20°C) and placing the tubes on a rotary shaker for 10
minutes. The solution was then centrifuged at 1200 rpm for 1 minute
to separate the phases and 800 pi of Nucleon silica suspension was
added. The solution was then centrifuged at 1800 rpm for 3 minutes.
The DNA in the top phase was transferred to a fresh tube and
centrifuged to remove any remaining silica; the solution was
transferred to a second fresh tube. Two volumes of cold Ethanol 100%
were added to precipitate the DNA. A Pasteur pipette was sealed and
bent using heat and the DNA was spooled out and left to dry on the
bench overnight. It was resuspended in 2 ml 1 X TE and the
concentration was estimated by spectrophotometry. The final
concentration was adjusted to 1 mg/ml.
2.1.3 Rapid Miniprep Extraction Of DNA For Microsatellite Analysis
This was conveniently performed using the QIAamp DNA extraction
kit (Qiagen):
107 washed cells were suspended in a final volume of 200 pi PBS.
25 pi Proteinase K stock solution and 200 pi buffer AL were added and
the solution was mixed by vortexing.
The solution was incubated for 10 min at 70°C.
210 pi of 100% ethanol was added and the solutions were mixed by
vortexing.
The lysate was applied to a QIAamp spin column and centrifuged for 1
min at 8000 rpm.
The solution was washed with 500 pi of buffer AW and centrifuged for
1 min at 8000 rpm and repeated.
200 pi 10 mM Tris-HCl pH 9.0 were added ( preheated to 70°C) and
centrifuged for 1 min at 8000 rpm to elute the DNA, which was stored
at 4°C after the concentration was estimated using spectrophotometry.
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2.1.4 Extraction Of DNA From Fixed Archival Material
Extraction of DNA from fixed specimens was performed by cutting 3
xlO [im sections from the block, dewaxing in xylene for 30 min. twice,
removing the xylene by washing 3 times in ethanol 100%, and
desiccating the specimen under heat. Proteinase K (200 pg/ml)
digestion was performed overnight at 37^C and then the proteinase K
was heat inactivated at 95®C for 5 min and debris was removed by
centrifugation . The resultant preparation provided adequate DNA
template for PCR.
2.1.5 Quantification of DNA by spectrophotometry
5 pi of the DNA solution were added to 995 pi TE ( 1 in 200 dilution).
Spectrophotometric reading of absorbance at 260 nm (O.D. 260) is
proportional to the concentration of DNA in the sample. Absorbance
at 280 nm divided by absorbance at 260 nm indicates the purity of the
sample. A value of 1.8 is optimal and ratios below this indicate
contamination of the sample, an O.D. 260 of 1.0 is equivalent to a DNA
concentration of 50 pg /ml, allowing simple proportional calculations
to determine DNA concentration of any sample.
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2.2 Polymerase chain reaction
Analysis Of Polymorphic Microsatellites By PCR
Oligonucleotides were obtained from the MRC Human Genetics Unit
nucleotide synthesis service and from the ICRF oligonucleotide
laboratory. The primers were selected on the basis of recently
generated microsatellite index maps (Gyapay et al, 1994; Litt et al, 1993;
Weissenbach et al, 1992; Couillin et al, 1994) for locus, informativeness
and spacing. A recently generated high resolution radiation hybrid
map allowed reasonable estimates of physical distances separating
these markers (James et al, 1994). Table 2.1 shows all the primers used
for polymorphic microsatellite mapping in this project, their locus
symbols, their locations, and associated references. For microsatellite
analysis of chromosome fragments transferred by microcell mediated
chromosome transfer, fluoresceinated primers were used and analysed
using the ALF system (see below).
2.2.1 Polymerase chain reaction and polymorphic microsatellite
detection
Essentially, two standard PCR programmes were used for the
microsatellite analysis of patient material:
PCR was performed in a reaction volume of 50 pi under the following
reaction conditions: The first programme was (94°C for 3 min) x 1,
(94°C for 1 min/55°C for 1 min/72°C for 1 min) x 35, (72°C for 5 min) x 1
in a Hybaid thermocycler. For other primers, a touchdown PCR
programme was used:
Reaction mix contained 50 mM K CI, 10 mM Tris-HCl pH 9, 1% Triton
X-100,1.5 mM Mg CI2, 200 uM deoxyribonucleotide triphosphates, 1.25u
Taq polymerase, 10 pmol of each primer, and 100 ng DNA.
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2.2.2 Checking Of PCR Products By Agarose Gel Electrophoresis
Reaction product was checked on standard 2% agarose run at 100-150
volts in 1 X TAE, stained with ethidium bromide and visualised under
UV light.
2.2.3 Separation Of Alleles By Denaturing Polyacrylamide Gel
Electrophoresis
10 pi of the PCR reaction product was loaded onto 9% or 6%
(sequencing) denaturing polyacrylamide gel run in 1 X TBE, and
separated by electrophoresis(55 watts for 6 hours for sequencing gels;
300 volts for 5-6 hours for 9% Biorad gels)
Multiple loadings can be performed per track,
2.2.4 Passive Transfer Of DNA To Nylon Filter
Separated DNA was passively transferred to Hybond nylon by laying a
distilled-water soaked hybond sheet on the polyacrylamide, covering
with four sheets of whatman filter paper, and placing a glass plate and
weight on top. Passive transfer was allowed to occur overnight. The
filter was peeled off the polyacrylamide, washed in 1 X TBE to remove
residual polyacrylamide and urea, dried between blotting paper sheets
and the DNA was then covalently linked by exposure of the DNA side
of the filter to UV light for 4 minutes.
2.2.5 Radiolabelling Of DNA For Detection Of Alleles
Detection of the alleles was performed by hybridisation of the filter
with ^P end-labelled poly(CA) probe. The single stranded (CA^
oligonucleotide was synthesised an 10 pg of this probe was mixed with
50 uCi of gamma ^2p dATP and 0.3u polynucleotide kinase
(Boehringer) and 1 X end labelling reaction buffer (Boehringer) in 20 pi
final volume, and incubated for 30 min at 37^C.
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2.2.6 Hybridisation Of Membranes
Pre-hybridisation and hybridisation were performed using the same






20 X SSC 250 ml
made up to 1 litre with distilled water.
Pre-hybridisation of the filter was for 10 minutes at 48^C The fluid was
then replaced with fresh hybridisation mix containing the end-labelled
(CA) repeat olignucleotide and the filter was hybridised at 48^C for 4
hours. The filter was then washed in 4 X SSC at 48^C for 15 minutes
four times, and sealed in a plastic bag.
2.2.7 Detection Of Hybridisation
The filter was placed in a light-tight cassette with X-ray film and
exposed for varying amounts of time at room temperature, and then
developed. Two observers visually analysed the autoradiographs and
recorded allele imbalance when there was clear reduction in intensity
of one allele in tumour DNA. Multiple autoradiographs with different
exposure times are usually required since the sensitivity of detecting
allele imbalance varies with the intensity of signal. PCR's were
repeated at least twice until unequivocal results were obtained. For
detailed analysis of the Ilq22-q24 region, computerised densitometric
analysis was then performed on high-resolution flat-bed scanned
autoradiographs using Bio-image whole band analyser software system
on a SUN SPARC UNIX platform. The relative ratio of alleles was
determined, normalised and compared. Where the tumour allele ratio
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differed from the normal allele ratio by 30% or more (r < 0.7), LOH was
assigned.
2.3 Statistical Methods
The two-tailed Fisher's exact test was used to determine if there were
significant associations between LOH at different loci on chromosome
11 and 17. The same univariate analysis was applied to examine
relationships between LOH at any locus and FIGO stage, differentiation
grade, histological subtype or survival. Since numerous Fisher's
analyses were carried out, the cut-off for significance was set at p=0.01,
but we have included trends towards significance in the region of
0.07>p>0.01 where they have supported or suggested biological
hypotheses. Kaplan-Meier/ log-rank analysis was performed to
determine any relationship between LOH and survival. Multivariate
analysis was not attempted since the small initial population
precluded further reduction in number by sub-grouping for this type of
analysis.
Mann-Whitney U-test was used to compare the means and medians of
tumour PR content in populations with and without LOH for the
three microsatellite markers. Two-tailed p values were calculated.
Spearman rank correlation was used to examine correlations between
tumour ER and PR content in those with and without LOH.
Kaplan-Meier/ log-rank analysis was performed to determine any
relationship between allele loss and survival in D11S35 informative
subgroups.
Students' t-test and ANOVA were used to compare microcell hybrid
and parental control cell lines for functional assays.
2.4 Mouse Interspersed Repetitive Sequence PCR (IRS-PCR)
Microcell mediated chromosome transfer is thought to transfer single
chromosomes only. This conclusion is derived from karyotypic
analysis of microcell hybrids. The possibility was considered that small
fragments of mouse chromatin might be co-transferred, since
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microcells containing only one chromosome are statistically common
only as a result of size fractionation. Two methods were tested to look
for murine DNA of reduced genomic complexity. One method,
chromosome painting of the microcell hybrid with mouse cot-1
fluorescently labelled DNA is considered later. The other method,
outlined here, utilises PCR primers recognising different murine
repeat elements which orientate the direction of DNA synthesis in the
polymerase chain reaction out of the repeat element and into unique
DNA. Using such primer combinations that recognise different repeat
elements, a distinct PCR fingerprint is generated from any microcell
hybrid containing even small, sub-karyotypic, co-transferred fragments
of mouse DNA.
For this method, four such primers were utilised: LI, Bl, B2A and B2B.
LI is derived from the murine LI repeat is the most abundant member
of the long interspersed nuclear element (LINE) family, of which there
are 70-100,000 copies in the mouse genome. The most frequently found
members of the short interspersed nuclear repeat element (SINE)
family in the mouse are the Bl (130-180,000 copies) and B2 (80-120,00
copies) repeats. Oligonucleotide primers derived from these sequences
have been designed with their 3' ends directed out of the element and
into unique DNA (Cox et al 1991). These sequences are outlined in
Table 2.2. Empirically, the best fingerprint patterns were produced
using a combination of primers LI and Bl.
Table 2.2 Sequence of murine repeat PCR primers
Locus Primer sequence Refs.
Bl 5'GTCCGGCCGCCTGGAACTCACTCTGAAG Cox et al
AC 3' 1991
B2A 5'TAGACGCGGCCGCTCTTCTGGAGTGTCTG Cox et al
AAGA3' 1991
B2B 5'TAGACGCGGCCGCGACTGCTCTTCCGAA Cox et al
GGTCC3' 1991
LI 5'GGACGCAGATGTAGCTGTCTCTTGTGAG Simmler et
AC37 al 1991
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The optimal PCR reaction conditions for these primers were:
(94°C for 3 min.) X 1;
(92°C for 30 sec., 60°C for 60 sec., 72°C for 3 min) X 35.
2.5 Automated Laser Fluorescence (ALF) analysis of microsatellites
2.5.1 Method
This method conveniently allows three polymorphic microsatellites to
be analysed simultaneously in one loading. One of a primer pair is
labelled with fluorescein and a PCR is performed. PCR product is
denatured and the sample is loaded onto ALF polyacrylamide gels and
electrophoresed. A fixed laser coupled to the gel stimulates the
fluorescent PCR products as they reach its fixed position during
electrophoresis and the light is detected simultaneously by 40
photodetectors corresponding to the sample lanes. Since two runs of 3
microsatellites can be performed, it is possible to analyse 240 samples
in 6 hours. The data is automatically downloaded for analysis by ALF
Fragment Manager software.
2.5.2 Generating size standards
Fluorescent size standards were generated by PCR of M13 DNA
template using various M13 PCR oligonucleotide primers
(oligonucleotides and M13 DNA were kindly provided by Marian
Thompson, MRC HGU) labelled with fluorescent dUTP that define
standard sizes of PCR product. The combination of primers used is
shown in table 2.3.
Table 2.3 M13 oligonucleotide primers and expected




D405 175 bp 229 bp




The size standards were run on a check agarose gel to confirm the
correct size was generated prior to use in ALF polyacrylamide gels
(figure 2.1).
Figure 2.1 Fluorescent size standards for ALF
2.5.3 PCR programmes
A standard PCR programme was used for the fluorescent primers:
(94°C for 3 min.) X 1;
(94°C for 30 sec., 55°C for 30 sec., 72°C for 1 min) X 35.
2.5.4 Gel casting
The gel cassette was thoroughly cleaned using a nylon brush and non-
fluorescent detergent. The plates were rinsed with distilled water.
Isopropanol was applied to both inside surfaces of the plates. The top 5
cm of the plates were treated with Bind-Silane:
Absolute alcohol 2 ml
Bind Silane 7.5 pi
10% Acetic acid 0.5 ml
made up and used immediately.
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The gel cassette was assembled and cast as a 50 ml 6% acrylamide / 7M
urea /IX TBE gel polymerised using 54 pi TEMED and 210 pi 10%
Ammonium persulphate. The comb was fitted and the gel was left to
set for 90 minutes.
2.5.5 Gel electrophoresis
The gel was inserted into the electrophoresis unit and was clamped
tightly ensuring that the laser beam ran across the detectors. 0.6 X TBE
was used as running buffer and the gel was pre-warmed for 15
minutes.
0.5 pi of each sample from three PCRs were loaded together with 4 pi
Stop buffer containing three appropriate size standards in addition.
Electrophoresis was performed at 50 watts for 180 minutes at 40°C. The
photodetectors sample light every 2 seconds and build an electronic
image of light intensity over time corresponding to fragment sizes.
2.5.6 Data analysis
Before printing a hard copy of the data, the size standards were
horizontally adjusted to super-impose them and delineate small (1-2
bp) size differences accurately between samples.
2.6 Enzyme Immunoassay For Quantitative Detection Of Oestrogen
And Progesterone Receptor
This assay was performed by technical staff at R.A. Hawkins' laboratory
at the Department of Surgery, Edinburgh Royal Infirmary.
Tumour specimens snap-frozen at operation were homogenised in
buffer (10 mM Tris, 0.25M sucrose, 1 mM EDTA, pH 8.0, plus 1% v/v
monothiolglycerol and 10% v/v glycerol) as previously described (37).
After centrifugation at 105,000#, the supernatant cytosol was assayed
using enzyme immunoassay kits according to the manufacturer's
method (ER-EIA and PR-EIA kits, Abbott Laboratories, Maidenhead,
Berkshire, UK)(38). The protein content of the cytosol was determined
by the method of Bradford (39) and receptor concentrations were
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expressed as fmol/mg protein. The PR antibody used was Kd68, a rat
monoclonal antibody which recognises both the A and B subunits of
PR ( and therefore recognises sequences downstream of codon 165, the
start site for subunit A) and binds both free and complexed PR receptor,
presumably avoiding the hormone binding site (40).
Recognising that cutoff values for steroid receptor levels are
controversial, ER-poor or PR-poor was defined as less than 30 fmol/mg
protein and ER-rich or PR-rich was defined as 30 fmol/mg protein or
more. These values derive from reports describing clonogenic assays
of human ovarian carcinoma cells from clinical specimens, human
ovarian cancer cell lines, and clinical work showing that these
approximate cut-off values for ER and PR represent a reasonable index
of hormone sensitivity (13, 41, 42).
2.7 Bacterial Culture And Plasmid Preparation
2.7.1 Media And Additives
All media was sterilised by autoclaving prior to use .
Terrific broth (TB)
12g Bacto-tryptone, 24g yeast extract, 4g glycerol per 900 ml distilled
water. After autoclaving, 100ml solution containing a final
concentration of 0.1M potassium dihydrogen phosphate and 0.72M
dipotassium hydrogen phosphate was added.
L-Broth and agar
2.46 g magnesium sulphate, 10 g Bacto-tryptone, 5 g yeast extract and 10
g sodium chloride per litre of distilled water. For L-Agar, 15 g agar was
added per litre of L-Broth
Ampicillin
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Ampicillin was added to the above media at a final concentration of
50jig/ml to select for bacteria carrying the amp antibiotic resistance
marker conferred by the plasmid transformed into the bacteria.
Ampicillin (Sigma) stock solution was prepared sterile at a final
concentration of 50 mg/ml and stored at -20°C.
2.7.2 Bacterial Strains
HB101 is a general purpose strain of E. coli used commonly in large
scale preparation of plasmids. It was generated in the late 1960's by
hybridisation of E. coli K12 and B strains and is highly transformable
(Maniatis et al, 1989).
2.7.3 Plasmids
Two plasmids were used for their capacity to confer resistance to hmB
and to G418.
tgCMV/HgTK (kindly donated by Dr Paul Dickinson), a 5Kb plasmid,
was able to confer resistance to hmB under the control of the CMV
promoter (Lupton et al, 1991).
pMClneoPolyA (kindly donated by Dr Julia Dorin) is a 3.8Kb plasmid
which expresses the Tn5 neo sequence under control of the TK
promoter and provides a polyadenylation signal for this gene (Thomas
and Capecchi, 1987).
2.7.4 Bacterial Transformation
A sterile loop was used to streak out the bacterial host strain from
frozen glycerol stock onto L-Agar plate. The next day a colony was used
to inoculate 5ml Terrific broth in a universal tube. This was incubated
overnight at 37°C on a shaker. 2 ml of this culture was used to
inoculate 100ml pre-warmed Terrific broth and the solution was
incubated as above until OD550 = 0.6 was achieved (usually 1-2 hours).
The culture was transferred to a chilled sterile flask and incubated on
ice for 20 minutes with gentle swirling to arrest cell division.The cells
were transferred to 50 ml tubes and pelleted by spinning for 5 minutes
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at 3000rpm at 4°C. The pellet was resuspended in 20 ml ice cold buffer I
(30mM potassium acetate, lOOmM rubidium chloride, lOmM calcium
chloride, 50mM manganese chloride, 15% glycerol (v/v), pH5.8 (using
filter sterilised acetic acid), stored at 4°C). The suspension was
incubated on ice for 15 minutes and thereafter the competent cells
were aliquoted into Eppendorf tubes in a dry ice/ethanol bath so that
the cells were snap-frozen, thereafter the cells were stored at -70°C
ready for heat-shock transformation.
immediately prior to heat shock transformation, a vial of competent
cells was thawed out on ice. 0.5pg of plasmid was added to the cells and
mixed gently.. The cells were incubated on ice for a further 20 minutes,
and then subjected to heat shock by insertion in a 42°C water bath for
90 seconds. The bacteria were then immediately chilled on ice for a
further 2 minutes and L-Broth was added to the Eppendorf to a final
volume of 1 ml. The Eppendorf was shaken overnight at 37°C and
then 100 pi of the culture was streaked out on L-Agar plates containing
ampicillin. The plates were incubated overnight in order to provide
Amp' colonies for large scale plasmid preparation.
2.7.5 Plasmid DNA Preparation
(After Maniatis, 1989). A single colony of the transformed HblOl
bacteria grown on L-Agar containing ampicillin was used to inoculate
500ml of Terrific Broth containing 50pg/ml ampicillin and the culture
was shaken overnight at 37°C. Next morning the cells were pelleted by
centrifugation (6000 rpm at 4°C for 10 minutes) and resuspended in 20
ml GET (50mM glucose, lOmM EDTA pH8.0, 25mM Tris pEI8.0). To
this solution, a further 20 ml GET was added containing 40 mg
lysozyme. The solution was mixed gently and incubated on ice for 30
minutes to promote cell lysis. 80 ml of Alkaline Lysis buffer (0.2M
sodium hydroxide, 1% SDS) at room temperature was then added to
complete lysis of the cells. The solution was gently stirred with a
bacterial loop until well mixed and then incubated on ice for 10
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minutes. 60 ml of high salt solution (5M acetate, 3M potassium) was
then added to precipitate the unwanted high molecular weight
bacterial DNA. The solution was stirred vigorously for 10 minutes,
placed on ice for a further 30 minutes and then centrifuged at 10,000
rpm for 10 minutes at 4°C without brake. The supernatant was
collected, filtered through muslin and 0.6 volumes of isopropanol
were added, mixed, and the solution was incubated for at room
temperature for 20 minutes. The solution was then centrifuged at
10,000 rpm for 10 minutes at 4°C without brake and the pellet was
washed with 70% ethanol and dissolved in 10 ml 7.5 M ammonium
acetate and incubated on ice for 20 minutes. The supernatant was then
centrifuged at 10,000 rpm for 20 minutes at 4°C and the supernatant
was collected. 2 volumes of 100% ethanol (-20°C) were added and the
solution was incubated for 20 minutes at -20°C then pelleted by
centrifugtion at 10,000 rpm for 10 minutes at 4°C. The plasmid pellet
was dried under vaccuum (5 minutes) and resuspended in 1 X TE (10
mM Tris Hcl pH 7.5, 1 mM EDTA). The solution was extracted with
phenol, phenol/chloroform, chloroform and the plasmid was re-
precipitated using 2 volumes of ethanol and pelleted as above. The
plasmid was resuspended in a final volume of 7 ml 1 X TE. 7g caesium
chloride and lOOpl ethidium bromide (10 mg/ml) were added to give a
concentration of 1.55 g/ml. This solution was divided between two
quickseal ultracentrifuge tubes and centrifuged for 18 hours at 100,000
rpm in a fixed-angle rotor ultracentrifuge. The covalently closed
circular DNA was seen as a band half way up the centrifuge tubeand
extracted using an 18 guage needle and 2 ml syringe and poled in a
polypropylene tube. The ethidium bromide was extracted using water
saturated butan-l-ol, discarding the organic phase repeatedly until it
was clear. The plasmid was precipitated by adding 3 volumes of sterile
water and 2 volumes of ethanol chilled to 4°C and refrigerated for 15
minutes, thereafter centrifuging at 10,000 rpm for 10 minutes at 4°C.
The pellet was vaccuum dried and resuspended in a volume of 500 pi 1
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X TE. The concentration of the plasmid was determined by
spectrophotometry.
2.7.6 Linearisation Of Plasmid DNA
The plasmids were linearised using the restriction enzyme Xho I
which cuts outwith the resistance marker in each of the plasmids. This
was done to improve the transfection efficiency of the plasmids. The
DNA was purified using the Sigma plasmid purification kit and used
for transfection.
98
2.8 Fluorescence in-situ hybridisation
Most of the Primed in-situ hybridisation and chromosome paint plates
presented in this thesis were performed by Dr Viv Watson, and I
gratefully acknowledge her help.
2.8.1 Metaphase Spreads From Cell Cultures
A confluent culture of cells in a T75 was used to re-seed a T75 as a 1 in
5 dilution in 12.5 ml. The flask was incubated until 60% confluent,
colcemid was added at a concentration of 100 ng/ml final
concentration was added and the flask was incubated for 5 hours. The
cells were shaken off and washed twice in PBS. The cells were pelleted
at 1200 rpm for 5 minutes and resuspended in 10 ml hypotonic
solution (60 mM K CI), with the first 4 drops added slowly to prevent
clumping, and were then incubated at 37^C for 15 minutes. The cells
were pelleted once more and resuspended in freshly made fix solution
(3:1 methanol: glacial acetic acid), adding the first ml of solution
dropwise while vortexing. The cells were stored for 1-5 days at 4^C.
The cells were then washed twice in 5 ml fresh fixative. The cells were
then resuspended in a small volume of fixatives such that the solution
was just cloudy. A single drop of this suspension was dropped from
height onto an acid cleaned glass slide that had been moistened with
condensation by breathing on it. The suspension was allowed to air dry
and observed by microscopy to confirm metaphase spreads. The slides
were stored under vacuum for subsequent in-situ hybridisation.
2.8.2 Primed in-situ hybridisation (PRINS)
The slides were dehydrated by passing the slides through an ethanol
series of 70%, 90% and 100% (3 minutes each). The slides were allowed
to air dry.
PRINS hybridisation mix was made up consisting of 250 ng primer (in
1 ,ul); 1 pi (10 mM) of each of dATP, dGTP and dCTP; 1 pi (1 mM) dTTP;
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1 pi FITC-dUTP; 5 pi PRINS buffer (0.5M K CI, 0.1M Tris H CI pH 8.3,
0.015M Mg C^, 0.1% BSA); 0.5 pi Taq polymerase (Cetus); 38.5 pi sterile
ddP^O. The PRINS hybridisation mix was aliquoted onto a large
coverslip and the slide was inverted and allowed to pick up the
coverslip by surface tension. The coverslip was sealed with vulcanised
rubber solution and allowed to dry in a closed box.
The slides were placed on the thermal cycler and a single denaturing
step at 94^C for 3 minutes followed by an annealing step of 60^C for 3
minutes and a single extension step of 72^C for 15 minutes was
sufficient.
The slides were immediately transferred to STOP mix (50 mM EDTA,
500 mM Na CI) at 65^C for 5 minutes and then rinsed in 4 X SSC. The
slide was then mounted directly in 40 pi Vectashield with DAPI and
PI(3.75 pi 100 pg /ml DAPI + 3.75 pi 20 pg /ml PI in 100 pi Vectashield)
to produce an R-(reverse) banding-like staining of the chromosomes.
The coverslip was sealed with vulcanised rubber solution.
2.8.3 Chromosome Painting
Slides were made as above but were allowed to age for 4-7 days before
use. The slides were dehydrated through 70%, 90% and 100% ethanol
(3 minutes each) and were allowed to air dry. Chromosome paint
(STAR*FISH Cambio) was warmed to 42^C and mixed well. 15 pi paint
was aliquoted for each slide and was denatured by incubating at 65^C
for 10 minutes. Pre-annealing was performed by incubating at 37^C for
15-60 minutes.
The slides were denatured in 70% formamide/ 2 X SSC at 68-70^C for 2
minutes. The slides were quenched in ice cold 70% ethanol and then
dehydrated again through 90% and 100% ethanol at room temperature
for 3 minutes each. The slides were allowed to air dry.
100
15 pi paint was placed on a pre-warmed coverslip, and sealed onto pre-
warmed slides. The slides were incubated overnight at 42^C.
The slides were then soaked in 2 X SSC at 42^C until the coverslip
floated off. They were then washed twice in 0.5 X SSC: 50% formamide
(1;1 mix of formamide + 1 X SSC) at 42^C for 5 minutes. The slides
were then washed twice in 2 X SSC at 42^C for 5 minutes. Finally the
slides were mounted in 40 pi Vectashield with DAPI and PI(3.75 pi 100
pg /ml DAPI + 3.75 pi 20 pg /ml PI in 100 pi Vectashield).
2.8.4 Microscopy
Samples were initially viewed under ultraviolet light using a Biorad
confocal microscope to identify metaphases which show specific
hybridisation signals. These metaphases were then scanned using a
laser directed through the confocal microscope. The confocal laser
scanning microscope contains two photomultiplier tubes enabling
signals of two different wavelengths to be collected simultaneously.
The two different wavelengths emitted by the FITC and PI can
therefore be collected when simultaneously excited by the laser. The
channels can be adjusted independently to alter or enhance the signal.
The image is sent to a computer screen using biorad software. The two
signals can be merged so that the FITC signal for the PRINS or paint
probe is superimposed on the PI signal from the chromosome. This
gives a composite image of the chromosome and metaphase spread of
interest. The images can be stored on an optical disc for future
reference.
2.9 Flow Cytometric Analysis
2.9.1 DNA Fluorescence Activated Cell Sorting (DNA-FACS) analysis
A single cell suspension was prepared by trypsinisation. Cells were
fixed and stained with propidium iodide to bind DNA, then passed
through the flow cytometer. Relative DNA content was assessed and
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distribution of the population of the cells with respect to the cell cycle
was observed. A typical DNA histogram is shown in Figure 2.2. Cells
are predominantly In with respect to DNA content, i.e., most are in
G0/Gj. The second peak is for those in G2/M phase post replication,
when cell DNA content is 2n. relatively few cells exist in S phase.
Figure 2.2 Typical FACS DNA histogram
2.9.2 FluoroTUNEL technique for Apoptotic Cells
Principle
This technique of fluoroTUNEL is an unpublished adaptation of the
TUNEL technique developed by Mike Sharrard and set up in our
laboratory by Eric Miller.
Programmed cell death (or apoptosis, its morphological equivalent),
when established, involves chromatin cleavage as a distinct
biochemical feature. Morphological recognition of apoptosis was often
difficult and subjective, and for this reason a more objective in-situ
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method was developed by Gavrieli and colleagues (Gavrieli et al, 1992).
This technique became known as TUNEL ( Terminal deoxynucleotide
transferase (TdT) mediated deoxy-Uridine triphosphate (dUTP) Nick-
End Labelling). This technique measures 3'-hydroxyl ends of DNA
fragments generated during programmed cell death. Terminal
deoxynucleotide transferase binds to the 3' ends of the fragmented
DNA and then generates synthesis of a polynucleotide polymer.
Biotinylated or digoxygeninylated deoxyuridine is incorporated at the
DNA strand breaks enabling histochemical identification of apoptosis
by light microscopy. Second layer FITC labelled anti-digoxygenin
antibodies have been used to enable fluorescent detection using
FACS(Goryczyca et al, 1994). However, in Dr Sharrard's protocol, there
is direct incorporation of FITC labelled dUTP which further simplifies
the protocol.
Method
10^ single cells were suspended in 1% paraformaldehyde for 10
minutes at room temperature. The cells were pelleted at 500g for 5
minutes and resuspended in 70% ethanol for 10 minutes at room
temperature. The cells were pelleted again and washed twice in TBS
(.05M Tris buffered Saline pH 7.5). 40 pi of 1 X TdT(terminal
deoxynucleotide transferase) reaction buffer added and cells were
resuspended for 10 minutes at room temperature. 25 pi TdT reaction
mix ( for 100 pi: 20 pi 5 X TdT buffer + 78 pi distilled water + 1 pi TdT +
1 pi Fluorosceinated dUTP) was added, mixed carefully and incubated
for 2h at 37^C. The cells were then washed twice in TBS and
resuspended in TBS. Apoptotic cells are then read on a display of green
fluorescence at flow cytometry. Apoptotic cells have high fluorescence
and side scatter. Necrotic cells have intermediate fluorescence and low
side scatter.
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2.9.3 Early Apoptosis detection using the FITC-Annexin-V assay
Principle
Annexin-V is a calcium and phospholipid binding protein, with a high
affinity for phosphlipids. Phospholipids such as phosphotidylserine
are normally only found on the inner surface of the cell membrane.
One of the earliest features of apoptosis is the loss of cell membrane
phospholipid symmetry, resulting in the exposure of
phosphotidylserine on to the outer membrane of the cell. Annexin-V
binding can therefore be useful in identifying cells undergoing early
apoptosis (Vermes et al, 1995). Binding will occur before the cell
becomes porous, and therefore if these cells are stained with
propidium iodide, they will not take up this dye into their nuclei.
Thus, at flow cytometry, three populations of cells can be identified;
live, non-apoptotic cells (PI negative, Annexin-V negative); necrotic
cells (PI positive, Annexin-V positive); and cells undergoing apoptosis
(PI negative, Annexin-V positive). Excitation wavelength was 488 nm.
The Annexin-V-FITC signal was detected in channel FL1, and the
propidium iodide signal was collected in channel FF2.
Method
The Apoptosis Detection Kit (R&D systems) was used for this
technique. Cells were washed twice in cold PBS and resuspended in 1 X
binding buffer (1 X HEPES / 0.25 mM Ca CI2) at a concentration of 10^
cells/ml. 100 pi cells were transferred to a 5 ml tube. 10 pi FITC-
Annexin-V and 10 pi propidium iodide were added, gently vortexed
and incubated for 15 minutes at room temperature in the dark. 400 pi
of 1 X binding buffer was added and the cells were analysed on a flow
cytometer immediately.
Controls were run of unstained, Annexin-V-FITC only stained, and PI
only stained cells.
Annexin-V associated fluorescence registers on the x-axis, propidium
iodide fluorescence registers on the y-axis. Thus the bottom left
quadrant consists of PI / Annexin V negative cells, i.e. non-apoptotic.
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The top right quadrant contains PI / Annexin V positive cells, i.e.
necrotic/late apoptotic (one cannot differentiate). The measure of early
apoptosis derives from the bottom right quadrant containing Annexin
positive PI negative cells.
Figure 2.3 shows typical results obtained with Colo 205 (top), a readily
apoptotic colorectal cell line which serves as a positive control. A
greater proportion of cells lie in the bottom right quadrant for this cell
line than OHN, a neo-transfected OH3 parent ovarian cancer cell line
(bottom).
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Figure 2.3 Dual FACS analysis of Annexin-V-FITC and
DNA-propidium iodide staining
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2.10 Mammalian Cell Culture and Techniques
2.10.1 General maintenance
Sterile conditions were maintained routinely. Cell lines were as far as
possible maintained on DMEM/10% FCS/P+S as far as possible. Cells
were routinely cultured in humidified incubators at 37® C, 5% CO2.
Sterile culture flasks, Universal tubes, freezing vials, glassware, and
solutions were used throughout. All tissue culture was carried out in a
laminar flow hood. Cells were harvested by washing twice in PBS and
incubating with a minimal amount of trypsin/versene. Cells were
resuspended in 10% FCS media and pelleted at 1200 rpm for 5 minutes
for further manipulation.
Cells were frozen in liquid nitrogen, after initial storage for 24 hours at
-70® C, preserved in freezing mix composed of 10% DMSO in FCS.
Recovery of the cells was effected by rapid thawing of the vial in a
beaker of water at 37® C, followed by two washes in media, and
plating in flasks.
2.10.2 Chromosome donor cell lines
MCF1556.1.5 is a mouse A9-human monochromosome somatic cell
hybrid containing a neo-tagged human chromosome 11 as its sole
human component (Bader et al 1991, Fugo et al 1987). A9(Neo-l)-4 is a
mouse A9-human monochromosome somatic cell hybrid containing
human chromosome 1 with integration of pSV2-neo into Ip34-p36 as
its sole human component (Koi et al 1989). A9(Neo-12)-4 is a mouse
A9-human monochromosome somatic cell hybrid containing human
chromosome 12 with integration of pSV2-neo into 12pl2 as its sole
human component (Koi et al 1989). These three cell lines were
maintained in DMEM/10%FCS/penicillin/streptomycin/G418 600 pg
/ml.
J1 C14 B/B1.22 is a Chinese hamster ovary- human monochromosome
somatic cell hybrid containing a single human chromosome 11 as the
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sole component which was precisely targeted using homologous
recombination into llql3 (Watson et al 1995).
2.10.3 Recipient cell lines
HeLa Ohio TK- was kindly provided by Aaron Cranston and Ivor
Hickey, maintained in RPMI/10%FCS/P+S. 278PH, 278HC1, 278HC2
and 278HC3 were derived by lipofection of pTKHyg (conferring
hygromycin-B, hmB resistance) into A2780, an ovarian cancer cell line
(Eva et al), and were maintained on DMEM/10%FCS/P+S/200 pg /ml
hmB.
PEOl and PE04 are poorly differentiated ovarian cancer cell lines
(Langdon et al 1988) maintained on DMEM/10%FCS/P+S.
OH3 is a cell line derived by lipofection (performed by JEV Watson and
K MacLeod)of pTKHyg into OVCAR3, a poorly differentiated ovarian
cancer cell line (Hamilton et al 1983), and maintained on
DMEM/10%FCS/P+S/hmB 75 pg /ml. OHX is a cell line derived from
a SCID mouse xenograft of OH3 and rescued back into cell culture
using hmB 100 pg /ml selection. OVCAR4 and OVCAR5 are ovarian
cancer cell lines maintained on DMEM/10%FCS/P+S.
2.10.4 Lipofection of plasmid DNA into cell lines
This technique utilises Lipofectin (BRL) which is a 1:1 (w/w) liposome
formulation of the cationic lipids DOTMA and DOPE in water. This
method was used to confer either neomycin or hygromycin resistance
to various cell lines, in order to provide clonal lines for further
somatic cell genetic manipulation and analysis.
The lipofectin amount was first optimised for each cell line, keeping
the amount of DNA and time for transfection constant. After this,
transfection was routinely performed.
Typically, 2 x 10^ cells per 60 mm dish in a six-well plate were seeded
and incubated for 24-48 hr until 30-50% confluent. Lipofectin and
plasmid were allowed to warm up to room temperature for at least 20
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minutes prior to use. A similar length of incubation time for DMEM
(serum-free and 10%FCS, both antibiotic free) at 37^C was allowed
before use.
100 pi serum-free DMEM was aliquoted into sterile eppendorfs, two per
lipofection.
2 pg plasmid DNA was added to the first eppendorf. The optimised
amount of lipofectin is put into the second (range 3-25 pi ). The
solutions were then gently mixed in a 5 ml tube and incubated at
room temperature undisturbed for 15 minutes. Immediately prior to
lipofection, the recipient cultures were washed once in serum-free
DMEM. 1.8ml DMEM/5%FCS(no antibiotic) was added to the
plasmid/lipid suspension and the 5 ml tube was inverted several
times gently. The 2 ml resultant suspension was added to the recipient
petri dish and were incubated at 37^c for 6-18 hr (depending on
optimisation). The suspension was then removed and 4 ml
DMEM/10%FCS(no antibiotic) was added and the cells were incubated
without selective pressure for at least 48 hr to expand cell numbers.
The cells were sub-cultured 1:5 into G418 selective media at previously
optimised concentration. Clones were picked by trypsinised using
either fine tipped pastettes or ring cloned at 2-4 weeks.
2.10.5 Selection conditions
Two exogenous dominant selectable markers were used for positive
selection.
The bacterial gene neo confers resistance to the antibiotic G418
(geneticin or neomycin) in mammalian cells, neo encodes
aminoglycoside phosphotransferase which inactivates this antibiotic.
The bacterial gene hph, hygromycin B (hmB) phosphotransferase is a
gene isolated from E. Coli which inactivates hmB, an aminocyclitol
antibiotic produced by Streptomyces hygroscopicus which inhibits
protein synthesis by interfering with ribosomal translocation and with
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aminoacyl-tRNA recognition. hmB resistance was mediated by the
expressing plasmid pTKHyg.
Kill curves for each of these antibiotic were performed for each of the
parent un-transfected cell lines prior to introduction of the selectable
markers by either lipofection or microcell mediated chromosome
transfer.
2.10.6 Picking of resistant clones
After selection of cells using the above antibiotics and under
conditions that completely kill parallel controls, resistant clones
arising from single cells were picked at between 2 and 6 weeks after
imposition of selection. When colonies reached over 1 mm in size, the
flask was washed with PBS . The top of the flask was removed with a
hot probe apparatus. The tip of a fine tipped pastette was half filled
with trypsin/versene and applied to the clone, pipetting gently up and
down until the cells were dislodged and then transferred to 24 well
plates containing 500 pi selection media. The next morning, the media
was replaced by 1-2 ml media with the appropriate selection antibiotic
at the appropriate concentration for that cell line.
2.11 Microcell Mediated Chromosome Transfer
This technique was developed based on two different methods, one by
Stanbridge, the other by Stubblefield. Development of this method was
a protracted process outlined in the results section, and the method
presented here represent optimal conditions for our laboratory.
2.11.1 Preparation Of Donor Cell Lines
The cell lines used were rodent cell lines with apparently normal
human monochromosomes. (see table)
MCH556.1.5 is a mouse A9 cell line containing a human chromosome
11 neo-tagged at Ilql4-q22 (Obtained from Aswin Menke, Molecular
Carcinogenesis, Silvius Laboratory, Leiden with agreement from Eric
Stanbridge, Univ of California at Irvine). 12-neo is a mouse A9 cell line
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containing a neo-tagged human chromosome 12 (Kindly provided by
Carlo Conti, MD Anderson Cancer Center, Texas with agreement from
Carl Barrett, NIEHS, Bethesda ). 1-neo is an A9 mouse cell line
containing a neo-tagged human chromosome l(Kindly provided by
Rosemary Bayne, MRC Human Genetics Unit, with agreement from
Carl Barrett, NIEHS, Bethesda). J1 Clone4 is a Chinese hamster ovary
cell line carrying a human chromosome ll(Fa Ten Kao). The neo-tag
in this line was introduced using rodent repetitive sequence mediated
targeting to chromosome llq23(Watson et al) (Kindly provided by
Vivienne Watson, ICRF Medical Oncology Unit, Edinburgh). These
cell lines were maintained on RPMI or DMEM, 10% FCS, with
penicillin and streptomycin and G418 to maintain the neo resistance
marker(concentrations of G418 between 400 and 600 pg /ml were used.
The donor cell lines were seeded in 6-12 X 25 cm^ flasks.
Colcemid(Demecolcine, Sigma) was added when they reached 70%
confluence and micronucleation of the cells was produced by exposure
to various concentrations of colcemid for various time periods
optimised for each cell line, along the lines of a method developed by
Stanbridge and colleagues. Micronucleation of the donor cell line was
assessed visually (see Figure 2.4)
Figure 2.4: Micronucleation of J1 C14
(75 ng colcemid for 48 hours)
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After adequate micronucleation, the donor cells were trypsinised for
microcell formation.
2.11.2 Formation Of Microcells
The object of the second part of the protocol is to produce microcells,
which are plasma membrane coated structures containing a single
chromosome, which can then be transferred into the recipient cell line.
A technique developed by Stubblefield and colleagues was used for this
part of the protocol. This method entails the use of centrifugal
force(19,000 rpm for 70 minutes) and the actin filament inhibitor
cytochalasin B (Aldrich, 20ug/ml final concentration, prepared as 2
mg/ml stock solution in DMSO)to extrude the microcells out of the
micronucleated donor cells on a Percoll(Pharmacia) : 10% FCS/DMEM,
1:1 gradient at 34^C. The Percoll solution was adjusted to a hypotonic
final concentration (68 mM Na CI) and was buffered at pH 7.2 (22.5 mM
HEPES); cytochalasin mediated extrusion is an active process. This
process is graphically demonstrated in figure 2.5 which shows
extrusion of microcells by budding from the long actin-inhibited
protrusions from the donor cells.
Figure 2.5 budding formation of microcells (Giemsa stained)
Centrifugation was performed in sterile Oak Ridge tubes using an SS34
rotor in an RC5B centrifuge (Sorvall) as above. The percoll/media
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gradient was then transferred out of the tubes and diluted with three
volumes of serum free DMEM.
This crude preparation consisting of karyoplasts and microcells was
then filtered through a 3 um pore size polycarbonate filter on a dual
membrane stirred cell holder (Nuclepore). The filtration step ensured
that the maximum size of 3 um limited the size of the microcells and
therefore the average number of chromosomes per microcell to one
(see Figure 2.6).
Figure 2.6 Size fractionated Microcells
2.11.3 Microcell Fusion into Recipient Cell Lines
The third part of the protocol consists of the delivery of these single
chromosomes to a recipient monolayer cell line. The recipient cell line
was seeded 24 hours previously in a 6 cm round dish such that it
achieved 50-70% confluence at the time of transfer. The filtered
microcell preparation was centrifuged at 1300 rpm for 15 minutes at
room temperature to pellet the microcells. The supernatant was
carefully removed and the microcells were gently resuspended with a
broad tipped pastette in 2.5 ml sterile Hanks balanced salt solution/25
mM HEPES pH 7.2 and 100 pg /ml Phytohaemagglutinin-P (PHAP,
sigma). The microcells were layered on the recipient monolayer and
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left to attach undisturbed for 20 minutes, the lectin PHAP mediating
attachment of the microcells to the recipient. At the end of this
incubation, the microcell suspension was aspirated. Pre-warmed (37^C)
2 ml 50% w/v polyethylene glycol in 75 mM HEPES (PEG, sterile,
fusion tested, Boehringer) was added for between 60 seconds and 90
seconds depending on the recipient cell line to fuse the lipid
membranes of the microcells and recipient cells. The monolayer was
then washed 3 times with serum free DMEM and left in non-selective
media (10% FCS, pen/strep) for three days to allow the cells to recover
and to expand the cell numbers. The cells were then trypsinised and re-
seeded into a T175 flask for 24 hours in 50 1 non-selective 10% FCS
media. Selection was then applied at concentrations of G418 (geneticin)
known to completely kill that recipient over a period two to four
weeks. The flasks had fresh media replaced twice per week until all the
control monolayers had died. At that time, clones present in the
microcell flasks were noted, and allowed to expand to a sufficient size
to be picked (usually 3-6 weeks). At the appropriate time, the clones
were picked according to the picking protocol (see above). DNA was
made for microsatellite analysis at the earliest possible time (passage 2-
4, from duplicate 24 well confluent plate), and each microcell hybrid




Concentrated Giemsa solution was diluted 1 in 5 with distilled H2O.
Cells were dropped onto a clean slide and fixed in 95% ethanol. Cells
were Giemsa stained in a slide carrier for 10 minutes. The specimen
was dehydrated through an ethanol series of 70%, 90%, and 100%




Log phase cultures were harvested and 10^ cells were seeded in 24 well
trays. The media was changed 24 hours prior to the first harvest and
every 3 days thereafter. Cell counts were harvested every 2 or 3 days
depending on the cell line up to 21 days in some cases.
2.13.2 Harvesting Cells
The medium from the wells to be counted was removed, and the cells
were washed twice with 250 pi PBS. 250 pi trypsin/versene was added
and the cells were left for 15 minutes to completely detach. The cells in
each well were syringed 3 times and 200 pi of the cell suspension was
transferred to one counting pot (see below).
2.13.3 Use of the Coulter Counter
The Coulter counter was allowed to warm up for 15 minutes. The
orifice tube was rinsed with saline. A background count was taken to
ensure that the counter is working properly (background counts >20
suggest caution). The sample was then counted by aliquoting 9.8 ml
saline to a counting pot and adding 200 pi trypsinised syringed single
cell suspension, mixing and sampling counts from each pot three
times. After sampling, the coulter counter was rinsed with saline.
2.13.4 Analysis
Cell counts were plotted against time either on logarithmic or linear
plots allowing comparisons between parent/control cell lines and
microcell hybrids.
2.14 Quantitative Adhesion Assay
This assay quantitates the ability of cells to attach to various
components of extra-cellular matrix or basement membrane protein,
on plastic in a 96 well tray. Non-specific binding was blocked using
albumin. The proteins were diluted in PBS to 2-50 ug /ml. 50 pi was
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added to quadruplicate wells and the tray was incubated overnight at
4®C. The plate was then washed twice with PBS to remove unbound
protein. 200 pi of 0.1% w/v BSA in PBS/0.1% azide (WaB) was added to
each well immediately, and incubated at 37^C for 1-2 hours.
Late log-phase cells were harvested and syringed to form a single cell
suspension. The cells were resuspended in standard 10%FCS medium.
110 pi of 10X Hanks buffered salt solution was added to a pot of
radioactive chromate (Sodium Chromate[^Cr], Amersham). 100 pi of
this mix ( 90u Ci) was added to the cells, mixed well and incubated at
37^C in a lead pot, resuspended every 10 minutes. After 60 minutes,
the cells were washed 3 times in serum free media. A count of known
number of cells at the last wash was taken, and 10 pi 0.4% trypan blue
due was added to determine cell count and viability. The cells were
resuspended at 2 X 10^ viable cells per ml in serum free media.
Plates were washed twice in PBS to get rid of traces of azide. After
removing PBS, plates were placed on ice. Labelled cells were
immediately added (50 pi, 10^ cells per well). Cells were incubated for
30 minutes to 6 hours at 37®C. After the allotted time the plates were
gently washed to eject unbound cells then slowly immersing the
whole plate into PBS supplemented with cations (1 mM Ca^+ and 0.5
mM Mg^+)and the amount of radioactivity remaining was counted.
The percentage adhesion was calculated by knowing how much
radioactivity was put into each well initially.
2.15 MTT Assay
The matrigel invasion and migration assays outlined below both
depended on the MTT assay in order to quantitate the differences
between microcell hybrid clones. Development of the MTT assay is
outlined in this section.
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An initial MTT toxicity curve was generated to determine the optimal
MTT concentration for the 3 hour incubation. 5 X 1(P cells were plated
in each well of a 96 well plate. MTT was made up as a filter sterilised
solution in PBS (2 mg/ml) and wrapped in foil (MTT is light
sensitive). 24 hours later MTT at a range of concentrations between
0.05 and 1.4 mg/ml was added to the 96 wells, and incubated for 3
hours after wrapping the plate in foil.
A computerised plate reader to read absorbance at 540 nm was allowed
to warm up for 15 minutes prior to use.
The 96 well plates were unwrapped and MTT was aspirated to a
burnable waste container. 200 pi Spectroscopic grade DMSO was added
and the content of the well was mixed to solubilise MTT. The OD at
540 nm was then read immediately and the data was output to a
simple output data display program. Data was printed out and the peak
concentration indicating activity at that cell number was observed
from a graph plotting concentration of MTT versus OD at 540 nm
(figure 2.7).
Figure 2.7: Optimisation ofMTT concentration for OVCAR3
[M.T.T] mg/ml
The plate was disposed of in a sawdust filled bag to a burnable waste
bin.
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2.15.1 Matrigel Invasion Assays
This assay is based on the principle that basement membrane plays an
important part as a barrier against tumour cell invasion.
The invasion assay measures the ability for cells to invade through a
matrigel layer in vitro. It is necessary to inhibit protease inhibitors
present in serum in order to allow invasion to occur. Therefore FCS
was pre-treated by lowering the pH to 3.0 for 2 hours with H CI and
then neutralised to pH 7.3 with Na OH.
Pre-aliquoted Matrigel (Beckton Dickinson) was thawed on ice and
diluted 1:5 in ice cold pre-treated culture medium at a final
concentration of 1 mg/ml.
The matrigel layer was formed in Transwell cell culture chambers
(Costar) which consist of 12 well plates with inserts containing a
porous Nuclepore 12 um polycarbonate membrane. The chamber's
margin at the interface with the filter was treated by rubbing a fine
layer of paraffin wax to provide a water-repellent treatment and
prevent meniscus formation thereby ensuring even matrigel thickness
over the surface of the polycarbonate membrane. The membrane was
wetted with cold culture medium and re-aspirated with a fine-tipped
pastette. 140 pi of cold diluted matrigel was aliquoted into each
transwell and even distribution of the extracellular matrix was
ensured by tilting. The matrigel was allowed to gel by incubating at
37°C for 30 minutes.
The cells to be used were trypsinised and washed 3 times in with cold
culture medium and resuspended at a concentration of 10^ cells per 0.5
ml. 1 ml culture medium was aliquoted into the lower compartment
and 0.5 rnl(lO^) cells were dispensed into the upper compartment. The
transwell plate was incubated in a humidified incubator for a varying
time course in order to optimise the time for the invasion assay.
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The number of cells on the upper and under-surface of the porous
membrane were assessed using the methyl toluene test (MTT) assay
(see below). 50 and 100 pi of MTT stain were added to the upper and
lower compartments of the transwell respectively and incubated for 3
hours. The crystals were removed from the under-surface of the
porous membrane using a 1 cm diameter circular whatman filter
paper, and the crystals were solubilised by immersing it in 1 ml DMSO.
The medium was decanted from the upper chamber and the transwell
was placed in a culture well containing 1 ml DMSO, and rotated on a
clinical specimen rotator. 200 pi aliquots of solubilised crystals were
transferred to an ELISA plate and read at 570 nm on a
spectrophotometer. Invasion was determined as the ratio of the under-
surface A570 reading relative to the upper surface A570 reading.
Figure 2.8 Invasion of OVCAR3 in matrigel: time course
0 24 48 72
hours
On the basis of the above experiment (figure 2.8) I routinely used 48
hours for OVCAR3 invasion in matrigel.
2.15.2 Transwell migration assay
The purpose of this assay was to quantify the haptotactic response of
the ovarian cancer cells to ECM components, i.e. observation and
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quantification of ECM component directed stimulation of cellular
migration. This assay allows assessment of the relative contribution of
the components to stimulation of migration and also allows an
assessment of the effect of chromosome 11 introduction on this
process.
Extracellular matrix component substrates (i.e. fibronectin, laminin,
collagen IV) were immobilised on the lower surface of the
polycarbonate membrane by incubating the under-surface of the 8.0 pm
pore-size transwell cell culture insert (Costar) in a 24 well plate with
250 pi of 10 pg /ml solution of the matrix component at 37°C for 1
hour. The transwells were blocked by transferring the transwell to a 24
well plate with BSA 0.1% for 1 hour at room temperature. The
transwell under-surface was washed twice by replacing the BSA with
PBS. 400 pi serum-free DMEM were applied to the lower compartment.
5 X 104 cells in a final volume of 100 pi serum-free DMEM were applied
to the top compartment of the transwell. The cells were allowed to
migrate across the membrane at 37° C for 72 hours. Non-adherent cells
were removed by rinsing the upper chamber with PBS X 2. 10 and 40 pi
of 2 mg/ml MTT were respectively added to the top and bottom
compartments of the transwell and incubated for 3 hours at 37° C.
Colorimetric analysis was performed (see above) and the percentage
migration was quantified at compared with control plates (transwells
coated with 0.1% BSA only on their under-surface).
2.16 Soft Agar Clonogenicity Assays
A 5% Seaplaque agar solution was made in distilled water and
autoclaved.
Soft agar plates were formed using an underlay consisting of 0.5%
Seaplaque agar (at 50C) made up in DMEM/20% FCS (5 ml per dish)
and left to set for 20 minutes. The cells were overlaid in a 0.3%
agar/media mix.
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Log-phase cultures of the cell lines to be tested were trypsinised and
single cell suspensions were formed by springing the cells through an
18 gauge needle.
The cells were resuspended at a volume of 5 ml and a concentration of
5x final desired plating density in a 25 ml tube. Final cell densities of
10^ cells per plate were used.
23 ml medium was aliquoted into a second tube and warmed to 37^c
for 20 mins. 2 ml 5% agar was added to the 23 ml medium and 20 ml of
this was immediately aliquoted to the tube containing the cells (to give
a final concentration of 0.32%). The cells were mixed quickly but gently
avoiding bubbles and 2.5 ml of the cell/agar mix into each of 8 petri
dishes. The plates were agitated to ensure even spreading without
bubbles. The dishes to set before moving (20 min) to avoid satellite
colonies. 1 ml media was overlaid on to the plate over the set agar and
incubated at 37^c. The media was changed weekly. The colonies for 8
plates per cell line were counted at 2 weeks by scoring the colonies (>50
cells) at low power to calculate the colony forming efficiency (CFE) for
each cell line.
2.17 Xenograft assay
Cells were grown in T175 flasks and were harvested by trypsinisation
and pooled. Varying cell numbers generally between 10^ and 4 X lO'7
cells (depending on the minimum cell number required) were
aliquoted, pelleted and resuspended in 100-500 pi serum free media,
transported on ice and sub-cutaneously injected within 3 hours into
either nude or SCID mice depending on the cell line. Tumour




Matrigel(Beckton Dickinson) is a solubilised basement membrane
preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse
sarcoma (which produces copious extracellular matrix protein). It
contains laminin, collagen IV, heparan sulphate proteoglycans,
entactin and nidogen. Additionally it contains TGF-beta, FGF, tissue
plasminogen activator, and other growth factors. Matrigel sets rapidly
at physiological temperatures above 22^C and must be kept at below
4^C until injection. Matrigel promotes cell attachment and invasion
and can therefore promote xenograft formation in the mouse
xenograft assay.
In those cell lines that did not grow using the standard method, the
cells were pelleted and resuspended in 250 pi 10%FCS media stripped
of protease inhibitors, mixed with 250 pi Matrigel transported on ice
and injected into SCID mice as above. In some experiments where cell
lines were known to increase their rate of proliferation in response to
oestradiol, pellets were depot injected 48 hours into the mice prior to
cell injection.
2.17.2 Recovery of Cell Lines from Xenografts
Xenografts were recovered into PBS in a universal under sterile
conditions. In a laminar flow hood, the xenograft was finely minced in
5 ml media using two sterile scalpel blades. The fragments were
transferred to a universal and roughly pipetted using a broad-tip
pastette to further dis-aggregate the xenograft. The cells were returned
to a 10 cm round dish with fungizone and, where appropriate, a
positive selection agent if a marker had been previously introduced, to
facilitate rapid deletion of background stromal mouse cells (see above).
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3. LOSS OF HETEROZYGOSITY ANALYSIS
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The cytogenetic and LOH( or allele imbalance) findings suggesting
several disrupted chromosome 11 regions in ovarian cancer (see
introduction) prompted the first experimental component, whereby I
repeated analysis of the major regions previously shown to be
involved and extended the LOH analysis into the sub-telomeric
portion of llq which was not previously examined.
3.1 Whole chromosome 11 LOH analysis
The initial study used 10 polymorphic (CA) repeat microsatellites to
screen a population of patients with ovarian tumours. These
polymorphic markers are outlined in Table 3.1:
Table 3.1 Polymorphic microsatellites: identity and location
Locus Location Name Reference
D11S922 llpl5.5 AFM217yblO 1,2
D11S569 llpl5.3 cCIII-434 2,3
D11S935 llpl3 AFM254zb9 1,2
D11S905 llpl3-12 AFM105xbl0 1,2
D11S873 llql4.3 Mfdl27 GDB ID no.
32638
D11S35 llq22 phage2-22 2,4
D11S897 llq23.1 Mfd231 GDB ID no.
34742
D11S925 llq23.3 AFM220yb6 1,2
D11S912 llq24.1 AFM157xh6 1,2
(Refs. and abbreviations: *1- Weissenbach et al, 1992; Gyapay et al.,
1994; Couillin et al 1994. 2=Litt et al., 1993. 3=Phromchotikul et al 1992.
4=Litt et al 1990. GDB=genome data base)
Molecular analysis of blood-tumour pairs from 60 patients with
ovarian tumours were used for this part of the analysis. The clinico-
pathological characteristics of the patient cohort are outlined in Table
3.2. The findings for stage and histology were validated within the
Edinburgh multidisciplinary combined gynaecological-oncology clinic
consisting of site-specialised pathologists, gynaecologists and
oncologists, ensuring rigorous quality control of the data.
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Table 3.2: Clinicopathological characteristics of 60 patients with ovarian
tumours
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Examples of allele loss for each of the markers are shown in Figure 3.1.
Figure 3.1: Examples of LOH analysis
Idiogram of chromosome 11 with examples of LOH at each of the loci.
Constitutive DNA(left lane) and tumour DNA(right lane) for each
microsatellite locus are shown with approximate distances between
loci
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Loss of heterozygosity was observed with variable frequency using
different markers and analysing the many heterogeneous subgroups of
ovarian cancer. LOH results for all markers and subgroups in this
study are summarised in Table 3.3.
Table 3.3 Loss of heterozygosity rates for all subgroups
LOCUSALL TUMOURS ADENOCA. SEROUS ENDOMETRIOID MUCINOUS EARLY FIGO ADVANCED FIGO
D11S 922 24/47 (51%) 16/36 (44%) 11/20 (55%) 4/11 (36%) 0/2 3/12 (25%) 11/22 (50%)
D 1 1 S 5 6 9 23/43 (54%) 14/30 (47%) 9/19 (47%) 3/5 (60%) 1/4 (25%) 4/9 (44%) 10/20 (50%)
D 1 1 S 9 2 9 13/47 (28%) 9/38 (24%) 3/20 (15%) 3/1 1 (27%) 1/4 (25%) 3/13 (23%) 5/23 (21%)
D 1 1 S 9 3 5 18/50 (36%) 13/39 (33%) 4/18 (22%) 6/13 (46%) 2/5 (40%) 4/15 (27%) 8/23 (34%)
D 1 1 S 9 0 5 21/45 (47%) 15/33 (45%) 7/16 (44%) 5/10 (50%) 1/5 (20%) 6/14 (43%) 9/18 (50%)
D11S 8 73 1 1/25 (44%) 9/22 (41%) 5/12 (42%) 0/5 2/3 (66%) 4/7 (57%) 5/14 (36%)
D11 S3 5 16/50 (32%) 14/39 (36%) 9/23 (39%) 0/9 2/4 (50%) 4/11 (36%) 9/26 (35%)
D 1 1 S 8 9 7 13/40 (32%) 9/32 (28%) 6/18 (33%) 1/6 (17%) 1/4 (25%) 3/12 (25%) 6/19 (32%)
D 1 1 S 9 2 5 24/45 (53%) 18/33 (54%) 11/19 (58%) 3/8 (38%) 2/3 (66%) 2/10 (20%) 13/21 (62%)
D 1 1 S 9 1 2 23/49 (47%) 18/37 (49%) 12/21 (57%) 3/7 (43%) 2/4 (50%) 3/13 (23%) 14/22 (64%)
LOCUS MOD/WELL DIFF POORLY DIFF DEBULK NO DEBULK ALIVE DEAD BENIGN/LMP
D 1 1 S 9 2 2 5/13 (38%) 8/20 (40%) 10/26 (38%) 4/8 (50%) 5/17 (29%) 10/18 (56% 3/5 (60%)
D11S569 4/12 (33%) 10/16 (62%) 9/20 (45%) 5/9 (56%) i/13 (38%) 9/16 (56%) 1/8 12.5%)
D 1 1 S 9 2 9 5/15 (33%) 3/18 (17%) 6/26 (23%) 3/11 (27%) 1/16 (25%) 5/21 (24%) 2/5 (40%)
D 1 1 S 9 3 5 6/15 (40%) 5/20 (25%) 11/28 (39%) 2/10 (20%) >/1 9 (26%) 8/20 (40%) 1/6 (17%)
D 1 1 S 9 0 5 7/12 (58%) 8/18 (44%) 13/24 (54%) 2/8 (25%) J/16 (56%) 6/16 (38%) 3/7 (43%)
D 1 1 S 8 7 3 5/7 (71%) 3/12 (25%) 6/13 (46%) 3/8 (37.5) 4/7 (57%) 5/14 (36%) 1/2 (50%)
D 1 1 S 3 5 4/13 (31%) 7/21 (33%) 11/25 (44%) 4/9 (44%) 5/17 (35%) 7/21 (33%) 1/4 (25%)
D 1 1S 8 97 4/13 (31%) 4/16 (25%) 5/21 (24%) 4/10 (44%) >/15 (13%) 7/16 (43%) 2/5 (40%)
D 1 1 S 9 2 5 5/11 (45%) 10/19 (52%) 14/22 (64%) 4/9 (44%) >/1 5 (40%) 9/17 (53%) 2/9 (33%)
D 1 1 S 91 2 5/15 (33%) 10/18 (56%) 9/24 (38%) 8/11 (73%) 1/17 (27%) 14/1 9 (74% 1/7 (14%)
Values given are the number of cases with LOH in that subgroup/total
number of informative cases in that subgroup (% LOH in brackets).
Early FlGO= F1GO stage 1+11. Advanced FIGO=FIGO stage III+IV.
Alive/dead refers to this status at 2 years minimum follow-up.
Debulk=complete debulking at primary operation. N o
debulk=incomplete debulking at operation. FMP=tumours of low
malignant potential (borderline tumours)
In summary, 52/60 of all ovarian tumours (87%), and 40/47 EOCs
(adenocarcinomas excluding borderline malignancies) (85%) had
evidence of LOH involving at least one locus on chromosome 11. Only
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one EOC had LOH at all informative loci and 7 EOCs (15%) had no
detectable LOH.
Serous, poorly differentiated and advanced stage EOCs had particularly
high levels of LOH at both the lip and llq sub-telomeric regions.
Conversely, EOCs which are early stage or moderately/well
differentiated appear to have high levels of LOH at the Ilql4.3-q22
region. The data from Table 3.3 above is summarised graphically
below.
3.1.1 Allele imbalance and histology
No significant difference was seen at any locus, comparing serous EOCs
with other histologies (Figure 3.2). However, of 9 informative
endometrioid tumours, none had LOH atDllS35, and comparing this
group with other histologies a trend towards significance was observed
for LOH of this marker with non-endometrioid histology (p=0.04).
Figure 3.2
3.1.2 Allele imbalance and FIGO stage
The only observed trend towards significance was for the association of
LOH at D11S912 with FIGO stage III/IV EOCs (p=0.035, see Figure 3.3).
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Figure 3.3
3.1.3 Allele imbalance and differentiation grade
The only apparent trend towards significance was between D11S873
LOH and well/moderately differentiated tumours (p=0.07).
Figure 3.4
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3.1.4 Allele imbalance in other ovarian tumour types
The non-EOC-tumour numbers were too small for statistically valid
conclusions. We considered benign and borderline (low malignant
potential, LMP) tumours together. Only 1/8 benign/borderline
tumours had LOH at D11S569 (llpl5.3) and 1/7 had loss at D11S912
(llq24.1). However, 3/5 benign/borderline tumours had LOH at
D11S922 (llpl5.5). Both the mixed mesodermal tumours had LOH at
both Ilpl5.5-pl5.3 and llq23-qter. One granulosa cell tumour had LOH
at all loci on lip suggesting whole arm loss. The ovarian teratoma in
our series was hemizygous at all 9 informative loci and this is
compatible with the usual description of these tumours as being
parthenogenetic.
3.1.5 Microsatellite Instability
Microsatellite instability (MSI) was noted in only 6.4% of EOCs (3/47).
2/2 granulosa cell tumours had evidence of MSI and one of these
tumours had evidence of instability at 3 loci. There were no cases of
MSI in 5 borderline, 3 benign, and 2 mixed mesodermal tumours.
3.1.6 Analysis of consensus regions of allele loss in ovarian cancer
lip Loss of Heterozygosity
LOH was observed for at least 1 short-arm locus in 77% (46/60) of all
informative tumours including 72% of EOCs (34/47).
For all ovarian tumours, high levels of LOH (>40%) were found for
three loci (see table 3.3): D11S922 at llpl5.5 in 24/47 informative
tumours (51%) and 16/36 EOCs (44%); D11S569 at llpl5.3 in 23/43
informative tumours (54%) and 14/30 EOCs (47%); and at D11S905 at
llpl3-12 in 21/45 informative tumours (47%) and 15/33 EOCs (45%).
When considering only those tumours that were informative at both
loci telomeric to llpl5.3 (D11S569 and D11S922) the rate of lip sub-
telomeric LOH was 16/24 (67%).
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The lowest frequencies of allele loss on lip were detected at D11S929
(llpl4.1) with only 28% LOH in ovarian tumours and 24% LOH in
EOCs.
llq Loss of Heterozygosity
llq LOH was observed for at least 1 locus in 65% (39/60) of all
informative tumours including 66% of EOC's(31/47)
For all ovarian tumours, high levels of LOH were seen at three loci
(see table 3.3): D11S873 at llql4.3 in 11/25 informative tumours (44%)
and 9/22 EOCs (41%); D11S925 at llq23.3 in 24/45 informative
tumours (53%) and 18/33 EOCs (54%); and D11S912 at llq24.1 in 23/49
informative tumours (47%) and 18/37 EOCs (49%).
When considering only those EOCs that were informative at both loci
telomeric to llq23.3 (D11S925 and D11S912) the LOH rate was 18/27
(67%).
The lowest frequencies of allele loss were detected at D11S897 (llq23.1)
with only 32% LOH in ovarian tumours and 28% LOH in EOCs.
Figure 3.5 shows those tumours that demonstrated partial loss on
chromosome 11. Deletions are shown in shaded bars and are limited by
the next heterozygous locus. In cases where a locus with allele loss is
separated from a locus that remains heterozygous by an uninformative
locus, that uninformative locus is included within the shaded bars as
part of the deletion (since this region could be deleted). 8 tumours had
lip only loss, 6 tumours had llq only loss and 25 tumours had partial
loss of both arms. This type of analysis suggests 3 shortest regions of
overlap (SRO's) corresponding to 3 consensus regions of
deletion/allele imbalance at llpl5.5-15.3, llq23.3-qter and Ilpl2-q22.
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Figure 3.5 Partial deletions reveal subchromosomal consensus regions
of LOH
Tumour No. D11S922 D11S569 D11S929 D11S935 D11S505 D11S873 D11S35 D11S897 D11S925 D11S912
11 p1 5.5 11 p1 5.3 1 1 p 1 4.1 1 1 p 1 3 1 1 p1 3-1 2 11 q14.3 11q22 11 q23.1 11q23.3 1 1 q24.1
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Horizontal boxes represent the extent of subchromosomal deletions in
EOCs. Black vertical lines represent approximate positions of the
shortest regions of overlap (SROs); three such regions are present. L=
constitutive heterozygosity with LOH in tumour material.
U-uninformative (constitutively homozygous). Constitutively
heterozygous pairs with no LOH are left blank
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3.1.7 Statistical analysis
Fisher's exact test was used to analyse the relationship for allele
imbalance between specific loci and also the relationship between
imbalance for specific loci and clinicopathological parameters for EOCs.
3.1.8 Relationship of allele imbalance between different loci
The three regions of deletion determined from figure 3.5 were
analysed for significant relationships.
No relationship was noted between LOH at lip sub-telomere region
(D11S922 and D11S569 at llpl5.5-15.3) and llq sub-telomere
region(DHS925 and D11S912 at llq23.3-24.1) (p= 0.5). Similarly, no
relationship was seen between LOH at Ilpl2-ql4.3 (D11S905 and
D11S873), and lip sub-telomere (p=1.0). However, a significant
relationship exists for LOH at the Ilpl2-ql4.3 region and the llq sub-
telomeric region (p=0.0025) suggesting that losses at these two regions
co-segregate. Alternatively they could be part of a single deletion group
although figure 3.5 suggests that this is not the case.
Lisher's exact test was used to test allele imbalance between all possible
combinations of loci and the findings are presented in Table 3.4. For
loci adjacent or close to each other, significant and borderline
significant findings are likely to reflect association simply as part of
substantial sub-chromosome deletions which may include a tumour
suppressor gene.
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Table 3.4 Fisher's exact test analysis of co-loss between









D11S922 D11S 56 9 D11S929 D11S935 D11S905 D11S873 D11S35 D11S897 D11S925 D11S912
11 p15.5 11 pi5 3 11 p14.1 11 p13 1 1 pi 3-12 11q14.3 1lq22 11q23.1 11q23.3 11q24.1
II I
D11S912 v D11S935 0.0073 88Mb I I I
D11S912 v D11S897 0.0088 21Mb | ] |
D11S905 v D11S929 0.0121 21Mb I l I I
D11S935 v D11S929 0.013 17Mb I •' 1 i
D11S897 v D11S873 0.0152 ,5M„ I 1 1 1
D11S925 v D11S35 0.0185 20Mb 1 1 II
D11S912 v D11S929 0.0189 106Mb ■Ml 1
D11S935 v D11S922 0.046 47Mb 1 ! II
D11S912 v D11S925 0.057 10Mb 1 1
For loci distant from each other, note that D11S912/D11S935 LOH
showed a significant statistical relationship (p=0.0073) and additionally,
the relationship for D11S935/D11S922 was of borderline significance
(p=0.046) suggesting the possibility that these loci harbour genes which
may be inactivated co-operatively.
3.1.9 Relationships between LOH and clinicopathological parameters
Figures 3.2, 3.3 and 3.4 suggested differences in LOH rates between
different clinicopathological parameters. Table 3.5 shows Fisher's test
p-values with significance trends for clinicopathological parameters at
the loci tested.
Table 3.5 Significant associations between LOH
and clinicopathological factors
LOH at LOCUS ASSOCIATION p-VALUE
D 1 1 S 9 1 2 1 1 q24.1 Dead (vs alive) with min. 24 months follow-up 0.0067
D 1 1 S 9 1 2 11 q24.1 Dead (vs alive) at 24 month follow-up point 0.067
D 1 1 S 9 1 2 1 1q24.1 Late FIGO stage (vs Early FIGO) at presentation 0.035
D 1 1 S 9 1 2 11q24.1 Non-debulked(vs completely debulked) post initial surgery 0.075
D 1 1 S 3 5 1 1q22 Non-Endometrioid (vs Endometrioid) histology 0.04
D 1 1 S 8 7 3 1 1q 1 4.3 Well/moderately (vs poorly) differentiated tumours 0.07
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3.1.10 Survival analysis
D11S912 loss of heterozygosity at Ilq23.3-q24.1 in primary tumours at
diagnosis was associated with adverse survival of patients with
adenocarcinoma, (p=0.0067) with minimum follow-up of 24 months.
Kaplan-Meier survival analysis
Sub-telomeric llq LOH (D11S925 and D11S912) was significantly
associated with adverse survival for patients with ovarian
adenocarcinoma (Figure 3.6).
Figure 3.6 Survival of ovarian cancer patients by LOH status
llq LOH status at presentation (found in primary tumour)
Significance was increased when D11S912 LOH was considered alone
(Figure 3.7). Actuarial survival of those without LOH shows 70%
survival at 4 years versus 20% for patients who had lost a D11S912
allele in their primary tumour at diagnosis.
135





























' LI—I no LCH N= 18
CHI = 6.362
P = 0.012
J LCH N= 18
Kaplan-Meier survival curve with log-rank analysis D11S912 LOH
status at presentation.
3.2 Integration of chromosome 11 and 17 LOH data from patients with
ovarian cancer: statistical analysis
3.2.1 Rationale
The initial chromosome 11 study (Gabra et al, 1995a) was performed in
Professor Michael Steel's laboratory using a cohort which included
many blood tumour pairs collected by Dr Diana Eccles who was a
research fellow in Professor Steel's laboratory. Dr Eccles and colleagues
had extensively analysed chromosome 17p and a chromosome 17q
(Eccles et al, 1990) marker in this series and Ms Lorna Gruber (now Mrs
Lorna Taylor) had continued to examine 17q for LOH in some detail.
This allowed me to analyse the tumours for chromosome 11/17 LOH
associations and relative strength of associations of LOH with other
parameters. The patient cohort examined was the same cohort as
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above although subgroup statistical analysis was limited in that many
tumours were collected by me and therefore did not have
chromosome 17p analysed in detail, although Lorna Gruber did
perform 17q LOH analysis on these tumours.
Figure 3.8 shows an overview of the markers used for this part of the
statistical analysis.
Figure 3.8: Chromosomal location of polymorphic microsatellites used
















































Table 3.6 shows the frequency of LOT! at the loci tested and their
location (The chromosome 11 data mentioned above is reiterated, and
Diana Eccles' chromosome 17p and D17S4 data is also mentioned (with
permission) in order to give a contextual overview).
Overall, chromosome 17 LOH was generally higher than chromosome
11 LOH. Rates were lowest at GH1 on chromosome 17q and D11S929
on chromosome lip.
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Table 3.6 Locus name, position and LOH rate for markers used
in the chromosome 11/17 analysis
CHROMOSOME 17 CHROMOSOME 11
Marker Location LOH informative %LOH Marker Location LOH informative s %LOH
p arm D17S5 17p13.3 9 1 7 53% D11S922 11 p15.5 1 6 36 44%
D17S28 1 7p1 3.3 9 1 9 4 7% D11S569 11 p 1 5.3 1 4 30 4 7%
C3068 1 7 p 1 3.3-p1 3.1 9 1 9 4 7% D11S929 11 p 1 4.1 9 38 24%
p53 1 7p1 3.1 1 1 20 55% D11S935 11 p 1 3 1 3 39 33%
D17S31 17p1 3.1-p11.2 5 1 3 38% D11S905 1 1 p13-p12 1 5 33 45%
D17S250 17q1 1 -q12 1 5 29 52% D11S873 11 q1 4.3 9 22 41%
THRA1 1 7 q1 1.2-q12 1 7 28 61 % D11S35 11q22 1 4 39 3 6%
D17S579 17q12-q21 1 8 35 51% D11S897 11q23.1 9 32 2 8%
D17S293 1 7q21 1 4 32 44% D11S925 1 1 q23.3 1 8 33 54%
q arm D17S588 1 7q21 1 8 33 55% D11S912 11q24.1 1 8 37 4 9%
NME 1 17q21-q22 25 38 66%
GH1 17q22-q24 9 33 27%
46 E 6 1 7q22-q24.3 23 4 1 56%
D17S4 1 7q23-q25.3 1 3 1 9 68%
3.2.2 Chromosome 17 and 11 regions of co-ordinate loss
The polymorphic marker LOH data were initially used for a "whole
arm" analysis to test if some of the chromosome arms were lost
together more frequently than predicted by chance (Table 3.7). In this
analysis, co-loss of 17p and 17q was noted with a high degree of
significance (p=0.0003). Co-loss of 17q and llq also showed a trend to
significance (p=0.035) and this trend became more significant when the
telomeric half of llq was considered (p=0.0175).
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Table 3.7 Chr 11/17 LOH whole arm associations
Whole arm co-losses p-va I u e n
17p vs 17q 0.0003 37
17p vs 11 p 1 34
17q vs 11 q 0.0351 4 1
17p vs 11q 0.119 32
17q vs 11p 0.624 43
11p vs 11q 0.651 4 1
17q vs 11q23-qter 0.01 75 40
Individual loci were then examined for evidence of significant co¬
ordinate loss (Table 3.8). As demonstrated above (Table 3.4), adjacent
loci demonstrating significant co-loss were ignored since this might
have been due to contiguous deletions. Within the confines of this
assumption, NME1 (17q21) and D11S922 (llpl5.5) were lost together
very significantly (p=0.0067) as were D11S912 (llq24.1) and D11S935
(llpl3) (p=0.0073). Co-ordinate losses of p53/D17S4 (17pl3/17q25) and
D11S912/D11S929 (Ilq24/llpl4) both occurred at borderline
significance. The only individual loci in this study demonstrating
17q/llq co-loss were Thra 1 and D11S35 at borderline significance
(p=0.049).
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NME1 and D11S922 17q21 -22 and 11 p15.5 30 0.0067
D11S912 and D11S935 11q24.1 and 11 p13 32 0.0073
p53 and D17S4 17p 13.1 and 17q23-25 1 2 0.018
D11S912 and D11S929 11q24.1 and 11 p14.1 34 0.019
THRA-1 and D11S35 17q11-12 and 11q22 1 8 0.049
3.2.3 LOH and associations with clinicopathological factors.
Fisher's test was then used to examine the relationship between whole
arm or individual locus LOH with clinicopathological prognostic
factors.
The only significant whole arm LOH association (Table 3.9) was
between 17p LOH and serous type histology (p=0.0052). There was also
a trend towards significance for 17p LOH with poorly differentiated
tumours (p=0.025) and advanced FIGO stage (p=0.031), but no
association with survival (p=0.171). The only other "whole arm" trend
to significance was found for llq LOH with adverse survival (p=0.031).
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Table 3.9 Statistical associations between chromosome arm loss
and clinicopathological features of ovarian cancer
Prognostic parameter chromosome arm number Fisher's
asociated associated informative p-value
Serous histology 1 7p 37 0.0052
1 7q 47 0.123
1 1 P 43 1
11 q 4 1 0.306
Poorly differentiated 1 7p 34 0.025
tumour 1 7q 42 0.099
1 1 P 38 0.709
11 q 36 0.483
Advanced FIGO stage 1 7p 35 0.031
1 7q 44 0.434
1 1 P 40 0.689
11 q 38 0.061
Adverse survival 1 7p 36 0.171
outcome 1 7q 46 0.117
1 1 P 42 0.708
11 q 40 0.031
Individual loci were then examined for an association between LOH
and prognostic clinicopathological factors (Table 3.10). In this part of
the analysis, LOH of individual 17p loci always occurred in concert,
and so 17p loss was considered as a single entity. D17S4 (17q25) LOH
was highly significantly associated with serous histology (p=0.0007)
(loss of D17S4 co-incided significantly with loss of 17p, associated with
serous histology). D17S588 LOH (17q21) was significantly associated
with advanced FIGO stage (p=0.0075). LOH at two loci were
significantly associated with adverse survival; D11S912 (llq24;
p=0.0067) and Thra 1 (17qll-12; p=0.0076). Other trends towards
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significance are shown in table 7 including two associations of LOH
which deserve further comment: D11S35 LOH was associated with
non-endometrioid histology (p=0.04), interesting because of the
proximity of the progesterone receptor to this locus (35); and D11S873
LOH associated with moderate/well differentiated tumours at
borderline significance (p=0.07).
Table 3.10 Statistical association between defined polymorphic
loci and clinicopathological features of ovarian cancer
Prognostic parameter microsatellite Location number significance of
associated with LOH marker associated informative statistical association
Histology:
serous D17S4 1 7q23-25.3 1 8 0.0007
1 7p 37 0.0052
D17S588 1 7q21 33 0.038
non-endometrioid D11S35 1 1q22 27 0.04
Differentiation:
poor D17S4 1 7q23-25.3 1 8 0.022
D17S579 1 7q12-21 3 1 0.023
1 7p 34 0.025
THRA-1 1 7q 1 1 .2-12 24 0.03
moderate/well D11S873 1 1 q 1 4.3 1 9 0.07
Advanced FIGO stage D17S588 1 7q21 31 0.0075
D11S912 11 q24.1 35 0.035
Adverse survival D11S912 11q24.1 36 0.0067
outcome THRA-1 1 7q 1 1 .2-12 27 0.0076
NME1 17q21-22 37 0.047
3.2.4 Survival analysis
In addition to the findings for llq LOH in association with adverse
survival(see figures 3.6 and 3.7 above), Kaplan-Meier / log-rank
analysis confirmed Fisher's exact test findings with respect to Thra Ion
17q, with a significant actuarial survival disadvantage for those who
had LOH at this locus at presentation (Figure 3.9). No other survival
associations were revealed in this analysis.
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Figure 3.9 Survival of ovarian cancer patients by LOF1














Kaplan-Meier / log-rank survival a?ialysis comparing patients
with or without LOH at THRA-1
3.3 LOF1 close to the progesterone receptor (PgR) locus in ovarian
cancer
3.3.1 Rationale
As mentioned in the preceding section, the progesterone receptor
(PgR) is of interest in understanding the endocrine regulation of
ovarian cancer, itself a component of growth regulation, and PgR
protein is implicated in growth suppression and differentiation of
breast and ovarian cancer. In this study we used a polymorphic
microsatellite lying close to the PgR gene to determine allele loss in
ovarian cancer. At the time of the study no intragenic microsatellite
with high heterozygosity was available for the PgR gene, RFLP analysis
for the PgR gene being even less informative. D11S35 was selected
because it was the closest microsatellite to the PgR gene (with an
indistinguishable map location at 0.41 and 0 cM separation) and had an
acceptably high heterozygosity rate (Litt et al, 1990; Litt et al, 1993).
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Subsequent to completing the study a high resolution physical map of
chromosome 11 suggested that it lay slightly (3 centirays,
approximately 150 kb) telomeric to the PgR gene (James et al, 1994).
PgR and ER content of these tumours was then measured and the
relationship between LOH at the PgR locus and tumoural steroid
receptor content was assessed. Two other incidental polymorphic
microsatellites were randomly selected to demonstrate specificity of the
correlation: D11S935 (llpl3) (Weissenbach et al, 1992), and NM23
(17q22) (Hall et al, 1992)
3.3.2 LOH analysis
Of 47 EOC patients, 38 were informative (constitutively heterozygous)
at D11S35 (72%). 14 of these (37%) exhibited LOH at this locus and 24
retained heterozygosity. There was inadequate tissue for ER and PgR
quantification in 7 of these informative specimens (2 with LOH and 5
heterozygous, no loss) and therefore the final allele loss rate in this
group was 12/31 (39%). For D11S935 the final allele loss rate was 13/33
(39%) and for NM23 (17q22), the final allele loss rate was 19/31 (61%).
The sample contained 9 informative endometrioid ovarian cancers,
none of which exhibited LOH at D11S35. Note that the initial
chromosome 11 analysis identified a significant correlation between
D11S35 retention of heterozygosity and endometrioid histology
(p=0.04) in the 38 informative tumours. This data is summarised in
Table 3.11 (next page).
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Table 3.11 Clinicopathologic parameters and hormone receptor













G3 9 3 SEROUS P.D. 159 29
G4 58 A 1 C CLEAR CELL M.D. ■ U ■ 2 5
G8 56 A 2 SEROUS P.D. □ ■ U 100 12
G11 27 3 SEROUS M.D. U U ■ 100 1 2
G1 2 5 4 SEROUS P.D. □ ■ u 1 1
G1 6 21 3 MUCINOUS NS □ ■ □ 1 1
G1 7 52 A 3 SEROUS M.D. u u □ 2 3
G1 8 1 1 1 A MUCINOUS M.D. □ ■ □ 29 8
G20 23 3 SEROUS P.D. ■ □ □ 4 229
G23 10 3 ENDOMETRIOID M.D. □ u ■ 21 9
G24 51 A 3 SEROUS P.D. □ ■ 2 160
G26 7 3 SEROUS PD. □ u □ 38 39
G 28 52 A 1 A MUCINOUS M.D. ■ ED ■ 7 6
G30 23 1 A ENDOMETRIOID P.D. U □ 12 1 2
G34 49 A 3 B SEROUS P.D. □ ■ □ 187 163
G35 1 3 SEROUS P.D. □ u □ 6 12
G38 48 A 1 A ENDOMETRIOID M.D. □ □ □ 139 161
G42 47 A 1 B ENDOMETRIOID P.D. □ ■ □ 9 10
G46 46 A 1 A MUCINOUS W.D. u □ □ 1 144 315
G 50 48 A 3 MUCINOUS NS ■ □ ■ 11 10
G55 1 1 4 SEROUS P.D. ■ ■ ■ 3 1 0
G56 43 A 1 A ENDOMETRIOID P.D. □ ■ ED 6 1 1
G 58 18 3 SEROUS P.D. ■ ■ ■ 6 1 9
G 59 38 3 ENDOMETRIOID P.D. u ■ ■ 74 109
G60 30 1 C SEROUS P.D. ■ ■ ED 11 40
H5 38 A 1 C ENDOMETRIOID P.D. u □ ■ 8 1 8
H9 37 A 3 ENDOMETRIOID M.D. □ □ ■ 130 59
H1 2 35 A 1 C CLEAR CELL M.D. ■ □ 3 7
H55 8 3 SEROUS P.D. u U 10 8
H58 31 1 ENDOMETRIOID M.D. u ■ ■ 4 116
H59 33 A 1 ENDOMETRIOID M.D. □ u ED 99 30
H60 16 3 ENDOMETRIOID W.D. □ ■ U 13 1 0
H69 25 3 SEROUS P.D. ■ ■ ■ 5 35
H76 25 3 SEROUS P.D. ■ ■ u 3 88
H77 27 3 CLEAR CELL M.D. ■ ■ □ 3 48
H80 1 8 3 SEROUS NS ■ ■ □ 4 46
H91 28 3 SEROUS P.D. □ □ ED 3 21
H95 24 A 1 C ENDOMETRIOID P.D. u □ □ 42 21
H96 9 ? ENDOMETRIOID NS ■ ■ 21 8
Clmicopathologic parameters and LOH status of the patient series.
A = alive at most recent analysis, PR = progesterone receptor, ER =
oestrogen receptor, U = un-informative/homozygous, filled boxes =
loss of heterozygosity, open boxes = heterozygous with no loss.
3.3.3 PgR distribution and relationships between LOH and PgR
Sufficient material was available for ER and PgR measurement in 39 of
the 47 tumours (see Table 3.11), and this estimation was performed in a
blind fashion at a different institution (by R.A. Hawkins and A.L.
Tesdale, Royal Infirmary of Edinburgh). A summary of PgR data
distribution by locus and allele loss status is shown in Table 3.12.
The mean tumoural PgR concentration for the 12 patients with LOH at
D11S35 was 5.2 fmol/mg with a median of 4 fmol/mg and a range of 2-
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11 fmol/mg. The mean tumoural PgR concentration for the 19
heterozygous patients with no loss at D11S35 was 51.4 fmol/mg with a
median of 21 fmol/mg, and a range of 1-187 fmol/mg. For D11S935 the
median PgR of the LOH group was 8 fmol/mg (range 2-130 fmol/mg),
for the no LOH group it was 7.5 fmol/mg (range 1-1144 fmol/mg). For
NM23 the median for the LOH group was 6 fmol/mg (range 1-187
fmol/mg), and for the no LOH group 10.5 fmol/mg (3-1144 fmol/mg).
The difference between the medians in the D11S35 LOH/no LOH
groups was statistically significant with the Mann-Whitney U-test
(p=0.014). These analyses were repeated for a chromosome 11 short
arm locus, D11S935 at llpl3; and for NM23, a chromosome 17 long
arm locus (17q22). Although large apparent differences were also noted
(see above) for the LOH and heterozygous/no loss groups at these two
loci, no statistically significant differences of mean and median PgR
concentration by allele loss status were recorded.
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Mann-Whitney U Statistic 5 3 1 25 76.5
2-tailed p-value 0.014 0.87 0.133
associated non-parametric statistics compare the LOH with the
heterozygousIno loss (HET) groups
Plotting tumoural PgR concentration against D11S35 allele loss status
as a log scatter plot shows the association of low/absent tumoural PgR
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with D11S35 LOH, but this clear difference is not apparent for the other
two markers (Figure 3.10).
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D 1 1 S 9 3 5 N M 2 3
Microsatellites/Allele Loss Status
Tumoural PgR content (log10 transformed values) plotted against
tumoural allele loss status for the three microsatellites used.
HET=heterozygous at the locus without LOH.
3.3.4 Relationship between ER and PgR
The whole D11S35 informative group was analysed for linear
correlation between tumoural ER and PgR content by Spearman rank
correlation. The ER and PgR values were natural-log transformed
There was no significant correlation for the whole group. However,
when patients with D11S35 LOH were removed from the analysis,
there was a linear correlation between tumoural PgR and ER content
(Spearman rank correlation, p=0.013). Figure 3.11 shows a scatter plot
of D11S35 heterozygous/no loss group and LOH group in terms of
their ER versus matched PgR contents.
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■+ D11S35 LOH. n=12, r=0.027, p=0.93
D11S35 Het. n=19, r=0.556, p=0.013
In PR (fmol/mg protein)
Scatter plot of natural-log transformed (In) ER and PR values
comparing tumors with allele loss ( = LOH) and tumors that were
heterozygous without LOH ( = Het). Data presented for D11S35 (llq22),
(b) D11S935 (llpl3), and (c) NM23.
The analysis was repeated for D11S935 (figure 3.12)












A D11S935 Het. n=21, r=0.42, p=0.058
+ D11S935 LOH. n=13, r=0.201, p=0.51
In PR (fmol/mg protein)
Scatter plot of natural-log transformed (In) ER and PR values
comparing tumors with allele loss ( = LOH) and tumors that were
heterozygous without LOH ( - Het). Data presented for D11S935.
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and NM23 (figure 3.13).
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4 NM23 LOH. n=19, r=0.109, p=0.655
A NM23 Het. n=12, r=0.552, p=0.063
In PR (fmol/mg protein)
Scatter plot of natural-log transformed (In) ER and PR values
comparing tumors with allele loss ( = LOH) and tumors that were
heterozygous without LOH ( = Het). Data presented for NM23.
Although there was no significant correlation between ER and PgR
content in either the heterozygous/no loss group or the LOH group for
either of these latter markers, it is interesting that both had trends to
significance in their respective heterozygous/no loss group, but these
trends were not different between the D11S935 marker on lip (p=0.058)
and NM23 on 17q (p=0.063).
3.3.5 Survival analysis
Kaplan-Meier/log rank survival analysis for ER-rich versus ER-poor
patients showed no significant difference between the two groups (data
not shown). PgR-rich versus PgR-poor showed a non-significant trend
in favour of the PgR-rich patients (p=0.08, data not shown). Comparing
patients with tumour D11S35 LOH versus patients with D11S35
heterozygous/no loss tumours also showed no difference (data not
shown). However, analysis of patients with D11S35 heterozygous/no
loss tumours only showed a survival advantage for patients with PgR-
rich (>30 fmol/mg) tumours compared to those with PgR-poor (<30
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fmol/mg) tumours (p=0.05, Figure 3.14a) and PgR poor patients did
equally badly whether they had LOH at D11S35 or not (figure 3.14b).




Kaplan-Meier / log-rank aiialysis for (a) D11S35 heterozygous, no loss
(HET/no loss) ovarian cancer patients subdivided by PgR content and
(b) PgR-poor patients subdivided by D11S35 allele loss status.
D11S35 heterozygous/no loss patients with ER-rich tumours (>30
fmol/mg) had a better outcome compared to those with ER-poor (<30
fmol/mg) tumours (p=0.025) (Figure 3.15a). It is interesting that a
paradoxical observation was noted those with LOH at D11S35: in this
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group those who had ER rich tumours did particularly badly as
compared with those who had ER poor tumours (Figure 3.15b).






























Patients who had D11S35 constitutively heterozygous ER-rich (>30
fmol/mg) tumours were then plotted according to whether they had
LOH at D11S35 or not (see figure 6.1), and a significant (p=0.014)
survival advantage in favour of those with no LOH at D11S35 was
observed (although this subgroup comprised only 12 patients).
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3.4 Detailed LOH analysis of llq 23.3-q24.3 in ovarian cancer
3.4.1 Rationale
In view of the llq LOH findings described above, refinement of the
LOH map of the llq22-qter region in epithelial ovarian cancer was
performed using selected tumours known to have loss somewhere on
chromosome 11, concentrating on the sub-region of LOH identified
above and associated with adverse survival(Figures 3.6 and 3.7).
Clinical and pathological characteristics of the patients selected for this
part of the study are outlined in Table 3.13.
Table 3.13 Clinicopathological characteristics of llq study cohort
Number of patients 40
Previously known to have Chromosome 11 LOH 40












Borderline Malignant Potential 3
Granulosa tumour 2
Teratoma 1
3.4.2 Results of Molecular Analysis
LOH was detected somewhere on chromosome 11 in all 40 tumours in
this series (selected for detailed analysis from our previous study).
Several blood/tumour pairs (H59, G56, G43, H5, G47, H55, G42, G46 and
G18) exhibited chromosome 11 LOH outside the Ilq22-q25 region (see
Figure 3.5).
Figure 3.16 shows that two separate regions of LOH are identified
within the Ilq22-q25: the minimum extent of the telomeric region of
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LOH (llq23.3-24.3) is defined by tumour G16. The centromeric extent of
this region is defined by D11S934 and the telomeric extent is defined by
D11S1320 (Figures 3.16 and 3.17). The size suggested for this region
from a recently published radiation hybrid map is 169 centirays (about
8.5 Mb) (15). Within this region, the frequency of LOH at D11S912 was
11/19 (58%) EOCs and 0/5 benign/borderline; at D11S707 it was 9/13
(69%) in EOCs and 0/1 borderline. LOH involving this distal deletion
unit occurred in 18/31 (58%) of EOCs.
The large centromeric region of LOH lies between D11S35 (llq22) and
D11S925 (llq23.3) as defined by tumours G36, G17, G34 and G55 (Figure
1). LOH involving this centromeric deletion unit occurred in 13/31
(42%) of EOCs.
Only a minority of tumours exhibited LOH at either Ilq22-q23.3 (4/31,
13%) or llq23.3-24.3 (8/31, 26%) alone. Nearly 30% of the cases
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3.4.3 Statistical Analysis of LOH in the telomeric llq region
Fisher's exact test was used to determine if loss from these two regions
was significantly associated with the clinicopathological features of
ovarian cancer. No significant correlations were seen between regional
losses and FIGO stage (p=0.15), histological type or differentiation
grade. The centromeric Ilq22-q23.3 region showed no statistical
association with survival for regional LOH alone or in combination
with other regions.
However LOH of the Ilq23.3-q24.3 region either alone or in
combination with LOH in other regions showed a strongly significant
correlation with survival by Fisher's exact test (p=0.004) (alive versus
dead patients with 33 month minimum follow-up), despite all the
tumours in the series exhibiting LOH somewhere on chromosome 11,
confirming our finding for D11S912 (see above).
Kaplan-Meier/ log-rank analysis showed no survival difference
(p=0.632) for the centromeric region of LOH (Figure 3.18a) but the distal
LOH region (Ilq23.3-q24.3) between D11S934 and D11S1320 correlated
significantly with adverse actuarial survival (log rank test p=0.011)
(Figure 3.18b).
However, the log-rank analysis was not significant when only
advanced FIGO stage cancers were considered in relation to llq23.3-
q24.3 LOH status (p=0.09).
3.4.4 Other tumour types
Data from a benign ovarian teratoma, regarded as haploid
parthenogenetic demonstrating LOH at all informative chromosome
11 loci was included. This tumour also had clear LOH at all other
informative chromosome 11 and 17 loci tested, and provides a useful
positive LOH control.
Benign and borderline epithelial tumours showed no case with secure
LOH involving the D11S934-D11S1320 distal SRO. The two granulosa
cell tumours had minimal LOH located out-with the critical region.
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Kaplan-Meier / log-rank analysis comparing survival after a diagnosis
of ovarian cancer in (A) those with or without LOH at Ilq22-q23.3 and
in (B)those with or without LOH at Ilq23.3-q24.3. LOH at Ilq23.3-q24.3
is associated with significantly reduced survival (p=0.011, log-rank test)
indicating an aggressive disease course.
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3.4.5 Further analysis of the distal llq in ovarian cancer cell lines: A
search for homozygous deletions
Having defined the distal llq LOH locus, the possibility was considered
that it might be homozygously deleted in ovarian cancer cell lines
along the same lines as pl6. In summary, no homozygous deletions
were demonstrated for 6 polymorphic microsatellites from the
telomeric llq locus in 14 ovarian cancer cell lines.
Table 3.14 Mapping the distal llq LOH locus for evidence
of homozygous deletions in ovarian cancer cell lines.
PRIMER->
SAMPLE
D11S934 D11S707 D11S1351 D11S450 D11S912 D11S1320
PE01 + + + + + +
PE06 + + + + + +
PE014 + + + + + +
PE016 + + + + + +
PEA2 + + + + + +
A2780 + + + + + +
OVCAR3 + + + + + +
OVCAR4 + + + + + +
OVGAR5 + + + + + +
41 M + + + + + +
59 M + + + + + +
OAW-28 + + + + + +
SKOV3 + + + + + +
OAW-42 + + + + + +
+ = allele(s) present by PCR
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4. MICROCELL MEDIATED CHROMOSOME TRANSFER
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The preceding investigation showed that frequent LOH was present at
specific regions on chromosome 11, suggesting the presence of tumour
suppressor genes in these regions. Additionally, the lack of correlation
of lip and llq LOH generally suggested that unlike chromosome 17,
whole chromosome 11 loss is uncommon in EOC. This fragmentation
with high rates of LOH at several discrete regions raises the possibility
that several TSGs may be involved. The alternative explanation is that
these regions do not contain TSGs and simply represent high
frequency non-specific distal chromosomal disruption as a part of
generalised genomic instability in ovarian cancer cells. This null
hypothesis was somewhat tempered this analysis by the observation
that LOH in individual tumours at the llq sub-telomeric locus was
restricted to an 8.5 Mb region with several examples of telomeric
retention of chromosome.
Furthermore, these regions demonstrated co-loss with other
polymorphic markers and were significantly associated with adverse
clinicopathological features of the disease suggesting that they might
house TSGs involved in ovarian tumour initiation and progression.
These findings allowed a speculative multistep model of ovarian
cancer development to be constructed (see discussion).
Clearly, a major reservation of such LOH analyses is that they do not
address questions such as "Does disruption of a TSG in this region
actually cause ovarian cancer ?" or "What component of progressive
ovarian neoplasia is unmasked by disruption of this TSG ?" In order to
address the issue of causation (in the absence of good candidates in
these regions), and as part of an integrated programme to ultimately
clone these genes, if they exist, I set out to transfer a single, normal
human chromosome 11 into ovarian cancer cell lines. The objective
was firstly to observe the effects that this would have, and secondly to
develop resources from which I could attempt to clone such genes.
This was a protracted and demanding process and a chapter on
developing this method and its results is warranted.
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As can be seen from the introduction, the ability to move specific
chromosomes between cells is an extremely powerful tool which
straddles cell function and gene position. However, MMCT (as I have
discovered) is a demanding empirical technique; optimal conditions
vary widely between different donor and different recipient cell lines,
and re-optimisation is required for each donor and recipient cell line.
Two rodent cell lines carrying a neo-tagged normal human
chromosome 11 were used to achieve MMCT into ovarian cancer cell
lines. Since this had not been previously achieved, optimisation of the
method using 556.1.5, a mouse cell line bearing a human chromosome
11 as a reliable donor and HeLa, an established permissive
chromosome recipient was performed initially.
4.1 Transfer of hyg and neo resistance to ovarian cancer lines
The first objective of this part of the work was to determine which
ovarian cancer cell lines would be suitable for chromosome transfer.
Since chromosome transfer had not been achieved in ovarian cancer
at the time I commenced this work, there was no guiding empirical
precedent. I reasoned (simplistically) that if a cell line would not take
up a plasmid by transfection, it was unlikely to take up a whole
chromosome. Additionally, it was important to derive neo-transfected
control cell lines for subsequent functional assays (see later).
Furthermore, it was also desirable to obtain a panel of ovarian cell
lines with hygromycin resistance to provide a counter-selection to
eliminate possible microcell donor contaminant cell lines during the
microcell mediated chromosome transfer selection procedure.
Several ovarian cancer cell lines were characterised with respect to
their toxicity profiles to geneticin (G418, G) and hygromycin B (hmB,
H) in order to determine the most utilitarian lines. Figure 4.1 shows
typical kill curves over a range of geneticin concentrations for the
ovarian cancer cell line PEOl.
Plotting best-fit curves for cells at certain days allowed the definition of
the optimal geneticin concentration to kill the parent cell lines over
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any defined time period, and these concentrations were typically very
similar (Figure 4.2).
Figure 4.1 PEOl kill curves over a range of geneticin concentrations








legend shows range of geneticin concentrations from control (GO) to
300 fag/ml geneticin (G300). Y axis is a log-scale.
Figure 4.2 Simple curve fitting (best-fit linear regression) outlining
optimal geneticin concentration for PEOl cell kill
[Gerieticin] (ug/ml)
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Thus survival was empirically calculated for several ovarian cancer
cell lines for both hmB and G418 marker (see Table 4.1). The time
given is that to complete cell death of the cells at the specified
concentrations of selection medium.
Table 4.1 Optimal lethal concentrations of hmB and G418 for
all lines used
Cell Line Toxic [hmB] Toxic [G418]
PEOl 75 pg /ml for 3 weeks 300 pg /ml for 16 days
OVCAR3 50 pg /ml for 2 weeks 325 pg /ml for 2 weeks
OVCAR4 100 pg /ml for 3 weeks
-
OVCAR5 100 pg /ml for 2 weeks 400 pg /ml for 2 weeks
A2780 250 pg /ml for 10 600 pg /ml for 2 weeks
weeks
HeLa (cervical) - 450 pg /ml for 2 weeks
hmB and G418 resistance were induced in the ovarian cancer cell lines
by lipofection of plasmids PUCY3/pTKHyg and pSVNeo respectively.
All the microcell donors that we used transferred neo-resistance as the
selectable marker for the chromosome. I attempted to confer hyg
resistance on all ovarian lines in order to have counter selection
against the rodent chromosome donor lines. Neo resistance was also
transferred in order to provide neor controls for subsequent functional
assays. The lipofection conditions using the lipofection protocol
(outlined in "methods", above) were established empirically for these
cell lines and are outlined in Table 4.2
Table 4.2 Optimal lipofection conditions for cell lines used
Cell Line Lipofectin volume Time
OVCAR3 10 pi 6 hours
OVCAR5 20 pi 12 hours
A2780 15pl 12 hours
PEOl 20pl 12 hours
HeLa 15 pi 6 hours
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Several cell lines were derived using this lipofection protocol, and
these are summarised in Table 4.3
Table 4.3 Clonally derived and pooled-clone cell lines obtained
by plasmid transfection
Cell Line Hygr cell line Neor cell line
PEOl not transfectable PEO-Neo (clonal)
OVCAR5 not transfectable not transfectable
OVCAR4 not transfectable not transfectable
A2780 278PH(pooled), 278PHX
278HC1, 278HC2 (both clonal)
278N(clonal)
OVCAR3 OH3 (clonal), OHX ON3 (clonal)
HeLa Not attempted PHN(pooled),
HN1,HN2, HN3
(all clonal)
4.2 Optimisation of microcell production
Having established which cell lines were transfectable and therefore
possibly capable of also taking up a whole chromosome, and having
established the conditions for selection of the neo marker, the next
component of the project was to optimise the production of microcells.
Initially, J1 C14 B/B1.22 was used as a donor cell line. This is a CHO cell
line with human chromosome 11 targeted with neor at llq23 using
repeat-mediated homologous recombination (Watson et al, 1995).
The only information in the literature regarding quality control of
microcells is that there is a "threshold" effect for the minimum
number of microcells required for successful MMCT, but no
subsequent increase in efficiency of generation of microcell hybrids
with further increases in microcell numbers (Sanford and Stubblefield,
1987; Stubblefield and Pershouse, 1992). For this reason, no other
surrogate endpoint to the protocol exists and one has to follow an
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experiment for 6-8 weeks as a "self fulfilling prophecy" and record
whether or not microcell hybrids are produced before one can
comment on the quality of the microcells.
Two methods were attempted, developed by Stubblefield and co¬
workers (Sanford and Stubblefield, 1987; Stubblefield and Pershouse,
1992), and by Stanbridge and co-workers (Saxon and Stanbridge, 1987).
The final protocol presented in the "methods" section ultimately
represented a hybrid of the two.
4.2.1 The Stubblefield method
The first protocol that I attempted was developed by Stubblefield and
co-workers (Stubblefield and Pershouse, 1992) and is attractive because
it claims to be able to generate microcells from cells in mitotic arrest
rather than requiring prolonged exposure to colcemid to promote the
micronucleation as in the Stanbridge protocol. Additionally, in the
Stubblefield protocol, microcells are actually formed in a percoll
gradient in oak-ridge centrifuge tubes (rather than by placing the 25
cm tissue culture flasks directly in the centrifuge as suggested in the
Stanbridge protocol - this was felt to be somewhat hazardous).
However despite these advantages and my persistence I report that this
technique does not work in my hands after 28 experiments each
observed for 6 weeks. These experiments are summarised below.
The initial experiment consisted of using the J1 donor (see above) to
attempt to transfer chromosome 11 into A2780, a poorly differentiated
ovarian cancer cell line (Eva et al, ). Microcells were formed using a
protocol involving 4 hour incubation of colcemid (60 ng/ml),
however no hybrids were obtained 6 weeks later. In order to try to
achieve a threshold of viable microcells, methotrexate block was
employed to increase the numbers of mitotically arrested cells in each
experiment (10~7M for 18 hours), but the next four experiments, all
performed with the addition of methotrexate failed to produce hybrids.
Methotrexate was then discontinued and colcemid incubations of
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progressively 24 hours (2 experiments) and then 48 hours (2
experiments) also failed to yield hybrids at six weeks.
Methotrexate was then used with a 6 hour colcemid incubation, and a
further two experiments generated a total of 77 clones, which was an
order of magnitude more than the expected number of clones. 20 of
these subsequently died in combined hmB/G418 dual selective
medium (as outlined above). The remaining clones showed a mixture
of morphologies of J1 and A2780. Clones picked from this experiment
were positive by neo-PCR and polymorphic microsatellite markers
were used to demonstrate chromosome transfer (Figure 4.3).
Figure 4.3 Microcell fusion experiment 11
J1 donor microcells, A2780 recipient cells
Microsatellite analysis of 22 clones derived from MMCT experiment
11. Samples are identical for the top and bottom lanes. Top
panel=DHS935 (llpl3). Bottom panel= D11S9T2 (llq24.3). Far right
lane= A2780 (ovarian cancer recipient cell line). Second from right= J1
C14 (CHO/human chr.ll somatic cell hybrid donor line).
As can be seen from the above autoradiograph, two clones, 11.3FG and
11.3JG appeared to have taken up both alleles from the donor
chromosome after microcell fusion.
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Despite this apparent evidence of chromosome transfer these clones
were ultimately shown to be contaminating co-cultures of donor and
recipient cells which on in-situ hybridisation showed no evidence of
chromosome transfer (data not shown, in-situ analysis performed by
Dr. Vivienne Watson). This early lesson demonstrated that in-situ
hybridisation was required for formal proof of chromosome transfer.
Following this, I adopted a "broad-spectrum" colcemid incubation
time of 24 hours (based on Pershouse et al, 1993) and attempted to vary
the temperature of the centrifuge to encourage the active cytochalasin-
B mediated process of microcell extrusion, first at 34UC and then at
37°C. Neither temperature resulted in hybrid production. I then
increased the time of exposure to polyethylene glycol (PEG) to fuse the
microcells to the recipient line from 60s to 90s. Still, no hybrids were
produced. These 28 failed experiments are summarised in Table 4.4,
representing nearly 10 months of work.
Table 4.4 Summary of "Stubblefield" protocol experiments
I Experimen Donor Recipient Method Microcell yield Selection Result (6 weeks)
1 J1 (Chr.11) A2780 parent 4 hr. colcemid G600 no hybrid clones
2 J1 (Chr. 11) A2780 parent MTX, 4 hr. colcemid G600 no hybrid clones
3 J1 (Chr. 11) A2780 parent MTX, 6hr. colcemid G600 clones grew after 6/52, senesced
4 J1 (Chr. 11) 278PH MTX, 6hr. colcemid G600 no hybrid clones
5 J1 (Chr.11) 278PH MTX, 6hr. colcemid G600 no hybrid clones
6 J1 (Chr.11) 278HC1 6 hr. colcemid G550/G450 no hybrid clones
7 J1 (Chr.11) 278HC1 24 hr. colcemid G550/G450 no hybrid clones
8 J1 (Chr.11) 278HC2 24 hr. colcemid G550/G450 no hybrid clones
9 J1 (Chr.11) 278PHX 24 hr. colcemid poor G450 no hybrid clones
1 0 A9:1 (Chr.1) 278PHX 24 hr. colcemid G450 no hybrid clones
1 1 J1 (Chr.11) 278PH MTX, 6hr. colcemid good G450 57 clones, 2 distinct populations
1 2 A9:1 (Chr.1) 278PH MTX, 6hr. colcemid good G450 2 distinct clones: died
1 3 278N 278HC2 48 hr. colcemid excellent G450/G400 no hybr d clones
1 4 A9:1 (Chr.1) 278HC2 48 hr. colcemid good G450/G400 no hybr d clones
1 5 J1 (Chr.11) 278HC2 24 hr. colcemid/37C spin good G450/G400 no hybr d clones
1 6 J1 (Chr.11) 278PH 24 hr. colcemid/37C spin good G450/G400 no hybr d clones
1 7 J1 (Chr.11) PE01 24 hr. colcemid/37C spin G300 no hybr d clones
1 8 J1 (Chr.11) OVCAR3 24 hr. colcemid/37C spin G325 no hybr d clones
1 9 J1 (Chr.11) 278PH 24 hr. colcemid/37C spin G450 no hybr d clones
20 A9:1 (Chr.1) PE01 24 hr. colcemid/34C spin G300 no hybr d clones
21 A9:1 (Chr.1) OVCAR3 24 hr. colcemid/34C spin G325 no hybr d clones
22 A9:1 (Chr.1) 278PH 24 hr. colcemid/34C spin G450 no hybr d clones
23 J1 (Chr.11) OVCAR3 48 hr. colcemid/34C spin G325 no hybr d clones
24 278N 278PH5hr. colcemid/34C spin PEG 90s G450 no hybr d clones
25 278N 278PH5hr. colcemid/34C spin PEG 90s G450 no hybr d clones
26 J1 (Chr.11) 278PH5hr. colcemid/34C spin PEG 90s G450 no hybr d clones
27 J1 (Chr.11) 278PH5hr. colcemid/34C spin PEG 90s G450 no hybr d clones
28 J1 (Chr.11) OH3 5hr. colcemid/34C spin PEG 90s G325 no hybr d clones
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4.2.2 The Stanbridge method
Having failed to apply the Stubblefield method, an attempt was made
to produce microcell hybrids using the Stanbridge method (Saxon and
Stanbridge, 1987). With the difficulties encountered with the
Stubblefield method, an alternative approach of using established
microcell donor (556.1.5) and recipient (HeLa) lines were included to
try and repeat Stanbridge's original experiment of chromosome 11
transfer to (and suppression of tumorigenicity of) the HeLa cell line. I
performed these experiments as a visiting worker at the Molecular
Carcinogenesis section of the Sylvius laboratory at the University of
Leiden, the Netherlands as a guest of Dr Aswin Menke, Dr A.G.
Jochemsen, and Prof. A. J. Van der Eb. In this protocol, the donor line
is grown to 70% confluence and colcemid 50 ng/ml is added for 48
hours to induce micronucleation. Colcemid/media is replaced by
warm serum free media with 20 pg/ml cytochalasin-B, and the bottles
are filled to the neck. The Nunc flasks are placed in a Beckman rotor
type 16 with 100 ml 37°C water in each bucket and spun at 14,000
rpm/34°C for 70 minutes. The colcemid/media is removed and the
microcell pellets are resuspended in 12 ml serum free media. This
suspension is then sequentially filtered through 8, 5 and 3 pm
Nuclepore polycarbonate filters, spun down and the microcell pellet is
resuspended in 2.5 ml serum free medium (HEPES buffered) with 50
|ig/ml PHA-P. 2.0 ml of this suspension is layered on to the receptor
cells and the remaining 0.5 ml is plated in a dish to observe for
contamination by viable donor cells. The microcells attach for 20
minutes at room temperature. The medium is then carefully removed
and 2 ml warm PEG is added. Fusion is allowed to occur for exactly 60
seconds and then the cells are washed three times in serum free
medium. Fresh 10%FCS media is added and the cells are grown
without selection for 3 days to recover. The cells are split 1:8-1:10 and
after a further 24 hours, selection is applied. Twenty-one experiments
were performed with this technique and these are summarised in
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Table 4.5. Unfortunately the vast majority of experiments developed
yeast infections. One experiment, however, did produce viable clones
from which had the appearance of HeLa which were neo resistant.
However, these also came down with late fungal infection, but it was
clear that I had managed to optimise conditions using previously
reported recipient 556.1.5 and HeLa (Saxon et al, 1986)
Table 4.5 Summary of "Stanbridge" protocol experiments
Experiment Donor Recipient Method Result (6 weeks)
29 J1 (Chr.11) OH3 3 urn f Iter yeast infection
30 556.1.5 (Ch r. 11) OH3 3 um f Iter yeast infection
3 1 J1 (Chr.11) OH3 3 um f Iter yeast infection
32 J1 (Chr.11) OH3 3 um f Iter yeast infection
33 J1 (Chr.11) 278PH 3 um f Iter cell death ++
34 J1 (Chr.11) 278PH 3 um f Iter yeast infection
35 J1 (Chr.11) 278PH 5 um f Iter yeast infection
36 J1 (Chr.11) 278PH 3 um f Iter yeast infection
37 J1 (Chr.11) 278PH 3 um f Iter yeast infection
38 J1 (Chr.11) 278PH 5 um f Iter yeast infection
39 556.1.5 (Chr. 11) 278PH 3 um f Iter cell death ++
40 556.1.5 (Chr.11) 278PH 3 um f Iter yeast infection
4 1 556.1.5 (Chr.11) 278PH 3 um f Iter yeast infection
42 556.1.5 (Chr.11) 278PH 3 um f Iter no clones
43 556.1.5 (Chr. 11) 278PH 3 um f Iter no clones
44 556.1.5 (Chr.11) 278PH 5 um f Iter no clones
45 556.1.5 (Chr.11) 278PH 3 um f Iter no clones
46 556.1.5 (Chr.11) 278PH 5 um f Iter no clones
47 556.1.5 (Chr.11) HeLa 5 um f Iter CLONES PRODUCED
48 556.1.5 (Chr.11) 278PH 5 um f Iter no clones
49 J1 (Chr.11) 278PH 5 um f Iter no clones
4.3 Development of high volume throughput MMCT.
4.3.1 Definition of a robust repeatable MMCT protocol
Experiment 47 (Table 4.5) established the optimal conditions for
transfer of chromosome 11 from 556.1.5 into HeLa (using a 5pm filter).
Back in Edinburgh, in order to achieve optimal monochromosome
transfer I repeated the experiment using a 3pm filter which further
limits the maximum size of the microcells. However, for convenience
I coupled the micronucleation and fusion conditions of the Stanbridge
protocol to the higher throughput component of the Stubblefield
protocol for generating microcells. Stubblefield's percoll/cytochalasin-
B method in oak ridge tubes allows one to generate up to 4 different
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microcell preparations per day, whereas the Stanbridge method limits
the worker to performing only 1-2 microcell preparations per working
day.
From this first modified protocol two neo-resistant microcell hybrid
clones appeared 3 weeks after G418 selection.
4.3.2 Definition of utilisable microcell donor and recipient cell lines
Flaving failed to generate hybrids between the J1 chr.ll donor line and
ovarian cancer lines using the standard Stubblefield or Stanbridge
protocols, I directly compared the ability of chr.ll-containing
microcells derived from either J1 or 556.1.5 to successfully produce
microcell hybrids in HeLa under carefully controlled identical
conditions. Under identical micronucleation conditions (75 ng/ml
colcemid for 48 hours), the J1 donor produced far fewer micronuclei
than 556.1.5. However both lines produced good yields of microcells
after 3pm filtration, although the micronuclei produced by 556.1.5
were larger. The microcell preparations were simultaneously fused
into two identical sister HeLa recipient plates seeded 24 hours
previously which had reached 60% confluence immediately prior to
fusion. Fusion was performed under identical conditions using the
same solutions. Under these identical conditions, microcells generated
from 556.1.5 produced microcell hybrid clones whereas those generated
from J1 C14 did not (see Table 4.6)
Table 4.6 Comparison of 556.1.5 and J1 C14 as
chromosome 11 donor cell lines using a
high-throughput optimised MMCT protocol
556.1 .5 J1CI.4 B/B 1.22
Colcemid 75 ng/ml 75 ng/ml
Spin speed/tem >1 8.2 5 K/3 2 C 1 8.25K/32C
Microcell yield good(large) good(smaller)
Recipient/split HeLa/1:8 (60%) HeLa/1:8 (60%)
PEG fusion time 1 min. 1 min.
recovery time 3 days 3 days
Selection G450 G450
Hybrids/when? 2 clones (3 weeks) no clones (8 weeks)
Having established that J1 was not a suitable donor, an extensive
attempt was made to transfer chromosome 11 from 556.1.5 into the
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available cell lines that I had. In summary, of the cell lines that I used
as recipients, only OVCAR3 and its derivative clonal lines served as
suitable recipients for transfer of chromosome 11 (see Table 4.7)
Table 4.7 Optimised MMCT protocol applied for chromosome
11 donor cell lines and ovarian cancer cell lines
Experiment Donor Recipient Result by 8 weeks
50 to 55 556.1 .5 HeLa 52 clones from 3 experiments
56 and 57 J1CI.4 OH3 no clones
58 to 61 556.1 .5 OH3 6 clones from 2 experiments
62 to 65 556.1 .5 PEOI no clones
66 and 67 556.1 .5 A2780 no clones
68 556.1 .5 PE014 no clones
69 to 72 556.1 .5 OHX 9 clones from 3 experiments
OHX is a derivative line of OH3 which was passaged once as a
xenograft in a SC1D mouse and rescued back to improve take rates of
OH3
The microcell hybrid clones generated from the above experiments
were picked, expanded, and stored in liquid nitrogen. They were then
mapped extensively for evidence of chromosome 11 transfer (see
below) prior to functional analysis for evidence of tumour suppressor
effects (see chapter 5). During expansion of the first HeLa microcell
clone, the line underwent growth arrest and the original cells died.
However, surviving revertants were observed and 38 of these were
picked and expanded for further characterisation in the hope that
reversion was associated with discrete disruption of a region of the
donated chromosome 11 locus. Table 4.8 shows a list of chromosome
11 microcell hybrid cell lines generated. As a general guide, the
naming of the microcell hybrid clones consists of prefixing with the
chromosome donated, then an abbreviation of the recipient line, and
finally a suffix consisting of the experiment and clone number.
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Table 4.8 Chromosome 11 microcell hybrids generated in this study
Clones Donor Recipient Comments
11 H1 r1 -20 556.1 .5 HeLa surviving revertant lines
1 1 H2.1 -1 0 556.1 .5 HeLa
1 1 H3.1 -1 0 556.1 .5 HeLa
110H1 556.1 .5 OH3
1 10H2.1-4 556.1 .5 OH3
110HX1.1-3 556.1 .5 OHX more tumorigenic than OH3
110HX2.1-3 556.1 .5 OHX
110HX3.1-3 556.1 .5 OHX
4.4 Generation of appropriate controls
Having obtained microcell hybrids containing chromosome 11 it was
necessary to demonstrate that any observed functional effects were not
simply due to clonal selection (even though the ovarian line OH3 was
clonal by virtue of hygromycin transfection prior to microcell fusion).
Two avenues were employed to obtain appropriate controls. The first
was transfection of pSVneo to HeLa, OH3 and OHX.
In the case of HeLa, lines consisting of both pooled transfection (PHN,
see Table 4.9) and clonal lines (HN1-3) were generated and compared
with the parent cell line to ensure the lines behaved representatively.
Transfer of human chromosomes 1, 11 and 12 from rodent donors to
human cervical and ovarian cancer recipients was performed
In the case of OH3 and OHX, a series of clonal nco-resistant sub-lines
were generated (OHN1-3 and OHXN1-3) and these did behave like the
parent lines in functional assays and growth patterns (see chapter 5).
Table 4.9 weo-transfected control cell lines
Recipient Line neo transfected lines behaviour
HeLa PHN, HN1-3 as parent
OH3 OHN1-3 as parent
OHX OHXN1-3 as parent
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Although these addressed the issue of clonal selection, they did not
address the possibility that non-specific chromatin transfer effects
could suppress growth, and it was therefore necessary to generate
microcell hybrid clones that behaved identically to the parent but
contained a "neutral" chromosome. Since many chromosomes are
implicated by LOH and cytogenetic studies as housing potential TSGs,
the choice of which chromosome to use in order to generate a control
microcell hybrid line containing a transferred "neutral" chromosome
was based simply on reviewing the LOH/cytogenetic evidence and
identifying chromosomes infrequently involved, determining which
of these were available as monochromosome somatic cell hybrids
which had been used as donors and then obtaining these for microcell
fusion. Chromosome 1 ( A9(neo-l)-4 from Dr Carl Barrett) and
chromosome 12 ( 12-neo from Drs Carlo Conti and Carl Barrett) donors
were obtained and MMCT was attempted with these donor lines. The
results of these fusions is outlined in Table 4.10 below.
Table 4.10 Chromosome 1 and 12 MMCT
Experiment Donor Recipient Result by 8 weeks
73-76 A9 (neo-1)-4 HeLa 1 clone senesced at 8 weeks
77-84 A9 (neo-1 )-4 OH3 2 clones senesced at 7 weeks
85-88 12-neo OH3 3 clones from 3 experiments
89-92 1 2-neo OHX 4 clones, all senesced
As can be seen from the above table, chromosome 1 and 12 both
exhibited senescence effects. Furthermore analysis of the remaining
viable chr. 12/OH3 hybrids showed that there were functional growth
suppression effects associated with introduction of chromosome 12
(see chapter 5 for description of data) and it was therefore unsuitable as
a control. In view of this difficulty, an alternative approach was
adopted. Reasoning that a good source of a chromosome without a
functionally active tumour suppressor gene for the OH3 cell system
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would be the parent cell line from which it was derived, a neo-
resistant OVCAR3 sub-line was generated by transfection (ON3, see
Table 4.3 above) and this was used as a microcell donor to transfer an
unidentified (but by definition non-suppressing) chromosome by
MMCT from ON3 to OH3. This was successfully achieved for both OH3
and OHX (see Table 4.11 and molecular analysis below) These cell lines
behaved as the parents from which they were derived.
Table 4.11 generation of control microcell hybrid clones
Experiment Donor Recipient Result by 3 weeks Behaviour
93 OHM OH3 7 clones, 3 picked ONOH1-3, as parent
94 OHM OHX 10 clones, 3 pickedONOHX1-3, as parent
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4.5 Molecular and cytogenetic analysis of microcell hybrids
4.5.1 Transfer of chromosome 11 to HeLa
4.5.1.1 Confirmation of transfer of selectable markers
As mentioned previously, HeLa was used as a well recognised
recipient to develop the MMCT method and act as proof of principle
that MMCT could be performed. Extensive analysis with HeLa was not
performed with HeLa hybrids although many clones were generated
and several unexpected conclusions were arrived at. After fusion of
chromosome 11 microcells to a 70% confluent monolayer of HeLa,
several clones grew in the fusion plates at a time when all HeLa cells
had died after exposure to G418 in control plates. At this time, clones
were picked and expanded, and DNA was prepared from them whilst
still in 24 well plates. Neo PCR was initially performed to confirm that
transfer had occurred. Although providing good circumstantial
evidence, this confirmation is not however formal since it is possible
for clones of apparently recipient morphology to grow in supportive
co-culture with background contamination of donor cell lines(see
Figure 4.3, above). Formal evidence of microcell transfer should
therefore rest on in-situ analysis (see below). Figure 4.4 shows
detection of transfer of neo sequence from 556.1.5 to HeLa in a series of
clones derived from 3 separate microcell experiments.
175
Figure 4.4 detection of neo sequence by PCR in
chromosome 11/Hela microcell hybrids.
4.5.1.2 In-situ hybridisation
As mentioned above, in-situ analysis provides formal proof of MMCT
and figure 4.5 shows Primed in-situ hybridisation (PRINS) using
chromosome 11 centromeric alphoid primers. 556.1.5, HeLa and the
microcell hybrid clone ... are shown in this example, with an increase
in chromosome 11 centromeric signals in the microcell hybrid relative
to HeLa. Figure 4.6 shows chromosome 11 in-situ painting with an
extra whole chromosome 11 within the hybrid. HeLa/chromosome 11
microcell hybrids generally appear to take up the whole chromosome
both by cytogenetic/in-situ analysis and also by microsatellite analysis.
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Figure 4.5 Primed in-situ hybridisation of HeLa and HeLa/chr 11
microcell hybrid 11H2.3
*■ •
human chromosome 11specific centromeric alphoid primers
demonstrate one more chromosome 11 centromere in the microcell
hybrid (bottom) than in HeLa (top right): this represents formal proof
of chromosome transfer to HeLa from 556.1.5 (top left)







Chromosome painting shows three copies of chromosome in HeLa
(top panel). Microcell hybrid 11H2.3 shows four copies of chromosome
11 confirming microcell mediated chromosome transfer
4.5.1.3 Polymorphic microsatellite analysis
Using the same microsatellites used in the LOH analysis of the
preceding chapter, DNA from the 556.1.5 donor, HeLa recipient and
microcell hybrids was examined to see which regions of the transferred
chromosome were retained or lost. Figure 4.7 shows examples of
transferred alleles in the chr 11/HeLa hybrids.
Figure 4.7 Examples of microsatellite analysis in donor, HeLa recipient






extensive analysis was performed and PCRs were repeated until all
results were confirmed. Figure 4.8 presents an overview of analysis of
all clones tested.
In summary, no deletions of the transferred chromosome were
detected in HeLa microcell hybrids and this situation was in marked
contrast to the results obtained with OVCAR3 (see below). Several
viable, rapidly growing revertants picked from senescent clone 11H1.1
(see chapter 5) were analysed and found to contain all informative
markers tested.
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4.5.1.4 Interspersed repetitive sequence (IRS) PCR: co-transfer of
murine sequences.
Reports of microcell fusion have universally commented on the lack
of mouse chromosome co-transfer in MMCT experiments using
cytogenetic analysis. I reasoned that small fragments of mouse
chromosomes could be transferred and not detected since they would
be beyond the limits of resolution of classical cytogenetics, especially in
a bizarre cytogenetic background of a malignant cell. PCR primers for
LI and B1 mouse repetitive sequences were used together to produce a
murine fingerprint. PCR analysis indeed showed that co-transfer of
cytogenetically tiny murine fragments was ubiquitous (figure 4.9), and
this was of importance since these fragments could potentially
interfere in a difference analysis cloning strategy (one of the ultimate
aims of generating these hybrids).










' • 4I 1
181
As can be seen from figure 4.9 above, two clones derived from the
same microcell fusion experiment exhibited identical murine IRS-PCR
fingerprints. This method of fingerprinting was extremely useful in
determining whether clones from the same microcell experiment
represented separate fusion events (until now an assumption made in
most microcell fusion reports). With only few exceptions, all clones
generated within a single experiment were identical with respect to
their murine fingerprints suggesting a single initial MMCT event.
This observation was utilised to great effect in cases where clones with
differing behaviour, identical IRS-PCR patterns and differently
fragmented donated human chromosomes were identified, and these
represent valuable gene cloning resources (see below).
Evidence from mouse cot-1 in-situ painting (see next section)
suggested that certainly in early passages, mouse fragments were seen
as small autonomously replicating structures and were not integrated
either into the donor human chromosome 11 or rearranged into the
recipient genome. Mouse cot-1 painting was not performed for later
passages of microcell hybrid lines, so no comment can be made about
the subsequent behaviour of these co-transferred murine fragments.
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4.5.2 Transfer of chromosome 11 to OVCAR3
The genealogy of microcell hybrids derived from the OVCAR3
recipient is shown in figure 4.10.
Figure 4.10 Genealogy of OVCAR3 microcell hybrid lines generated by
fusion with chromosome 11 and "neutral" control chromosome
microcells.
clonal cell lines from (and within 3 passages of derivation of) the cell
line llOHl.l from its original clone. ONOH and ONOHX represent
ideal "neutral chromosome" MMCT controls
4.5.2.1 Confirmation of transfer of selectable markers
Clones with clear OVCAR3 morphology were derived from several
microcell experiments as shown above and DNA prepared from these
clones was initially used for neo-PCR, providing good evidence of
microcell mediated chromosome transfer.
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Figure 4.11 shows examples of neo-PCR for the llOH series of
microcell hybrids generated by MMCT from 556.15 to OH3 (hyg-
transfected OVCAR3).
Figure 4.11 Neo-PCR of OH3 derived chromosome 11 microcell hybrid
clones
Similarly figure 4.12 shows neo and hyg PCR of clones derived from
control microcell experiments transferring a "neutral" neo-tagged
chromosome from ONI to OFI3 ( ONOH); and neo-plasmid transfected
OH3 (OHN). As can be seen, weak PCR bands representing single copy
detection of neo, derived from microcell mediated chromosome
transfer can be seen in comparison with multi-copy neo and hyg-
detection observed in DNA derived from plasmid transfected cells.
These control cell lines were important in the functional analysis
subsequently performed since they behaved as the parent cell line
despite having taken up ?zeo-plasmid or a tagged "neutral"
chromosome transferred from by MMCT.
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Figure 4.12 Control OH3 clones derived by neutral chromosome
transfer and weo-transfection
Microcell Hybrids iVeo-transfected clones
r-H CN CO
rH r-H r-H x r-H <N co xT <r,
X X X DC r-H r-H r-H r-H r-H
co X co o o o O Z Z Z z Z
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?;
r
Top band = neo; lower band = hyg
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4.5.2.2 In-situ hybridisation
Formal proof of microcell transfer was obtained by PRINS analysis of
the microcell hybrid clones. Figure 4.13 shows PRINS and
chromosome 11 paint of OH3, demonstrating that this ovarian cancer
cell line has apparently five centromeric regions and that chromosome
11 is markedly rearranged.
Figure 4.13 Chromosome 11 primed in-situ hybridisation and
chromosome painting of OH3
PRINS demonstrates 5 chromosome 11 centromeric signals in the
recipient (parent) cell line OH3 (top panel). Chromosome painting
demonstrates extensive re-arrangement of chromosome 11 in the
OH3 parent line.
Figure 4.14 shows that after chromosome transfer the microcell hybrid
now contains 6 centromeres. The example shown was observed over
many metaphase spreads for this hybrid.
Figure 4.14 PRINS demonstrates the transfer of chromosome 11 to
OH3
Microcell hybrid HOH2.3 shows six centromeric spots in these two
metaphase spreads, representing an increase of one centromeric signal
4.5.2.3 Flozv cytometric ploidy analysis
Relative ploidy determination was performed utilising propidium
iodide staining and flow cytometric analysis of the microcell hybrids
compared with the parent recipient. Table 4.12 presents these results.
In summary, OH3 is hypo-tetraploid, and the clones derived from
MMCT in the vast majority do not alter the ploidy significantly,
confirming that transfer occurs by microcell fusion and not
karyoplast/whole cell fusion. At this stage it is pertinent to point out
that in the case of HOH2.4, a non-disjunction event appears to have
occurred, with the ploidy being 2N with respect to OH3. This hybrid
contained a fragmented transferred chromosome 11 with identical
IRS-PCR patterns to 110H2.1 and 10H2.2 suggesting that these three
clones arose from the same microcell fusion event with a subsequent
non-disjunction event accounting for HOH2.4's ploidy pattern. The
identical behaviour of this clone compared with the other
chromosome 11 OH3 microcell hybrids in terms of growth suppression
(see chapter 5) suggests an absolute growth suppression effect has
occurred rather than a relative dosage effect. This is also supported by
the observation that OH3 is essentially tetraploid with 5 centromeric
signals from chromosome 11; introduction of a single copy of
chromosome 11 suppresses growth.











4.5.2.4 Polymorphic microsatellite analysis
Having confirmed cytogenetically that transfer had occurred, mapping
of the transferred chromosome 11 was then performed, initially using
the same microsatellites utilised in the LOH and HeLa analyses. In,
summary, in contrast to whole chromosome transfer being the rule (as
with HeLa), fragmentation of the donor chromosome with several
markers not transferred was a common occurrence, and this was in
keeping with the disordered status of chromosome 11 in OVCAR3, in
contrast with the stable single copy of this chromosome in HeLa. In
view of this further markers were analysed using the automated laser
fluorescence system at the MRC Human Genetics Unit which allowed
microsatellite analysis to be performed more rapidly (see "methods").
4.5.2.5 Autoradiographic analysis
Using the same markers and methods from the LOH analysis, the OH3
and OHX series of microcell hybrid clones were examined for transfer
of chromosome 11 at those loci. Figure 4.15 shows examples of
transfer. Note that although microcell hybrid llOHl.l has taken up
the entire chromosome 11 at all tested loci, hybrids 110H2.1-2.4 have
all failed to take up the region llq22-qter. These clones were all
derived from the same microcell fusion experiment, and provides
strong evidence that the clones were all derived from the same fusion
event, and were separated from each other at the time of trypsinisation
and seeding of the primary fusion plate on to selective media (see
"methods"). The interesting finding of partial fragmentation of the
chromosome required further analysis with more microsatellite
markers and also provided a resource to compare phenotypes of partial
versus whole chromosome 11 transfer into OH3.
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4.5.2.6 Analysis by automated laser fluorescence
Extensive further analysis using 23 fluorescently labelled primers was
performed. This data is summarised in Figure 4.16. Clones from the
same experiment which had identical microsatellite patterns were
regarded as identical for the purposes of presenting this data (although
they might differ in un-mapped regions). In general there were some
differences noted between some clones derived from the same
microcell fusion experiment and this is interesting since within an
experiment, the IRS-PCR fingerprints were generally identical
(attributable to co-transfer of autonomous murine chromatin). This
suggested that fragmentation resulting in differences between clones
had occurred after the primary fusion event (see below). Some
comments require to be made specifically about clones llOHl, llOHl.2
and HOH1.3. These are derived from the same experiment. However,
llOHl.2 and llOHl.3 are clonal cell lines derived from passage 4
llOHl.l, interesting because it had an initially suppressed phenotype
which reverted back to a malignant phenotype indistinguishable from
that of the parent OH3. The two clonally derived sub-lines from this
passage differ in very few microsatellite markers, yet have totally
different phenotypes (see later). Furthermore, the region where they
differ includes the Ilq24.3-q25 poor-prognosis region defined in the
preceding FOH analysis. IRS-PCR patterns are identical between the
two sub-clones, and this makes them particularly interesting as
potential cloning resources (see "discussion"). The critical region in
which these clones differ is shown in Figure 4.17. The AFF tracings are
presented for the three microsatellites D11S912, D11S910 and D11S969
from centromeric to telomeric covering a 5 Mb region on Ilq24.3-q25.
The top panel for each microsatellite shows the donor 556.1.5 allele in
green, the recipient OH3 allele in blue, and the hybrid clone llOHl.l
in purple. The bottom panel shows the derived sub-clones llOHl.2 in
blue and 110H1.3 in purple. Note that 110H1.2 has the lost the
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donated allele at D11S910 but retained it just 580 Kb telomerically at
D11S969 and 4.5 Mb centromerically at D11S912.
The other region demonstrating fragmentational loss in the revertant-
phenotype 110H1.2 clone wasDllS935 at llpl3, located in the vicinity
of two candidate genes, WT1 and KAI1 (see "introduction" and
"discussion").
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4.5.2.7 Interspersed repetitive sequence (IRS) PCR: co-transfer of
murine sequences.
IRS-PCR using Ll/Bl primers to produce a murine fingerprint of the
hybrid clones was performed. Figure 4.18 shows Ll/Bl IRS-PCR
fingerprint examples for the OH3 microcell hybrid clones.
Figure 4.18 Ll/Bl IRS-PCR comparison of
hybrids llOHl.l and HOH2.1
LOLO ■r_T_c\jc\jLOLO
As can be seen, the murine fingerprints differ between experiments
llOHl and 110H2.
However, within an experiment, the IRS-PCR fingerprints were
generally identical. Figure 4.19 shows that IRS-PCR is identical for
110H2.1, 2.2 and 2.4. It is, however, slightly different for 110H2.3
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Figure 4.19 Ll/Bl IRS-PCR fingerprints
for HOH2 microcell hybrids
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In-situ hybridisation using mouse cot-1 DNA showed that the IRS-
PCR fingerprint for 110H2.1 was associated with tiny co-transferred
murine chromosome fragments (see Figure 4.20)
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Figure 4.20 Mouse cot-1 chromosome paint for 556.1.5 and hybrid
HOH2.1
Left panel shows mouse cot-1 paint of the murine donor line 556.1.5.
Right panel shows microcell hybrid HOH2.1 containing a fragment of
murine chromosome demonstrated by mouse cot-1 painting
For llOHl.l, which had retained a whole copy of chromosome 11
initially, two derived sub-clones were isolated with markedly different
phenotypes. These phenotypic differences were associated with
differences in the retained regions of chromosome 11 (see above).
However, it could also have been possible that the suppressed
phenotype was generated by co-transferred murine chromatin, and
therefore phenotypic reversion to the malignant parent state could
have resulted from loss of that suppressor murine sequence since it
was not dominantly selected for. Gratifyingly, IRS-PCR confirms co-
identical murine fingerprints for llOHl.l and the derived sub-clones
llOHl.2 and llOHl.3, suggesting that it is indeed chromosome 11
alterations that are responsible for the altered phenotype (see Figure
4.21).
Figure 4.21 Ll/Bl IRS-PCR for llOHl.l
and derived sub-clones
EP= early passage LP=late passage (phenotypic reversion noted)
HOH1.1RXG- = llOHl.l grown as a xenograft(X) in a SC1D mouse and
recovered (R)as a cell line in G418 free media (G-). 110H1.1RXG+ =
llOHl.l grown as a xenograft and recovered as a cell line in G418
containing media. Background mouse cells from xenograft are deleted
by concurrent use of hygromycin in both media.
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5. FUNCTIONAL ANALYSIS OF MICROCELL HYBRIDS
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5.1 HeLa chromosome 11 microcell hybrids
Confirmation that whole chromosome 11 had been transferred to the
primary microcell hybrid clones afforded the opportunity to repeat
Saxon's experiment of 1986 (Saxon et al, 1986) which provided the first
evidence of functional suppression of tumorigenicity using MMCT.
5.1.1 Morphology
All chr. 11/HeLa microcell hybrid clones had the same morphological
characteristics as the parent HeLa Ohio cell line. One clone however
became progressively larger and the cells senesced. However, a
minority of revertant clones escaped senescence and grew rapidly with
the same characteristics as the parent HeLa line. Figure 5.1 shows the
sequence of events associated with clone 11H1.1.
The top left plate shows parent HeLa cells. Top right shows microcell
hybrid 11H1.1, with enlarged cells. Bottom left shows progressively
enlarging, senescing cells, and a revertant colony at 7 o'clock that has
escaped senescence. These revertant clones morphology identical to
the HeLa parent were expanded into cell lines for further analysis
(bottom right). Since the chr.ll/HeLa microcell experiments were not
the final objective of this work, they were not functionally analysed in
great detail, however, xenograft analysis was performed to repeat
Saxon's observation of suppression of tumorigenicity by the
introduction of chromosome 11 into HeLa.
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Figure 5.1 Photomicrographs of HeLa and microcell hybrids
HeLa parent cell line (top left); microcell hybrids 11H1.1 (top right);
revertant colony emerging from background of senescing cells (bottom
left); expansion of revertant colony rl as a cell line (bottom right).
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5.1.2 Xenograft analysis of HeLa and HeLa microcell hybrids.
Initially, the tumorigenicity of the HeLa parent was tested to provide a
guide for the required xenograft conditions to directly compare the
parent HeLa with the microcell hybrids.
Figure 5.2 shows titration of cell numbers versus xenograft growth for
the neo-transfected HeLa control cell line PHN in nude mice.
Figure 5.2 Growth of control HeLa cell line PHN in nude mice
ti PHN 1X105
PHN 5X105
Cell numbers injected are shown in the legend at top right. Mean
values for 4 tumours. Error bars represent standard deviation.
As can be seen, tumour growth did not occur at 1 X 105 cells per
injection but did occur at 5 X 105 cells per injection or more.
Several microcell hybrid clones were then tested in direct comparison
to the nco-transfected HeLa line PHN. This data is presented in Figure
5.3.
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Figure 5.3 Direct comparison of PFIN control HeLa cell line with HeLa
microcell hybrid (11H2 series)
Each point represents the mean of 4 tumours, with standard deviation
bars shown. 5 X 105 cells were used per injection.
As can be seen from the above figure, no suppression of
tumorigenicity was observed, a surprising finding given Saxon's
original report. However, apparent growth delay was observed for
some clones, and this was most pronounced for microcell hybrid
11H3.1. Xenograft experiments were repeated with this cell line,
compared directly with PHN at 5 X 105 cells per injection (Figure 5.4)
and also at 5 X 106 cells per injection (Figure 5.5). As can be seen from
both of these experiments, there was no difference in growth rate
between 11H2.3.1 and PHN suggesting no growth delay. This raises
many issues about the discrepancy with Saxon's original observations
(see discussion).
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Figure 5.4 Comparison of 11H2.3.1 hybrid clone with PF1N control:
5 X 105 cells per injection
Mean of 4 tumours.3.1 = 11H2.3.1 . PHN = pool of neo transfected HeLa
clones
Figure 5.5 Comparison of 11H2.3.1 hybrid clone with PHN control:
5 X 106 cells per injection
Mean of 4 tumours.3.1 = 11H2.3.1 . PHN = pool of neo transfected HeLa
clones
204
Several clonal revertant cell lines derived from 11H1.1 (see Figure 5.1)
were also tested against PHN as xenografts. Figure 5.6 presents this
data, In summary, there was an apparent growth delay effect, but this
was not statistically significant.
Figure 5.6 Comparison of tumorigenicity of clonal revertants derived
from 11H1.1 with HeLa control PHN
Clonal revertants R1-R10 all derived from 11H1.1
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5.2 OVCAR3 chromosome 11 microcell hybrids
5.2.1 Morphology of hybrids
The immortalised phenotype of the parent was retained in the
microcell hybrids, and with the exception of 110H1.1/1.3 and
110HX1.1, the morphology of the cells was identical to the parent OH3.
Altered morphology was observed in the aforementioned lines, most
strikingly with 110H1.3. The cells remained rounded, closely packed
and invisibly "corralled", though cell numbers were not noticeably
fewer than other chromosome 11 hybrids. This suggested a defect in
cell spreading or motility, and provided an interesting parallel
observation to the associations between llq24 LOH and advanced
stage/ poor survival from the clinical specimens. Photomicrographs of
different clones from the HOH series are presented in Figure 5.7
206
Figure 5.7 Morphology of OVCAR3 and chromosome 11 microcell
hybrids
Despite differing growth rates, OHN, HOH12 and HOH2.4 have very
similar morphology in-vitro. In contrast, HOH1.3 has completely
different morphological characteristics, the tendency to spread out on





5.2.2 In-vitro growth of hybrids
5.2.2.1 llOH microcell hybrid series
Five clonal hybrid cell lines were derived from microcell fusion
experiments HOH1 and 110H2. Clone llOFIl.l contained a complete
transferred chromosome 11. The four clones from the 110H2 fusion
(110H2.1-2.4) were identical in terms of transferred microsatellite
markers (with deletion of llq22-qter and llpl3, see figure 4.16) of the
donated chromosome and also by murine Ll/Bl IRS-PCR
fingerprinting (figure 4.19). Figure 5.8 shows in-vitro growth of these
clones in a typical experiment with quadruplicate samples with 1 X 104
cells initially seeded. This experiment was repeated three times and
the result was similar in each case. In summary, the 110H1 and 110H2
series of clones were equally growth suppressed, suggesting that a
growth suppressor exists out-with llpl3 and llq22-qter.
Figure 5.8 In-vitro growth of control OH3 lines
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However, prolonged growth showed that 110H1.1 grew rapidly at
higher confluence with a clear bi-phasic pattern suggesting that clonal
divergence had occurred with a sub-population which rapidly
overgrew the original clone (see Figure 5.9)
Figure 5.9 Evidence for a mixed population within llOHl.l
Clonal sub-lines were derived by single cell cloning of llOHl.l at
passage 4 which had clearly different phenotypes. Microsatellite
analysis of these showed deletion of a 5.5 Mb interval on Ilq24.3-q25
(see figure 4.20) despite identical IRS-PCR fingerprints. It is almost
certain that the phenotypic differences attributed to these clones are
due to fragmentation of the donated chromosome 11. The alternative
explanation is that the observed phenotypes are the result of clonal
selection. However the original recipient ovarian cancer line was
clonally derived by /tyg-plasmid transfection and the phenotypic
divergence of llOHl was noted within four passages of the derivation
of the clonal microcell hybrid line. These factors make it highly
unlikely that these effects are simply due to clonal selection. It is
possible that the phenotypic differences are due to clonal divergence by
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mutation at another (non-chromosome 11) locus. This possibility
cannot be formally excluded, however, the fact that the murine IRS-
PCR fingerprints are identical for 110H1.1, 1.2, and 1.3 strongly
suggests that other loci are not involved.
5.2.2.2 The llOHX microcell hybrid series.
Due to the difficulties in establishing convenient xenografting
conditions with OH3 (see below), a single xenograft that grew
successfully was rescued back and the OHX cell line was established
from it. This cell line much more readily formed tumours in SCID
mice. In view of this three further microcell fusions were carried out
transferring chromosome 11 to the OHX recipient ovarian cancer cell
line. Clones from two fusion experiments received whole
chromosome 11 (110HX1 and 110HX3) and partial transfer was
achieved in a further experiment (110HX2) (see Figure 4.16).
Figure 5.10 shows comparison of these clones, seeding 1000 cells
initially.
Figure 5.10













Transferred chromosome status is: llOHXl (whole 11), HOHX2 (del
llq22-qter; del llp!3), HOHX3 (whole 11)
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110HX2.3 grows with the same characteristics as the nco-transfected
control cell line. By day 12, 110HX2.2 is starting to diverge.
In another experiment, using 104 cells initially, the HOH2 series
clearly demonstrates faster relative growth compared with llOHXl or
HOHX3 (see figure 5.11).
Figure 5.11 Comparison of growth rates of llOHXl, 2, and 3
Time (days)
10 cells plated. HOHXl.l and 3.1 retain whole chromosome 11.
HOHX2.2 has deletions of llq22 and llpl3.
In order to address the reasons for the observed growth suppression
for chromosome 11 microcell hybrids seen in figures 5.8 and 5.9, the
possibilities were considered that such growth inhibition was due to
cell-cycle block caused by the introduction of a cell-cycle regulator, or
that apparent growth inhibition was in fact due to increased apoptosis.
5.2.3 Cell-cycle distribution of hybrids by flow cytometry
Analysis of the cell cycle was performed on two separate occasions for
each hybrid line grown to mid-log phase simultaneously as a group.
Flow cytometric (FACS) cell-cycle analysis of propidium iodide stained
cells was performed. In summary, there was no significant difference
in any of the microcell hybrids compared with the control in terms of
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cell-cycle distribution. This information is summarised in Tables 5.1
and 5.2 for the 110H series and in Table 5.3 for he HOHX series
Table 5.1 Cell-cycle analysis of llOH series microcell hybrids
OH3 50H3.1 50H3.2.1 50H3.2.2 50H3.2.3
G1 57% 43% 39% 43% 42%
S 2 9% 30% 2 7% 35% 28%
G2+M 14% 27% 3 4% 23% 31%
PROLIFERATIVE 43%
INDEX
58% 61% 58% 59%
PLOIDY 1.80 1.89 1 .78 1.72 1.74
Table 5.2 2nd analysis of llOH series microcell hybrids
COLO 205 ONOH OHN 110H1.2 11 OH 1.3 110H2.2 110H2.4
G1 85% 64% 69% 67% 64% 57% 75%
S 5% 29% 17% 21% 18% 28% 18%
G2+M 10% 8% 14% 12% 18% 16% 7%
PROLIFERATIVE 15%
INDEX
38% 31% 33% 36% 44% 25%
PLOIDY 1.71 3.50 1.84 2.83 1.89 1.71 3.34
Colo205= readily apoptot ic colorectal cancer cell line
The HOHX series also did not show evidence of alteration of cell-cycle
distribution.
Table 5.3 Cell-cycle analysis of the HOHX microcell hybrids
OHXN OHX 110HX1.1 110HX1.3 11 OHX2.2 11 OHX2.3 11 OHX3.1
G1 52% 63% 62% 62% 55% 58% 58%
S 27% 26% 20% 23% 26% 26% 22%
G2 +M 21% 12% 18% 15% 19% 16% 20%
PROLIFERATIVE
INDEX
48% 38% 38% 38% 45% 42% 42%
PLOIDY 1.61 1.83 1.7 1.75 1.66 1.58 1.66
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5.2.4 Apoptosis analysis of hybrids by Annexin V flow-cytometry and
the FluoroTUNEL assay
The possibility was also considered that apoptosis (programmed cell
death) might be responsible for the observed growth inhibition of the
chromosome 11 microcell hybrids. Using FITC labelled Annexin V in
a flow-cytometric analysis (Vermes et al, 1995), the population
corresponding to "early apoptosis" (Annexin V positive, propidium
iodide negative) were identified. In summary, the microcell hybrid
clones did not exhibit increased apoptosis under normal conditions of
cell growth to explain their impaired growth rate (see Table 5.4).
Table 5.4 Annexin V-FACS analysis of llOH hybrid series
Cell Line % Apoptosis
(Annexin V +; PI -)







As can be seen, no induction of apoptosis is associated with transfer of
chromosome 11 into OH3. This analysis was repeated twice with
almost identical results. Additionally, this finding was confirmed
using the FluoroTUNEL technique, with no evidence of induction of
apoptosis for the microcell hybrid under conditions of normal cell
growth relative to the percentage of apoptotic cells found in the parent
cell lines.
The same analysis was applied to the 110HX series of hybrids. OHX
had a higher apoptosis score but again, no induction of apoptosis was
apparent (Table 5.5).
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Table 5.5 Annexin V-FACS analysis of HOHX hybrid series
Cell Line % Apoptosis








5.2.5 Soft-agar clonogenicity of hybrids
The ability of cancer cells to grow in soft agar, does represent a
measure of their tumorigenic potential zn-vivo although the
correlation is by no means strict. The soft agar clonogenic assay was
employed to assess differences in the clonogenic potential of the
microcell hybrids. Given the lack of ease of xenograft tumour
formation, it was not surprising that clonogenicity was fairly low in
the parent cell line. An example of an OH3 soft agar clone is shown in
Figure 5.12
Figure 5.12 OH3 clone growing in soft agar
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The results of the soft agar assay are presented in Table 5.6, and in
summary show no alteration in the microcell hybrids of the already
poor clonogenic potential of the parent cell line.







Mean derived from 4 plates; colonies per 105 cells seeded
5.2.6 Tumorigenicity of xenografted hybrids
Difficulties were encountered in trying to optimise conditions for
routine xenograft formation. Cell numbers up to 4 X 107 per injection
failed to produce xenografts in nude mice in more than 2/6 injections
on three occasions using OH3, derived from the tumorigenic
OVCAR3. Since microcell hybrids had already been produced, it was
imperative that the conditions for routinely successful xenografting
were determined for OH3. Matrigel, a commercially available
basement membrane preparation derived from the Engelbreth-Holm-
Swarm murine tumour (Kleinman et al, 1982) was used to stimulate
xenograft formation, but no growth was observed in nude mice. The
decision was then taken to change to using SCID (severe combined
immunodeficiency) mice, since these had no humoral or cell
mediated immune response, although they had the disadvantage of
being furry (more difficult to accurately and precisely measure the
tumours). The take rate using matrigel was substantially improved in
SCID mice. OVCAR3 is known to be ER and PR positive, and that
oestradiol can moderately increase the cell line's growth rate
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(Hamilton et al, 1983). In view of this, low dose oestradiol pellets (0.72
mg) were implanted sub-cutaneously at a site distant from the
injection sites, and this resulted in a moderate increase in the
tumours' growth rates but more importantly, a more consistent take
rate approaching 100% with 107 cells per injection. Figure 5.13 shows
the effect implanting oestradiol sustained release pellets (0.72 mg) sub-
cutaneously in SCID mice and injecting 107 OH3 cells suspended in
matrigel. In summary, there is a moderate but statistically non¬
significant effect of adding oestradiol. In view of this, SCID mice,
matrigel and low dose oestradiol pellets were routinely used in order
to ensure conditions for 100% take rate of the parent OH3 cell line.
This allowed comparison with microcell hybrids.
Figure 5.13 Comparison of OH3 cell line subcutaneous xenografts
grown in SCID mice in matrigel with or without low-dose oestradiol
pellets








5.2.6.1 llOH microcell hybrids
Having established the optimal conditions for xenograft growth using
the parent OH3, clones form the 110H1 and 110H2 fusion
experiments were directly tested against nco-transfected and "neutral"
chromosome transfer hybrid clones to observe the effect of
chromosome 11 introduction into OH3 (see Figure 5.14). Note that
110H2.4 was growth delayed but not suppressed for tumorigenicity.
Furthermore, the same pattern was initially observed for llOHl but
then growth accelerated, mirroring the pattern observed in the in-
vitro growth experiments (see Figure 5.9), providing further evidence
for a divergent mixed cell population in llOHl.
Figure 5.14 Subcutaneous tumorigenicity of llOHl and 110H2 using
low dose oestradiol pellets (0.7 mg) in SCID mice
ONOH and OH3 = controls. Each point represents mean of 10
tumours, error bars represent standard error for each cell line
Two clonal sub-lines were derived from the llOHl cell, one retaining
whole chromosome 11 including llq24, the other with a 5.5 Mb
deletion in llq24 (see chapter 4). These were tested in SCID mice in
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direct comparison with the parent control containing the neutral
transferred chromosome from OVCAR3 (ONOH). Obvious growth
retardation was seen of the xenografts containing whole chromosome
11 (110H1.3) as compared with the clones containing either a neutral
OVCAR3 transferred chromosome or chromosome 11 with a 5.5 Mb
deletion in llq24 (HOH1.2) (see figure 5.15). As can be seen, llOHl.3,
derived from llOHl which grew rapidly in the experiment shown in
figure 5.14, now grows with identical characteristics as HOH2.4. This
strongly supports the view that we have isolated suppressed and non-
suppressed clones from the llOHl cell line.
Figure 5.15: Direct comparison of subcutaneous tumorigenicity of
HOH1.2 and HOH1.3 in SCID mice
ONOH = control with neutral transferred chromosome. Each point
represeitts mean of 4 tumours, error bars represent standard error for
each cell line
218
These findings are consistent with the observation of an ovarian
cancer suppressor of growth but not tumorigenicity on chromosome
11, out-with the regions llpl3 and llq22-qter.
5.2.6.2 Effect ofOestradiol
The effect of high dose oestradiol was directly compared in the same
experiment with low dose oestradiol, to look for ways of accentuating
differences in the assay. In summary, 110H2.4 was completely
suppressed for tumorigenicity using high dose oestradiol, whereas
there was a mildly stimulatory effect of high dose oestradiol on the
control cell lines and llOHl (figure 5.16)
Figure 5.16 Subcutaneous tumorigenicity of HOH2.4 and controls
using high dose oestradiol pellets (1.7 mg) in SCID mice
Mean tumour volume of 10 tumours, error bars signify standard error.
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5.2.6.3 Xenografts of microcell hybrids derived from the cell line OHX
Due to the difficulties in establishing convenient xenografting
conditions with OH3 (see above), a single xenograft that grew
successfully was rescued back and the OHX cell line was established
from it. This cell line much more readily formed tumours in SCID
mice and down-titration of the cell numbers required for OH3 and
derived cell lines for growth are shown in figure 5.17. 5 X 106 were
used as the optimal cell number for subsequent xenograft experiments.
Figure 5.17: Down-titration of OHX for optimum xenografting
Mean of 4 tumours. Error bars = standard error
In view of this, three further microcell fusions were carried out
transferring chromosome 11 to the OHX recipient ovarian cancer cell
line. Clones from two fusion experiments received whole
chromosome 11 (110HX1 and 110HX3) and partial transfer was
achieved in a further experiment (110HX2). Figure 5.18 shows the
relative growth of xenografts derived from OHX microcell hybrids.
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Mean of 6 tumours. Error bars = standard error
5.2.7 Assays for other components of the cancer phenotype
The preceding LOH analysis suggested that advanced stage and poor
prognosis were associated with loss of the Ilq24-q25 region.
Furthermore, LOH analysis differentiated between early and advanced
cancer, not benign or malignant tumours. The above tumorigenicity
experiments confirmed that growth of the chromosome 11 hybrids
was generally delayed rather than suppressed (although it was possible
to suppress tumorigenicity of the hybrids selectively under certain
conditions). These factors suggested one or several progression-
suppressors located on chromosome 11. In view of this, a series of
experiments were performed to assess the role of chromosome 11 in
suppression of other components of the cancer phenotype; i.e. tumour
cell invasiveness /metastasis and components of this pathway such as
tumour cell attachment and migration.
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5.2.7.1 Invasiveness of OH3 and the HOH microcell hybrids in
matrigel
The initial experiment to assess tumour cell invasion into matrigel
produced an unexpected result. In summary, although both 110H2.4
and 110H1.1 were suppressed for invasiveness in matrigel, 110H1.1
was much more suppressed in its ability to invade than 110H2.4.
This is demonstrated in Figure 5.19
Figure 5.19 Comparison of matrigel invasion of OH3 (control) with
HOH2.4 and llOHl
HOH2.4 (del llq22-qter) and llOHl (whole 11 retained) compared in
48 hour matrigel invasion assay. Error bars represent standard
deviation
In view of this finding, it was imperative to analyse the relationship
between 110H2.4 and llOHl in terms of invasiveness by performing
more invasion assays. However, small differences in preparation of
the matrigel with minor batch to batch variations produced large
differences in the actual percentage invasiveness. However, when the
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invasiveness 110H1 was expressed as a percentage of the invasiveness
of 110H2.4, there was remarkably little variation, allowing the pooling
of 4 experiments in triplicate directly comparing these two cell lines,
and indeed there are precedents in the literature for analysing the data
in this way (Tanaka et al, 1996). Within any single experiment, the
most invasive sample is given a normalised relative invasiveness
value of 100% and the other samples are given a relative invasiveness
index as a percentage of this value). Figure 5.20 presents the data from
these 4 experiments in triplicate directly comparing HOH2.4 with
110H1.
Figure 5.20 Matrigel invasion assay comparing llOHl and HOH2.4:
12 values from 4 separate experiments
Error bars represent standard deviation
As can be seen, a highly statistically significant difference was revealed
using the non-parametric Mann-Whitney U test, and this suggests that
an invasiveness suppressor function can be mapped to either the
llq22-qter region or the llpl3 region.
223
In view of the altered growth characteristics observed for 110H1, two
clones were derived as sub-lines, HOH1.2 and 110H1.3. These clones
showed distinct morphological differences (see Figure 5.7) and differed
only in a 5 Mb deletion at Ilq24-q24 (overlapping over 4 Mb with the
region identified by LOH) and deletion of llpl3. It is possible that the
llpl3 region is responsible for the observed morphological differences.
However clone llOHXl.3 has the same morphology as llOHl.2 yet it
retains the llpl3 region and has lost the llq24 region (see figure 4.16).
This suggests that the phenotype of invasiveness inhibition can be
ascribed to the 11 q24 region.
Direct comparison of the invasiveness of llOHl.2, 1.3, 2.4 and the
parent control is presented in Figure 5.21.
Figure 5.21 Comparison of matrigel invasion of llOHl.1/1.2 with
control cell line
ON 110H2.4 110H1.2 110H1.3
Cell Line
Error bars represent standard deviation
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Importantly, clone 110H1.3 is significantly inhibited for invasiveness
compared with 110H1.2 (see Table 5.7) differing only in a small
deletion at Ilq24-q25 overlapping with the region of interest defined
by LOH and demonstrating marked morphological differences from
110H1.3.
Table 5.7 T-tests comparing invasiveness differences between
cell lines from Figure 5.17
HOH2.4 HOH1.2 llOHl.3
OHN p=0.9, NS p=0.25, NS p=0.0004
HOH2.4 p=0.31, NS p=0.0014
HOH1.2 p=0.024
Two-tailed p-values are given. NS= non-significant.
In order to further define which components of the invasiveness
process are responsible for the observed inhibition effect associated
with chromosome Ilq24-q25, the effect of individual components of
matrigel extra-cellular basement membrane were individually tested
in cellular attachment and migration assays, in order to document
differences between the hybrid clones and the parent/control cell lines.
5.2.7.2 Cellular attachment assay
The ability of the cell lines to attach to individual components of the
extra-cellular matrix was tested by radioactively labelling the cells with
chromium and then allowing them to attach to plastic wells coated
with the individual matrix components for 2 hours. Figure 5.22
presents this data, and in summary, microcell hybrid 110F11.3,
containing whole chromosome 11 was significantly and specifically
inhibited in its attachment to laminin, whereas the other cell lines
were not. This specific inhibition of attachment was not seen with
collagen IV or fibronectin.
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Figure 5.22 2 hour radioactive chromium attachment assay comparing









ON 110H2.4 110H1.2 110H1.3
Cell Line
CN IV=collagen IV, FN=fibronectin, LN=laminin. Attachment values
are tiormalised for control OHN. Hybrid clones are expressed as %
attachment in relation to OHN. Error bars signify standard deviation
from a quadruplicate derived mean.
To confirm this observation, plain photomicrographs were taken in
two separate further experiments and these confirmed obvious
qualitative differences occurring specifically on the laminin coated
plates. After 24 hours llOHl.3 remained rounded up whereas
110H1.2, 110H2.4 and the parent cell line ONOH had stuck down and
spread out in a strikingly different way (see Figure 5.23).
226
Figure 5.23 Morphology after 24 hour attachment of control cell line
and microcell hybrids to laminin coated plastic wells
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5.2.7.3 Cell migration assay comparing microcell hybrids
Using 8 pm pore size Nuclepore filters in transwell chambers whose
under-surface had been coated with components of the extracellular
matrix, an assessment was made of migration of the cell lines over 72
hours in response to the ECM components. In summary, collagen IV
and fibronectin but not laminin generated a haptotactic stimulation of
migration over baseline (bovine serum albumin, BSA) in microcell
hybrid 110H1.2. This stimulation of migration was abrogated in hybrid
110H1.3 (which contains whole transferred chromosome 11)
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suggesting that this component of invasiveness could be ascribed to
the same region of the chromosome. This data is summarised in
Figure 5.24
Figure 5.24 72 hour transwell migration assay
BASS bovine serum albumin (basal migration), LN=laminin, CIVET
collagen IV, FN= fibronectin.
Note that laminin does not stimulate migration in hybrid llOFIl.2,
which is in contrast to the promotion of cell adhesion in this hybrid as
determined by the attachment assay. This experiment was only
performed once due to time constraints and requires repetition.
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5.3 OVCAR3 chromosome 12 microcell hybrids
Several fusion experiments were performed to transfer chromosome
12 to OH3 (see chapter 4). In two of these, rapid senescence occurred of
the clone at 10 weeks. In two other fusions, immortal cell lines were
isolated.
5.3.1 Morphology
Morphology of the chromosome 12 hybrids was similar to parent OH3.
5.3.2 In-vitro growth ofmicrocell hybrids
In-vitro growth showed that one hybrid was growth inhibited but the
other was not. Figure 5.25 presents this data.
Figure 5.25 Growth of 120H series of microcell hybrids
200000
Time (days)
5.3.3 Cell cycle analysis
Flow-cytometric cell-cycle analysis was performed using propidium
iodide staining of cells. Table 5.8 demonstrates that no obvious cell-
cycle effect was associated with the introduction of chromosome 12
into OF13.
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PLOIDY 1 .7 1 .72
5.3.4 Apoptosis
No evidence was found for significant induction of apoptosis. Table
5.9 shows FACS-AnnexinV analysis of the 120H series of microcell
hybrids
Table 5.9 Annexin V-FACS assay for 120H series of hybrids
Cell Line % Apoptosis







Microcell hybrids 120H1 and 120H2 were xenografted in SCID mice in
a direct comparison with ONOH (microcell hybrid with neutral
transferred chromosome from OVCAR3). 1 X 107 were injected with
matrigel sub-cutaneously into SCID mice. As can be seen from figure
5.26,120H2 was not suppressed for tumorigenicity, but tumours were
much smaller compared with ONOH. 120H1 was also growth retarded
but to a lesser extent.
Figure 5.26 Comparison of tumorigenicity of chromosome 12
microcell hybrids with parent control microcell hybrid.
Day





Ovarian cancer kills women. Its high mortality is related to its late
presentation. We know relatively little about how it develops at the
molecular level, and much work is still required to provide us with a
comprehensive grasp of its molecular pathophysiology. The prospect
of fresh conceptual insights from a functional and molecular genetic
approach leading to novel therapeutic strategies is a powerful
motivating factor for any researcher.
This work is an exploration of the role of chromosome 11 disruption
in the development and progression of malignant neoplasia of the
human ovarian surface epithelium. Several reports point to the
importance of the p arm of chromosome 11 (see "Introduction"). The
role of the q arm in ovarian cancer is much less well defined and this
thesis focuses on the long arm particularly.
The power of LOH analysis resides in its capacity to sample a
representative clinical population for evidence of restricted
chromosomal re-arrangement. The ability to identify associations of
LOH with adverse clinicopathological features directly relates to the
quality control of staging, histopathological and survival data. In this
respect, access to blood-tumour pairs from the Edinburgh Combined
Gynaecological Oncology clinic brings with it standardised operative
technique and staging, and standardised histopathological reporting
with minimisation of the inter-observer variability of both. Regular
follow-up and standardisation of primary and salvage non-surgical
therapy has produced a closely followed cohort of patients in whom
one can begin to identify a multitude of heterogeneous phenotypes
(morphological, pathophysiological or prognostic) that are involved in
the multistep pathway to ovarian carcinogenesis. Univariate analysis
can then identify phenotypes (or "factors") which segregate
significantly with LOH at particular loci. These LOH associations are by
their nature preliminary and mark only the beginning of serious
investigation.
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Unlike the use of polymorphic microsatellites in linkage analysis of
constitutive disorders, a positional cloning approach based only on loss
of heterozygosity analysis (as opposed to homozygous deletions)
utilising malignant neoplasms is a risky approach since there is a high
chance that LOH may simply be due to non-specific genome instability
associated with disruption of a few genes controlling generalised
genomic stability. The need to gather evidence that these LOH
associations house biologically active suppressor functions with a role
in the development and progression of clinical cancer is therefore of
importance. It follows that functional approaches are necessary to
make an assessment of the relevance of these regions. We can expect
that this will not only increase confidence for but also narrow down
the region of interest. Furthermore, it raises the possibility of a direct
functional cloning approach (see later).
In order to unambiguously assign function to regions of chromosome
11, the principles of somatic cell genetic analysis have been employed
in the technique of microcell mediated chromosome transfer, whereby
chromosome 11 as a whole or as a spontaneously fragmented part was
transferred to an ovarian cancer cell line. The transferred fragments
were mapped and an attempt was made to assign function to intervals
of the chromosome. This section will discuss the evidence for
important LOH and functional findings that bring together these
independent strategies in a convergent and complementary way to
highlight the importance of a small region in the distal part of
chromosome llq involved in the progression of ovarian cancer.
Loss of Heterozygosity and its associations
With a panel of 10 highly informative, well distributed, accurately
mapped polymorphic microsatellites (MSPs), significant levels of
chromosome 11 LOH were detected in a well characterised population
of 60 patients with ovarian tumours, many of whom had been
previously studied with respect to their chromosome 17 status by Dr
Diana Eccles, my predecessor (Eccles et al, 1990).
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Although the term LOH is used interchangeably with allele imbalance
in this work, it must be borne in mind that imbalance can also be a
consequence of allele specific amplification and need not necessarily
imply deletion of a region of DNA. Furthermore, amplification of a
region of DNA is not mutually exclusive with loss of function at a
tumour suppressor locus; loss of a chromosome or subchromosomal
region may occur with reduplication of the other allele/chromosome,
and amplification of a region of DNA is not necessarily associated with
gain of function if accompanying inactivating mutations are involved.
In contrast to findings with chromosome 17 (Steel et al., 1994; Foulkes
et al, 1993; Tavassoli et al, 1993), where whole homologue or whole
arm loss is common, interstitial and small terminal deletions are in
fact more common in chromosome 11 in this same group of ovarian
tumours. A highly significant association between allele imbalance on
17p and 17q in this material was noted (see results). No such
association is observed for imbalance on lip and llq as a whole, and
this argues for caution in the general interpretation of allelotyping data
that utilise only one or two loci per chromosome arm where no
previous biological hypothesis associates that chromosome arm with
involvement in neoplasia.
However, significant relationships for LOH between distant
chromosome 11 loci were observed; not only between adjacent sites
(which are likely to reflect larger deletions) but also between distant
loci despite retention of intervening loci. These pairs of loci may
harbour genes which are co-operatively inactivated as part of a
multistep process.
6.2 Loss of Heterozygosity
6.2.1 Allele loss of the short arm of chromosome 11 in ovarian cancer
In contrast to previous reports (Kiechleschwarz et al., 1993; Zheng et
al., 1991), I found no significant association between differentiation
grade and LOH at the llpl5 region (despite a rate of 67% LOH) in our
sample of EOCs, and this may reflect the lack of uniformity in ovarian
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cancer grading methodology. I could not confirm the previously
described association between llpl5 LOH and advanced stage disease
(Viel et al., 1992), although there appeared to be non-significant trends
for both these parameters. Significant LOH rates at llpl3 near the site
of WT1 have been detected in several studies, although direct analysis
of the WT1 locus suggests that it is not the gene involved (Bruening et
al., 1993; Viel et al, 1994). There was also evidence of significant LOH at
D11S922 in benign and borderline tumours. With this high level of
loss in EOCs, and without significant correlations with advanced
disease/poor prognosis subgroups, the likelihood is that an estimated
18.6 Mb interval within llpl5 houses a gene involved at an early stage
in ovarian carcinogenesis, occurring as part of the development of
benign and borderline tumours and also detectable at roughly similar
rates in adenocarcinoma. Allele loss at D11S569 (llpl5.3) is low (12.5%)
in benign and borderline tumours, but is much higher in carcinomas,
and there is no difference in LOH rate between early and advanced
FIGO stage adenocarcinomas. This raises the possibility of a second
locus at llpl5.3 which is inactivated as part of the development of
frank adenocarcinoma (albeit at an early stage of adenocarcinoma
development).
6.2.2 The centromeric parts of chromosome 11
The Ilpl2-ql4.3 region (which is a large region containing the
centromeric half of llq), although exhibiting high levels of loss, does
not appear to segregate significantly with any particular parameter,
although there is a non-significant trend towards LOH in association
with better prognosis tumours was associated with favourable
clinicopathological parameters. Higher LOH rates are observed in those
with mucinous histology, early FIGO stage and well/moderately
differentiated tumours. Higher rates of allele loss at D11S873 are also
seen in those patients remaining. These findings suggest that some
well differentiated, early FIGO stage carcinomas may belong to a
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genetically distinct sub-category of EOC rather than being simply
precursors of aggressive late stage disease, and that allele loss in the
Ilpl2-q22 region may confer changes incompatible with rapid
progression of the disease, e.g. deletion of an oncogene locus essential
for tumour progression. It is possible that LOH detected in this region
could reflect amplification of the llql3 region similar to that observed
in breast cancer (Karlseder et al., 1994) and this possibility has not been
ruled out, although previous studies of this region in ovarian cancer
(Foulkes et al., 1993) suggest that amplification occurs infrequently.
However, the explanation for our findings of better prognosis
associated with allele loss at this locus remain obscure and require
further work.
6.2.3 Proximal llq LOH and the progesterone receptor locus
The absence of LOH at D11S873 and D11S35 specifically in
endometrioid adenocarcinoma is of considerable interest, though the
finding approached statistical significance only for the latter MSP
(p=0.04).
D11S35 lies about 160 Kb from the site of the progesterone receptor
gene (PGR). At least 6 previous studies have reported that
endometrioid tumours contain progesterone receptor (PR) levels that
are elevated relative to other histological types (Slotman and Rao
1988). Furthermore, there is evidence that in breast cancer, gene dosage
plays a secondary but significant role to regulatory change for hormone
receptor levels; tumours that were cytogenetically 6q-/llq- had half the
average ER or PR value of tumours without losses on 6q or llq
(Magdelenat et al., 1994).
Further analysis of the Edinburgh patient cohort demonstrated that
allele loss close to the progesterone receptor gene on chromosome
llq22 was associated with low tumoral PR content suggesting the
possibility that genomic structural disruption including or flanking
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the progesterone receptor gene may have a significant role in the
dysregulation of PR content of at least some ovarian cancers.
That allele loss at the PR gene locus may genuinely disrupt PR
expression is also suggested by the observation that when tumours
with LOH at this locus are excluded from the informative sample, a
significant correlation between tumoral ER and PR content is revealed,
indicating that in many of these heterozygous tumours, the regulatory
link between oestradiol, ER and PR is intact, and that the converse is
true in those with LOH at the PR gene locus. Although trends also are
observed for distantly physically linked (D11S935; lip) and unlinked
(NM23; 17q) markers, they do not reach conventional significance
levels nor are the trends substantially different from each other. The
fact that there are non-significant trends is consistent with the
likelihood that PR gene disruption will not be the only mechanism of
tumoral PR down-regulation.
Not all previous literature is supportive of these observations. Fuqua
et al (1991) investigated the status of RFLPs within the PR gene in a
large series of breast tumours and found no correlation with PR
expression. Additionally 0/5 informative breast cancer
normal/tumour pairs exhibited allele loss using one of these RFLPs,
and the authors concluded that PR gene rearrangements were not a
significant mechanism for the alteration of tumoral PR content.
However, the extent of contaminating normal stroma (containing
constitutive DNA) in these tumours was not discussed, and the 6
human breast cancer cell lines tested in the study were all homozygous
at the reported RFLPs. However, more recently, it has been shown that
alterations in methylation in regions flanking the ER and PR receptor
genes is associated with reduced expression of these genes in breast
cancer ( Lapidus et al, 1996).
The observed tight link between D11S35 LOH and loss of PR
expression may be due to variations on the classical Knudson two-hit
model (Knudson, 1971).
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Clearly, analysis of the PR gene locus and RNA species in these
tumours is required to demonstrate the nature of these abnormalities,
since the Kd68 anti-PR antibody may not detect truncated forms of the
PR protein.
Analogous work with the oestrogen receptor in breast cancer has
demonstrated an ER variant lacking exon 5 of the hormone-binding
domain in ER-negative/PR-positive breast cancers that constitutively
activates the oestrogen response element (Fuqua et al, 1991b). A
truncated ER species which inhibits the binding of ER to its response
element has been identified in ER-positive/PR-negative breast
tumours (Fuqua et al, 1992), and an ER variant co-species lacking exon
3 of the DNA-binding domain was identified from ER-positive
tumours which was unable to function as a transcriptional inducer
(Fuqua et al, 1993).
Kaplan-Meier survival analysis in the small subgroups of our series
must be treated with caution given the sample sizes. Nevertheless, it is
interesting that patients with ER-rich tumours and allele loss close to
the PR gene had particularly poor survival, all 6 patients having died
within two and a half years; whereas those with ER-rich tumours that
retain heterozygosity at the PR gene locus have particularly good
survival with 5 of the 6 patients alive beyond three years (figure 6.1).
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Figure 6.1 Survival of ER rich patients according to D11S35
LOH status
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A prospective analysis in a larger series of patients is warranted to
confirm this potentially important prognostic marker.
Our finding that none of the endometrioid tumours had loss of
heterozygosity close to the PR gene is intriguing, and consistent with
the many reports that this histological subtype is associated with
higher tumoral PR content (Slotman and Rao, 1988) and the finding in
one study that endometrioid tumours can have a 54% response rate to
progestin therapy (Rendina et al, 1982)
The analysis of PR content in relation to survival may well be
complicated by the presence of LOH in association with abnormal PR
protein which is undetected by antibodies. Removing tumours with
LOH from our series, and examining those that had retained
heterozygosity resulted in the survival patterns that would have been
expected; patients with ER-rich and PR-rich tumours exhibited a
survival advantage
In conclusion, structural alteration at the PR locus on chromosome
llq22 may represent a significant mechanism for the dysregulation of
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tumoral PR content. Subsequent to publication of this work (Gabra et
al, 1995b), further analysis of PR gene structure, expression, and
associated clinical correlations in these tumours to determine the
mechanism(s) involved are currently underway in our laboratory.
6.2.4 Definition of a distal locus at llq24 associated with poor
prognosis
As part of the initial study, the finding of extensive allele loss distal to
llq23.3 (Foulkes et al., 1993) was confirmed and extended (both in
numbers and chromosomal position), with 67% of EOCs exhibiting
LOH at Ilq23.3-q24.1 in our sample. The proximal marker (D11S925) in
this region mapped about 1.2 Mb telomeric to the most distal marker
in Foulkes' study. Loss of heterozygosity at the distal MSP (D11S912) at
llq24.1 was significantly associated with adverse survival and
advanced stage, although the latter p value at 0.035 was borderline.
No borderline tumours exhibited allele imbalance at D11S912. These
initial findings suggested that a TSG primarily acting as a "progression
suppressor" might be located at llq23.3-24.1(or telomeric), and that its
inactivation could be a significant late event in the pathogenesis of
epithelial ovarian cancer. The publication of this work (Gabra et al,
1995a) which confirmed and extended Foulkes' analysis prompted a
more thorough investigation of this region which determined that
there were two loci with high rates of LOH in the distal portion of llq.
The proximal SRO (which is a large region defined by only two
microsatellites in our study) contains the ataxia-telangiectasia and
progesterone receptor genes and is lost frequently (in 40% of cases), but
does not crudely correlate with survival or other adverse prognostic
features in EOCs, although it is associated with low tumoral
progesterone receptor content (see above). This proximal region
broadly corresponds to a region that has recently been identified in
breast cancer (Carter et al, 1994; Hampton et al, 1994; Negrini et al, 1995)
A more telomeric Ilq23.3-q24.3 region, excludes the ATM locus and
the region recently mapped in breast cancer. The SRO has been
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narrowed by this analysis to 8.5 Mb lying between D11S934 and
D11S1320 at llq23.3-24.3 based on recently published physical (Van
Heyningen and Little, 1995; James et al, 1994). Kaplan-Meier survival
analysis revealed that LOH involving this 8.5 Mb region is associated
with poor survival in EOCs (Figure 6.2).
Figure 6.2 Telomeric llq loss of heterozygosity and patient survival
Regions of chr.ll telomeric LOH are shown in thick vertical lines
However, when only the advanced stage tumours were considered, the
Log rank test did not reach significance, although Kaplan-Meier
analysis showed a trend towards worse survival in those with LOH of
the distal region. This suggests that the late acting progression-
suppressor mentioned above may be located within this telomeric
interval.
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Interestingly, a paper by Winqvist and colleagues (Winqvist et al, 1995)
demonstrated that LOH of telomeric llq was associated with adverse
survival in women with node positive breast cancer. LOH within this
region should therefore be subjected to a larger prospective analysis to
assess its role as an independent prognostic factor, and its value in
assessing survival prospectively. The distal deletion interval currently
contains 5 candidate genes: (from centromeric to telomeric) SRPR,
ETS-1, FLI1, ZNF1 and NFRKB (James et al, 1994).
The possibility that high frequency non-specific genome instability
might be responsible for the observed regional losses was controlled by
selecting tumours with chromosome 11 loss preferentially, making it
unlikely that the observed survival association in this population
could be attributed to random high frequency genetic alteration.
Additionally, the retention of heterozygosity telomeric to the llq23.3-
q24.2 LOH region suggested that this distal unit is not simply due to
high frequency non-specific telomeric breaks. Analysis of a panel of 14
ovarian cancer cell lines using 6 MSPs from the critical region showed
no homozygous deletions. This study was published in early 1996
(Gabra et al, 1996a).
Within two weeks of the publication of this work, the same journal
published another paper which had simultaneously and completely
independently confirmed these findings using a comparable analysis.
Davis and colleagues (Davis et al, 1996) working in Southampton,
confirmed my initial study (Gabra et al, 1995a) and defined almost an
identical telomeric locus of LOH, overlapping over a region of about
4.5 Mb at llq24. Although they could not confirm the relationship
with advanced stage in their study, they did suggest that it was possible
that many of their early stage tumours might in fact have been
advanced tumours that were not sufficiently well staged. Finally, the
relationship of telomeric llq LOH and adverse survival in ovarian
cancer has now been confirmed by another worker (Georgia Chenevix-
Trench, personal communication).
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6.2.5 Associations of LOH on chromosomes 11 and 17 with
clinicopathological features of ovarian cancer.
Extensive chromosome 17 microsatellite and RFLP analysis of this
same cohort of patients had been performed (Eccles et al, 1992a; Steel et
al, 1993) prior to the chromosome 11 analysis. The data were combined
to provide an overview of the role of these two chromosomes in
ovarian cancer.
Chromosome 17 and 11 LOH affecting individual polymorphic loci
and whole chromosome arms showed significant concordant events
and associations with prognostically important clinicopathological
features of ovarian cancer. The data presented in this study do not
allow interpretation of the prognostic independence of these markers,
as only associations can be reported with this type of univariate
analysis.
Most striking among the "whole arm" co-loss events was the
association between 17p and 17q LOH. This has been described
previously in allelotype analyses using fewer polymorphic markers
than this study (Foulkes et al, 1993; Osborne et al, 1994) and our
findings are also highly supportive of the hypothesis that chromosome
17 whole homologue loss is a very common event in ovarian cancer.
In contrast, there was no association between lip and llq LOH in the
same patient population, demonstrating that although LOH on
chromosome 11 is a frequent event, it is unlikely to be explained by
whole homologue loss (by mechanisms such as non-disjunction
postulated to be important in chromosome 17). There is also an
association between telomeric llq LOH and 17q LOH, which has also
been observed for breast cancer (Gudmundsson et al, 1995). The
significance of this observation is not clear, although both these
regions contain polymorphic markers where LOH is associated with
adverse survival.
Significant associations of LOH between individual polymorphic
markers were also noted in this study, and for some of these, plausible
candidates or biological hypotheses exist (see chapter 4).
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Several observations were made in this analysis with regard to the
association of LOH with prognostically important clinicopathological
factors in ovarian cancer. Whole arm loss was significantly associated
with clinicopathological factors only for chromosome 17p. This is
perhaps not surprising when one considers that of the four
chromosome arms in this study, only 17p appeared to be lost
uniformly as a whole arm, i.e. all 17p polymorphic markers
underwent LOH together. This may be a reflection of the importance of
the p53 gene and its role in neoplasia. The most significant association
noted was of 17p LOH with serous ovarian adenocarcinoma. The
observation of p53 mutation in serous ovarian cancer is well described
in several previous studies (Eccles et al, 1992a; Niwa et al, 1994;
Kupryjanczyk et al, 1993; Klerni et al, 1994) 17p LOH is also associated
with poor differentiation of the primary tumour and advanced stage at
presentation, although these associations are at borderline significance.
However, there was no association of 17p LOH with adverse survival.
It is of interest that several extensive studies have reported no
relationship between p53 abnormality and survival in ovarian cancer
(Niwa et al, 1994; Sheridan et al, 1994; Kohler et al, 1993). The only
other notable "whole arm" observation was an association of
borderline significance between llq whole arm loss and adverse
survival.
An analysis of LOH at individual polymorphic loci with prognostic
clinicopathological features revealed several significant associations.
One can speculate that polymorphic markers undergoing frequent
LOH, where no significant difference is noted between favourable and
adverse clinicopathological features, may represent early events in
ovarian carcinogenesis. Conversely, polymorphic markers segregating
with adverse clinicopathological phenotypes may be intermediate or
late acting events (depending on phenotype). One can begin to
construct a preliminary picture of the possible involvement of
chromosomes 17 and 11 in a multistep model of ovarian neoplasia
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similar that constructed by Vogelstein for colorectal cancer. The model
published with this analysis (Gabra et al, 1996b) demonstrates not only
multistep but also multipath components in the pathway to ovarian
cancer (Figure 6.3).
Figure 6.3 Integrated model of ovarian carcinogenesis with respect to
allele loss of chromosomes 11 and 17.
In this model, 17p (p53) LOH represents an intermediate or early event;
17q and telomeric llq LOH represent late events. Although the
evidence is inconclusive, I have included D11S35 LOH as an early
event in neoplasia, perhaps involving the progesterone receptor, and
D11S873 LOH as an early event in generating a genetically distinct,
prognostically advantageous, subgroup which presents as the relatively
rare early stage form of ovarian adenocarcinoma.
It is clear that this univariate analysis is a crude tool with limits to the
extent of inferences that one can draw about ovarian neoplasia.
However, it does allow some general observations to be made
regarding comparisons of subchromosomal abnormalities in a small
but well-defined cohort of patients with ovarian cancer. It is to be
hoped that refinement of these regions will provide further
mechanistic answers to the observed associations as positional cloning
efforts ultimately yield genes involved in these processes.
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Considering the LOH studies discussed above as a whole, they have
extended the previous observations of distinctive patterns of
aneusomy or molecular aberrations in ovarian cancers belonging to
different clinico-pathological subgroups. The observations do not
imply that LOH at each of the defined regions of chromosome 11
represent independent prognostic factors, although llq sub-telomere
imbalance should perhaps be subjected to a large prospective study.
6.3 Microcell mediated chromosome transfer
6.3.1 Structural analysis
Having used a clinical resource to define frequent LOH rates at specific
loci on chromosome 11 and their association with the
clinicopathological features of ovarian cancer, I set out to determine
whether or not tumour suppressor genes of importance in ovarian
cancer actually reside on chromosome 11.
A normal human chromosome 11 was transferred by microcell
mediated chromosome transfer to the ovarian cancer cell line
OVCAR3.
OVCAR3 was established from the malignant ascites of a patient with
progressive adenocarcinoma of the ovary after combination
chemotherapy with cyclophosphamide, Adriamycin, and cisplatin and
represents a poorly differentiated ovarian cancer (Hamilton et al, 1983).
In-situ hybridisation revealed that 5 centromeric spots are observed by
chromosome 11 specific alphoid PRINS. Chromosome painting
showed that chromosome 11 was markedly rearranged. Flow
cytometric analysis and karyotyping showed that OVCAR3 was hypo-
tetraploid with a DNA content of 1.8N relative to normal diploid
blood lymphocytes. However, microsatellite analysis of OVCAR3
demonstrated homozygosity of all markers suggesting that whole
homologue loss of this chromosome had occurred with reduplication.
No homozygous deletions in OVCAR3 were detected with the markers
used in this analysis.
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The normal donor human chromosome 11, tagged with a neo-marker
was available from two different monochromosome somatic cell
hybrids: J1 C14 and 556.1.5. J1 C14, a CHO cell line proved to be a poor
microcell donor under a wide range of conditions. 556.1.5 proved to be
a good chromosome 11 donor, with broad tolerance conditions for
micronucleation. A neo-retrovirus was used to tag this chromosome
(Lugo et al 1987), and the retroviral site of integration was Ilql4-q22
(Bernard Weissman, personal communication). It was therefore
expected that chromosomal retention would cluster around this
region, which indeed turns out to be the case (sec figure 4.14) with
individual microcell hybrid clones variously containing donated chr
11 with fragmentations of the p arm and llq22-qter but no instances of
deletion of proximal llq.
The potential problem of heterogeneity within the OVCAR3
population might have resulted in microcell hybrid clones (MHCs)
with artefactual functional differences from the parent control due to
simple clonal selection. In order to address this, a clonal sub-line of
OVCAR3 (OH3) was generated by hyg-tagging of OVCAR3 and
selection of colonies. This clonal sub-line was used as a recipient for
MMCT. In order to avoid the possibility that non-specific functional
effects were produced by the introduction of the neo-marker itself
rather than the chromosome 11 into which it was integrated, control
cell lines were generated that were dually transfected with hyg and
neo. Furthermore in order to avoid the possibility that the non-specific
introduction of chromatin into the cell line produced suppressive
effects, a "control" chromosome was transferred to OH3. Initially,
chromosome 1 was transferred; however this universally produced
extreme growth arrest/ senescence. Chromosome 12 was then
transferred and it also produced cell death at about 8 weeks of the
entire population of cells. However some clones did avoid death and
went on to be developed into cell lines, one of which was functionally
suppressed for growth and delayed for tumorigenicity. In view of both
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of these chromosomes being functionally active as suppressors for
OH3, the ultimate non-suppressing chromosome was transferred:
OVCAR3 was transfected with neo-plasmid and a clonally derived cell
line (ON3) was used as a microcell donor to transfer a nco-tagged
chromosome to OH3. Since functionally active TSGs are already
dysfunctional in OVCAR3, any chromosome transferred from
OVCAR3 (ON3) to itself (OH3) should by definition not contain a TSG.
These highly appropriate controls behaved as they were expected to,
conferring no functional alterations.
Transfer of chromosome 11 to OH3 was confirmed by neo PCR and in-
situ hybridisation. MMCT using J1 C14 resulted in a "bystander
survival" effect whereby in hygromycin/geneticin dual selective
media, the OH3 and J1 C14 population protected each other from cell
death until the concentrations in the media were increased. When
these mixed population clones were expanded and DNA was extracted,
both donor and recipient alleles were detected resulting in the
erroneous conclusion that chromosome transfer had been successfully
achieved. Painstaking analysis was required to prove that these were
mixtures of donor contaminant cells with parent recipients. This leads
to the view, which I hold strongly, that in-situ hybridisation is the best
formal proof of chromosome transfer. This has implications for the
interpretation of the majority of published functional analyses.
Another iconoclastic notion derived from this work was the extent to
which transfer of murine sequences occurred in microcell mediated
chromosome transfer. In general, this issue is not addressed in most
publications concerned with MMCT, or worse, assumed to be
irrelevant. The need to identify the incidence of this phenomenon
arose since it was implicit that the MHCs would eventually be used to
as a difference cloning resource. The question therefore arose of the
amount of murine expressing chromatin that could interfere in such
difference cloning experiments. By murine cot-1 in-situ painting it
became clear that transfer of small amounts of murine chromatin is
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ubiquitous. In the bizarre neoplastic recipient karyotype containing
extreme fragmentation and an incidence of double minutes, it is
almost impossible to identify these small fragments of murine
chromatin by simple karyotyping, and this illustrates the power of in-
situ technology. This technique was further supported with great
convenience and sensitivity by murine IRS-PCR which produced a
characteristic and unique murine fingerprint for each MHC fusion
event. Using this technique, one could determine if within a particular
fusion experiment the clones were derived from the same or
independent fusion events. The answer was almost invariably a single
fusion event with several clones dispersed by trypsinisation prior to
selection. Clonal evolution of the human transgene but not the mouse
transgene was observed which correlated with changes in components
of the neoplastic phenotype.
In keeping with the clinical observation of high rates of LOH on
chromosome 11 in the absence of lip and llq LOH concordance, and
also with the observation of extreme re-arrangement of chromosome
11 in OVCAR3, it was not surprising to find fragmentation of the
donated chromosome 11 in the MHCs. Indeed, the majority of hybrids
contained fragmentation of chromosome 11 and these events included
MHCs derived from the same fusion event with identical murine IRS-
PCR fingerprints yet obvious differences due to fragmentation of the
donated chromosome 11 by LOH analysis. Fragmentation of llpl3 and
llq24 occurred together frequently, dramatically observed for one clone
(llOHl.2) which had a completely different neoplastic reverted
phenotype despite an identical murine IRS-PCR fingerprint to another
clone (llOHl.3) which retained the entire chromosome 11 and a
suppressed, invasion-inhibited phenotype. It is interesting to note that
the most significant concordant losses between MSPs on chromosome
11 in the clinical LOH studies were for D11S935 and D11S912, from the
same region. The basis for this observed fragmentation and the same
observation in clinical samples is unclear but may be due to two co-
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ordinately inactivated tumour suppressor genes. The generation of
OH3 as a clonal derivative of OVCAR3 whilst essential prior to
microcell fusion, was nevertheless problematic because this sub-clone
proved to be extremely sluggish at subcutaneous xenograft growth.
Changing from nude to SCID mice, and manipulation of the matrigel
and oestradiol environment did result in repeatable conditions for
xenograft growth. One successfully generated xenograft was taken back
into cell culture and the cell line OHX was developed from it. This
line only required one fifth the number of cells to form a tumour and
therefore further microcell fusions were performed using OHX as a
recipient.
6.3.2 Identification of three functional loci.
Functional analysis provided unambiguous evidence for suppressor
function associated with the introduction of chromosome 11 and 12.
Furthermore, there is some evidence that two separable functions are
located on chromosome 11.
It is difficult to interpret the chromosome 1 experiments. Several
senescence functions are known to be located on chromosome 1 and
the chromosome 1 donor that we used has been used previously by
Carl Barrett's group to assess senescence (Sugawara et al, 1990). I was
unable to extract an adequate amount of DNA from these clones for
PCR so I cannot confirm that microcell transfer actually occurred.
Microsatellite analysis of lip was hampered by the unexpectedly large
number of uninformative markers found (i.e. the alleles for 556.1.5
and OH3 being identical). This means that information is lost about
potential tumour suppressors and this is relevant since there are
translocation breakpoints at llpl5.5 and Ilql2-ql3 in OH3 (Andy
Walker, personal communication)
Clear in-vitro growth suppression occurred for all chromosome 11
microcell hybrids except those with fragmentation/deletion of
D11S533, D11S1358 and telomeric lip suggesting that the growth
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suppressor could tentatively be assigned to these intervals. In
particular, clone 110HX2.3 which appeared to have lost all informative
markers on the short arm of the donated chromosome grew
particularly briskly.
Cell cycle analysis revealed no evidence of accumulation of the MHCs
in any particular phase as compared with parental controls. This
precluded an obvious effect of a cell cycle regulator. Furthermore FITC
labelled Annexin-V binding was not elevated in the growth
suppressed MHCs, implying that this growth suppression effect was
not due to induction of apoptosis. In-vivo tumorigenicity (in SCID
mice, with matrigel and oestradiol) was not completely suppressed, but
tumour growth was delayed. Under conditions of high oestradiol dose,
however, tumour growth could be completely suppressed, evidence in
itself of the arbitrary nature of the subcutaneous xenograft assay.
Closer inspection of the growth suppressed cell lines revealed two
distinct morphological patterns (figure 5.7). In two clones (llOHl.l and
110HX1.1) distal llq was retained and a dramatic effect was observed.
The cells grew in tight, clustered colonies and did not spread and
migrate to occupy the available surface on the tissue culture dish. In
comparison, the parent and control cell lines and MHCs containing
chromosome 11 with deletions in llq24 as small as 5.5 Mb grew with
the same spread-out characteristics as the parent regardless of their in-
vitro growth rates. For llOHl.l and llOHXl.l, the self-imposed lack of
spreading/migration combined with continued cellular proliferation
resulted in colonies with apparently very small cells reminiscent of
over-confluent cell cultures, which in three dimensional reality
probably represent rounded up cells. In order to begin to understand
this phenomenon, functional assays which address these phenotypes
were employed.
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6.3.3 The llq invasion suppressor: dissecting the components
involved
The clone containing a whole copy of chromosome 11 (llOHl.l) was
investigated in more detail. Within 4 passages of the cell line being
developed, the clustered phenotype described above had begun to
revert to the parental spread-out phenotype. Two clonal sub-lines were
developed from llOHl.l (called 110H1.2 and 110H1.3). These clones
had identical murine PCR fingerprints implying that they were closely
related but exhibited dramatically different in-vitro phenotypes.
HOH1.3 retained the original clustered appearance of llOHl.l and
microsatellite mapping demonstrated retention of all transferred
chromosome 11 loci examined. HOH1.2 had deletions of the
transferred chromosome 11 atDllS935 (llpl3) and a 5.5 Mb deletion
centred around D11S910 (Ilq24-q25) which overlaps with the distal
LOH region defined in the ovarian cancer patients described above.
IIOHI.3 was significantly inhibited (to about 37%) in its ability to
invade into a matrigel layer compared with controls (and clones with
deletion of the llq24 locus including llOHl.2). The functional effect of
disrupting this locus is therefore a substantial increase in invasiveness,
and it is noted at this point that the clinical phenotype which preceded
these experiments was one of advanced stage, i.e. disseminated
nodules invading widely over the surface of the peritoneum resulting
in poor prognosis.
In order to understand which component of invasiveness was
involved, dissection of the invasion assay into the component assays
of tumour cell attachment and migration were performed. The effect
of the basement membrane components laminin and collagen IV, and
the plasma protein fibronectin (which is also a component of the extra¬
cellular matrix) were observed on migration and attachment of parent
cells and MHCs.
6.3.3.1 Tumour cell attachment
A striking and specific effect of inhibition of laminin mediated
attachment was observed which could be ascribed to the llq24 locus
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both quantitatively and qualitatively. In addition to integrins
mediating attachment to laminin, a specific laminin receptor (32/67 kD
laminin binding protein, or 67 LR) has been described and is
upregulated in carcinomas (Liotta et al, 1984; Wewer et al, 1986).
Laminin receptor has also been specifically examined in the OVCAR3
ovarian cancer cell line (Liebman et al, 1993). Sub-lines of 0VCAR3
which form ascites/advanced disease have high expression of 67LR
and low levels of expression of basement membrane
components/collagenase IV. The converse is true for OVCAR3 cells in
prolonged in-vitro culture or those that form subcutaneous tumours
but not intra-peritoneal tumours. Over-expression of the laminin
receptor has been shown to correlate with an adverse prognosis in
lung and breast cancer. At least 5 integrins mediate attachment to
laminin including a2|31 (Languino et al, 1989; Maemura et al, 1995)
and a6(34 (Lee et al, 1992). The morphological alterations associated
with introduction of the llq24 locus are not dissimilar to the
phenomenon of compaction whereby cells develop extensive and
intimate contacts along their surfaces resulting in tightly adherent
polarised epithelial sheets. These effects may be mediated by cadherins,
catenins or the actin cytoskeleton (Reviewed in Gumbiner 1996), but it
may simply be that inhibition of integrin pathways that ensure cell
spreading on extra-cellular surfaces in the absence of down-regulation
of cadherins and catenin results in default compaction due to a shift in
balance between catenin/cadherin expression on the one hand and
integrin expression on the other. This, of course, is purely speculative,
but is worth mentioning.
6.3.3.2 Tumour cell migration
A further distinct effect was observed in addition to laminin
attachment-inhibition. Clone llOHl.2 with the 5.5 Mb deletion in
llq24 showed distinct stimulation of migration in response to a
haptotactic collagen IV or fibronectin signal emanating from the
under-surface of the transwell. Curiously, no such stimulation of
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migration was seen in response to a laminin signal. In clone 110H1.3,
with the llq region intact, clear abrogation of the collagen
IV/fibronectin migratory stimulation phenomenon is observed
suggesting that a pleiotropic process is co-ordinately inhibited in
association with the introduction of the llq24 region into OVCAR3.
6.4 Hypothesis
An 8.5 Mb region located in llq24, when disrupted in primary
tumours from patients with ovarian cancer, is associated with
advanced stage (with widespread peritoneal dissemination of tumour)
and poor prognosis. Introduction of chromosome 11 into a poorly
differentiated ovarian cancer cell line (OVCAR3) with extensive re¬
arrangement of chromosome 11 mediates two distinct suppression
phenotypes. One of these is growth inhibition and the function maps
in the region between llpter-ql4. The other phenotype is inhibition of
tumour cell invasiveness, which maps to a 5.5 Mb region in the
microcell hybrids and overlaps over 4.5 Mb with the 8.5 Mb region
described above (see figure 6.4). The region described independently by
Davis et al (1996) in ovarian cancer also spans this 4.5 Mb region,
confirming the LOH analysis. The invasion inhibited phenotype can be
shown to be inhibited for both laminin mediated attachment and
fibronectin/collagen IV stimulated migration suggesting that the llq24
region may mediate suppression of a pleiotropic, co-ordinated and
complex process of tumour cell invasion (figure 6.5).
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Figure 6.5 Phenotypic effects ascribed to the llq24 locus
Parent OVCAR3













6.5 Summary and future directions
This study has succeeded in taking the adverse clinical phenotype of
poor actuarial survival and developing an association between this
and LOH at distal llq. By a functional approach utilising somatic cell
genetics, an underlying cell biological basis for this adverse phenotype
has been defined, that of enhanced invasiveness in association with
loss of this region. The matrigel invasion assay has been further
dissected into its component parts, a specific cell adhesion/spreading
effect mediated through laminin binding; and a cell migratory effect
mediated by collagen IV / fibronectin haptotactic signals.
Further immunofluorescent analysis of integrins may allow the
definition of some of the downstream components of this pleiotropic
response associated with the introduction of distal llq. Analysis of the
expression of cx2, a3, a6, (31 and (34, as well as catenins and cadherins
may further define the basis of these phenotypic differences.
Further identification of chromosome 11 candidate genes may give
some indication whether these genes may have some role to play in
these phenotypes. In particular, genes within the llq24 region (FLI1,
ETS1, SRPR, FLI1, ZNF1 and NFRKB) may be involved, although they
do not represent logical candidates based on their known functions.
Known tumour suppressor genes on chromosome 11 (p57 at llpl5.5,
WT1 at llpl3, KAI1 at llpl2 and NCAM at llq22) may have some role,
although microsatellite analysis suggests that they are not involved.
An integrated positional-functional approach to cloning the llq
invasion-suppressor
A YAC-contig spanning the consensus region of deletion in figure 6.4
is already available from the Human Genome Mapping Project and
will be constructed for a positional cloning approach. However, at 4.5
Mb it is a little large for a small group such as ours and therefore it will
be used in conjunction with markers derived from a difference cloning
approach (see below).
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Representational difference analysis (RDA) is an extremely powerful
technique which allows anonymous sequences to be cloned from two
closely related genetic complements with relatively few differences. It
was developed by Nikolai Lisitsyn (Lisitsyn et al, 1993) and represents a
major advance in difference cloning technology. In summary,
representations of the genome are made by digestion with a 6 cutter
restriction endo-nuclease and then PCR amplification in order to
simplify the complexity of the genome and increase the amount of
DNA available. Generating a representation improves the
completeness of subsequent subtractive hybridisation. The genomic
resource lacking the gene of interest is mixed in 80 fold excess (driver)
with the resource containing the gene of interest which has had
adapter ligated its ends (tester) (figure 6.6).
















The samples are mixed, heated and re-annealed resulting in
subtractive hybridisation of sequences common to both driver and
tester. The only sequences which find other sequences with the ligated
adapter are sequences unique to the tester representation. These are
then selectively exponentially amplified by PCR. The entire process is
repeated 3 times resulting in enrichment of the target by a factor of at
least 106. The resultant sequences are cloned into bluescript and can be
used to isolate genes encoding phenotypic differences. We have
established RDA in our laboratory and demonstrated that it can be
used to clone the contents of a homozygous deletion found in an
ovarian cancer cell line (Watson et al 1996). The application of RDA to
the resources described in this thesis relate to its adaptation to cloning
the difference between 2 closely related cDNA populations (Hubank
and Schatz, 1994). Essentially identical conditions are employed for
cDNA-RDA except that a 4-cutter is utilised instead of a 6-cutter since
cDNA populations intrinsically are representations of the genome.
Explicitly, the cDNA population from HOH1.2 with an invasive
phenotype and a 5.5 Mb deletion at llq24 will be used as the driver and
cDNA from IIOITI.3 retaining llq24 intact will be used as the tester.
Since they have identical murine IRS-PCR fingerprints, I would not
expect to clone murine sequences from this experiment. This
technique will, of course, not be successful if expression of the gene of
interest is not deleted or structurally disrupted in a major way.
Isolation of cDNA-RDA clones from this region will be the next major
step in this project and will provide the link to identification of the
structure of this gene and its biological role in ovarian cancer.
This thesis has taken the clinical phenotype of adverse prognosis and
developed an integrated positional/functional strategy to identify
genes responsible, when disrupted, for this adverse phenotype. The
strategy allows an approach to a previously difficult problem in
somatic cell genetics of cancer, that of how to proceed from a
phenotype back to the gene. What is clear is that this process, though
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demanding technically and in terms of interpretation, provides a real
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Chromosome 11 allele imbalance and clinicopathological correlates in
ovarian tumours
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CM Steel25
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Summary Allele imbalance on chromosome 11 loci in ovarian cancer is a frequent event, suggesting the
presence of tumour-suppressor genes for ovarian carcinogenesis on this chromosome. Ten highly polymorphic
(CA) repeat microsatellites were used to determine allele imbalance in 60 primary ovarian tumours, including
47 epithelial ovarian cancers (EOCs). Forty EOCs (85%) showed allele imbalance at one or more loci, and in
39 of these (83%) the data suggested subchromosomal deletions: eight of lip only; six of 11 q only; and 25 of
both lip and llq. Three consensus regions of deletion were indicated at 11 pi5.5 pi5.3, 11 q 12 — q22 and
11 q23.3 q24.1. Allele imbalance at the llq subtelomeric region (D11S912) correlated significantly with
adverse survival, while imbalance at 11 q 14.3 and retention of heterozygosity at 11 q22 (close to the site of the
progesterone receptor gene) were associated with favourable clinicopathological features. The findings allow
development of a preliminary model for the molecular evolution of epithelial ovarian cancer.
Keywords: chromosome 11; tumour-suppressor genes; ovarian cancer; loss of heterozygosity
Epithelial ovarian cancer is the main cause of death from
gynaecological cancer in British women, primarily because of
its late presentation, which carries a poor prognosis despite
available treatment modalities. Interest is focusing on the
molecular basis of ovarian cancer in order to uncover new
and hopefully effective management strategies.
Strong circumstantial evidence for the location of tumour-
suppressor genes (TSGs) can be obtained by observed allele
mbalance (loss of heterozygosity, LOH) in tumour DNA
:ompared with a matched constitutional DNA specimen at
iefined chromosomal loci (Ponder, 1988). Minimum consen¬
sus regions of allele imbalance may lead to isolation and
:loning of these 'deleted' genes, and LOH studies in many
umour types have suggested putative TSGs located on
:hromosome 11.
In ovarian cancer, cytogenetic analysis has demonstrated
>artial deletions of chromosome 11 affecting both the long
ind short arms (Bello and Rey 1990; Pejovic et al., 1992;
enkins et al., 1993). Frequent LOH has been demonstrated
it 11 p 15 (Lee et al., 1989; Ehlen and Dubeau, 1990; Eccles et
il., 1992a; Gallion et al., 1992; Vandamme et al., 1992; Viel
•t al., 1992; Kiechleschwarz et al., 1993), although not all
tudies have confirmed this high level of loss (Sato et al.,
991; Zheng et al., 1991; Yangfeng et al., 1992). A proximal
ocus at 11 p 13 (site of WTl) exhibits lower rates of LOH in
ivarian cancer (Call et al., 1990; Vandamme et al., 1992; Viel
t al., 1992; Bruening et al., 1993). A minority of these
tudies have proposed a correlation of lip LOH with poorly
iifferentiated (Zheng et al., 1991; Kiechleschwarz et al., 1993)
nd more advanced (Viel et al., 1992) tumours. Molecular
tudies of the proximal llq region have shown low rates of
ioth LOH and amplification of the 11 q 13 amplicon in
'varian cancer (Lee et al., 1989; Li et al., 1991; Sato et al.,
991; Viel et al., 1992; Foulkes et al., 1993). In contrast, the
nly study that has looked specifically at the subtelomeric
sgion of llq (Foulkes et al., 1993) recorded a high rate of
llele imbalance at llq23.3-qter in a small sample of
amours. The advent of highly polymorphic, well-mapped,
licrosatellites distributed evenly throughout the genome
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(Weissenbach et al., 1992; Gyapay et al., 1994) and amenable
to polymerase chain reaction (PCR) amplification has
allowed rapid LOH analysis using small amounts of DNA
(Futreal et al., 1992), which can be derived, if necessary,
from archival material.
We have used 10 (CA)„ polymorphic microsatellites to
determine allele imbalance on chromosome 11 in ovarian
tumours removed from 60 women [47 epithelial ovarian
cancers (EOCs), five borderline malignancies, three
adenofibromas, two mixed mesodermal tumours, two
granulosa cell tumours and one teratoma]. The data have
been analysed in relation to clinicopathological findings.
Materials and methods
Clinical specimens
Fresh primary ovarian tumour tissue from 60 patients was
transferred directly to dry ice or liquid nitrogen and stored at
— 70°C. The normal tissue for comparison was blood in 39
patients and normal regions from formalin-fixed blocks in 21
patients. FIGO staging, histopathology and differentiation
state were determined and reviewed in a standardised fashion
at a multidisciplinary combined gynaecological oncology
clinic. Treatment was in accordance with standard protocols,
which consisted of the best possible surgical debulking
followed by adjuvant/palliative chemotherapy. Minimum
follow-up from diagnosis is 24 months, with median follow-
up (by reverse Kaplan-Meier method) of 47 months. All
deaths that have occurred have been due to ovarian cancer.
Patient characteristics are outlined in Table I.
DNA extraction
DNA from fresh-frozen tissue and blood was extracted by a
standard technique as previously described (Eccles et al.,
1990). DNA extraction from fixed specimens was performed
by cutting 3x10 pm sections, dewaxing in xylene, washing in
100% ethanol and desiccating the specimen. Proteinase K
(200pgml~') digestion was performed overnight at 37°C fol¬
lowed by heat inactivation. Debris was removed by centri-
fugation, providing a preparation containing adequate DNA
template for PCR.
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Table I Clinicopathological characteristics of the 60 patients with
ovarian tumours
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'rimers were selected on the basis of recently generated
nicrosatellite index maps for locus, informativeness and
pacing. Table II shows these primers and associated inform-
tion. A high-resolution radiation hybrid map allowed reas-
•nable estimates of physical distance separating these
narkers (Figure 1) (James et al., 1994).
Polymerase chain reaction and polymorphic microsatellite
'election
'CR was performed under conditions specified in the original
iapers. A 10 pi volume of the PCR reaction product was
jaded onto 8% denaturing polyacrylamide gel, separated by
lectrophoresis, passively transferred to Hybond nylon and
•robed with a 32P end-labelled poly(CA) probe as previously
escribed (Cohen et al.. 1992). Two observers visually
nalysed the autoradiographs and recorded allele imbalance
/hen there was a clear reduction in the intensity of one allele
t tumour DNA.
'tatistical analysis
he two-tailed Fisher exact test was used. Since numerous
nalyses were performed, significance was set at P = 0.01, but
'e have included trends towards significance in the region of
.07>P>0.01 where they have supported or suggested
iological hypotheses. Kaplan-Meier curves and log-rank
nalysis were performed (ICRF ICNET PDPLOT actuarial
arvival program, W Gregory) to determine LOH-survival
ilationships. Multivariate analysis was not performed
ecause of the small sample number.
Table II Polymorphic chromosome 11 microsatellite markers used in
this study: identity and location
Locus Location Name Referenced
D11S922 11pi 5.5 AFM217yblO 1,2
D11S569 11 p 15.3 cCIII-434 2,3
D11S929 11 p 14.1 AFM234xc3 1,2
D11S935 11 p 13 AFM254zb9 1,2
D11S905 11p13 12 AFM 105xbl0 1,2
D11S873 11q 14.3 Mfdl27 GDB ID no. 32638
D11S35 1 lq22 Phage2-22 2,4
D11S897 1 lq23.1 Mfd231 GDB ID no. 34742
D11S925 1 lq23.3 AFM220yb6 1,2
D11S912 1 lq24.1 AFM157xh6 1,2
"1, Weissenbach et al. (1992), Gyapay et ai (1994), Couillin et al.
(1994). 2, Litt et al. (1993). 3, Phromchotikul et al. (1992). 4, Litt et al.
(1990). GDB, genome database.
Results
Molecular analysis
Clinicopathological characteristics of the patient cohort are
outlined in Table I. Table 111 shows the allele imbalance
results for all markers and subgroups in this study.
Eighty-seven per cent of all ovarian tumours (52/60) and
85% of EOCs (adenocarcinomas excluding borderline malig¬
nancies) (40/47) had evidence of LOH involving at least one
locus on chromosome 11. Only one EOC had LOH at all
informative loci, and seven EOCs (15%) had no detectable
LOH. Examples of allele loss for each of the markers are
shown in Figure 1.
Analysis of consensus regions of allele imbalance in ovararian
EOCs Figure 2 is a graphic representation of the data from
Table III showing that serous, poorly differentiated and
advanced stage EOCs have particularly high levels of LOH at
both the lip and llq subtelomeric regions. Conversely,
EOCs which are early stage or moderately/well differentiated
appear to have high levels of LOH at the Ilql4.3-q22
region.
Figure 3 shows those tumours that have partial losses on
chromosome 11. Deletions are shown in shaded bars and are
limited by the next heterozygous locus. In cases where a
locus with allele loss is separated by an uninformative locus
from a locus that remains heterozygous, that uninformative
locus is included within the shaded bars as part of the
deletion (since this region could be deleted). Eight tumours
had only lip loss, six tumours had only llq loss and 25
tumours had partial loss of both arms. This type of analysis
suggests three shortest regions of overlap (SROs) correspond¬
ing to three consensus regions of deletion/allele imbalance at
11 p 15.5 — 15.3, 1 lq23.3-qter and Ilpl2-q22.
lip loss of heterozygosity LOH was observed for at least
one short arm locus in 77% (46/60) of all informative
tumours, including 72% of EOCs (34/47).
For all ovarian tumours, high levels of LOH (>40%) were
found for three loci (see Table III): D11S922 at 11 p 15.5 in
24/47 informative tumours (51%) and 16/36 EOCs (44%);
D11S569 at 11 p 15.3 in 23/43 informative tumours (54%) and
14/30 EOCs (47%); and at D11S905 at 1 lpl3-12 in 21/45
informative tumours (47%) and 15/33 EOC's (45%). When
considering only those tumours that were informative at both
loci telomeric to 11 p 15.3 (D11S569 and D11S922), the rate of
lip subtelomeric LOH was 16/24 (67%).
The lowest frequencies of allele loss on lip were detected
at D11S929 (11 p 14.1), with only 28% LOH in ovarian
tumours and 24% LOH in EOCs.
llq loss of heterozygosity llq LOH was observed for at
least one locus in 65% (39/60) of all informative tumours,
including 66% of EOCs (31/47).
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Figure I Idiogram of chromosome 11 with examples of allele imbalance. Constitutive DNA (left lane) and tumour DNA (right
lane) for each microsatellite locus are shown with approximate distances between loci.
For all ovarian tumours, high levels of LOH were seen in
ree loci (see Table III): D11S873 at 11 q 14.3 in 11/25 infor-
ative tumours (44%) and 9/22 EOCs (41%); D11S925 at
q23.3 in 24/45 informative tumours (53%) and 18/33 EOCs
4%); and D11S912 at llq24.1 in 23/49 informative
mours (47%) and 18/37 EOCs (49%).
When considering only those EOCs that were informative
both loci telomeric to llq23.3 (D11S925 and D11S912),
e LOH rate was 18/27 (67%).
The lowest frequencies of allele loss were detected at
11S897 (1 lq23.1), with only 32% LOH in ovarian tumours
id 28% LOH in EOCs.
llele imbalance in other ovarian tumour types The non-
OC tumour numbers were too small for statistically valid
inclusions. We considered benign and borderline (low
aligant potential, LMP) tumours together. Only 1/8 benign
■ borderline tumours had LOH at D11S569 (11 pi 5.3) and
7 had loss at D11S912 (11 q24.1). However, 3/5 benign or
irderline tumours had LOH at D11S922 (1 lpl5.5). Both
e mixed mesodermal tumours had LOH at both 11 p 15.5 —
5.3 and llq23-qter. One granulosa cell tumour had LOH
at all loci on lip, suggesting whole arm loss. The ovarian
teratoma in our series was hemizygous at all nine informative
loci, and this is compatible with the usual description of
these tumours as being parthenogenetic.
Microsatellite instability Microsatellite instability (MSI)
(Aaltonen et al., 1993; Thibodeau et al., 1993) was noted in
only 6.4% of EOCs (3/47). Both granulosa cell tumours had
evidence of MSI, and one of these tumours had evidence of
instability at three loci. There were no cases of MSI in five
borderline, three benign and two mixed mesodermal
tumours.
Statistical analysis
Fisher's exact test was used to analyse the relationship for
allele imbalance between specific loci and also the relation¬
ship between imbalance for specific loci and clinicopatho-
logical parameters for EOCs.
Relationship of allele imbalance between different loci The
three regions of deletion determined from Figure 3 were
Chromosome 11 allele imbalance in ovarian tumours
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analysed for significant relationships. No relationship was
noted between LOH at the lip subtelomeric region
(D11S922 and D11S569 at 1 lpl5.5-15.3) and at the llq
subtelomeric region (D11S925 and D11S912 at
1 lq23.3-24.1) (P = 0.5). Similarly, no relationship was seen
between LOH at 1 lpl2—ql4.3 (D11S905 and D11S873) and
the lip subtelomere (P = 1.0). However, a significant rela¬
tionship exists for LOH at the Ilpl2-ql4.3 region and the
llq subtelomeric region (P = 0.0025), suggesting that losses
at these two regions co-segregrate. Alternatively, they could
be part of a single deletion group, although Figure 3 suggests
that this is not the case.
Fisher's exact test was used to test allele imbalance
between all possible combinations of loci (Figure 4). For loci
adjacent or close to each other, significant and borderline
Figure 2 Graphic representation of allele imbalance rates from
Table III for various clinicopathological parameters, (a) CZZ] ,
Serous; 1^3 , endometrioid; ■. mucinous, (b) □, Moderately/
well differentiated; ■, poorly differentiated, (c) □, Early FIGO;
■ advanced FIGO.
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findings are likely to reflect association simply as part of
substantial subchromosome deletions which may include a
tumour-suppressor gene. For loci distant from each other,
D11S912/D11S935 LOK showed a significant statistical rela¬
tionship (P = 0.0073) and the relationship for D11S935/
D11S922 was of borderline signifiance (P = 0.046), suggesting
the possibility that these loci harbour genes which may be
inactivated cooperatively.
Relationship between allele imbalance and clinicopathological
parameters Table IV shows Fisher's test P-values with
significance trends for clinicopathological parameters at the
loci tested.
Allele imbalance and histology No significant difference was
seen at any locus, comparing serous EOCs with other histo¬
logies. However, of nine informative endometrioid tumours.
D11S922 D11S569 D11S929









































Figure 3 Grey horizontal bars represent the
approximate positions of the shortest regions of
with allele loss/imbalance in tumour DNA. U =
D11S935 D11S905 D11S873 D11S35 D11S897 D11S925 D11S912
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extent of subchromosomal deletions in EOCs. Black vertical lines represent
overlap (SROs); three such regions are apparent. L = constitutively heterozygous
= constitutively homozygous and therefore uninformative at that locus.
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Loci tested P-value Distance D11S922 D11S929 D11S905 D11S35 D11S925
between loci 11 pi 5.5 11 p 14.1 11 pi3—12 11q22 11q23.3
(Mbp) D11S569 D11S935 D11S873 D11S897 D11S912
11 pi 5.3 11 pi 3 11q14.3 11 q23.1 11q24.1
D11S905 vs. D11S935 0.0015 4 1
D11S912 vs. D11S935 0.0073 88 1wmm vmmm
D11S912 vs. D11S897 0.0088 21 mrnrn.1
D11S905 vs. D11S929 0.0121 21 Vzmmza wmm
D11S935 vs. D11S929 0.013 17 mwm 1
D11S897 vs. D11S873 0.0152 15 tmmsm mmm>,1
D11S925 vs. D11S35 0.0185 20 immm wmm1
D11S912 vs. D11S929 0.0189 106 wmmm wmm
D11S935 vs. D11S922 0.046 47 mmmn \mmm
D11S912 vs. D11S925 0.057 10 mimm
Figure 4 Fisher's exact test analysis of co-loss between markers on chromosome 11.
Table IV Fisher's exact test comparing ovarian adenocarcinoma
clinicopathological groups at chromosome 11 loci
Marker LOH Segregation parameter P-value
D11S912 Dead (vs alive) patients with 24 months 0.0067
minimum follow-up
D11S912 Dead (vj alive) patients at 24 months 0.067
D11S912 Late (vs early) FIGO stage tumours 0.035
D11S35 Non-endometrioid (vs endometrioid) 0.04
histology
D11S873 Well (vs poorly) differentiated tumours 0.07
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Figure 5 Kaplan Meier survival curve with log-rank analysis
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Figure 6 Kaplan-Meier survival curve with log-rank analysis
for D11S912 (11 q24.1) allele imbalance status at presentation.
survival of patients with adenocarcinoma (P = 0.0067) with
minimum follow-up of 24 months.
Kaplan-Meier survival analysis Telomeric 11 q LOH
(D11S925 and D11S912) was significantly associated with
adverse survival for patients with ovarian adenocarcinoma
(Figure 5), and significance was increased when D11S912
LOH was considered alone (Figure 6). Actuarial survival of
those without LOH shows 70% survival at 4 years vs. 20%
for patients who had lost a D11S912 allele in their primary
tumour at diagnosis.
lone had LOH at D11S35, and comparing this group with
ither histologies a trend towards significance was observed
'or LOH of this marker with non-endometrioid histology
P = 0.04).
Allele imbalance and FIGO stage The only observed trend
owards significance was for the association of LOH at
311S912 with FIGO stage 111/1V EOCs (P = 0.035).
Allele imbalance and differentiation grade The only apparent
rend towards significance was between D11S873 LOH and
veil/moderately differentiated tumours (P = 0.07).
Survival D11S912 loss of heterozygosity at llq23.3-24.1 in
trimary tumours at diagnosis was associated with adverse
Discussion
With a panel of ten highly informative, well-distributed,
accurately mapped microsatellite polymorphisms (MSPs),
significant levels of chromosome 11 allele imbalance were
detected in our population of 60 ovarian tumours. Although
the term allele imbalance is used interchangeably with LOH
in this paper, we have opted to use this term rather than
LOH since imbalance can also be a consequence of allele-
specific amplification and need not necessarily imply deletion
of a region of DNA. Furthermore, amplification of a region
of DNA is not mutually exclusive with loss of function at a
tumour-suppressor locus; loss of a chromosome or sub-
chromosomal region may occur with reduplication of the
other allele/chromosome, and amplification of a region of
DNA is not necessarily associated with gain of function if
accompanying inactivating mutations are involved.
Chromosome 11 allele imbalance in ovarian tumours
H Gabra et al &
In contrast to findings with chromosome 17 (Steel et al.,
1994), in which whole homologue or whole arm loss is
common, interstitial and small terminal deletions are in fact
more common in chromosome 11 in this same group of
ovarian tumours. A highly significant association between
allele imbalance on 17p and 17q in this material has been
observed previously (Fisher's exact test, P = 0.0007; data not
presented). No such association is observed for imbalance on
lip and llq (P = 0.65) as a whole, and this argues for
caution in the interpretation of allelotyping data that utilise
only one or two loci per chromosome arm where no previous
biological hypothesis associates that chromosome arm with
involvement in neoplasia.
However, relationships for allele imbalance between distant
chromosome 11 loci do occur; not only between adjacent
sites (which are likely to reflect larger deletions). Significant
associations do occur between two distant loci while inter¬
vening loci are excluded from the relationship, as shown for
example by D11S912/D11S935 and D11S935/D11S922 (at
borderline significance). These pairs of loci may harbour
»enes which are cooperatively inactivated as part of a multi-
step process. Consensus analysis of those EOCs with partial
deletion suggests at least three distinct regions of allele im¬
balance, at 1 lpl5.5—pi5.3, 1 lq23.3-24.1 and Ilpl2-ql4.3.
In contrast to previous reports (Zheng et al., 1991; Kiech-
eschwarz et al., 1993), we found no significant association
between differentiation grade and allele imbalance at the
11 p 15 region (despite 67% LOH) in our sample of EOCs,
tnd this may reflect the lack of uniformity in ovarian cancer
grading methodology; nor could we confirm an association
between 1 lpl5 LOH and advanced stage disease (Viel et al.,
1992), although there appeared to be a non-significant trend
or both these parameters (Figure 2). D11S922 LOH
11 p 15.5) did correlate at a borderline level of significance
P = 0.046) with LOH at D11S935. (Significant LOH rates
lave been detected in several studies at lip 13, near the site
)f WT\. although direct analysis of the WT\ locus suggests
hat it is not the gene involved; Bruening et al., 1993; Viel et
//., 1994.) There was also evidence of significant LOH at
311S922 in benign and borderline tumours. With this high
evel of loss in EOCs, and without significant correlations
vith advanced disease/poor prognosis subgroups, the likeli-
lood is that an 18.6 Mb interval within 11 p 15 houses a gene
nvolved at an early stage in ovarian carcinogenesis, occur-
ing as part of the development of benign and borderline
umours and also detectable at roughly similar rates in
idenocarcinoma. Allele loss at D11S569 (11 p 15.3) is low
12.5%) in benign and borderline tumours, but is much
ligher in carcinomas, and there is no difference in LOH rate
between early and advanced FIGO stage adenocarcinomas.
This raises the possibility of a second locus at 1 lpl5.3 which
is inactivated as part of the development of frank adenocar¬
cinoma (albeit at an early stage of adenocarcinoma develop¬
ment).
We have confirmed and extended (in both numbers and
chromosomal position) the recent finding of extensive allele
loss distal to llq23.3 (Foulkes et al., 1993), with 67% of
EOCs exhibiting LOH at llq23.3-24.1 in our sample. Our
proximal marker (D11S925) in this region maps about
1.2 Mb telomeric to the most distal marker in the study of
Foulkes et al. Loss of heterozygosity at the distal MSP
(D11S912) at 11 q24.1 is significantly associated with adverse
survival and advanced stage, although the latter P-value, at
0.035, is borderline.
No borderline tumours exhibited allele imbalance at
D11S912. Allele imbalance at the subtelomeric region at
D11S912 showed significant correlation with D11S897
(11 q23.1) and D11S935 (11 pi3 in the region of WT\). These
findings suggest that a TSG acting primarily as a 'progres¬
sion suppressor' may be located at llq23.3-24.1 (or telo¬
meric), and that its inactivation may be a significant late
event in the pathogenesis of epithelial ovarian cancer.
The 11 pl2—q 14.3 region (which is a large region contain¬
ing the centromeric half of llq), although exhibiting high
levels of loss, does not appear to segregate significantly with
any particular parameter, although there is a non-significant
trend towares LOH in association with better prognosis
tumours. Allele imbalance in this region does, however,
segregate significantly with imbalance of the llq subtelomeric
region. D11S873 LOH at Ilql4-q22 seems to correlate with
favourable clinicopathological parameters: higher LOH rates
are observed in those with mucinous histology, early FIGO
stage and well/moderately differentiated tumours. Higher
rates of allele loss at D11S873 are seen in those patients
remaining alive (also seen at the neighbouring locus,
D11S905 at 1 lpl3-12). These findings suggest the possibility
that some well-differentiated, early FIGO stage carcinomas
may belong to a genetically distinct subcategory of EOC
rather than being simply precursors of aggressive late-stage
disease (Figure 7), and that allele loss in the Ilpl2-q22
region may confer changes incompatible with rapid progres¬
sion of the disease, e.g. deletion of an oncogene locus essen¬
tial for tumour progression. It is possible that LOH detected
in this region could reflect amplification of the 11 q 13 region
similar to that observed in breast cancer (Karlseder et al.,
1994), and we have not ruled out this possibility in the
present study, although previous studies of this region in
ovarian cancer (Foulkes et al., 1993) suggest that
373
11 p 15 and 11q24 LOH
Rapid evolution
Figure 7 Hypothesis for chromosome 11 involvement in ovarian carcinogenesis. For abbreviations, see text.
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amplification occurs infrequently. However, the explanation
for our findings of better prognosis associated with allele loss
at this locus remains obscure and requires further work.
The absence of LOH at D11S873 and D11S35 specifically
in endometrioid adenocarcinoma is of considerable interest,
though the finding approached statistical significance only
for the latter MSP (P = 0.04). D11S35 lies about 160 kb from
the site of the progesterone receptor (PgR) gene. At least six
studies have reported that endometrioid tumours contain
PgR levels that are elevated relative to other histological
types (Slotman and Rao, 1988). Furthermore, there is evi¬
dence that, in breast cancer, gene dosage, although secondary
to regulatory change, plays a significant role in determining
hormone receptor levels: tumours that are cytogenetically
6q—/llq— have half as many oestrogen receptors (ER) and
PgRs as tumours without losses on 6q or llq (Magdelenat et
al., 1994). We would therefore speculate that there may be a
role for the PgR gene in the regulation of histological sub¬
types of ovarian cancer, and possibly that its structural dis¬
ruption contributes to the generation of adverse histological
and prognostic subtypes at a relatively early stage in the
development of ovarian cancer.
The findings in this study extend the previous observations
of distinctive patterns of aneusomy or molecular aberrations
in ovarian cancers belonging to different clinicopathological
subgroups. They do not imply that LOH at each of the
defined regions of chromosome 11 represents independent
prognostic factors, although llq subtelomere imbalance
should perhaps be subjected to a large prospective study.
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Abstract
Forty-seven epithelial ovarian cancers were analyzed
or loss of heterozygosity (LOH) at D11S35 (llq22), close to
he progesterone receptor (PR) gene, and for tumoral estro-
;en receptor (ER) and PR content. Thirty-eight of 47 tumors
rere informative, and, of these, 14 exhibited LOH. There
ras a significant association (P = 0.014) between D11S35
.OH and low tumoral PR content. For all informative tu-
aors, there was no correlation between ER and PR; how-
ver, exclusion of tumors with LOH from the informative
eries revealed a linear correlation between tumoral ER and
R (P = 0.013), and established ER (P = 0.025) and PR (P =
.05) content as significant factors in relation to patient
urvival. Patients with ER-rich tumors with D11S35 LOH
ad particularly poor survival compared with ER-rich,
U1S35 heterozygous, no loss patients (P = 0.014).
Analysis of the same tumors using two other microsat-
llites, D11S935 (llpl3) and NM23 (17q22), showed no sta-
stically significant relationships, although there were non-
ignificant trends for the correlation of ER and PR
xpression in informative tumors without allele loss at these
>ci.
We propose that genomic structural alteration at or
lose to the PR gene locus has biological and clinical sequelae
i ovarian cancer.
ritroduction
Ovarian cancer is the leading cause of death from gyneco-
igical malignancy, and its etiology is poorly understood. Epi-
smiological and animal studies indicate that ovarian cancer
lay be an endocrine-related tumor. Chronic estrogen and pro-
-stin administration in animal studies results in ovarian cancer
L, 2). "Incessant ovulation" appears to be a major premeno-
ausal risk factor (3, 4). Nulliparity and a low mean number of
pregnancies have been associated with increased risk (5). In¬
creased total pregnancy and lactation time, and the use of oral
contraceptives (6, 7) confer a protective effect. The high gona¬
dotrophs milieu of the postmenopausal state may confer addi¬
tional risk (8). Ovarian cancer has been reported to respond to
antiestrogens in about 10-20% of cases and to progestins with
an average of 36%, with a range between 0 and 60% (9, 10).
The ovary is the main site of synthesis of estrogen and
progesterone, and is also a target organ for these hormones. The
actions of these hormones are mediated by specific intracellular
receptors that function as hormone-inducible nuclear transcrip¬
tion factors with context-specific, often conflicting effects on
proliferation and differentiation of target tissues (11).
PR3 is regulated by estrogen via ER (12); estradiol-induced
PR expression has been demonstrated in ovarian cancer cell
lines that express ER (13).
That histopathological subtypes of epithelial ovarian can¬
cer differ in their PR expression is suggested by at least six
reports demonstrating that endometrioid ovarian tumors contain
relatively more PR than other histological types (9), and that PR
positivity is associated with well-differentiated ovarian tumors
in premenopausal women (14). High PR content in breast (15)
and ovarian (16, 17) cancer has been shown to correlate with a
favorable prognosis, although the biological relevance of steroid
hormones and their receptors to ovarian cancer remains contro¬
versial.
The PR gene has been localized to chromosome llq22 (18,
19), so that it is now possible to determine whether structural or
regulatory disturbances of the chromosomal locus affect the PR
content of endocrine-regulated epithelial cancers and hence
these tumors' relationships with prognosis. In breast cancer,
allele losses on chromosome lip were found to correlate with
PR-negative tumors (20). Despite initial studies suggesting that
llq LOH is an infrequent event (21, 22), several recent studies
suggest that it is, in fact, a common event in breast cancer
(23-25). Furthermore, a recent breast cancer cytogenetic study
(26) demonstrated that llq- but not 6q- tumors contained a low
PR:ER ratio, whereas 6q- but not llq- tumors had a low ER:PR
ratio, suggesting some role for genomic structural alteration in
the regulation of tumoral steroid receptor content.
In ovarian cancer, evidence has accrued to suggest that
distal chromosome llq cytogenetic abnormalities (27) and LOH
(28, 29) are frequent events of clinicopathological significance.
In this study, we used a polymorphic microsatellite lying
close to the PR gene to determine allele loss in ovarian cancer.
At the time of the study, no intragenic microsatellite with high
heterozygosity was available for the PR gene, RFLP analysis for
the PR gene being even less informative. D11S35 was selected
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Fig. 1 Examples of heterozygosity, homozygosity, and allele loss by
PCR analysis of the three polymorphic microsatellites used. N, PCR
from normal constitutive DNA; T, tumor DNA. Microsatellite markers
map to 1 lq22 (D11S35), llp!3 (D11S935), and 17q22 (NM23).
because it was the closest microsatellite to the PR gene (with the
same Kosambi genetic distance of 0.41) and had an acceptably
high heterozygosity rate (30, 31). Subsequent to completing the
study, a high resolution physical map of chromosome 11 sug¬
gested that it lay slightly (3 centirays, approximately 150 kb)
telomeric to the PR gene (32). Two other incidental polymor¬
phic microsatellites were randomly selected to demonstrate
specificity of the correlation: D11S935 (llpl3) (33) and NM23
(17q22) (34). The PR and ER content of these tumors was then
measured, and the relationship between allele loss and tumoral
steroid receptor content was assessed.
Materials and Methods
Clinical Specimens. Fresh primary ovarian tumor tissue
from 47 patients (mean age, 60 years) with epithelial ovarian
cancer was transferred directly to dry ice or liquid nitrogen
perioperatively, and stored at —70°C until processing. Hepa-
rinized blood was obtained from 34 patients postoperatively. In
the remaining 13 patients, normal tissue was obtained from
formalin-fixed blocks. The International Federation for Gyne¬
cology and Obstetrics staging, histopathology, and differentia¬
tion state were determined and reviewed in a standardised
fashion at a multidisciplinary combined Gynecological Oncol¬
ogy Clinic. Treatment was planned and delivered in accordance
with standard protocols, which consisted of the best possible
surgical debulking followed by adjuvant/palliative chemother¬
apy where appropriate. Minimum follow-up on living patients is
24 months, maximum follow-up is 60 months, and all deaths
that have occurred have been due to ovarian cancer.
Numbers of patients with tumors that were ultimately in¬
formative for steroid receptor content and constitutive hetero-
the microsatellite used. Patient characteristics are outlined in
Table 1.
DNA Extraction. DNA from fresh frozen tissue was
extracted using a standard technique as described previously
(35). Extraction of DNA from fixed specimens was performed
by cutting 3- X 10-p.m sections from the block, dewaxing in
xylene for 30 min twice, removing the xylene by washing three
times in 100% ethanol, and desiccating the specimen under heat.
Proteinase K (200 p-g/ml) digestion was performed overnight at
37°C, and then the proteinase K was heat inactivated at 95°C for
5 min and debris was removed by centrifugation. The resultant
preparation provided adequate DNA template for PCR.
Oligonucleotide Primers. The oligonucleotide primer
sequences for D11S35 (30) were S35-S (5'-ACAATTGGA-
TTACTACTAGCACC-3') and S35-AS (5'-AACTATGTATT-
TGTATCGATTAAC C-3')- For D11S935 (33), the primer se¬
quences were afm 254zb9-CA (5'-TACTAACCAAAAGAGT-
TGGGG-3') and afm 254zb9-GT (5'-CTATCATTCAGAAAA-
TGTTGGC-3'). The primer sequences for NM23 (34) were (5'-
TTGACCGGGGTAGAGAACTC-3') and (5'-TCTCAGTACT-
TCCCGTGACC-3').
PCR and Polymorphic Microsatellite Detection. PCR
was performed in a reaction volume of 50 pi under the follow¬
ing reaction conditions: 94°C for 3 min X 1 cycle, 94°C for 1
min/55°C for 1 min/72°C for 1 min X 35 cycles, and 72°C for
5 min X 1 cycle in a Hybaid thermocycler. Reaction mix
contained 50 mM KC1, 10 mM Tris-HCl (pH 9), 1% Triton
X-100, 1.5 mM MgCl2, 200 |xm deoxyribonucleotide triphos¬
phate, 1.25 units Taq polymerase, 10 pmol of each primer, and
100 ng DNA.
Ten pi of the PCR reaction product were loaded onto 8%
denaturing polyacrylamide gel, separated by electrophoresis,
passively transferred to Hybond nylon, and probed with a 32P
end-labeled poly(CA) probe as previously described (36). Two
observers visually analyzed the autoradiographs and recorded
allele imbalance when there was clear reduction in the intensity
of one allele in the tumor DNA.
Determination of ER and PR by EIA. Tumor speci¬
mens snap frozen at operation were homogenized in buffer (10
mM Tris, 0.25 m sucrose, 1 mM EDTA, pH 8.0, plus 1% v/v
monothiolglycerol and 10% v/v glycerol) as previously de¬
scribed (37). After centrifugation at 105,000 X g, the superna¬
tant cytosol was assayed using EIA kits according to the man¬
ufacturer's method (ER-ELA and PR-EIA kits; Abbott
Laboratories, Maidenhead, Berkshire, United Kingdom; Ref.
38). The protein content of the cytosol was determined accord¬
ing to the method of Bradford (39), and receptor concentrations
were expressed as fmol/mg protein. The PR antibody used was
Kd68, a rat mAb which recognizes both the A and B subunits of
PR (and therefore recognizes sequences downstream of codon
165, the start site for subunit A) and binds both free and
complexed PR, presumably avoiding the hormone-binding site
(40).
Recognizing that cutoff values for steroid receptor levels
are controversial, ER poor or PR poor was defined as less than
30 fmol/mg protein and ER rich or PR rich was defined as 30
fmol/mg protein or more. These values derive from reports
describing clonogenic assays of human ovarian carcinoma cells
Clinical Cancer Research 947


















G3 9 3 Serous P.D. H H H 159 29
G4 58 A 1 c Clear cell M.D. L U L 2 5
G8 56 A 2 Serous P.D. H L U 100 12
Gil 27 3 Serous M.D. U U L 100 12
G12 5 4 Serous P.D. H L U 1 1
G16 21 3 Mucinous NK H L H 1 1
G17 52 A 3 Serous M.D. U U H 2 3
G18 11 1 A Mucinous M.D. H L H 29 8
G20 23 3 Serous P.D. L H H 4 229
G23 10 3 Endometrioid M.D. H U L 21 9
G24 51 A 3 Serous P.D. H L H 2 160
G26 7 3 Serous P.D. H U H 38 39
G28 52 A 1 A Mucinous M.D. L H L 7 6
G30 23 1 A Endometrioid P.D. H U H 12 12
G34 49 A 3 B Serous P.D. H L H 187 163
G35 1 3 Serous P.D. H U H 6 12
G38 48 A 1 A Endometrioid M.D. H H H 139 161
G42 47 A 1 B Endometrioid P.D. H L H 9 10
G46 46 A 1 A Mucinous W.D. U II H 1144 315
G50 48 A 3 Mucinous NK L H L 11 10
G55 11 4 Serous P.D. L L L 3 10
G56 43 A 1 A Endometrioid P.D. H L H 6 11
G58 18 3 Serous P.D. L L L 6 19
G59 38 3 Endometrioid P.D. U L L 74 109
G60 30 1C Serous P.D. L L H 11 40
H5 38 A 1 C Endometrioid P.D. U H L 8 18
H9 37 A 3 Endometrioid M.D. H H L 130 59
H12 35 A 1 C Clear cell M.D. L H H 3 7
H55 8 3 Serous P.D. U H U 10 8
H58 31 1 Endometrioid M.D. U L L 4 116
H59 33 A 1 Endometrioid M.D. H U H 99 30
H60 16 3 Endometrioid W.D. H L U 13 10
H69 25 3 Serous P.D. L L L 5 35
H76 25 3 Serous P.D. L L U 3 88
H77 27 3 Clear cell M.D. L L H 3 48
H80 18 3 Serous NK L L H 4 46
H91 28 3 Serous P.D. H H H 3 21
H95 24 A 1C Endometrioid P.D. U H H 42 21
H96 9 ? Endometrioid NK H L L 21 8
" FIGO, International Federation of Gynecology and Obstetrics; A, alive at most recent analysis; U, uninformative/homozygous; L, LOH; H,
heterozygous with no loss; NK, not known.
clinical work showing that these approximate cutoff values for
ER and PR represent a reasonable index of hormone sensitivity
(13, 41, 42).
Statistical Analysis. The Mann-Whitney U test was used
to compare the means and medians of tumor PR content in
populations with and without LOH for the three microsatellite
markers. Two-tailed P values were calculated.
Spearman's rank correlation was used to examine correla¬
tions between tumor ER and PR content in those with and
without LOH.
Kaplan-Meier/log rank analysis was performed to deter¬
mine any relationship between the allele loss and survival in
D11S35 informative subgroups.
Results
Allele Loss Analysis. Fig. 1 shows examples of the three
microsatellite markers used in this study. Of 47 epithelial ovar¬
ian cancer patients, 38 were informative (constitutively het¬
erozygous) at D11S35 (72%). Of these, 14 (37%) exhibited
LOH at this locus and 24 retained heterozygosity. There was
inadequate tissue for ER and PR quantification in seven of these
informative specimens (two with LOH and five heterozygous,
no loss), and therefore the final allele loss rate in this group was
12 (39%) of 31. For D11S935, the final allele loss rate was 13
(39%) of 33 and for NM23 (17q22), the final allele loss rate was
19 (61%) of 31 (Table 1). The sample contained nine informa¬
tive endometrioid ovarian cancers, none of which exhibited
LOH at D11S35. Fisher's exact test for endometrioid versus
other histologies revealed a significant correlation between
D11S35 retention of heterozygosity and endometrioid histology
(P = 0.04) in the 38 informative tumors.
PR Distribution and Relationships between Allele Loss
and PR. Sufficient material was available for ER and PR
measurement in 39 of the 47 tumors (Table 1), and this estima¬
tion was performed in a blind fashion at a different institution
(by R. A. H.). A summary of PR data distribution by locus and
allele loss status is shown in Table 2. The mean tumoral PR
concentration for the 12 patients with LOH at D11S35 was 5.2
948 llq22 LOH and Tumoral PR in Ovarian Cancer
Table 2 Distribution of PR data by allele loss status for three microsatellites"
D11S35 D11S935 NME-1
LOH llq22 HET* LOH 1 lpl3 HET LOH 17q22 HET
No. 12 19 13 20 19 12
Mean PR (fmol/mg protein) 5.2 51 30 93.2 25 138
Median PR (fmol/mg protein) 4 21 8 7.5 6 10.5
SD 3.1 62 43 254 47 322
Minimum 2 1 2 1 1 3
Maximum 11 187 130 1144 187 1144
Mann-Whitney U statistic 53 125 76.5
Two-tailed P 0.014 0.87 0.133




























Fig. 2 Tumoral PR content (log10 transformed values) plotted against tumoral allele loss status for the three microsatellites used. HET, heterozygous
at the locus without LOH.
fmol/mg, with a median of 4 fmol/mg (range, 2-11 fmol/mg).
The mean tumoral PR concentration for the 19 heterozygous
patients with no loss at D11S35 was 51.4 fmol/mg, with a
median of 21 fmol/mg (range, 1-187 fmol/mg). For D11S935
the median PR of the LOH group was 8 fmol/mg (range, 2-130
fmol/mg), for the no-LOH group it was 7.5 fmol/mg (range,
1-1144 fmol/mg). For NM23 the median for the LOH group
was 6 fmol/mg (range, 1-187 fmol/mg), and for the no-LOH
group 10.5 fmol/mg (3-1144 fmol/mg). Plotting tumoral PR
concentration against D11S35 allele loss status as a log scatter
plot (Fig. 2) shows the association of low/absent tumoral PR
with D11S35 LOH, but this clear difference is not apparent for
the other two markers.
The difference between the medians in the D11S35 LOH/
no-LOH groups was statistically significant with the Mann-
Whitney U test (P = 0.014). These analyses were repeated for
a chromosome 11 short arm locus, D11S935 at llpl3; and for
NM23, a chromosome 17 long arm locus (17q22). Although
large, apparent differences were also noted (see above) for the
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+ D11S935 LOH. n-13, r-0.201, p-0.5t
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Fig. 3 Scatter plot of natural log-
transformed (In) ER and PR values
comparing tumors with allele loss
(LOH) and tumors that were het¬
erozygous without LOH (Het).
Data presented: a, D11S35
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Fig. 4 Kaplan-Meier survival curves with log rank analysis for D1IS35 heterozygous, no loss (HET/no loss) ovarian cancer patients subdivided by
PR content (a) and PR-poor patients subdivided by DI1S35 allele loss status (b). Vertical lines, censored patients.
statistically significant differences of mean and median PR
concentration by allele loss status were recorded (Table 2 and
Fig. 2).
Relationship between ER and PR. The whole D11S35
informative group was analyzed for linear correlation between
tumoral ER and PR content by Spearman's rank correlation.
There was no significant correlation for the whole group. How¬
ever, when patients with D11S35 LOH were removed from the
analysis, there was a linear correlation between tumoral PR and
ER content (Spearman's rank correlation, P = 0.013). Fig. 3a
shows a scatter plot of D11S35 heterozygous/no loss group and
LOH group in terms of their ER versus matched PR contents.
The analysis was repeated for D11S935 (Fig. 3b) and NM23
(Fig. 3c). Although there was no significant correlation between
ER and PR content in either the heterozygous/no loss group or
the LOH group for either of these latter markers, it is interesting
that both had trends to significance in their respective heterozy¬
gous/no loss group, but these trends were not different between
the D11S935 marker on lip (P = 0.058) and NM23 on 17q
(P = 0.063).
Survival Analysis. Kaplan-Meier/log rank survival
analysis for ER-rich versus ER-poor patients showed no
significant difference between the two groups (data not
shown). PR-rich versus PR-poor showed a nonsignificant
trend in favor of the PR-rich patients (P = 0.08, data not
shown). Comparing patients with tumor D11S35 LOH versus
patients with D11S35 heterozygous/no loss tumors also
showed no difference (data not shown). However, analysis of
patients with D11S35 heterozygous/no loss tumors only
showed a survival advantage for patients with PR-rich (>30
fmol/mg) tumors compared to those with PR-poor (<30
fmol/mg) tumors (F = 0.05, Fig. 4a) and PR-poor patients
did equally as badly whether they had LOH at D11S35 or not
(Fig. 4b).
D11S35 heterozygous/no loss patients with ER-rich tumors
(>30 fmol/mg) had a better outcome compared to those with
ER-poor (<30 fmol/mg) tumors (P = 0.025; Fig. 5a).
Patients who had informative ER-rich (>30 fmol/mg) tu¬
mors were then plotted according to whether they had LOH at
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Fig. 5 Kaplan-Meier survival curves with log rank analysis for D11S35 heterozygous, no loss (HET/no loss) ovarian cancer patients subdivided by
ER content (a) and ER-rich ovarian cancer patients subdivided by allele loss status at D11S35 (b). Vertical lines, censored patients.
advantage in favor of those with no LOH at D11S35 was
observed (although this subgroup comprised only 12 patients).
Discussion
This report demonstrates that allele loss close to the PR
gene on chromosome llq22 is associated with low tumoral PR
content, suggesting the possibility that genomic structural dis¬
ruption including or flanking the PR gene may have a significant
role in the dysregulation of the PR content of at least some
ovarian cancers.
That allele loss at the PR gene locus may genuinely disrupt
PR expression is also suggested by the observation that when
tumors with LOH at the PR gene locus are excluded from the
informative sample, a significant correlation between tumoral
ER and PR content is revealed, indicating that in many of these
heterozygous tumors, the regulatory link between estradiol, ER,
and PR is intact, and that the converse is true in those with LOH
at the PR gene locus. Although trends also are observed for
distantly physically linked {D11S935-, lip) and unlinked
(NM23; 17q) markers, they do not reach conventional signifi¬
cance levels, nor are the trends substantially different from each
other. (One might have expected that substantial deletions in¬
volving lip as well as llq, resulting in co-loss of the chromo¬
some 11 markers, might be responsible for a higher level of
borderline significance with this distant but physically linked
marker than for an unlinked marker.) The fact that there are
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nonsignificant trends is consistent with the likelihood that PR
gene disruption will not be the only mechanism of tumoral PR
down-regulation.
Steroid receptor negativity in the literature is variably and
arbitrarily defined: in the case of ER from as low as 1-5
fmol/mg protein (indicating the background level of EIA) to
between 15 and 20 fmol/mg (indicating the clinical levels below
which hormonal therapeutic manipulations are unlikely to yield
benefit). Interestingly, all tumors with LOH at D11S35 had PR
of 11 fmol/mg or less.
Not all previous literature is supportive of our observations.
Fuqua et al. (22) investigated the status of RFLPs within the PR
gene in a large series of breast tumors and found no correlation
with PR expression. Additionally, none of five informative
breast cancer normal/tumor pairs exhibited allele loss using one
of these RFLPs, and the authors concluded that PR gene rear¬
rangements were not a significant mechanism for the alteration
of tumoral PR content. However, the extent of contaminating
normal stroma (containing constitutive DNA) in these tumors
was not discussed, and the six human breast cancer cell lines
tested in the study were all homozygous at the reported RFLPs.
The observed tight link between D11S35 LOH and loss of
PR expression may be due to variations on the classical Knud-
son two-hit model (43). Loss of imprinting (for which there is
some evidence on 1 lq, although not in ovarian cancer; Ref. 44)
of one allele in association with large deletions of the other may
occur in concert and may affect regulatory rather than structural
regions, perhaps explaining the negative findings of Fuqua et al.
(22).
Clearly, analysis of the PR gene locus and RNA species in
these tumors is required to demonstrate the nature of these
abnormalities, since the Kd68 anti-PR antibody may not detect
truncated forms of the PR protein.
Analogous work with the ER in breast cancer has demon¬
strated an ER variant lacking exon 5 of the hormone-binding
domain in ER-negative/PR-positive breast cancers that consti-
tutively activates the ER response (45). A truncated ER species
which inhibits the binding of ER to its response element has
been identified in ER-positive/PR-negative breast tumors (46),
and an ER variant co-species lacking exon 3 of the DNA-
binding domain was identified from ER-positive tumors which
was unable to function as a transcriptional inducer (47).
Kaplan-Meier survival analysis in the small subgroups of
our series must be treated with caution given the sample sizes.
Nevertheless, it is interesting that patients with ER-rich tumors
and allele loss close to the PR gene had particularly poor
survival; all six patients having died within 2Vi years, whereas
those with ER-rich tumors that retain heterozygosity at the PR
gene locus have particularly good survival, with five of the six
patients alive beyond 3 years. Clearly, such small numbers
inevitably introduce bias, and this observation should perhaps
stimulate a prospective analysis in a larger series of patients.
Our finding that none of the endometrioid tumors had LOH
close to the PR gene is intriguing, and consistent with the many
reports that this histological subtype is associated with higher
tumoral PR content (9) and the finding in one study that endo¬
metrioid tumors can have a 54% response rate to progestin
therapy (42).
The analysis of PR content in relation to survival may well
be complicated by the presence of LOH in association with
abnormal PR protein, which is undetected by antibodies. Re¬
moving tumors with LOH from our series and examining those
that had retained heterozygosity resulted in the survival patterns
that would have been expected; patients with ER-rich and PR-
rich tumors exhibiting a survival advantage (Figs. 4 and 5).
We suggest that structural alteration at the PR locus on
chromosome llq22 may represent a significant mechanism for
the dysregulation of tumoral PR content. Further analysis of the
PR gene structure, expression, and associated clinical correla¬
tions in these tumors to determine the mechanism(s) involved
will be important and is currently under way in our laboratory.
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Abstract. Many regions of the genome exhibit loss of
heterozygosity (LOH) in epithelial ovarian cancer (EOC)
suggesting sites of recessive genetic elements such as tumor
suppressor genes. We performed detailed LOH studies of
chromosomes 17 and 11 using 24 microsatellite repeat markers
in a population of 47 patients with EOC. Univariate statistical
analysis revealed that significant co-losses of chromosomal
loci occurred between 17p and I7q whole arms (p=0.0003),
NME1 (1 7q21) with D11S922 (lip 15.5) (p=0.0067) and
D 1 I S9 1 2 (1 1 q24) with D1 1S935 (1 1 p 1 3) (p=0.0073).
Statistical analysis of the relationship between LOH on
particular chromosomal arms and clinicopathological factors
evealed a significant association between serous histological
subtype of ovarian adenocarcinoma and chromosome 17p
'p=0.0052) and telomeric 17q (p=0.0007) LOH. An analysis
if specific polymorphic chromosomal loci demonstrated that
.idverse survival was significantly associated with LOH at
11 q24 (p-0.0067) and 17q21 (p=0.0076). There were non¬
significant trends suggesting a relationship between
thromosome 17p LOH and poorly differentiated (p=0.025)
ind advanced FIGO stage (p=0.031) tumours. Considering
hese statistical associations, a preliminary multistep model
'or involvement of chromosomes 1 I and 17 in ovarian
icoplasia can be constructed.
Introduction
Dvarian cancer is the commonest cause of death from
tynaecological malignancy in the developed world. Its poor
prognosis is primarily the result of its late presentation due to
Correspondence to: Dr H. Gabra, 1CRF Medical Oncology Unit.
Western General Hospital. Crewe Road. Edinburgh EH4 2XU, UK
Key words: ovarian cancer, loss of heterozygosity, chromosome 11,
chromosome 17, survival, prognostic factors, microsatellite markers
early symptoms being insidious in onset and non-specific in
nature.
Cytogenetic studies have revealed that non-random
chromosomal abnormalities occur frequently in ovarian
cancer (1-5). Cumulative genetic lesions experienced by the
ovarian surface epithelium provide a multistep pathway to
ovarian neoplasia.
Inactivation of recessive genetic elements such as tumour
suppressor genes represent frequent and important events en-
route to frank neoplasia (6). Evidence for such inactivation
events may be inferred from loss of heterozygosity (LOH)
when it is demonstrated in DNA from a tumour sample
compared with matched constitutive DNA (7). Frequent LOH
has been demonstrated for many chromosomes in ovarian
cancer. Among these are chromosomes 17 and 1 1. Chromosome
17 (carrying p53 on pi3.3 and BRCA1 on q21.2) has been
implicated in many tumour types, and is believed, in many
instances to be lost in its entirety (as a whole homologue).
w ith or without reduplication of the other chromosome in
ovarian cancer (8,9). Chromosome 11 p 15.5 has been implicated
in ovarian (10-13), breast (14.15) and other cancers. The
1 1 p 13 region exhibits lower LOH rates in ovarian cancer, li
is of potential interest since it is the approximate site of vvtl
and has been investigated by several groups (16,17). I 1 q 13.
the site of an 'amplicon' involved in breast cancer, exhibits
less LOH in ovarian cancer (18). More recently it has been
demonstrated that the 1 lq22-qter region exhibits high levels
of LOH in melanoma (19). breast (14,15,20,21), ovarian
(10.18), cervical (22) and lung (23) cancer.
In previous studies, we determined the extent ol LOH in
ovarian cancer using 24 microsatellite markers; 14 located on
chromosome 17. and 10 located on chromosome II. In thi<
study we present the results of a univariate statistical analysis
in 47 EOCs comparing LOH rates at these loci and their
association with loss ol other loci, and with piognosticalK
important clinicopathological features of ovarian cancer.
Materials and methods
Clinical specimens. Fresh primary ovarian turnout tissue
from patients was transferred directly to dry ice ot liquid
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Surgical treatment Completely debulked 32
Incompletely debulked 15
Not known 2























nitrogen and stored at -70°C until processing. Heparinised
blood was obtained postoperatively. FIGO staging and
histopathology (including differentiation) were determined
and reviewed in a standard fashion at a multidisciplinary
combined gynaecological oncology clinic. Treatment was
planned and delivered in accordance with established protocols
implemented by the multidisciplinary clinic at the time,
comprising the best possible surgical debulking followed by
adjuvant/palliative chemotherapy. Minimum follow-up is
33 months, and all deaths that have occurred have been due
to ovarian cancer. Patient characteristics are outlined in Table I.
DNA extraction. DNA from fresh frozen tissue was extracted
by a standard technique as previously described (24).
Oligonucleotide primers. Chromosome 11 oligonucleotide
primers were selected on the basis of recently generated
microsatellite index maps (25-28) for locus, informativeness
and spacing as previously described. Chromosome 17
microsatellite primers were derived from the human genome
mapping project. D17S250, THRA1, NME1 and GH1 are
listed in a recent mapping compendium (29). Other sources
were used to derive the remaining microsatellites D17S579
(30), D17S293 (30) and D17S588 (31).
The approximate positions of the chromosome 11 and 17
polymorphic markers used in this study are shown in Fig. 1.
Polymerase chain reaction and polymorphic microsatellite
detection. PCR was performed in a reaction volume of 50 (il.
100 ng DNA was amplified using reaction conditions specified
Figure 1. Chromosomal location of polymorphic loci used in this analysis.
in the original papers. PCR reaction product was loaded onto
6% or 9% denaturing polyacrylamide gel, separated by
electrophoresis, passively transferred to Hybond nylon and
probed with 32P end-labelled (using polynucleotide kinase)
poly(CA) probe as previously described (32). Two observers
visually analysed the autoradiographs and recorded LOH
when there was clear reduction in intensity of one allele in
tumour DNA.
Southern blot analysis. Southern blot analysis was performed
for the chromosome 17p markers and D17S4 (THH59) as
previously described (24,33) (Table II). D17S5, D17S28,
C3068, D17S31 and D17S4 (34) were DNA probes used for
Southern analysis and had generally lower heterozygosity
rates than the CA repeat PCR probes used for the analysis.
The approximate positions of the chromosome 17 polymorphic
markers used in this study are shown in Fig. 1.
Statistical analysis. The two-tailed Fisher's exact test was
used to determine if there were significant associations between
LOH at different loci on chromosome 11 and 17. The same
univariate analysis was applied to examine relationships
between LOH at any locus and FIGO stage, differentiation
grade, histological subtype or survival. Since numerous
Fisher's analyses were carried out, the cut-off for significance
was set at p<0.01, but we have included trends towards
significance in the region of 0.07>p>0.01 where they have
supported or suggested biological hypotheses. Kaplan-
Meier/log-rank analysis was performed to determine any
relationship between LOH and survival. Multivariate analysis
was not attempted since the small initial population
precluded further reduction in number by sub-grouping for
this type of analysis.
Results
LOH at chromosomes 11 and 17. Table II shows the frequency
of LOH at the loci tested and their locations. Chromosome 17
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Tabic II. Locus name, position LOH rate for markers used in the analysis.
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Chromosome 17 Chromosome 11
Marker Location LOH Informative %LOH Marker Location LOH Informative %LOH
D17S5 17p 13.3 9 17 53 D11S922 lip 15.5 16 36 44
D17S28 17p 13.3 9 19 47 D11S569 11 p 15.3 14 30 47
C3068 17p 13.3-p 13.1 9 19 47 D11S929 11 p 14.1 9 38 24
p53 17p 13.1 11 20 55 D11S935 1 lp 13 13 39 33
D17S31 17pl3.1-pl 1.2 5 13 38 D11S905 1 lp 13-p 12 15 33 45
D17S250 17q 1 I -q 12 15 29 52 D11S873 11 q 14.3 9 22 41
THRA1 17q 11.2-q 12 17 28 61 D11S35 1 lq22 14 39 36
D17S579 17q 12-q21 18 35 51 DUS897 1 lq23.1 9 32 28
D17S293 17q21 14 32 44 D11S925 1 lq23.3 18 33 54
D17S588 17q21 18 33 55 D11S912 11 q24.1 18 37 49
NME 1 17q21-q22 25 38 66
GH1 17q22-q24 9 33 27
46 E 6 17q22-q24.3 23 41 56
D17S4 17q23-q25.3 13 19 68
Table III. Statistical associations between chromosome 11
and 17 arm LOH.
Whole arm Co-losses p-value n
17p vs 7q 0.0003 37
17p vs IP 1 34
17q vs iq 0.0351 41
17p vs iq 0.119 32
17q vs ip 0.624 43
1 lp vs iq 0.651 41
17q vs lq23-qter 0.0175 40
-OH was generally higher than chromosome 11 LOH. Rates
.vere lowest at GH1 on chromosome 17q and D11S929 on
jhromosome I lp. The individual LOH rates for chromosome
11 (10) in all tumours and 17p (24,33) in most tumours have
jeen reported previously. The 17q data, however, are previously
mreported.
Correlations between LOH at different polymorphic
nicrosatellite loci. The polymorphic marker LOH data were
nitially used for a 'whole arm' analysis to test if some of the
;hromosome arms were lost together more frequently than
predicted by chance (Table III). In this analysis, co-loss of
17p and 17q was noted with a high degree of significance
^p=0.0003). Co-loss of 17q and 11 q also showed a trend to
significance (p=0.035) and this trend became more significant
.vhen the telomeric half of 1 lq was considered (p=0.0175).
Individual loci were then examined for evidence of
significant co-ordinate loss (Table IV). In this analysis,
adjacent loci demonstrating significant co-loss were ignored
Table IV. Statistical associations between LOH at defined
polymorphic loci.
Co-losses Location Number p-value
informative
NME1, D11S922 17q21 -22, 11 p 15.5 30 0.0067
D11S912, D11S935 1 lq24.1, 11 p 13 32 0.0073
p53, D17S4 17p 13.1, 17q23-25 12 0.018
D11S912,D11S929 1 lq24.1, 11 p 14.1 34 0.019
THRA-1, D11S35 17q 11-12, 1 lq22 18 0.049
since this might have been due to contiguous deletions.
Within the confines of this assumption, NME1 (17q21) and
D11S922 (1 1 p 15.5) were lost together very significantly
(p=0.0067) as were D11S912 (11 q24.1) and D11S935
(1 1 p 13) (p=0.0073). Co-ordinate losses of p53/D17S4
(17pl3/17q25) and D11S912/D11S929 (1 lq24/l lp 14) both
occurred at borderline significance. The only individual loci
in this study demonstrating 17q/llq co-loss were Thral and
D11S35 at borderline significance (p=0.049).
LOH and correlation with clinicopathological factors, fisher s
test was then used to examine the relationship between whole
arm or individual locus LOH with clinicopathological
prognostic factors.
The only significant whole arm LOH association (Table V)
was between 17p LOH and serous type histology (p=0.0052).
There was also a trend towards significance for I7p LOH
with poorly differentiated tumours (p=0.025) and advanced
FIGO stage (p=0.031), but no association with survival
(p=0.171). The only other 'whole arm' trend to significance
was found for 1 Iq LOH with adverse survival (p=0.031).
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Tabic V. Statistical association between chromosome arm
loss and clinicopathological features of ovarian cancer.
Prognostic Chromosome Number Two-tailed
parameter arm informative p-value
associated associated




Poorly differentiated 17p 34 0.025
tumour 17q 42 0.099
lip 38 0.709
nq 36 0.483
Advanced FIGO 17p 35 0.031
stage 17q 44 0.434
I'P 40 0.689
nq 38 0.061
Adverse survival 17p 36 0.171
outcome 17q 46 0.117
HP 42 0.708
Hq 40 0.031
Individual loci were then examined for an association
between LOH and prognostic clinicopathological factors
(Table VI). In this part of the analysis, individual 17p locus
LOH always occurred in concert, and so 17p loss was
considered as a single entity. D17S4 (17q25) LOH was highly
significantly associated with serous histology (p=0.0007)
(loss of D17S4 co-incidcd significantly with loss of 17p.
associated with serous histology). D17S588 LOH (17q21)
was significantly associated with advanced FIGO stage
(p=0.0075). LOH at two loci were significantly associated
with adverse survival; D1 1S912 (1 Iq24; p=0.0067) and Thral
(17q I 1-12; p=0.0076). Other trends towards significance are
shown in Table VI including two associations of LOH which
deserve further comment: D11S35 LOH was associated with
non-endometrioid histology (p=0.04), interesting because of
the proximity of the progesterone receptor to this locus (35);
and D11S873 LOH associated with moderate/well differentiated
tumours at borderline significance (p=0.07).
Survival analysis. Kaplan-Meier/log-rank analysis confirmed
the Fisher's exact test findings for DI 1S912 [previously
described (10)] and Thral, with a significant actuarial survival
disadvantage for those who had LOH at either of those two
loci (Fig. 2).
Discussion
This analysis demonstrates that chromosome 17 and 1 1 LOH
affecting individual polymorphic loci and whole chromosome
arms show significant concordant events and associations
with prognostically important clinicopathological features of
ovarian cancer. The data presented in this study do not allow
interpretation of the prognostic independence of these markers,
as only associations can be reported with this type of univariate
analysis.
Most striking among the 'whole arm' co-loss events is the
association between 1 7p and 17q LOH. This has been
described previously in allelotype analyses using fewer
Table VI. Statistical association between defined polymorphic loci and clinicopathological features of ovarian cancer.
Prognostic parameter Microsatellite Location Number Significance of
associated with LOH marker associated informative statistical association
Histology:o; .
serous D17S4 17q23-25.3 18 0.0007
17p 37 0.0052
D17S588 17q21 33 0.038
non-cndomctrioid D11S35 1 lq22 27 0.04
Differentiation:
poor D17S4 17q23-25.3 IS 0.022
D17S579 17q 12-21 31 0.023
17p 34 0.025
THRA-I 17q 1 1.2-12 24 0.03
moderate/well Dl 1S873 I lq 14.3 19 0.07
Advanced FIGO stage D17S588 17q21 31 0.0075
D11S912 1 lq24.1 35 0.035
Adverse survival Dl1S912 I lq24.1 36 0.0067
outcome THRA-1 17q 11.2-12 27 0.0076
NME1 17q21 -22 37 0.047
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Figure 2. K;iplan-Meier/log-rank survival analyses comparing patients with
or without loss of heterozygosity (LOH) at THRA-I (upper graph); and
patients with or without LOH at Dl 1S9I2 (lower graph).
polymorphic markers than this study (8,9); and our findings
are also highly supportive of the hypothesis that chromosome
17 whole homologuc loss is a very common event in ovarian
cancer. In contrast, there is no association between 1 Ip and
1 Iq LOH in the same patient population, demonstrating that
although LOH on chromosome 11 is a frequent event, it is
unlikely to be explained by whole homologuc loss (by
mechanisms such as non-disjunction postulated to be important
in chromosome 17). There is also an association between
telomeric 1 lq LOH and 17q LOH, which has also been
observed for breast cancer (36). The significance of this
observation is not clear, although both these regions contain
polymorphic markers where LOH is associated with adverse
survival (see below).
Significant associations of LOH between individual
polymorphic markers were also noted in this study, and for
some of these, plausible candidates or biological hypotheses
exist. It has been recognised in a substantial body of work
that a putative tumour suppressor gene resides at chromosome
I 1 pi5.5 in ovarian (10-13) and other (15,37-39) cancers.
Additionally, it is recognised that the nm23 gene may play a
role as a progression suppressor in ovarian cancer (40). It is
therefore of interest that co-loss of Dl 1S922 at 11 p15.5 and
NMEI at 17q21 (site of nm23) should occur so significantly.
Similarly LOH of Dl 1S912 [associated with adverse survival
in ovarian and more recently, breast cancer (41)] was found
to be significantly associated with Dl 1S935 at 1 1 p 13, known
to be the approximate site of the Wilms' tumour gene (wtl).
Significant rates of LOH at 11 p 13 have been noted in previous
analyses, although SSCP and DNA sequencing in two studies
failed to demonstrate any wtl mutation in these tumours with
II p 13 LOH (16,17). Several observations were made in this
analysis with regard to the association of LOH with
prognostically important clinicopathological factors in ovarian
cancer. Whole arm loss was significantly associated with
clinicopathological factors only for chromosome I7p. This is
perhaps not surprising when one considers that of the four
chromosome arms in this study, only 17p appeared to be lost
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underwent LOH together. This may be a reflection of the
importance of the p53 gene and its role in neoplasia. The
most significant association noted was of 17p LOH with
serous ovarian adenocarcinoma. The observation of p53
mutation in serous ovarian cancer is well described in several
previous studies (42-45). 17p LOH is also associated with
poor differentiation of the primary tumour and advanced
stage at presentation, although these associations are at
borderline significance. However, there was no association of
17p LOH with adverse survival. It is of interest that several
extensive studies have reported no relationship between p53
abnormality and survival in ovarian cancer (43,46,47). The
only other notable 'whole arm' observation was an
association of borderline significance between 11q whole
arm loss and adverse survival.
An analysis of LOH at individual polymorphic loci with
prognostic clinicopathological features revealed several
significant associations. A marker at 17q25 (D17S4) was
noted to be significantly associated with serous histology,
which we have previously reported (33). A marker at 17q21
was significantly associated with advanced FIGO stage
(D17S588). Finally, two markers, D11S912 at 11 q24 (10)
and THRA1 at 17q21 were found to be associated
significantly with adverse survival, suggesting the potential
presence of late-acting progression-suppressors involved in
ovarian cancer. If one considers that polymorphic markers
undergoing frequent LOH, where no significant difference is
noted between favourable and adverse clinicopathological
features, may represent early events in ovarian carcino¬
genesis; while polymorphic markers segregating with
adverse clinicopathological phenotypes may be intermediate
or late acting events (depending on phenotype), then one can
begin to construct a crude picture of the possible involvement
of chromosomes 17 and 11 in a multistep model of ovarian
neoplasia similar to one that we have previously postulated
for chromosome 11 alone (10) (Fig. 3). In this model, 17p
(p53) LOH represents an intermediate or early event; 17q and
telomeric 1 1 q LOH represent late events. Although the
evidence is inconclusive, we have included D11S35 LOH as
an early event in neoplasia, perhaps involving the
progesterone receptor (35), and D11S873 LOH as an early
event in generating a genetically distinct, prognostically
advantageous, subgroup which presents as the relatively rare
early stage form of ovarian adenocarcinoma.
It is clear that this univariate analysis is a crude tool with
limits to the extent of inferences that one can draw about
ovarian neoplasia. However, it does allow some general
observations to be made regarding comparisons of
subchromosomal abnormalities in a small but well-defined
cohort of patients with ovarian cancer. It is to be hoped that
refinement of these regions will provide further mechanistic
answers to the observed associations as positional cloning
efforts ultimately yield genes involved in these processes.
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Abstract
Previous cytogenetic and loss of heterozygosity (LOH) data suggest that
disruption of chromosome llq23-qter occurs frequently in epithelial ovar¬
ian cancer and is associated with an adverse clinicopathological pheno-
tvpe. Ten polymorphic microsatellite repeat loci were analyzed by PCR
from the Ilq22-q25 region between D11S35 and D1IS968 in 40 ovarian
lumors (including 31 epithelial ovarian cancers). Two distinct regions of
oss were detected, suggesting possible sites for genes involved in epithelial
jvarian neoplasia: a large ccntromeric region between D11S35 and
D1IS933 (Ilq22-q23.3) and a telomeric 8.5-Mb region lying between
911S934 and D11S1320 (llq23.3-24.3) not previously defined. LOH of the
atter region but not the former one was significantly associated with poor
iurvival, despite all tumors in this study having LOH somewhere on
hromosome 11. This analysis provides a starting point for positional
lolling.
ntroduction
EOC3 the most common cause of death from gynecological malig-
lancy. is typically a late-presenting disease with poor prognosis. The
lathophysiological pathways to this common, aggressive phenotype
ire determined by multiple genetic lesions accumulated by the ovarian
urface epithelial cells. Inactivation of tumor suppressor genes are
requent and important components of these pathways, and regions of
he genome containing such genes may be delineated by cytogenetic
nd LOH analyses. The list of putative tumor suppressor regions is
[rowing rapidly, and many chromosomes appear to have such regions
ost at fairly high frequencies in EOC. The llq23-qter region has
eceived much recent interest as the site of a putative tumor suppres-
or gene(s) in cancers of the ovary (1. 2), breast (3-5), lung (5), colon
7). cervix (8), and cutaneous malignant melanoma (9, 10). The region
vas shown to be significantly associated with advanced stage and
ioor prognosis in cancers of the ovary (2) and breast (11). The recent
loning and localization to chromosome llq of the ataxia telangiec-
asia gene (12) (thought to contribute as a modifying gene to perhaps
10°!c of breast cancer) provides a plausible candidate in this region,
vhich is increasingly described in solid tumors.
The present study refines the LOH map of the 1 lq22-qter region in
-OC using selected tumors known to have loss somewhere on chro-
nosome 11. concentrating on the subregion of LOH previously iden-
ifted and associated with adverse survival (2).
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Materials and Methods
Patient Population and Tumor Samples. Fresh primary ovarian tumor
tissue from 40 patients with ovarian tumors (31 with epithelial ovarian cancer)
was obtained as previously described (2). FIGO staging, histopathology, and
differentiation state were determined and reviewed in a standardized fashion at
a multidisciplinary combined gynecological oncology clinic. Treatment was
planned and delivered in accordance with standard protocols, and follow-up
data on this group are complete. Minimum and maximum follow-up on living
patients are 33 and 52 months, respectively; all deaths that have occurred have
been due to ovarian cancer. Patient characteristics are outlined in Table 1.
Primary tumor and constitutive DNA were extracted using standard meth¬
ods as previously described (13). In the present study, all tumors were known
to have LOH somewhere on chromosome 11, including I lp and proximal 1 lq
in cases H59, G56, G43, H5, G47, H55, G42. G46, and G18, prior to
refinement of the telomeric region (2).
LOH Analysis. DNA samples were analyzed as normal/tumor pairs by
PCR using primers for the following CA repeat polymorphic microsatellites
lying in the region 1 lq22 to 1 lq24.3: DI1S35, Dl IS925, Dl ISI336, D11S933,
D11S934, D11S707. D11SI351, D1IS9I2, DUS1320, and D1IS968. Primer
sequences were obtained from the Genome Data Base. The PCR products were
resolved by electrophoresis on a 6 or 9% denaturing urea/polyacrylamide gel.
passively transferred to Hybond nylon and probed with y— ,2P end-labeled
(CA),5 oligonucleotide as previously described (14). LOH was initially scored
on the basis of independent visual reporting by two observers who registered
for clear reduction in intensity of one tumor allele. Computerized densitometric
analysis of the autoradiographs was then performed on a high-resolution flat
bed scanner using a Bioimage whole band analyzer software system (v3.2.2)
run on a SUN SPARC UNIX platform. The relative ratio of alleles was
determined, normalized, and compared. Where the tumor allele ratio differed
from the normal allele ratio by 30% or more (r £ 0.7). LOH was assigned, as
previously described (4).
Statistical Analysis. Two-tailed Fisher's exact test was used to look for
associations between LOH regions and clinicopathological parameters.
Kaplan-Meier analysis and the log rank test were used to analyze overall
Table I Clinicopathological characteristics ot the study cohort
Number of patients 40
Previously known to have chromosome 11 LOH 40
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Fig. 2. Primary LOH data from three cases critical to the definition of the 1 Iq23.3-q24 locus. iV, normal DNA; , tumor DNA shown at top from patients G16, G21, and G28 (left).
Microsatellite loci are shown form centromeric (lop left) to telomeric (top right). Arrows, alleles showing LOH (allele imbalance). Densitometry ratios of allele intensity were calculated
(shown at bottom), and values between 0.0 and 0.7 are taken to indicate LOH. (J, uninformative (homozygous). Note microsatellite instability at D11S925 for patient G26.
survival (diagnosis to death) for those patients with versus those without LOH
in defined regions of chromosome I Iq.
Results
Molecular Analysis. Clinical and pathological characteristics of
the cohort are outlined in Table 1. LOH was detected somewhere on
chromosome 11 in all 40 tumors in this series (selected for detailed
analysis from our previous study). H59, G56, G43, H5, G47, H55,
G42, G46, and G18 all had been shown to have chromosome 11 LOH
outside the 1 Iq22-q25 region from a previous analysis (Ref. 2; data
not shown). Data from DIIS35, D11S925, and D11S912 have been
included from this previous report for most of the tumors, although the
latter two microsatellite PCR reactions were repeated for this study.
Fig. 1 shows that two separate regions of LOH are identified within
the I Iq22-q25: the minimum extent of the telomeric region of LOH
(11123.3-24.3) is defined by tumor G16. The centromeric extent of
this region is defined by DI IS934. and the telomeric extent is defined
by DI ISI320 (Figs. 1 and 2). The size suggested for this region from
a recently published radiation hybrid map is 169 centirays (about 8.5
Mb; Ref. 15). Within this region, the frequency of LOH at D11S912
was 11 (589c) of 19 EOCs and 0 of 5 benign/borderline; at DI IS707
it was 9 (69%) of 13 in EOCs and 0 of 1 borderline. LOH involving
this distal deletion unit occurred in 18 (58%) of 31 EOCs.
The large centromeric region of LOH lies between DI 1S35 (1 lq22)
and DIIS925 (11 q23.3) as defined by tumors G36, G17, G34. and
G55 (Fig. 1). LOH involving this centromeric deletion unit occurred
in 13 (42%) of 31 EOCs.
Only a minority of tumors exhibited LOH at either Ilq22-q23.3
(4/31, 13%) or 1 lq23.3—24.3 (8/31. 26%) alone. Nearly 30% of the
cases simultaneously exhibited LOH at both Ilq22-q23.3 and
Ilq23.3-q24.3 (fig. 1).
Statistical Analysis. Fisher's exact test was used to determine
whether loss from these two regions was significantly associated with
the clinicopathological features of ovarian cancer. No significant
correlations were seen between regional losses and FIGO stage
(P = 0.15), histological type, or differentiation grade. The centro¬
meric Ilq22-q23.3 region showed no statistical association with
survival for regional LOH alone or in combination with other regions.
However, LOH of the 1 Iq23.3-q24.3 region, either alone or in
combination with LOH in other regions, showed a strongly significant
correlation with survival by Fisher's exact test (P = 0.004; alive
versus dead patients with 33-month minimum follow-up), despite all
of the tumors in the series exhibiting LOH somewhere on chromo¬
some 11, confirming our previous finding for DIIS912 (2).
Kaplan-Meier/log rank analysis showed no survival difference
(P = 0.632) for the centromeric region of LOH (Figure. 3A) but the
distal LOH region (1 Iq23.3-q24.3) between DIIS934 and DI 1S1320
correlated signifficantly with adverse actuarial survival (log rank test,
p = 0.011; Figure 3B). However, the log rank analysis was not
significant when only advanced FIGO stage cancers were considered
in relation to 1 Iq23.3-q24.3 LOH status (p = 0.09).
Other Tumor Types. We have included data from a benign ovar¬
ian teratoma, regarded as haploid parthenogenetic. • demonstrating
LOH at all informative chromosome 11 loci. This tumor also had clear
LOH at all informative chromosome 17 loci tested (data not shown)
and provides a useful positive LOH control.
Benign and borderline epithelial tumors showed no case with
secure LOH involving the DI IS934—D11S1320 distal SRO. The two
granulosa cell tumors had minimal LOH located outside the critical
region.
Discussion
This study demonstrates that two regions of LOH within 1 lq22—
q25 can be defined in ovarian tumors. As has been shown from
previous studies (1, 5, 16), LOH in this region appears to correlate
with genetic loss rather than amplification.
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Fig. 3 Kaplan-Meier survival curves comparing
survival after a diagnosis of ovarian cancer in those
with or without LOH at 11 q22—q23.3 (A) and in
those with or without LOH at I Iq23.3-q24.3 (B).
LOH at 1 Iq23.3-q24.3 shows significantly reduced
actuarial survival (P = 0.011, log rank test), indi¬
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The proximal SRO (which is a large region defined by only two
microsatellites in our study) contains the ataxia telangiectasia and
progesterone receptor genes and is lost frequently (in 40% of cases),
but does not crudely correlate with survival or other adverse prog¬
nostic features in EOCs, although it is associated with low tumoral
progesterone receptor content (17). This proximal region broadly
corresponds to a region that has recently been identified in breast
cancer (3-5).
The telomeric 1 Iq23.3-q24.3 region, which we concentrated on
due to previous association of D11S912 LOH with poor prognosis,
excludes the ATM locus and the region recently mapped in breast
cancer. The SRO has been narrowed by our analysis to 8.5 Mb lying
between D11S934 and D11S9I2 at 1 Iq23.3-q24.3 based on recently
published physical maps (15, 18). Kaplan-Meier survival analysis
revealed that LOH involving this 8.5-Mb region is significantly as¬
sociated with poor survival in EOCs. However, when only the ad¬
vanced stage tumors were considered with this telomeric locus, the log
rank test did not reach significance, although Kaplan-Meier analysis
showed a trend toward worse survival in those with LOH of the distal
region. This suggests that a late-acting progression-suppressor may be
located within this interval. LOH within this region should be sub¬
jected to a larger prospective analysis to assess its role as an inde¬
pendent prognostic factor and its value in assessing survival prospec¬
tively. The distal deletion interval currently contains five candidate
genes: (from centromeric to telomeric) SRPR, ETS-1. FLU. ZNF1,
and NFRKB (15). The possibility that high-frequency nonspecific
genome instability might be responsible for the observed regional
losses xvas controlled by selecting tumors with chromosome 11 loss
preferentially, making it unlikely that the observed survival associa¬
tion in this population could be attributed to random high-frequency
genetic alteration. Additionally, the retention of heterozygosity telo¬
meric to the 1 Iq23.3-q24.3 LOH region suggests that LOH at this
distal unit is not simply due to high-frequency non specific telomeric
breaks.
The development of comparative genomic and expression tech¬
niques as they impact on positional and functional cloning strategies
should allow identification of genes from these critical regions.
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